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Abstract 
Histamine, the product of histidine decarboxylation, is an evolutionary 
conserved signaling molecule. It acts as a powerful stimulant of gastric acid secretion, 
neurotransmission, bronchocontriction, vasodilation, and immune modulation. 
Histamine plays a central role in innate and acquired immunity: in allergy and 
inflammation, closely associated with mast cell functions, in immunomodulation 
regulating T-cell and B-cell function. Histamine synthesis, signaling, and function is 
controlled by a variety of immune signals and in turn, modulates antibody and 
cytokine networks and function. Histamine modulates its function via four receptors 
(HIR, H2R, H3R and H4R). All these four receptors are members of the 7-
transmembrane (heptahelical) spanning family of G protein-coupled receptors, and are 
expressed on various histamine responsive target tissues and cells and suggest an 
important critical role of histamine in immune regulation, allergic disorder and 
autoimmunity. Histamine can selectively recruit the major effector cells into tissue 
sites and affect their maturation, activation, polarization, and other functions leading 
to chronic inflammation. Histamine also regulates dendritic cells, T-cells and B-cells, 
as well as related antibody isotype responses. Histamine modulates antibody 
production. It directly affects B-cell antibody production as co-stimulatory receptor 
on B-cells. Histamine HIR- and H2R-deficient mice have an imbalance in Thl/Th2 
cell function and a lower susceptibility to develop autoimmunity. Histamine HIR 
predominantly expressed on Thl cells may block humoral immune responses by 
enhancing Thl type cytokine IFN-y. In contrast, through histamine H2R, histamine 
enhances humoral immune responses. Allergen-specific IgE production is 
differentially regulated in histamine HIR and H2R-deficient mice. Histamine HIR-
deleted mice show increased allergen-specific IgE production, whereas histamine 
H2R-deleted mice show suppressed IgE production. In contrast, more sever 
autoimmune diseases are observed in mice lacking H3R, the receptor confined to the 
CNS. H4R on immune cells regulate cell migration and allergic responses in the 
periphery. Thus, humoral immune role of histamine in immunomodulation by 
histamine HI- and H2-receptors is documented (however it seems preliminary in 
nature), while its role by histamine H3- and H4-receptors are still unclear or 
elementary. However, the studies evaluating the role with receptors intact, but 
blocked by respective agonists/antagonists, and especially studying the 
(i) 
immunomodulatory profile over a span of time are lacking in the existing literature. 
Moreover, the studies in rabbit model are elementary, and the existing studies 
(histamine HI- and H2-receptors) have demonstrated the immunomodulatory role 
studying only single blood samples taken after immunizing the animal. Therefore, the 
present study has been planned to fulfill the requirement of histamine role in immune 
modulation and regulation through histamine HI-, H2-, H3- & H4-receptors against 
sheep red blood cells (SRBC) (a T-cell dependent antigen) and has been presented in 
two parts. 
In the first part of study we have delineated the histamine role in immune 
modulation and regulation. To study the humoral immune aspects of histamine in 
immunomodulation, the present part of study is divided into seven chapters. In the 
first chapter we have studied in vivo immunomodulation and immunomodulatory 
profile of histamine receptors. Furthermore, on the basis of histamine dose, 
immunization schedule and tin^ ie factor, this section has been presented in two sub-
chapters: (i) role of histamine on antibody profile generated by primary- and 
secondary-immunization and (ii) dose-dependent effect of histamine on antibody 
generation profile. In the first sub-chapter we have demonstrated potential role of 
histamine on antibody (total immunoglobulins (Igs), immunoglobulin-M and 
immunoglobulin-G) generation. These results have provided evidence that histamine 
has a short-term effect (until its presence in the body) on humoral immune system and 
affects B-cell for antibody class switching and potentially modulates antibody (Igs, 
IgM & IgG) generation titer. Secondary-immunization study has provided support to 
primary-immunization results of histamine role in antibody generation. In the second 
sub-chapter we have studied dose-dependent effect of histamine on antibody 
generation profile, and evaluated the antibody (Igs, IgM & IgG) generation titer in 
vivo affected by the concentration of histamine. 
In the second chapter we have studied in vivo immunomodulation and 
immunomodulatory profile of histamine Hl-receptors and demonstrated that the 
histamine treated-rabbits showed immunopotentiating properties by enhancing the 
anti-SRBC-antibodies levels as compared to control group (strengthen the previous 
findings of chapter first). HlR-antagonist-treated group suppressed the anti-SRBC-
IgM profile as compared to positive control group, on the other hand HlR-agonist-
treated group enhanced the anti-SRBC-IgM levels as compared to all experimental 
(ii) 
groups and demonstrated that HI-receptors have role of IgM generation. While anti-
SRBC-lgG profiles showed that HlR-antagonist-treated group suppressed the anti-
SRBC-IgG levels during complete study as compared to positive control group, while 
in contrast, HlR-agonist increased anti-SRBC-IgG profile as compared to other 
experimental group and further illustrated that HI-receptors have an important role in 
IgG generation. In this study, we noticed that exogenously added histamine in vivo 
(until its presence in the body) enhanced the antibody generation profile against 
SRBC whereas; on further metabolism its effect disappeared on the antibody 
generation profile bringing it in the range of control antibody level. We also observed 
that HlR-antagonist (until their presence) suppressed the antibody profile, which 
came to normal level (control range) in later phase due to their metabolism. 
Therefore, on the basis of the present study we reached to a conclusion that the results 
obtained due to histamine and HlR-antagonist were of short duration which 
disappeared in latter stage due to clearance of the body from these substance in 
rabbits. The results of both groups (histamine-treated and antagonist-treated) after 
metabolism of drugs were identical to each other and also similar to control group. 
Thus, histamine HI-receptors showed principle role in modulation of 
immunoglobulins and demonstrate important immunomodulatory effects in IgG and 
IgM generation. 
In the third chapter v/e have evaluated in vivo immunomodulation and 
immunomodulatory profile of histamine H2-receptors and showed that H2R-
antagonist-treated group enhanced IgM profile as compared to positive control-group, 
while agonists study showed different profile i.e., H2R-agonist-treated group 
enhanced the anti-SRBC-IgM levels as compared to H2R-antagonist-treated group 
and positive control. These data showed that H2-receptors have dominant role in IgM 
generation. While anti-SRBC-IgG profiles revealed that H2R-antagonist-treated group 
suppresses the anti-SRBC-IgG level during complete study as compared to positive 
control, and in contrast, H2R-agonist increased IgG profile as compared to all 
experimental groups and showed that H2-receptors have dominant modulatory role in 
IgG generation. In this study, we noticed that H2R-antagonist (until their presence) 
suppressed the antibody profile, which came to normal level (control range) in later 
phase due to their metabolism. Therefore, on the basis of the present study we reached 
to a conclusion that the results obtained due to H2R-antagonist were of short duration 
(iii) 
which disappeared in later stage due to clearance of the body from these substance in 
rabbits. Thus, the result of H2R-antagonist-treated group, after metabolism of drug 
was similar to control group. This study provided evidence that histamine H2-
receptors have dominant role in IgM generation. 
Jn the fourth chapter we have studied in vivo immunomodulation and 
immunomodulatory profile of histamine H3-receptors and demonstrated suppressed 
generation profile of total anti-SRBC-Igs, anti-SRBC-IgM and anti-SRBC-IgG in 
H3R-agonist-treated group. H3R-antagonist-treated group demonstrated increased 
generation profile of total anti-SRBC-Igs, anti-SRBC-IgM and anti-SRBC-IgG during 
whole of the study period. These results are contrast to our previous study of 
histamine HI- and H2-receptors-agonists/antagonists (chapter 2 and 3) and 
demonstrated that H3-receptors on inhibition by H3R-antagonist showing modulatory 
activity (enhancing the antibody generation levels). On the other hand H3-receptors 
on stimulation by H3R-agonist showing modulatory activity (suppressing the 
antibody generation levels). These data provide evidence that histamine H3-receptors 
in biological system serve as regulator for other histamine HI-, H2- or H4-receptors 
and auto-regulator for itself. Therefore, present study exhibits that H3-receptors 
regulate biological histamine level and its function in the body, and modulate 
histamine role in antibody production. In this study, we noticed again that 
exogenously added histamine in vivo (until its presence in the body) enhanced the 
antibody generation profile against SRBC whereas; on further metabolism its effect 
disappeared on the antibody generation profile bringing it in the range of control 
antibody level (strengthen previous histamine results of chapters 1, 2 and 3). 
Furthermore, H3R-antagonist (until their presence) increased the antibody profile, 
which came to normal level (control range) in later phase due to their metabolism. 
The present results provided evidence that histamine through histamine H3-receptors 
have important role in modulation of total immunoglobulins (Igs, IgM and IgG) 
generation. 
In the fifth chapter we have evaluated in vivo immunomodulation and 
immunomodulatory profile of histamine H4-receptors and showed enhanced 
generation profile of total anti-SRBC-Igs, anti-SRBC-IgM and anti-SRBC-IgG in 
H4R-agonist-treated group. In contrast, H4R-antagonist-treated group revealed 
initially suppressed and then later enhanced the profile of total anti-SRBC-Igs, anti-
(iv) 
SRBC-IgM and anti-SRBC-IgG throughout the study. These resuhs demonstrated that 
H4-receptors by H4R-antagonis1-treatment showing similar profile of antibody (Igs, 
IgM and IgG) generation as positive control group. On the other hand H4R-agonist-
treatment showing modulatory activity (enhancing the antibody generation levels) as 
compared to other experimental groups. These data provided evidence that histamine 
through histamine H4-receptor modulates immunological function and stimulates 
antibody production in vivo biological system. Again in this study, exogenously added 
histamine in vivo (until its presence in the body) enhanced the antibody generation 
profile against SRBC whereas; on further metabolism its effect disappeared (showed 
same findings of histamine as chapter 1-4). H4R-antagonist (until their presence) 
showed normal level of antibody profile, which was similar to control range whereas; 
on further metabolism its effect appeared as modulator and enhanced the antibody 
generation profile, which came to normal level (control range) at the last experimental 
day (in later phase). The conclusion of present study provided evidence that histamine 
H4-receptors have role in modulation of Igs, IgM and IgG generation. 
In the sixth chapter we have studied in vivo immunomodulation and 
immunomodulatory profile of histamine receptors (HI-, H2-, H3- & H4-): a 
comparative agonists study and demonstrated that enhanced generation profile of anti-
SRBC-antibody (anti-SRBC-lgs, IgM and IgG) in HlR-agonist-, H2R-agonist- and 
H4R-agonist-treated rabbits, while it showed suppression in H3R-agonist-treated 
rabbits as compared to positive control rabbits during the whole study period (same 
results were analyzed in chapter 2 - 5). Further we noticed that exogenously added 
histamine in vivo (until its presence in the body) enhanced the antibody generation 
profile against SRBC on 7* day post-l whereas; in later stages its effect disappeared 
on the antibody generation profile bringing it in the range of control antibody level 
(same as chapter 1 - 5). The conclusion of the present comparative study has provided 
evidence that histamine receptors (HIR, H2R and H4R) on stimulation have 
important role in modulation by enhancing the antibody generation, in which HIR 
have dominant role in immune modulation as compared to H2R and H4R. On the 
other hand, H3R on stimulation have dominant immune suppressive role and regulates 
other histamine receptors (HI, H2 and H4) in immune system. 
In seventh chapter v/e have evaluated in vivo immunomodulation and 
immunomodulatory profile of histamine receptors (HI-, H2-, H3- & H4-): a 
(V) 
comparative antagonists study and showed that the histamine treated-rabbits 
illustrated immunopotentiating properties by enhancing the anti-SRBC-antibodies 
levels as compared to positive control group (strengthen our previous histamine 
findings documented in earlier chapters) and the comparative study of HI-, H2-, H3-
& H4-antagonists-treated groups demonstrated enhanced generation profile of anti-
SRBC-lgs, IgM and IgG in H3R-antagonist-treated rabbits as compared to positive 
control rabbits, while H4R-antagonist, H2R-antagonist- and HlR-antagonist-treated 
rabbits revealed suppressed generation profile of anti-SRBC-lgs, IgM and IgG as 
compared to positive control rabbits (until the presence in the body). Whereas, on 
further metabolism of antagonists in the body showed enhanced anti-SRBC-lgs, IgM 
and IgG generation profile in H4R- & H2R-antagonists-treated rabbits (H4R- showed 
more marked immune modulation as compared to H2R-) as compared to positive 
control rabbits. HlR-antagonist-treated rabbits showed suppressed antibody 
generation profile throughout the study period as compared to other experimental 
groups. The conclusion of the present study has provided evidence that histamine 
receptors (HIR, H2R, H3R & H4R) have important role in modulation of antibody 
generation, in which HIR have dominant immune enhancing role as compared to 
H2R and H4R (H2R revealed more marked immune enhancing role as compared to 
H4R). On the other hand, HSR have dominant immune modulatory role in 
suppressing the antibody generation. Therefore, HSR have regulatory role and 
regulates other histamine receptors (HI, H2 and H4) in immune system. 
In the second part of study we have delineated toxicological effects of 
histamine receptors (HI, H2, H3 & H4)-agonists/antagonists used in the present 
immunomodulation study. To study the toxicological effects of HRs-
agonists/antagonists, the present part of study is divided into two chapters: (i) 
Hepatotoxicity by histamine receptors (HI, H2, H3 & H4)-agonists in rabbits: a 
histopathological & biochemical study, and (ii) Hepatotoxicity by histamine receptors 
(HI, H2, H3 & H4)-antagonists in rabbits: a histopathological & biochemical study. 
In the first toxicological chapter we have demonstrated that AST and ALT 
levels were significantly increased in all drug-treated groups as compared to control 
and showed the increased rates of liver degeneration in histamine and HRs-agonists-
treated groups, which support hepatotoxic findings in all drug-treated groups 
compared to control group. Furthermore, increased alkaline phosphatase and bilirubin 
(vi) 
levels in all drug-treated groups as compared to control group also support liver 
degeneration and sustain our histological findings of liver damage. The 
histopathological study of liver revealed that short-term treatment by histamine and its 
receptors-agonist produce differential patterns of heptotoxicity in terms of hepatic 
congestion (histamine and H2R-agonist), centrilobular necrosis (HlR-agonist), 
binucleated (H4R-agonist) and multinucleated hepatocytes (H2R- and H3R-agonist), 
and prominent KCs (H4R-agonist) as compared to control group. Thus, the 
conclusion of these results suggests that histamine receptors on induction via their 
specific-agonist produce differential pattern of hepatotoxicity warranting further 
studies. 
In the second toxicological chapter we have demonstrated the maintained 
hepatic lobular architecture, portal triad, hepatic cords and sinusoids in control, 
histamine and DMSO-treated groups. The notable findings included increased 
binuclearity in HIR, trinuclearity in H2R, oxyphilic clusters of hepatocytes in H3R, 
and moderate centrilobular necrosis in H3R and H4R-antagonist-treated groups 
without obvious lymphocytic infiltration and Kupffer cell prominence. Thus, the 
conclusion of present study revealed that short-term treatment by histamine receptors-
antagonists produce different patterns and intensities of hepatotoxicity in terms of 
hepatocellular necrosis and hepatocyte polyploidy congruent with biochemical 
alteration in the blood but had minimal effects on hepatic congestion, inflammatory 
cells infiltration or Kupffer cell prominence. 
(vii) 
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Chapter 1 General Introduction 
The immune system protects the host from various pathogens and consists of the 
innate (natural, non-specific) and the acquired (adaptive, specific) systems (Calder, 
1995). These two systems are highly inter-related through cytokines and signaling 
molecules. The innate immune system consists of physical barriers (e.g. skin, the 
endothelial cell layer in the respiratory tract, and the gastrointestinal tract), 
mononuclear phagocytes (e.g. monocytes and macrophages), dendritic cells, 
polymorphonuclear granulocytes (e.g. neutrophils, eosinophils and basophils), mast 
cells, natural killer (NK) cells, platelets and humoral factors including coUectins, 
complements, lysozymes, C-reactive proteins and interferons (Peng et al. 2007). 
Recently, neutrophil extracellular traps, comprising DNA and proteins as major 
structural components, were discovered as a mechanism against bacterial infection 
(Buchanan et al. 2006). The innate immune system can rapidly respond to invading 
microbes, but its major disadvantages include non-specificity and a lack of memory. 
When infection cannot be fully cleared by the innate immunity over a short period, 
the adaptive immune system is activated to destroy infectious agents (Peng et al. 
2007). 
The adaptive (acquired) immune system consists of T-lymphocytes, B-
lymphocytes and humoral factors (Calder 2006). The bone marrow is primarily 
responsible for hematopoiesis and lymphopoiesis, while the thymus is required for T-
cell development. The spleen, lymph nodes and the mucosa associated lymphoid 
tissues in the gastrointestinal, respiratory and reproductive tracts, and other organs are 
secondary lymphoid tissues. Because each lymphocyte carries surface receptors for a 
single antigen, the acquired immune response is highly specific. This immune system 
becomes effective over days after initial stimulation and possesses immunological 
memory (Calder 2006). 
B-lymphocytes are unique in their ability to produce and release specific 
antibodies in the humoral immunity. The antibodies can neutralize microorganisms 
(including viruses) or toxins by binding to them; activate complement proteins in 
plasma for the destruction of bacteria by phagocytes; immobilize bacteria; and 
opsonise various pathogens. When pathogens escape by the humoral immunity, they 
are targeted by the cell-mediated immunity that involves the production of cytokines 
[e.g. interferon-y (IFN-y)] and other cytotoxic proteins by T-lymphocytes. Antibodies 
are highly effective against extracellular pathogens. 
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In contrast, host cells infected with intracellular pathogens (e.g. viruses and 
certain bacteria) are generally cleared by cytotoxic T-lymphocytes and the major 
histocompatibility complex (MHC) are presented on the host cell surface and 
recognized by the T-cells (Peng et al. 2007). 
Innate and acquired immune systems are regulated by a highly interactive 
network, of chemical communications, which includes the synthesis of the antigen-
presenting machinery, immunoglobulins and cytokines (Calder 2006). Both immune 
systems are highly dependent upon an adequate availability of biogenic amines for the 
synthesis of these proteins and polypeptides, as well as other molecules with 
enormous biological importance (Kim et al. 2007). These substances include 
histamine, nitric oxide (NO), superoxide, hydrogen peroxide, glutathione and 
anthranilic acid. Individual amino acids affect immune responses either directly or 
indirectly through their metabolites. While the immune system is vital to health, it 
may be dysfunctional under certain conditions, resulting in the development of 
autoimmune and hypersensitivity diseases (Wu 1995, Field 2005). 
In historical evolution, histamine (biogenic amine) is probably one of the most 
important phlogistic ancient mediator and even one of the most intensely studied 
molecules. Biological systems have been using histamine, catecholamines and other 
chemical mediators to communicate among cells (MacGlashan 2003). Histamine was 
synthesized in 1907 and characterized in 1910 as a substance ("beta-1") (Barger and 
Dale 1910), owing to its significant competence to constrict guinea pig ileum, and its 
cogent vasodepressor action. However, it took 17 years to demonstrate its presence in 
normal tissues (Best et al. 1927). The relation between histamine and anaphylactic 
reactions was made rapidly in 1929, and was identified as a mediator of anaphylactic 
reactions in 1932 (Dale 1929, Steinhoff et al. 2004), whereas its connection to mast 
cells was not made until 1952 (Riley and West 1952), and its relation to basophils was 
identified in 1972 (Ishizaka et al. 1972). The search for compounds being potent to 
neutralize the pathological effects of histamine began at the Pasteur Institute in Paris 
during the 1930s, and these compounds were found to partially block the effects of 
histamine; based on the ethylenediamine structure. The first antihistamine compound 
was the adrenolytic benzodioxan, piperoxan (933F), reported by Ungar, Parrot and 
Bovet in 1937 and was shown to block the effect of histamine on the guinea-pig ileum 
(Parsons and Ganellin 2006). 
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It was shortly followed by the report of Bovet and Staub in 1937 which states 
that identified antihistamine compound was structurally related to aryl ethers such as 
the thymol ether (929F) (Parsons and Ganellin 2006). The latter antihistamine 
compound proved to be highly toxic for clinical development; however, the 
replacement of ether oxygen by an amino group lead to the search of aniline ethylene 
diamine derivatives. For this noble research on antihistamines and curare, Bovet was 
awarded the Nobel Prize in 1957 (Parsons and Ganellin 2006). It was being 
documented that histamine played an important role as a mediator of allergic reactions 
indicated by a series of compounds with antihistamine activity which protected guinea 
pigs from anaphylaxis. However, the clinical use of these compounds in humans was 
precluded due to their toxicity (Bouvet and Staub 1937). The first antihistamine, 
Antergan™(phenbenzamine, RP 2339) was being used in humans (Halpern 1942), but 
this compound was subsequently replaced by Neoantergan"^ " (mepyramine, 
pyrilamine, RP 2786), which is still in use to counteract the uncomfortable effects of 
histamine release in the skin. Many other antihistamines such as diphenhydramine 
(Benadryl ), tripelennamine, chlorpheniramine and promethazine are also used in 
similar manner to counteract the adverse effects of histamine (Parsons and Ganellin 
2006). Subsequently, after 1945, these antihistamines were widely used in the 
treatment of various allergic diseases such as hay fever, urticaria, and allergic rhinitis. 
However, the side effects were not uncommon and the sedation was a drawback to 
their use. A very few side effects were put to their good use; therefore, some 
antihistamines such as cyclizine (Marzine™) and diphenhydramine in the form of its 
8-chlorotheophyllinate (Dramamine ) are being used as an antiemetics for travel 
sickness (Parsons and Ganellin 2006). By 1950 there were only 20 compounds 
clinically available to block the effects of histamine (MacGlashan 2003), but advances 
in histamine receptors (HRs) ligands have ever attracted many researchers for 
pharmaceutical developments and are still highly topical (lUPHAR Receptor database 
2008). 
Histamine {2-(imidazol-4-yl) ethylamine} is a monoamine and was coined after 
the Greek word for tissue ''histos", with the broadest spectrum of activities in various 
physiological and pathological conditions including the cell proliferation, 
differentiation, hematopoiesis, embryonic development, regeneration, wound healing, 
aminergic neurotransmission and various brain functions (sleep/nociception, food 
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intake and aggressive beliavior), secretion of pituitary hormones, regulation of 
gastrointestinal and circulatory functions, cardiovascular system (vasodilatation and 
blood pressure reduction), as well as inflammatory reactions, modulation of the 
immune response, energy of endocrine and homeostasis (Shahid et al. 2009). Several 
studies have highlighted the evidence that histamine elicits immune-modulatory and 
pro-inflammatory effects by the differential expression of histamine receptors (HIR, 
H2R, H3R and H4R). These receptors easily modulated the diverse effects of 
histamine on immune regulation and distinct intracellular signals. All these four 
receptors are members of the 7-transmembrane (heptahelical) spanning family of 
receptors, found to be G protein-coupled (GPCR), and are expressed on various 
histamine responsive target tissues & cells and suggest an important critical role of 
histamine in immunomodulation and allergic diseases (Jutel et al. 2002, Schneider et 
al. 2002, MacGlashan 2003, Dy and Schneider 2004, Parsons and Ganellin 2006, 
Shahid et al. 2009). 
Immunomodulators can be defined as substances may be biological or synthetic 
which can stimulate, suppress or modulate any of the components of immune system. 
The basic function of immune system is to protect individual against infectious agent 
and potential pathogens which puts the immune system in a vital position between a 
healthy and diseased state of the host. Networking and interaction with in the immune 
system are so complex that modulation of immune system to achieve designed 
therapeutic success is still in the realm of philosophical editorials rather than definite 
efficacy studies (Benson 1993). The use of immunostimuiants, particularly as an 
adjunct for chemotherapy to control and prevention (Chatterjee et al. 1988) holds 
great promise but has not yet received the attention that it deserves. 
Immunomodulators can be classified immuno-adjuvants, immunostimuiants and 
immunosuppressant. Immunoadjuvants are used to increase the efficacy of vaccines 
and since specific immunoadjuvants are used with specific vaccines, therefore they 
can consider as specific immunostimuiants. Lack of availability of suitable adjuvant 
for human use has been one of the important stumbling blocks in our ability to 
develop various prophylactic means to control the infection (Allison 1997). 
Immunostimuiants, by definition, are inherently non-specific in nature as they are 
envisaged to enhance body's resistance against infection. They can act through innate 
as well as adaptive immune response. 
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In healthy individuals the immunostimulants are expected to serve as 
prophylactic or promoter agents i.e. immunopotentiater by enhancing the basic level 
of immune response (Allison 1997). Immunosuppressants could be used to control 
pathological immune response, are active in autoimmune diseases, immediate and 
delayed type of hypersensitivity immune reactions, and graft rejections. In clinical 
medicine, both aspects of immunomodulation viz. immunostimulation and 
immunosuppression are equally important. In conventional chemotherapy, 
immunopotentiation is an ideal choice when the host defense mechanisms are to be 
activated under condition of impaired immune response (Allison 1997). 
Thus, there are multiple, complex methods for assessing immune function in 
individuals, depending on experimental conditions, the availability of analytical 
facilities and the investigator's interest (Field 1996, Calder and Yaqoob 1999). The 
classic functional measurements in vivo include: (i) serum antibody titres or the 
humoral immunity in response to primary or secondary (booster) immunization; (ii) 
the delayed-type hypersensitivity response measured by skin testing; (iii) blood levels 
of different lymphocyte subsets as well as serum concentrations of cytokines and 
other immune mediators; (iv) the weights of lymphoid organs; and (v) morbidity and 
recovery from infectious disease. The in vitro assays of immune function often consist 
of: (i) the metabolism of immunocytes; (ii) lymphocyte blastogenesis in response to 
mitogens; (iii) cell morphology and apoptosis; (iv) the phagocytosis of particles by 
monocytes and macrophages; and (v) the production of antibodies, cytokines and low-
molecular weight cytotoxic substances. 
Histamine itself is an agonist of its four receptors (HI R, H2R, H3R & H4R) and 
modulates several immunological reactions both in vivo and in vitro (Shahid et al. 
2009). It is a well known mechanism that histamine directly affects B-cell antibody 
production as a co-stimulatory receptor on B-cells (Akdis and Blaser 2003, Jutel et al. 
2005, Akdis and Simons 2006, Shahid et al. 2009). It has been documented that in 
mice, histamine enhances anti-IgM induced proliferation of B-cells which is abolished 
in HIR deleted mice. In HlR-deleted mice antibody production against a T cell-
independent antigen-TNP-FicoIl is decreased (Banu and Watanabe 1999), suggesting 
an important role of HIR signaling in response triggered from B-cell receptors. Jutel 
et al. 2001 showed a different pattern of antibody responses to T-cell dependent 
antigens like ovalbumin and demonstrated that HlR-deleted mice produced high 
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ovalbumin-specific IgGl and IgE in comparison to wild type mice. However, studies 
evaluating the role with intact receptors, but blocked by respective histamine 
receptors (HIR, H2R, H3R & H4R)-agonists/-antagonists, and especially studying the 
immunomodulatory profile over a span of time are lacking in the existing literature. 
Moreover, the studies in rabbit model are elementary, and the existing studies have 
demonstrated immunomodulatory role studying only single blood samples taken after 
immunizing the animals. The investigations account for an important regulatory 
mechanism in the control of inflammatory functions in immune regulation through 
effector cells (mast cells and basophils)-derived histamine, exogenous histamine and 
its receptors-agonistZ-inverse agonist (histamine antagonist). 
According to the document of the International Conference on Harmonization 
(ICH) S8 Guideline on Immunotoxicity Testing for Pharmaceuticals (adapted by EU 
in 2005, and by the FDA and MHLW in 2006), the evaluation of a primary antibody 
response to a T-lymphocyte-dependent antigen (e.g., Sheep red blood cells [SRBC] or 
Keyhole limpet hemocyanin [KLH]) is recommended as one of the most sensitive 
immune tests following chemical exposures (Kognai et al. 2007). The T-lymphocyte-
dependent antibody response assay is a sensitive indicator of immunological integrity. 
When SRBC is used as the particular T-lymphocyte dependent antigen, this response 
requires the coordinated interaction of various immune system cells (i.e., antigen-
presenting cells, T-lymphocytes and B-lymphocytes) (Benacerraf 1978, Kognai et al. 
2007). Moreover, several studies have demonstrated that the modulation of antibody-
mediated immune response against SRBCs following chemical exposures (i.e., 
immunomodulatory and immunosuppressive agents) (Zhang et al. 2005, Bafna and 
Mishra 2005). 
Keeping in view the above facts, especially the paucity of literature {i.e., 
immunomodulatory role of histamine receptors (HIR, H2R, H3R & H4R)}, defining 
the co-relation of histamine receptors-agonistZ-antagonist in immune regulation, and 
fragmentary histamine literature describing existing immunomodulatory role of 
histamine in vivo system, the present study was proposed with the following broad 
objectives: 
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AIMS AND OBJECTIVES 
• To find out the role of histamine in immunomodulation by measuring 
the generated antibody profile against SRBCs. 
• To find out the pre-clinical effects of specific histamine receptors 
(HIR, H2R, H3R and H4R) role in immunomodulation by immunomodulatory profile 
of antibody generation against SRBCs following histamine receptors-specific 
agonist/antagonist exposures. 
*t* To compare hepatotoxicity (if any) of histamine receptors (HIR, H2R, 
H3R and H4R)-agonist/antagonist (used in this study) by histopathological and 
biochemical analysis. 
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2.1. Biology of Histamine 
Histamine exhibits two main important basic functionalities sucli as primary 
aliphatic amine (pKai 9.4) and imidazole (pKa2 5.8). These make the monocation with 
different tautomers; the preferred form at physiologic pH value (96%) with a minor 
dicationic fraction (3%) and a very small amount of the neutral form (Cooper et al. 
J990). The nomenclature for histamine positions may be highly significant for 
histamine biology including synthesis, regulation, metabolism, and also histamine 
derivatives; see Fig. (1). 
H 
Figure 1. Specific nomenclature for histamine positions. 
2.1.1. Synthesis of histamine 
Histamine was first identified as an autocoid having potent vasoactive 
properties. It is a low molecular weight amine synthesized from L-histidine 
exclusively by L-hisddine decarboxylase (HDC) (B.C. 4.1.1.22 or B.C. 4.1.1.26), 
which is dependent on the cofactor pyridoxal-5'-phosphate to a putative binding site 
(TFNPSKW) on the protein. Histamine cannot be generated by another enzymatic 
pathway (Dy and Schneider 2004, Parsons and Ganellin 2006). Histidine 
decarboxylase (HDC) is an enzyme that is expressed in various cells through out the 
body, including central nervous system, neurons, gastric-mucosa, parietal cells, mast 
cells (~3 pg/cell histamine), and basophils(~l pg/cell histamine). Histamine has an 
important role in human health, and exerting its diverse biologic effects by 4 types of 
receptors (Lovenberg et al. 1999, Schneider et al. 2002, MacGlashan 2003, Akdis and 
Blaser 2003). Histamine is synthesized by enterochromaffin-like cells (ECL) in the 
stomach and plays an important role in gastric acid secretion. Only basophils and mast 
cells can store the amine in specific granules. In the hematopoietic system, histamine 
is closely associated with anionic proteoglycans heparin (in mast cells) and 
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chondroitin-4-sulfate (in basophils). In this specific form, histamine can be released in 
large amounts during degranulation in response to various immunological 
(immunoglobulin-E, or cytokines) or non-immunological (compound 48/80, calcium 
ionophore, mastoparin, substance P, opioids, or hypo-osmolar solutions) stimuli (Dy 
and Schneider 2004). Histamine synthesis in Golgi apparatus can be inhibited by a-
fluoromethylhistidin (Hill etal. 1997). 
Recently, many myeloid and lymphoid cell types that do not store histamine 
show more HDC activity and are capable of synthesis of high amounts of histamine 
(Szeberenyi et al. 2001). This so called "neo synthesized histamine," has been shown 
in various cells, including hematopoietic progenitors, macrophages, neutrophils, 
platelets, dendritic cells (DCs) and T-cells (Shiraishi et al. 2000, Ghosh et al. 2002, 
Dy and Schneider 2004, Yokoyama et al. 2004, Tanaka et al. 2004). Histamine 
synthesis in non-mast cells was first confirmed using mice, which genetically 
lack mature mast cells, upon stimulation with a phorbol ester (Taguchi et al. 1982). 
HDC activity is demonstrated in vitro through cytokines, such as lL-1, IL-3, IL-12, 
IL- 18, GM-CSF, macrophage-colony stimulating factor, TNF-a, and calcium 
ionophore (Schneider et al. 1987, Yoshimoto et al. 1999). Histidine decarboxylase 
(HDC) activity has been modulated in condifions such as LPS stimulation, 
inflammation, infection and graft rejection, in vivo (Dy et al. 1981). 
It is being demonstrated that the generation of HDC-knockout mice provides 
histamine-free system and it is more beneficial to study the role of endogenous 
histamine in a broad range of normal and disease processes. Such mice demonstrate 
diminished numbers of mast cells and significantly decreased granule content, which 
suggests that histamine might affect the production of mast cell granule proteins 
(Ohtsu et al. 2001). In a recent study, interleukin-3 (IL-3)-dependent bone marrow 
derived mast cells (BMMCs) have been found to be activated by certain 
immunoglobulin-E (IgE) clones in absence of specific antigen, leading to their 
survival, cytokine secretion, histamine production, adhesion, and migration 
(Kawakami and Kitaura 2005). In addition to this study, Tanaka et al. (2002) has 
shown a drastic and transient induction of HDC (~ 200-fold in activity) in BMMCs 
stimulated by IgE alone, which was found much higher than that upon antigen 
stimulation. Thus, this induction resulted in the increase in stored histamine. Another 
study suggested that the anti-apoptic effects of monomeric IgE on BMMCs were 
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mediated by interleuk;in-3 (IL-3) in an autocrine fashion (Kohno et ai. 2005). 
Although Schneider et al. (1987) found the potential role of IL-3 to induce HDC in 
bone marrow cells, it is clearly indicated that monomeric IgE-induced histamine 
synthesis may not be mediated through IL-3 (Kohno et al. 2005). Since stimulation of 
histamine synthesis occurs upon IgE-mediated antigen induction, and this remains 
controversial if these two modes of FceRl activation share a common signal 
transduction pathway. However, many recent studies have demonstrated the 
qualitative differences between both modes: such as monomeric IgE-induced Ca^ "^  
influx is mediated by a distinct channel from that activated upon antigen stimulation 
(Tanaka et al. 2005), and protein kinase C beta-ll (PKCpiI) plays a significant role in 
monomeric IgE-induced histamine synthesis in mast cells, but not upon antigen 
stimulation (Liu et al. 2005). Since, only small levels of increase in histamine 
synthesis were found by monomeric IgE both in purified rat peritoneal mast cells and 
in vitro maturated BMMCs, inducing effects of monomeric IgE on mast cells may be 
limited to immature mast cells (Tanaka et al. 2005). However, Tanaka and Ichikawa 
(Tanaka and Ichikawa 2006) has suggested that monomeric IgE-induced histamine 
synthesis exacerbates the symptoms of chronic allergy, while drastic increases in the 
levels of serum IgE are often observed in such diseases. 
2.1.2. Regulation of histamine 
Histamine is synthesized only by HDC enzyme. Therefore, histamine 
regulation is dependent on the gene of HDC enzyme, which is expressed in the cells 
throughout the body. It has been shown that complementary deoxyribonucleic acids 
(cDNAs) of HDC enzyme have been isolated from mouse mastocytoma, fetal rat 
liver, erythroleukemia cells and human basophil leukemia cells. Based on structural 
studies, mouse and human genes are composed of 12 exons spanning nearly 24 kb. 
The 2.4 kb single transcript is produced by mouse gene, whereas two splice variants 
of 3.4 kb and 2.4 kb exist in humans, and later encode the functional HDC 
(Yatsunami et al. 1994). HDC gene is found on chromosome 2 in mice and 
chromosome 15 in human and their expression is controlled by lineage-specific 
transcription factors. These factors interact with a promoter region consist a GC box, 
four GATA consensus sequences, a c-Myb-binding motif and four CACC boxes 
(Nakagawa et al. 1997). It has been demonstrated in several studies that the HDC 
transcription is regulated by various factors in gastric cancer cells such as gastrin, 
(10) 
Chapter 2 Review of Literature 
oxidative stress and PMA, through a Ras-independent, Raf-dependent mechanism, 
MAP icinase/ERK and a protein Icinase C (PKC) pathways functioning on three 
overlapping cisacting elements (GAS-RE 1, GAS-RE 2 and GAS-RE3) known as 
gastrin response elements (Hocker et al. 1998, Raychowdhury et al. 2002). The 
negative control on HDC expression in gastric epithelial cell line is exerted by 
expression of the transcription factors GATA-4 and GATA-6 (Watson et ai. 2002). 
This is well known that the expression of HDC in basophils and mast cells seems to 
be a consequence of the state of CpG methylation in the promoter region (Kuramasu 
et al. 1998). Many studies on the mast cell line HMCl and the pluripotent 
hematopoietic cell line UT7D1 have demonstrated that HDC-gene expression is 
subject to post-transcriptional control. Therefore, the chromosomal configuration and 
methylation of the HDC-promoter is likely to account for its cell-specific expression 
(Maeda et al. 1998, Oh et al. 2001). It has also been reported that PMA, the cell line, 
stimulates a strong increase in HDC activity which is affected by actinomycin D and 
that is not paralleled by enhanced HDC mRNA expression. Similar effect was noted 
in cell lines (HEL and CMK) with megakaryocyte/basophil differentiation potential 
(Dy et al. 1999). In addition to this effect, a mechanism that accounts for the strong 
enhancement of HDC activity in ECL cells in response to gastrin is explained by a 
translation control of HDC expression (Zhao et al. 2003). Two essential mechanisms 
of translational control have been explained in hematopoietic cells: 
(i) a rapamycin dependent pathway that is linked to phosphoinositide 3-kinase 
(PI3K), FRAP/mTOR and phosphorylation/dephosphorylation of repressor of 
translation 4E-binding protein (4E-Bps). 
(ii) ERK- and p38-dependent pathway that control the 4E-BP expression by 
the induction of Egr-1 (Rolli-Derkinderen etal. 2003). 
The multiple carboxy-truncated isoforms are formed due to post-translational 
processing of HDC gene; the gene is initially translated 73-74 kDa protein in 
mammals, and originally it was assumed that enzymes purified from native sources 
corresponded to a dimer of two processed isoforms of 53 and 55 kDa. According to 
Fleming and Wang (2003), the biosynthesis of histamine involves primarily the 55 
kDa isoform and it is being acknowledged that many other isoforms generated from 
74 kDa primary translation product can also be active. Ft is also being documented 
that enhancing the histidine decarboxylase activity might cause reduction in 
(11) 
Chapter 2 Review of Literature 
messenger RNA (mRNA) degradation by amino acid carboxyl-terminal PEST 
domains (Fleming and Wang 2000). Here is a need to completely understand the 
negative feed back regulation of HDC activity that differs from one cell type to 
another. This activity has been shown in AGS-B cells that over expression of the 
HDC protein inhibited histidine decarboxylase promoter activity by down regulation 
of ERK signals (Colucci et al. 2001). 
However, in gastrin-stimulated ECL cells, this type of feed back mechanism 
was not observed. It was also demonstrated that in the hematopoietic cells, as well as 
in the stomach, negative feed back signals could be produced through high cytosolic 
histamine concentration (Rolli-Derkinderen et al. 2003). Histamine reuptake 
mechanism comparable to that of the other aminergic neurotransmitters has not been 
observed (Masahito et al. 2006). 
2.1.3. Metabolism of histamine 
It is noteworthy that only a small amount of released histamine (2 to 3%) is 
excreted unchanged. The remaining histamine (more than 97%) is controlled via two 
major pathways for the metabolizing enzymes: histamine A'^-methyltransferase 
(HMT) (EC 2.1.1.8) and diamine oxidase (DAO) (ECI.4.3.6) before excretion (Hill et 
al. 1997, Maintz and Novak 2007). Histamine A'^-methyltransferase metabolizes the 
majority of histamine (50 to 80%) to TV-methyl histamine, which is further 
metabolized to the primary urinary metabolite A/-methylimidazole acetic acid by 
monoamine oxidase. Diamine oxidase metabolizes the histamine (15 to 30%) to 
imidazole acetic acid (Akdis and Blaser 2003). The study of the former pathway was 
greatly facilitated by the availability of a potent and highly specific inhibitor of 
diamine oxidase, aminoguanidine. HMT appears to be the most important enzyme 
contributing to the degradation of histamine in the airways, because blockers of HMT 
(such as SKF 91488) increase the bronchoconstricting action of histamine in vitro and 
in vivo, whereas diamine oxidase inhibition remained uneffected (Sekizawa et al. 
1993). HMT is expressed in airway epithelial cells and may therefore be responsible 
for the local metabolism of histamine released from airway mast cells. Mechanical 
removal of airway epithelium enhances the bronchoconstriction response to histamine 
in vitro (Barnes et al. 1985, Flavahan et al. 1985, Knight et al. 1990); this might be the 
result, in part, of loss of the metabolizing enzyme. Furthermore, experimental viral 
infections resulted in reduced epithelial HMT activity in association with increased 
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responsiveness to inhaled histamine (Nai<azawa et al. 1994). The half-life of 
pharmacologically active doses of histamine is less than 10s in the rat and 20-30s in 
the dog. In earlier studies, histamine levels were measured by bioassay, but 
subsequently fluorometric and radio-enzymatic techniques were employed (Parsons 
and Ganellin 2006). 
2.2. Histamine Receptors 
Histamine is an important biogenic amine and has multiple effects that are 
mediated through specific surface receptors on specific target cells. Four types of 
histamine receptors have now been identified. In 1966, histamine receptors were first 
differentiated into HI and H2 (Ash and Schild 1966), and it was reported that some 
responses to histamine were inhibited by low doses of mepyramine (pyrilamine), 
whereas others were unsympathetic. In 1999, a third histamine receptor subtype was 
cloned and termed as H3 (Lovenberg et al. 1999). Subsequently in 2000, the fourth 
histamine receptor subtype was reported which was termed as H4 (Oda et al. 2000) 
and introduced a significant chapter in the story of histamine effects. 
2.2.1. Histamine Hl-Receptor 
2.2.1.1. Cellular distribution and functional characterization 
In different mammalian tissues, the study of the distribution of histamine HI-
receptors (HlRs) has been significantly helped by the development of specific 
radioligands for this subtype. In 1997, [3H]mepyramine a selective radioligand was 
developed (Table 1) (Hill et al. 1977), and since then it has been used to identify Hl-
receptors in a wide variety of tissues such as gastrointestinal tract, centra! nervous 
system, airways, vascular smooth muscle cells, mammalian brain, hepatocytes, nerve 
cells, endothelial cells, chondrocytes, monocytes, neutrophils, dendritic cells, T and 
B lymphocytes (Table 2), the cardiovascular system and genitourinary system, 
endothelial cells and adrenal medulla. In many pathological processes of allergy, 
including allergic rhinitis, atopic dermatitis, conjunctivifis, urticaria, asthma, and 
anaphylaxis, HI-receptors are involved. The receptors also mediate 
bronchoconstriction and enhanced vascular permeability in the lung (Smit et al. 1999, 
Haas and Panula 2003, Togias 2003). It has been noticed that [3H]mepyramine binds 
to secondary non-HI-receptor sites in various tissues and cells (Arias-Montano and 
Young 1993, Dickenson and Hill 1994, Leurs et al. 1995). In addition to 
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[3H]mepyramine, which predominantly binds to a protein homologous with 
debrisoquine 4-hydroxylase cytochrome P450 in rat liver (Fukui et al. 1990), this 
nonspecific binding can be blocked by quinine. This investigation led to the 
demonstration that quinine may be used to block binding to other lower affinity sites 
(Liu et al. 1992). However, it is clear that not all secondary binding sites for 
[3H]mepyramine are sensitive to inhibition by quinine. Thus, in DDTlMF-2 cells, a 
38 to 40 kDa protein has been isolated, which binds HIR antagonists with KD values 
in the micromolar range but which is not sensitive to inhibition by quinine. 
Nevertheless, DDTIMF-2 cells can be shown to additionally possess 
[3H]mepyramine binding sites that have the characteristics of HIR (i.e., KD values in 
the nanomolar range) and to mediate functional responses, which are clearly produced 
by histamine HIR activation (Hill et al. 1997). 
Furthermore, HIR is also responsible for changes in vascular permeability as a 
result of endothelial cell contraction (Meyrick and Brigham 1983, Svensjo and Grega 
1986); in synthesis of prostacyclin (Mclntyre et al, 1985, Carter et al. 1988); in 
platelet-activating factor synthesis (Mclntyre et al. 1985); in release of Von 
Willebrand factor (Hamilton and Sims 1987), and in nitric oxide release (Van de 
Voorde and Leusen 1993). The study of HIR on human T lymphocytes has been 
characterized by use of [l25I]iodobolpyramine (Villemain et al. 1990) (see also Table 
1). HlR-deficient mice display both strong systemic T-cell and efficient B-cell 
responses to antigen (Bryce et al. 2006). HIR has also been demonstrated to increase 
(Ca^ "^ )i (Kitamura et al. 1996). The relationship of HlRs to adrenal medulla which 
elicits the release of catecholamines has been established many years ago (Livett and 
Marley 1986, Noble et al. 1988). Thus, histamine can stimulate the release of both 
adrenaline and noradrenaline (Livett and Marley 1986), and also induce 
phosphorylation of the catecholamine biosynthesis enzyme tyrosine hydroxylase by a 
mechanism which mediates release of intracellular calcium from cultured bovine 
adrenal chromaffin cells (Bunn et al. 1995). 
The effects of histamine are also seen to elicit the release of leucine- and 
methionine- enkephalin (Bommer et al. 1987). Furthermore, many investigators have 
demonstrated a marked increase in mRNA-encoding proenkephalin A after prolonged 
exposure to histamine (Bommer et al. 1987, Wan et al. 1989). 
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Table 1. Characterization of histamine receptors agonist, antagonist and Radioligand 
Receptor 
subtypes 
Agonists with potency Antagonists with 
potency 
lHistamJne(Ioor^ 
Dimethylhistaprodifen 
(240f, Methylhistaprodifen 
(340)^ Histamine-
trifluoromethyl-toluidine 
(HTMTf, 
2-(3-trifluoromethylphenyl) 
histamine (128)''\ 
2-Thiazolylethyiamine 
(26r, 
2-Pyridy!ethylamine (6)" 
Radioligands with 
equilibrium constant for 
dissociation (Kd) 
HI Mepyramine (pA2 9.4) , 
(+)-Chlorpheniramine 
(pA2 9.4r,(-)-
Chlorpheniramine (pAj 
6.7) ^  Trans- triprolidine 
(pA210.0)\ Temelastine 
(pA2 9.5)\ Promethazine 
(pA2 8.9)^ 
Diphenhydramine (pA2 
9.0)^ Tripeiennamine 
(PA28.5)', 
Chlorpromazine (pA2 
8.9)' 
['H]-Mepyramine (Kd 0.8nM; 
guinea-pig brain, ileum)'''', 
['"l]-Iodoboipyramine (Kd 
0.0 InM, guinea-pig brain)', 
['^ ^I]-Iodoazidophen-pyramine 
(Kd 0.0InM, guinea-pig 
cerebellum)''^ 
7HpTlotiin7(25nM)^^^ 
['^ ^I]-Iodoamino-potentidine 
(Kd0.3nM)'•^ 
['^ ^l]-lodoazido-potentidine 
(Kd lOnM)''*' 
(all guinea-pig brain 
membrains) 
H2 Histamine(100)''°, 
Arpromidine( 10230)'-'', 
lmpromidine(4810)''^ 
Sopromidine(740)^^ 
Amthamine(I50)'•^ 
Dimaprit(71)'•^ 
4-Methylhistamine (43)'''' 
Cimetidine(pA2 6.1) , 
Ranitidine (pA2 6.7)', 
Famotidine (pA2 7.8)', 
Zolantidine (pA2 7.6)', 
Mifentidine(pA2 7.6)', 
Titotidine(pA2 7.8)', 
lodoaminopotentidine 
(PA28.6)' 
H3 Histamine(100)''°, 
Imetit(6200)''^ 
Immepip (2457)'' \ 
R-a-methylhistamine (1550) 
a,b 
Imetit (pA2 8.6)", 
Immepip (pAi 8) , 
*Clobenpropit (pA2 7.9, 
partial agonist)'', 
4-Methylhistamine (pA2 
7.3)'' 
*Thioperamide (pA2 
8.4)', lodophenpropit 
(pAj 9.6)', 
*Clobenpropit(pA2 9.9) 
', Ciproxifan(pA2 9.3)', 
Impentamine (pA2 8.4)', 
GR174737(pA2 8.1)''^ 
Impromidine (pA2 7.2)' 
[ H]-R-a-methylhistamine (Kd 
0.5nM)'•^ 
f HJ-N^-methylhistamine (Kd 
2.0nM)'•^ ['"!]-
lodophenpropit (Kd 0.3nm) 
rl25 
a,b 
['"l]-Jodoproxyfan (Kd 
0.065nM)''^ 
[3H]-GR168320(Kd0.1nM)'' 
(all rat cerebral cortical 
membranes in Tris buffer) 
H4 •INJ 10191584(7.6)'', 
*Thioperamide(7.6)'' 
None to date 
_. 
"lUPHAR receptor database 2008, "Hill et al. 1997, 'Bell et al. 2004, "Alexander et al. 2006. 
"^ These compounds act as agonist/antagonist for different histamine receptors at variable 
potencies (Shahid et al. The Open Immunology Journal 2009, 2, 9-41). 
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Its negative inotropic effects have been observed in human atrial myocardium and 
also in guinea pig ventricle (Guo et al. 1984, Genovese et al. 1988). 
Genovese et al. (1988) suggested that the negative inotropic response to 
histamine in human myocardium is associated with inhibitory effects on heart rate. 
This can be unmasked when the positive responses of histamine on the heart rate, and 
force of contraction (due to histamine H2-receptors) are mediated through conjoint 
administration of adenosine or adenosine A1-receptor agonists. However, histamine 
produces a positive inotropic effect in guinea pig left atria and rabbit papillary muscle 
by a specific mechanism which is not related to a rise in adenosine 3c, 5c-cyc]ic 
monophosphate (cAMP) levels (Hattori et al. i988a, Hattori et al. 1988b). The 
distribution of HlRs in mammalian brain shows higher densities in neocortex, 
hippocampus, nucleus accumbent, thalamus, and posterior hypothalamus (Schwartz et 
al. 1991), however, cerebellum and basal ganglia have lower densities (Yanai et al. 
1992, Shahid et al. 2009). The distribution of HlRs in rat and guinea pig is very 
similar (Ruat and Schwartz 1989, Shahid et al. 2009). HI-receptor binding sites and 
mRNA levels were overlapped in most areas of brain except in hippocampus and 
cerebellum in which the inconsistency is mostly to reflect the presence of exuberance 
HlRs in dendrites of pyramidal and Purkinje cells (Traiffort et al. 1994). The 
activation of HIR inhibits the firing and hyperpolarization in hippocampal neurons 
(Haas 1981) and also an apamine sensitive outward current in olfactory bulb 
intemeurons (Jahn et al. 1995), and these effects are mostly generated by intracellular 
Ca^ "^  release. However, HIR excite various notable factors such as vegetative ganglia 
(Christian et al. 1989), hypothalamic supraoptic (Hill and Ganellin 1997), brainstem 
(Khateb et al. 1990), thalamic (McComiick and Williamson 1991), and human 
cortical neurons (Reiner and Kamondi 1994) through a block of potassium 
conductance. Histaprodifens are very potent HIR agonists and are more effective than 
histamine in activating HIR (Elz et al. 2000). 
The functional characterization of HIR has benefitted from the use of many 
potent and specific antagonists (see Table 1 & 3) (Sharma and Hamelin 2003, Shahid 
et al. 2009). HI-receptor antagonists were developed initially as the anti-allergic 
drugs with the known side effect of sedation due to the disturbance of circadian 
rhythms and locomotor activities as well as the impairment of the exploratory 
behavior by histamine in the brain. Later the so-called "non-sedating" HI antagonists 
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which cannot cross the blood-brain barrier were designed (Shahid et ai. 2009). Some 
anti-inflammatory effects of HIR antagonists at high doses could be non-specific 
because of histamine and other inflammatory mediators like leukotriene and platelet 
activating factors released from basophils in response to certain HlRs antagonists 
(Shahid et al. 2009). Bordetella /?errw5«-induced histamine sensitization (Bphs) 
controls Bordetella pertussis toxin (PTX)-induced vasoactive amine sensitization 
elicited by histamine (VAASH) and has established an important role of histamine in 
autoimmunity. The congenic mapping links Bphs to the histamine HI-receptor gene 
(Hrhl/H]R) and that HlR differs at three amino acid residues in VAASH-susceptible 
and -resistant mice. Hrhl-/- mice are protected from VAASH, which can be restored 
by genetic complementation v^ 'ith a susceptible Bphs/Hrhl allele, and experimental 
allergic encephalomyelitis and autoimmune orchitis due to immune deviation. Thus, 
natural alleles of Hrhl control both the autoimmune T cells and vascular responses 
regulated by histamine after PTX sensitization. The exact mechanism through which 
this effect occurs remains unclear and its clinical relevance is still uncertain (Ma et al. 
2002). The chemical structure of specific HlR-antagonists and agonists are shown in 
Fig. (2) and Fig. (3). 
2.2.1.2. Structural biology of receptor 
HI receptors have been cloned from cows, rats, guinea pigs and also from 
humans. The HI receptor contains 486, 488 or 487 amino acids in rat, mouse and 
humans, respectively. It contains the typical properties of G protein coupled receptor 
(GPCR), namely, seven transmembrane domains of 20-25 amino acids predicted to 
form an a-helice which spans the plasma membrane and an extra cellular NH2 
terminal domain with glycosylation site. HIR is encoded by a single exon gene that is 
located on the distal short arm of chromosome 3p25 in humans see in Fig. (2) and 
chromosome 6 in mice. Histamine binds to aspartate residues in the transmembrane 
domain 3 of the HI-receptor, and to asparagine + lysine residues within the 
transmembrane domain 5 (Shahid et al. 2009). Its structural studies done by 
photoaffinity binding properties using [125I]iodoazidophenpyramine (Table 1) and 
subsequent sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis demonstrated that the HI-receptor protein (molecular weight 56 kDa) is 
found under reducing conditions in the brain of rat, guinea pig, and mouse (Ruat et al. 
1990, Shahid etal. 2009). 
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Figure 2. Chemical structures of some histamine HI-receptor antagonists. 
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Figure 3. Chemical structures of some histamine HI-receptor agonist. 
Similar studies have also been done by using photoaffinity ligand [3H] 
azidobenzamide in bovine adrenal medullar membranes and found labeled peptides in 
the size range 53 to 58 kDa (Yamashita et al. 1991). In guinea pig heart, the 
specifically labeled HIR with [125I]iodoazidophenpyramine was found to contain 
substantially higher molecular weight, while there was no obvious difference in the 
characteristics of the HIR in tissues (Table 1) (Ruat et al. 1990). In 1991, HIR was 
cloned from the bovine adrenal medulla by expression cloning in the Xenopus oocyte 
system. Interestingly, 491 amino acid protein with a calculated molecular weight of 
56 kDa was represented by the deduced amino acid sequence (Yamashita et al. 1991); 
this protein has the seven transmembrane domains expected of a G-protein coupled 
receptor (GPCR) and contains N-terminal glycosylation sites. The main feature of the 
proposed HIR structure is the very large 3^ '^  intracellular loop with 212 amino acids 
and relatively short intracellular C terminal tail with 17 amino acids. The availability 
of the bovine sequence and lack of introns has enabled the HI-receptor to be cloned 
from several species including rat (Fujimoto et al. 1993), guinea pig (Horio et al. 
1993), mouse (Inove et al. 1996), and human (De Backer et al. 1993, Smit et al. 
1996). The human HI-receptor gene has now been localized to chromosome 3 bands 
3pl4-p21 (Table 2). These clones should be regarded as true species homologues of 
the HI-receptor, while there are notable variations amongst them in some antagonist 
potencies (Shahid et al. 2009). Nevertheless, it is clear that the stereoisomers of 
chloipheniramine show marked differences between species. For example, the guinea 
pig HI-receptor has a KD of 0.9 nM for (I)-chlorpheniramine, whereas for the rat Hl-
receptor, the value is nearly 8 nM (Shahid et al. 2009). Similar variations for 
chlorpheniramine and other compounds (mepyramine and triprolidine) have been 
shown in guinea pig and rat brain, respectively (Shahid et al. 2009). The species 
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differences may explain why compound [125I]iodobolpyramine can label guinea pig 
CNS H1-receptors, but it is unable to identify HlRs in the brain of rat (Shahid et al. 
2009). In brain membranes of both guinea pig and rat the native HI-receptor protein 
has been solubilized (Toll and Snyder 1982, Treheme and Young 1988), and the 
solubilized receptor retains similar differences in Hl-antagonist potency for (1)-
chlorpheniramine as that detected in membranes (Toll and Snyder 1982). It is 
important to note that mepyramine seems to be potent antagonist of the recombinant 
rat Hl-receptor (i.e. expressed in C6 cells) than of the native histamine Hl-receptor in 
the brain membrane of rat (Shahid et al. 2009). 
In addition, the recombinant studies performed in rat C6 cells (Fujimoto et al. 
1993) are complicated by the presence of a low level of endogenous histamine Hl-
receptors (HlRs) (Peakman and Hill 1994), but in the functional studies in 
untransfected C6 cells, a high affinity for mepyramine (KD 51 nM) has been deduced 
(Peakman and Hill 1994). The amino acid sequence alignment of the cloned histamine 
HI- and H2-receptors led to the suggestion that the third and fifth transmembrane 
domains (TM3 and TM5 respectively) of receptor proteins are responsible for 
histamine binding (Birdsall 1991, Timmerman 1992). In third transmembrane (TM3) 
of the human Hl-receptor, Aspartate (107) that is conserved in entire aminergic 
receptors, has appeared to be essential for the histamine binding, and also Hl-receptor 
antagonists to the Hl-receptor (Ohta et al. 1994). In Hl-receptor, the amino acid 
residues corresponding to Asparagine (198) and Threonine (194) are in corresponding 
positions in 5"' transmembrane domain (TM5) of the human Hl-receptor, while the 
substitution of an Alanine for Threonine (194) did not influence the binding properties 
of either agonist or antagonist (Ohta et al. 1994, Moguilevsky et al. 1995). However, 
the substitution of Alanine (198) for Asparagine (198) decreased agonist affinity, 
while the affinity of antagonist remained unchanged (Ohta et al. 1994, Moguilevsky et 
al. 1995). Similar results have been seen in the mutations to the corresponding 
residues Threonine (203) and Asparagine (207) in the guinea pig-HlR sequence 
(Leurs et al. 1994). In addition to these mutations 2-methylhistamine is affected by 
the Asparagine (207) Alanine mutation, and HI-selective agonists 2-
thiazolylethylamine, 2-pyridylethylamine, and 2-(3-bromophenyl) histamine are much 
less influenced through this mutation (Leurs and Smit 1995). This suggested that 
Asparagine (207) interacts with the Nt-nitrogen of histamine imidazole ring. 
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However, it has been shown that Lysine (200) interacts with the Np-nitrogen 
of histamine ring, and that it is important for the activation of the HIR by histamine 
and the nonimidazole agonist, 2-pyridyIethylamine (Shahid et ai. 2009). Furthermore, 
Leurs et ai. (1995) has demonstrated that the Lysine (200) Alanine mutation did not 
alter the binding affinity of 2-pyridy!ethylamine to HIR of guinea pig. Thus, the 
studies on the organization, genomic structure and promoter function of the human 
HIR revealed a 5.8 kb intron in the 50 flanking region of this gene, different binding 
sites for various transcription factors, and the absence of TATA and CAAT sequences 
at the appropriate locations (De Backer et ai. 1998). 
2.2.1.3. Signaling mechanisms 
Hl-receptor is a Gaq/11-coupled protein with a very large third intracellular loop and 
a relatively short C-terminal tail see in Fig. (4). The main signal induced by ligand 
binding is the activation of phospholipase C-generating inositol 1, 4, 5-triphosphate 
and 1, 2-diacylglycerol (DAC) leading to increased cytosolic Ca^ "^  (Shahid et al. 
2009). The enhanced intracellular Ca^"*^  levels appear to account for the different 
pharmacological properties promoted through the receptor including nitric oxide (NO) 
production, liberation of arachidonic acid from phospholipids, contraction of smooth 
muscles, dilatation of arterioles and capillaries, increase in vascular permeability in 
vessels as well as stimulation of afferent neurons, and increased cAMP. and also 
cGMP levels (Bakker et al. 2002) (see also Table 2). 
This receptor also stimulates nuclear factor kappa B (NFKB) by Gaq/11 and 
Gpy upon binding of agonist, while stimulation of NFKB occurs only via GPy leading 
to (pro)inflammatory mediators (Bakker et al. 2001). 
In a number of tissue and cell types HlR-mediated increases in either inositol 
phosphate accumulation or intracellular calcium mobilization has been described 
extensively and further details are provided in several comprehensive reviews (Hill 
and Donaldson 1992, Leurs et al. 1994). 
In Chinese hamster ovary (CHO) cells Ca^ ^ mobilization and [3H]inositol 
phosphate accumulation has been observed due to stimulation by histamine when 
CHO cells are transfected with HlR-complementary deoxyribonucleic acid (cDNA) 
of the human, bovine, and guinea pig origin (Leurs et al. 1994, Megson et al. 1995). 
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Figure 4, The classical binding sites of histamine and their main signaling pathways such 
as AC (adenylate cyclase), PKC (protein kinase C), PKA (protein kinase A), PLC 
(phospholipase C), Hl^ or H2^ (stimulation via HI or H2 receptor), H3' & H4" (inhibition 
via H3 and H4 receptors) (Shahid et al. The Open Immunology Journal 2009; 2: 9-41). 
It is important to note that in some tissues histamine can stimulate inositol 
phospholipid hydrolysis independently of HIRs. Thus, in the longitudinal smooth muscle 
of guinea pig ileum and neonatal rat brain (Claro et al. 1987), a component can be 
identified in response to histamine that is resistant to inhibition by HlR-antagonists. It is 
yet to be established whether these effects are due to "tyramine-like" effects of histamine 
on neurotransmitter release or direct effects of histamine on the associated G-proteins 
(Bailey et al. 1987, Seifert et al. 1994). In addition to well known effects on the inositol 
phospholipid signal transduction systems, several other signal transduction pathways can 
lead to stimulation of HIR and seem to be secondary to changes in intracellular 
2+ Ca" concentration or protein kinase C (PKC) activation. Thus, nitric oxide synthase 
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activity (via a Ca Vcalmodulin-dependent pathway), and subsequent stimulation of 
soluble guanylyl cyclase in a wide variety of various cell types can be activated by 
histamine (Schmidt et al. 1990, Leurs et al. 1991, Yuan et al. 1993, Hattori et al. 1990). 
The HIR can stimulate arachidonic acid release and it also promotes the catabolism of 
arachidonic acid to produce prostacyclin and thromboxane (Muriyama et al. 1990). It has 
been interestingly demonstrated that the histamine-stimulated release of arachidonic acid 
is partially inhibited (~ 40%) by pertussis toxin, when CHO-Kl cells transfected with the 
guinea pig HIR and the same response is also shown in HeLa cell possessing a native 
HIR to resist pertussis toxin treeitment (Shahid et al. 2009). The substantial changes in 
the intracellular levels of cAMP can be produced by Hl-receptor activation, but in most 
tissues, HIR activation does not stimulate adenylyl cyclase directly, and acts for the 
amplification of cAMP responses to histamine H2 receptor, adenosine A2 receptor, and 
also vasoactive intestinal polypeptide receptors (Donaldson et al. 1989, Garbarg and 
Schwartz 1988, Marley et al. 1991). The role of both intracellular Ca ^ ions and protein 
kinase C has been demonstrated in various cases in this augmentation response (Garbarg 
and Schwartz 1988). HIR stimulation can also lead to both cAMP responses and to an 
enhancement of forskolin-activated cAMP formation when CHO cells are transfected 
with the bovine or guinea pig HIR (Sanderson et al. 1996, Shahid et al. 2009). 
2.2.2. Histamine H2-Receptor 
2.2.2.1. Cellular distribution and functional characterization 
The H2R is located on chromosome 5 in humans. Similar to what has been 
demonstrated for HIR, the histamine binds to transmembrane (TM) domains 3 (aspartate) 
and TM 5 (threonine and aspartate). The short 3'^ intra-cellular loop and the long C-
terminal tail are also a feature of H2R subtype, and the rat N-terminal extracellular tail 
has N-linked glycosylation sites (Del and Gantz 1997). Similar to HIR, H2R is expressed 
in different cell types (Table 2) (Shahid et al. 2009). It has been documented that H2R is 
mostly involved in suppressive activities of histamine, while stimulative effects are 
mediated through HIR. The activation of H2R regulates various functions of histamine 
including heart contraction, gastric acid secretion, cell proliferation, differentiation and 
immune response. H2R antagonists, such as zolantidine, are effective in the treatment of 
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stomach and duodenal ulcers and the clinical potency relates to the suppressive effect of 
these drugs on the secretion of stomach acids (Dy and Schneider 2004, Shahid et al. 
2009). 
Hill (1990) designed a study to map the distribution of H2Rs by using 
radiolabeled H2R-antagonists, and achieved more affinity with [3H] titotidine (Table 1) 
for the H2R in guinea pig brain, lung parenchyma and CHO-Kl cells transfected with the 
human H2-receptor cDNA (Gajtkowski et al. 1983, Sterk et al. 1986, Gantz et al. 1991), 
but it was not successful in the studies of rat brain (Maayani et al. 1982). The most useful 
H2R-radioligand is [125I]iodoaminopotentidine, which has high affinity (KQ 50.3 nM) 
for the H2R in brain membranes (Table 1) (Hirschfeld et al. 1992, Traiffort et al. 1992a, 
Traiffort et al. 1992b) and also in CHO-Kl cells expressing the cloned rat H2R (Traiffort 
et al. 1992b). This compound has also been used for autoradiographic mapping of H2Rs 
in the brain of mammal (Traiffort et al. 1992a). [125I]iodoaminopotentidine is also a 
useful H2R-radioligand (Table 1), which was used to map the distribution of H2Rs in 
human brain with highest densities in the basal ganglia, hippocampus, amygdala, and 
cerebral cortex, and also lowest densities were identified in cerebellum and hypothalamus 
(Traiffort et al. 1992a). In guinea pig brain, a similar distribution has been observed 
(Shahid et al. 2009). Irreversible labeling has also been successfully accomplished by 
[125I]iodoazidopotentidine (Table 1) (Shahid et al. 2009). 
H2R-stimulated cyclic AMP accumulation or adenylyl cyclase activity in Fig. (4) 
has been shown in various tissues including gastric cells, cardie tissue and brain (Al-Gadi 
and Hill 1985, Al-Gadi and Hill 1987) and gastric cells (Johnson 1982). The potent effect 
of H2Rs have been demonstrated on gastric acid secretion and the inhibition of this 
secretory process through H2R antagonists had provided evidence for physiological role 
of histamine in gastric acid secretion (Black and Shankley 1985, Soil and Berglindh 
1987). 
In cardiac tissues of most animal species, high concentrations of histamine were 
present which can mediate positive chronotropic and inotropic impacts on atrial or 
ventricular tissues by H2R stimulation (Hescheler et al. 1987, Levi and AUoatti 1988). 
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Also H2R-mediated smooth muscle relaxation has been documented in vascular smooth 
muscle, uterine muscle and in airways (Foreman et al. 1985, Ottosson et al. 1989). 
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Figure 5. Chemical structures of some histamine H2-receptor antagonists. 
Hill (1990) had demonstrated that the effects of H2Rs can inhibit a variety of 
functions within the immune system. H2Rs have been showTi to negatively regulate the 
release of histamine in basophils and mast cells (Ting et al. 1980, Plaut and Lichtenstein 
1982). The inhibition of antibody synthesis, T-cell proliferation, cell-mediated cytolysis, 
and cytokine production point to the evidence of H2Rs on lymphocytes (Melmon and 
Khan 1987, Banu Watanabe 1999, Jutel et al. 2001). The chemical structure of specific 
H2R-antagonist and -agonists are shown in Fig. (5) and Fig. (6). 
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2.2.2.2. Structural biology of receptor 
The structural studies of H2R have been conduvted using 
[125I]iodoazidopotentidine and sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and it was suggested that the H2R in guinea pig 
hippocampus and striatum has a molecular weight of 59 kDa (Shahid et al. 2009). 
However, comparison with the calculated molecular weights (40.2 to 40.5 kDa) for the 
cloned H2Rs indicates that the native H2R in the brain of guinea pig was glycosylated. 
The cloned H2R proteins possess N-glycosylation sites in the N-terminus region (Gantz 
et al. 1991, Ruat et al. 1991, Traiffort et al. 1995). Fukushima et al. (1995) has suggested 
that removal of these glycosylation sites by site-directed mutagenesis showed that N-
glycosylation of the H2R is not essential for cell surface localization, ligand binding, or 
coupling via Gs to adenylyl cyclase. Gantz and colleagues for the first time successfully 
cloned H2R using the polymerase chain reaction to amplify a partial length H2R 
sequence from canine gastric parietal cDNA using degenerate oligonucleotide primers 
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and this sequence was then used to identify a full length H2R clone following screening 
of a canine genomic library (Shahid et al. 2009). Following this cloning, many 
researchers have cloned the rat, human, guinea pig, and mouse H2Rs (Kobayashi et al. 
1996, Shahid et al. 2009). These intronless gene (DNA) sequences encode 359 amino 
acids for canine, human, guinea pig or 358 amino acids for rat receptor protein which has 
the general properties of a G-protein-coupled receptor (GPCR) (Table 2). 
The radioligand binding studies using [125I]iodoaminopotentidine were 
attempted to show the expression of rat and human H2R proteins in CHO cells and 
revealed the expected pharmacological specificity as shown in Table 1 (Shahid et al. 
2009). Chromosomal mapping studies have demonstrated that the H2R gene is localized 
to human chromosome 5 (Shahid et al. 2009). Birdsall (1991) has compared H2R 
sequence with other biogenic amine G-protein coupled receptors (GPCRs), and 
demonstrated that an aspartate in transmembrane (TM) domain 3 and an aspartate and 
threonine residue in TM 5 were more responsible for histamine binding. Replacement of 
aspartate (98) with asparagine residue in the canine H2R results in a receptor that does 
not bind the titotidine, an antagonist, and hence does not stimulate cyclic adenosine 
monophosphate (cAMP) accumulation in histamine response (Gantz et al. 1992). 
On changing the aspirate (186) residue of TM 5 to an alanine residue occurs 
complete loss of the antagonist titotidine binding without affecting the EC 50 for cAMP 
formation in response to histamine stimulation. Changing the threonine (190) residue to 
an alanine residue, resulted in a lower KD for titotidine antagonist and also a reduction in 
both the histamine EC 50 value and maximal cAMP response (Gantz et al. 1992). 
Mutation of Aspirate (186) and Glycine (187) residue in the canine histamine H2-
receptor to Alanine (186) and Serine (187) residue produces a bifunctional receptor, 
which can be activated through adrenaline, and inhibited via both cimetidine and 
propranolol (Delvalle et al. 1995). These results indicate that pharmacological specificity 
of the H2R resides in only limited key amino acid residues. 
2.2.2.3. Signaling mechanisms 
H2R is coupled both to adenylate cyclase and phosphoinositide second messenger 
systems via separate GTP-dependent mechanisms. Receptor binding stimulates activation 
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of c-Fos, c-Jun, protein kinase C (PKC) and p70S6kinase (Shahid et al. 2009) see in Fig. 
(4). Histamine shown proved to be a highly potent stimulant of cAMP accumulation in 
various cells, and H2R-dependent impacts of histamine were predominantly mediated 
through cAMP, particularly those of central nervous system (CNS) origin (Shahid et al. 
2009). Thus, H2R-mediated impacts on cAMP accumulation have been well documented 
and demonstrated in brain slices, gastric mucosa, fat cells, cardiac myocytes, vascular 
smooth muscle, basophils and neutrophils (Batzri et al. 1982, Gespach and Abita 1982, 
Shahid et al. 2009). In addition, H2R-mediated cAMP accumulation had been observed 
in Chinese hamster ovary (CHO) cells transfected with the rat, canine, or human H2R 
cDNA (Leurs et al. 1994, Shahid et al. 2009). In both brain and cardiac muscle 
membranes, the direct stimulation of adenylyl cyclase activity in cell free preparations 
had been detected (Newton et al. 1982, Olianas et al. 1984). 
However, Hill (1990) has suggested need for caution in interpretation of receptor 
characterization studies using histamine-stimulated adenylyl cyclase activity alone. A 
most striking feature of studies of H2R-stimulated adenylyl cyclase activity in membrane 
preparations was the potent antagonism demonstrated with certain neuroleptics and 
antidepressants (Green 1983). In intact cellular systems, most of the neuroleptics and 
antidepressants were approximately 2 orders of magnitude weaker as antagonists of 
histamine-stimulated cAMP accumulation (Kitbunnadaj 2005, Kamba and Richelson 
1983). One highly potential explanation for these variations resides within the buffer 
systems used for the cell-free adenylyl cyclase assays, and some differences in potency of 
some antidepressants and neuroleptics have been demonstrated when membrane binding 
of H2Rs has been evaluated using [125I]iodoaminopotentidine (Table 1) (Shahid et al. 
2009). However, the variations observed in the Ki values deduced from studies of ligand 
binding in different buffers are not as large as the variations in KB values obtained from 
functional studies. For example, in the case of amitriptyline, no difference was observed 
in binding affinity in Krebs and Tris buffers (Traiffort et al. 1991). In addition to Gs-
coupling to adenylyl cyclase, H2Rs are coupled to other signalirig systems also. For 
example, H2R stimulation has been demonstrated to enhance the intracellular free 
concentration of calcium (Ca^^) ions in gastric parietal cells (Chew and Petropoulos 
1991, Delvalle et al. 1992). In some cell systems, Ga^ coupling to PLC and intracellular 
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Ca ^ had been demonstrated (Table 2). In HL-60 cells, similar calcium (Ca^ "^ ) response to 
H2R stimulation had been demonstrated (Seifert et al. 1992), and same was observed in 
hepatoma-derived cells transfected with the canine H2Rs cDNA (Delvalle et al. 1992). 
The influence on [Ca^^]i was accompanied by both an increase in inositol trisphosphate 
accumulation and a stimulation of cAMP accumulation in these cells (Shahid et al. 2009). 
Both the H2R-stimulated calcium and inositol trisphosphate responses were inhibited by 
cholera toxin treatment, whereas cholera toxin produced the expected increase in cAMP 
levels (Shahid et al. 2009). H2Rs release Ca-^  from intracellular calcium stores in single 
parietal cells (Negulescu and Machen 1988) and no effect of H2R agonists was observed 
on intracellular calcium levels or inositol phosphate accumulation in CHO cells 
transfected with the H2R of human. Thus, the effect of H2R stimulation on intracellular 
Ca^ "^  signaling may be highly cell-sipecific (Shahid et al. 2009). 
The stimulation of H2R produces both inhibition of P2u-receptor-mediated 
arachidonic acid release and an increase in cAMP accumulation in CHO cells transfected 
with the rat H2R (Traiffort et al. 1992). Traiffort et al. (1992) has demonstrated that the 
effect on phospholipase A2 activity (i.e., arachidonic acid release) is not mimicked by 
forskolin, PGEl, or 8-bromo-cAMP, suggesting a mechanism of activation that is 
independent of cAMP-mediated protein kinase A activity. However, inhibitory effects of 
H2R stimulation were observed on phospholipase A2 activity in CHO cells transfected 
with the human H2R. Thus, these cAMP-independent effects might depend on the level 
of receptor expression or subtle differences between clonal cell lines (Shahid et al. 2009). 
2.2.3. Histamine H3-Receptor 
2.2.3.1. Cellular distribution and functional characterization 
The neurotransmitter function of histamine was established with the discovery of 
the H3R. This involves brain functions, as well as the peripheral effect of histamine on 
mast cells via H3Rs, that might be connected to a local neuron-mast cell interaction 
(Dimitriadou et al. 1994). Its involvement in cognition, sleep-wake status, energy 
homeostatic regulation and inflammation led to research as therapeutic approaches 
mainly for central diseases (Passani et al. 2004, Hancock and Brune 2005). A recent 
study reported that H3R is presynaptically located as on autoreceptor controlling the 
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synthesis and release of histamine (Leurs et al. 2005). This H3-autoreceptor activation 
stimulates the negative feedback mechanism that reduces central histaminergic activity 
(Teuscher et al. 2007). H3R's heterogeneity in binding and its functional studies has been 
well documented, which suggests more than one H3R subtype. This has been confirmed 
by demonstration of several H3R variants, generated from the complex H3R gene by 
alternative splicing. The three functional isoforms have been found in the rat, and they all 
vary in length of the 3'^ '' intracellular loop, their distinct central nervous system (CNS) 
localization, and differential coupling to- adenylate cyclase and MAPK signaling. Similar 
results were obtained for humans (Drutel et al. 2001, Coge et al. 2001, Wellendorph et al. 
2002). 
Thus, numerous isoforms found in different species and different tissues leads to 
the assumption that fine-tuning of signaling may be controlled via receptor 
oligomerization or formation of isoforms (Bongers et al. 2007). 
H3R is anatomically localized primarily to the CNS with prominent expression in 
basal ganglia, cortex hippocampus and striatal area. In the periphery, H3R can be found 
with low density in gastrointestinal, bronchial and cardiovascular system (Stark 2007). 
The high apparent affinity of R-(o,)-methylhistamine for the H3R has enabled the use of 
this compound as a radiolabeled probe (Table 1) (Arrang et al. 1987). In rat cerebral 
cortical membranes, this compound [R-(a)-methylhistamine] has been used to identify a 
single binding site, which has the important pharmacological characteristics of the H3R 
(Arrang et al. 1990). In rat brain membranes, [3H]R-(a)-methylhistamine binds with high 
affinity (KD 50.3 nM), although its binding capacity is low (~ 30 fmol/mg protein) 
(Shahid et al. 2009). The autoradiographic studies with [3H]R-(a)-methylhistamine have 
described the presence of specific thioperamide-inhibitable binding in several rat brain 
regions, especially cerebral cortex, striatum, hippocampus, olfactory nucleus, and the bed 
nuclei of the stria terminalis, which receive ascending histaminergic projecfions from the 
magnocellular nuclei of the posterior hypothalamus (Shahid et al. 2009, Pollard et al. 
1993). In human brain and the brain of nonhuman primates, the H3Rs have also been 
visualized (Martinez-Mir et al. 1990). H3R binding has been characterized using [3H]R-
(a)-methylhistamine in guinea pig lung (Arrang et al. 1987), guinea pig cerebral cortical 
membranes (Kilpatrick and Michel 1991), guinea pig intestine and guinea pig pancreas 
(31) 
Chapter 2 Review of Literature 
(Korte et al. 1990). Na-methylhistamine has been useful as a radiolabeled probe for the 
H3R (Table 1). The relative agonist activity of Na-methylhistamine (with respect to 
histamine) was significantly similar for all three histamine receptor (HRs) subtypes, but 
the binding affinity of histamine and Na-methylhistamine for the H3R was several orders 
of magnitude higher than for either HI- or H2-receptors (Shahid et al. 2009). Na-
methylhistamine can identify high-affinity H3R sites in both rat and guinea pig brain 
(Clark and Hill 1995, West et al. 1990, Korte et al. 1990). The binding of H3-receptor-
agonists to H3Rs in brain tissues was found to be regulated by guanine nucleotides, 
implying its relation to heterotrimeric G-proteins (Zweig et al. 1992). Also the binding of 
H3R agonists appears to be affected by several cations. For example magnesium (Mg^ '*") 
and sodium (Na"^ ) ions inhibit [3H]R-(a)-methylhistamine binding in guinea pig and rat 
brain, and the presence of calcium (Ca )^ ions has been shown to reveal heterogeneity of 
agonist binding (Shahid et al. 2009). It is important to note that the inhibitory effect of 
sodium (Na ) ions on agonist binding means higher Bmax values that were usually 
obtained in sodium-free Tris buffers compared with the Na/K phosphate buffers (Clark 
and Hill 1995). The multiple histamine H3R subtypes exist in rat brain (termed H3A and 
HBB) on the basis of [•'H]N"-methylhistamine binding in rat cerebral cortical membranes 
in 50 mM Tris buffer (Table 1) (West et al. 1990). Based on these conditions, the 
selective histamine H3-antagonist thioperamide can discriminate two affinity-binding 
states (West et al. 1990). Heterogeneity of thioperamide binding is sodium (Na ) ion 
concentration dependent or depends on guanine nucleotides within the incubation 
medium. Thus, in the presence of 100 mM sodium chloride, thioperamide binding 
conforms to a single binding isotherm, and H3R can exist in different conformations 
which thioperamide, but not agonists or other H3R-antagonists (clobenpropit) can 
discriminate. This suggests that the equilibrium between these conformations is altered 
by guanine nucleotides or sodium (Na^ "^ ) ions (Shahid et al. 2009). If this speculation is 
correct, it is likely that the different binding sites represented resting, active, or G-
protein-coupled conformations of the H3R. Furthermore, if thioperamide preferentially 
binds to uncoupled receptors, then this compound should exhibit negative efficacy in 
functional assays. Radiolabeled H3R antagonist [125I]iodophenpropit, has been used to 
label histamine H3Rs in rat brain membranes (Table 1) (Jansen et al. 1992). The 
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inhibition curves for iodoplienpropit and thioperamide were consistent with interaction 
with a single binding site, but H3fl agonists were found to be able to discriminate both 
high- [4 nM for R-(a)-methylhistamine] and low- [0.2 mM for R-(a)-methylhistamine] 
affinity binding sites (Jansen et al. 1992). [^H]GR16820 and [125I]iodoproxyfan have 
been useful as high-affinity radiolabeled H3R-antagonists (Brown et al. 1994, Ligneau et 
al. 1994). In rat striatum, in the lUPHAR classification of histamine receptors 267 
guanine nucleotides such as guanosine 590- (3-thiotriphosphate) (GTPgS), 40% of the 
binding sites exhibited a 4t)-fold lower affinity for H3-agonists, providing further 
evidence for a potential linkage of H3Rs to G-proteins (Shahid et al. 2009). In rat brain 
membranes, [ H]thioperamide and [ H]5-methylthioperamide, have both been used to 
label H3R. However, [ Hjthioperamide was shown to bind additionally to low affinity, 
high-capacity, non H3R sites (Alves-Rodrigues et al. 1996). The localization of H3Rs is 
based on functional studies, primarily involving inhibition of neurotransmitter release. 
The H3R was first characterized as an auto receptor regulating histamine synthesis and 
release from rat cerebral hippocampus, cortex and striatum. The H3R-mediated inhibition 
of histamine release has also been demonstrated in human cerebral cortex (Arrang et al. 
1988). Differences in the distribution of H3R binding sites and the levels of histidine 
decarboxylase (an index of histaminergic nerve terminals) suggested at an early stage that 
H3Rs are not confined to histamine-containing neurons within the mammalian CNS (Van 
der Werf and Timmerman 1989). It has been demonstrated that H3Rs can regulate 
neurotransmitter release in mammialian brain as serotonergic, noradrenergic, cholinergic, 
and dopaminergic (Schlicker et al. 1989, Schlicker et al. 1992, Clapham and Kilpatrick 
1992, Schlicker et al. 1993). H3R activation inhibits the firing of the histamine-neurons 
in the posterior hypothalamus by a mechanism different from auto-receptor functions 
found on other aminergic nuclei, and is presumably a block of Ca current (Haas 1992), 
H3Rs were found to regulate the release of sympathetic neurotransmitters in guinea pig 
mesenteric artery, human saphenous vein, guinea pig atria and human heart (Ishikawa 
and Sperelakis 1987, Molderings et al. 1992, Endou et al. 1994, Imamura et al. 1994, 
Imamuraetal. 1995). 
An important inhibitory effect of H3R activation on release of neuropeptides 
(tachykinins or calcitonin gene-related peptide) from sensory C fibers has been reported 
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from airways, meninges, slcin, and heart (Ichinose et al. 1990, Matsubara et al. 1992, 
Ohkubo and Shibata 1995, Imamura et al. 1996). The modulation of acetylcholine, 
capsaicin, and substance P effects by H3Rs in isolated perfused rabbit lungs has also been 
reported (Delaunois et al. 1995). There is evidence that H3R activation can inhibit the 
release of neurotransmitters from nonadrenergic- noncholinergic nerves in guinea pig 
bronchioles and ileum (Burgaud and Oudart 1994, Taylor and Kilpatrick 1992). In guinea 
pig ileum, the H3R-antagonists betahistine and phenylbutanoylhistamine were much less 
potent as inhibitors Df H3R-mediated effects on nonadrenergic-noncholinergic 
transmission than they were as antagonists of histamine release in rat cerebral cortex 
(Taylor and Kilpatrick 1992). 
A similar low potency has been reported for betahistine and phenylbutanoyl 
(histamine antagonists) for antagonism of H3R-mediated [^HJacetylcholine release from 
rat entorhinal cortex (Clapham and Kilpatrick 1992), and antagonism of H3R-mediated 5-
hydroxytryptamine release from porcine enterochromaffin cells (Schworer et al. 1994). 
These investigations provide support for the potential existence of distinct H3R subtypes. 
In addition, it has been shown that phenylbutanoylhistamine can inhibit [^ H] 
acetylcholine release from rat entorhinal cortex slices, and synaptosomes by a 
nonhistamine receptor mechanism (Arrang et al. 1995). Therefore, the potency of 
phenylbutanoylhistamine as H3R-antagonist in those preparations can be highly 
underestimated because of the additional nonspecific activities of the drug (Arrang et al. 
1995). The inhibitory effect of H3-receptor stimulation on 5-HT release from porcine 
enterochromaffin cells in strips of small intestine (Schworer et al. 1994) provides 
evidence for H3-receptors regulating secretory mechanisms in non-neuronal cells. Hence, 
it can be concluded that H3R may be present in gastric mast cells or enterochromaffin 
cells and exerts an inhibitory effect on histamine release and gastric acid secretion. H3R 
activation was found to inhibit gastric acid secretion in conscious dogs and fundic 
mucosal cells in isolated rabbit. The H3R relaxes rabbit middle cerebral artery by an 
endothelium-dependent pathway involving both nitric oxide and prostanoid release (Ea 
Kim and Oudart 1988). H3-receptor stimulation can activate adrenocorticotropic 
hormone release from the pituitary cell line AtT-20 (Clark et al. 1992). Therefore, H3R 
provides constitutive properties, which means part of the receptor population 
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spontaneously undergoes allosteric transition leading to a conformation, to which G 
protein can bind, and also H3R-knock out mice manifest an obese phenotype 
(characterized by increased body weight, food intake, adiposity, and reduced energy 
expenditure) (Morisset et al. 2000, Rouleau et al. 2002). Recently, it has been observed 
that H3R expresses insulin and leptin resistance as well as a diminution of the energy 
homeostasis-associated genes UCPl and UCP3 (Takahashi et al. 2002). The chemical 
structure of specific H3R-antagonists and -agonists are shown in Fig. (7) and Fig. (8). 
2.2.3.2. Structural biology of receptor 
The H3R is G protein-coupled receptor (GPCR) and has been cloned (Shahid et 
al. 2009). Its gene consists of 4 exons spanning 5.5 kb on chromosome 20 (20ql3.33) in 
humans (Table 2). Structural studies of H3R are very limited and there are only few 
reports on its purification studies. 
By using [•'HJhistamine as a radioligand, the solubilization of a H3R protein from 
bovine whole brain has been reported. Size-exclusion chromatography has revealed an 
apparent molecular mass of 220 kDa. However, because the solubilized receptor retained 
its guanine nucleotide sensitivity and it is likely that the molecular mass of 220 kDa 
represents a complex of receptor, G-protein, and digitonin (Shahid et al. 2009). 
Cherifi et al. (1992) have reported the solubilizafion (with Triton X-100) and 
purificafion of the H3-receptor protein from the human gastric tumoral cell line HGT-1. 
After gel filtration and sepharose-thioperamide affinity chromatography, protein has been 
purified with a molecular mass of approximately 70 kDa (see Table 2). 
2.2.3.3. Signaling mechanisms 
The signal mechanisms used by the H3R remain largely subject to speculation, 
but there is increasing evidence to suggest that this receptor belongs to the G-protein-
coupled receptors (Gi/o) (Table 2), and its activation leads to inhibition of cAMP 
formation, accumulation of Ca^ "^  and stimulation of mitogen-activated protein kinase 
(MAPK) pathway (Shahid et al. 2009), see Fig. (4). 
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This evidence has been obtained from ligand-binding studies that involve the 
modulation by guanine nucleotides of H3R-agonist binding and inhibition of H3R-
antagonist binding (Jansen et al. 1994, Shahid et al. 2009). 
The direct evidence for a functional H3R-G-protein linkage came from studies of 
[^ ^SJGTPgS binding to rat cerebral cortical membranes (Clark and Hill 1996). In rat 
cerebral cortical membranes, the presence of HIR- and H2R-antagonists (0.1 mM 
mepyramine and 10 mM titotidine), and both R-(a)-methylhistamine and N-(a)-
methylhistamine generated a concentration dependent stimulation of [35S]GTPgS 
binding (EC50 = 0.4 and 0.2 nM) (Clark and Hill 1996). Notably, this response was 
inhibited by pretreatment of membranes with pertussis toxin, implying a direct coupling 
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to a Gi or Go protein (Clark and Hill 1996). The evidence of pertussis toxin-sensitive G-
proteins in the response to H3R stimulation came from studies of H3R signaling in 
human and guinea pig heart (Shahid et al. 2009). H3R-activation appeared to lead to an 
inhibition of N-type Ca^"*" channels responsible for voltage dependent release of 
noradrenaline in human and guinea pig heart, but several investigations have failed to 
demonstrate an inhibition of adenylyl cyclase activity in different tissues and cells, which 
suggest that H3Rs couple to Go proteins (Schlicker et al. 1991, Shahid et al. 2009). 
2.2.4. Histamine H4-Receptor 
2.2.4.1. Cellular distribution and functional characterization 
The discovery of the H4-receptor adds a new chapter in the histamine story. The 
H4R is preferentially expressed in intestinal tissue, spleen, thymus, medullary cells, bone 
marrow and peripheral hematopoietic cells, including eosinophils, basophils, mast cells, 
T lymphocytes, leukocytes and dendritic cells (Shahid et al. 2009). However, moderate 
positive signals have also been detected in brain, spleen, thymus, small intestine, colon, 
heart, liver and lung. Although expression studies did not H4Rs in the central nervous 
system (CNS), in situ hybridization studies suggested evidence for their localization in 
human brain in low density (Shahid et al. 2009). The relatively restricted expression of 
the H4R provides an important role in inflammation, hematopoiesis and immunity by the 
regulation of H4R expression via stimuli such as IFN, TNF-a, IL-6, IL-IO and IL-13. 
Basophils and mast cells express H4R-mRNA. The H4R mediates chemotaxis of mast 
cells and eosinophils as well as cc'ntrols cytokine release from dendritic cells and T cells 
(Shahid et al. 2009). 
H4R participates along with the H2R, in the control of IL-16 release from human 
lymphocytes. The H4R selective antagonist might be useful anti-inflammatory agents in 
asthma, arthritis, colitis and pruritis (Shahid et al. 2009). Antagonists, such as JNJ 
7777120, have been shown to be effective in various model of inflammation (Shahid et 
al. 2009). At this point, very little is known about the biological functions of H4R. There 
are few reports in the literature, providing evidence for its role in chemotactic activity in 
mast cells and eosinophils or control of IL-16 production by CDS'" lymphocytes. It 
suggests an important role of H4R in the regulation of immune function and offers novel 
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therapeutic potentials for histamine receptor ligands in allergic and inflammatory diseases 
(Shahid et al. 2009). 
A recent study showed the role of H4R in mast cell, eosinophil and T-cell 
function as well as the effects of its antagonist, JNJ 7777120, in a mouse peritonitis 
model pointing to a more general role for H4R in inflammation. In many diseases such as 
allergic rhinitis, asthma and rheumatoid arthritis, conditions where eosinophils and mast 
cells are involved, H4R antagonists have potential therapeutic utility (Thurmond et al. 
2004). 
The discovery of H4R and its emerging role in inflammation had spurred new 
interest in the functions of histamine in inflammation, allergy and autoimmune diseases. 
Early results in animal models suggest that H4R antagonists may have utility in treating 
various conditions in humans particularly diseases in which histamine is known to be 
present and HIR antagonists are not clinically effective (Thurmond et al. 2008). 
Obviously, a better functional characterization of H4R will be possible by new, specific 
tools, such as the recently developed potent and selective non-imidazol H4R antagonist 
(Thurmond et al. 2004). It can be expected that the role of H4R will be more important in 
autoimmune disorders, allergic conditions and nociceptive responses in the near future. 
The chemical structure of specific H4R-antagonists and -agonists are shown in Fig. (9). 
2.2.4.2. Structural biology of receptor 
The human H4-receptor gene was mapped to chromosome 18qll.2 which 
encodes a 390 amino acid and related to G-protein coupled receptor (GPCR). It shares 
37-43% homology (58% in transmembrane regions) with the H3-receptor and is similar 
in genomic structure (Shahid et al. 2009). The H4R gene spans more than 21 kbp and 
contains three exons, separated by two large introns (>7 kb) (Table 1) with large 
interspecies variations from 65-72% homology in sequences. Analysis of the 5' flanking 
region did not reveal the canonical TATA or CAAT-boxes. The promoter region contains 
several putative regulatory elements involved in proinflammatory cytokine signaling 
pathways. 
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Figure 9. Chemical structures of specific H4-receptor-antagonists and -agonists. 
H4Rs are coupled to Gi/o, which initiates various transduction pathways such as 
inhibition of forskolin-induced cAMP formation, enhanced calcium influx and MAPK 
activation. In accordance with the homology between the two receptors, several H3R-
agonists and antagonists were recognized by the H4R, although with different affinities. 
It has been observed that H3R-agonist R-a-methyl histamine acts on H4R with several 
hundred times less potency. Similar effect has been seen with thioperamide, the classical 
H3R antagonist which also behaves like a H4R antagonist (Table 1), of much lower 
affinity. Clobenpropit, also a HSR antagonist, exerts agonistic activity on H4R (Shahid et 
al. 2009). 
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Histamine binding to H4R is very similar to that reported for the other histamine 
receptors which shows the significance of the Asp 94 residue in transmembrane region 
(TM) 3 and the Glu 182 residue in the TM 5. However, some differences exist and these 
were exploited to design specific tools (Shahid et al. 2009). Mouse, rat and guinea pig 
H4Rs have been cloned and characterized and were found to be only 68, 69, and 65% 
homologous respectively to their human counterparts. These studies have revealed 
substantial pharmacological variations between species, with higher affinity of histamine 
for human and guinea pig receptors than for their rat and mouse equivalents (Liu et al. 
2001, Shahid etal. 2009). 
2.2.4,3. Signaling mechanisms 
The signal mechanisms used by the H4R are related to the G-protein-coupled 
receptors (Gi/o), and its activation leads to an inhibition of adenylyl cyclase and 
downstream of cAMP responsive elements (CRE) as well as activation of mitogen-
activated protein kinase (MAPK) and phospholipase C with Ca^ "^  mobilization (Table 2); 
see Fig. (4) (Shahid etal. 2009). 
2.3. Histamine: Non-Classical Binding Sites 
2.3.1. Cytochrome P450 
The human cytochrome P450 (CYP450) superfaraily comprises 57 genes 
encoding heme-containing enzymes, which are found in the liver as well as in 
extrahepatic tissues (adrenals, and peripheral blood leukocytes); where they can be 
stimulated by various stimuli (Malinke et al. 1996, Morgan 2001), see Fig. (10). They are 
not only involved in metabolism of large number of foreign substances, but also play an 
important role in diverse physiological processes [generation, transformation or 
inactivation of endogenous ligands (steroids and lipids)], which are involved in cell 
regulation (Nebert and Russell 2002). 
Binding of histamine to CYP450 had been shown by Branders, who proposed a 
second messenger role for intracellular histamine via this binding site. This hypothesis is 
mainly based on a finding that N, N diethyl-2-(4-(phenylmethyl)phenoxy) ethanamine 
(DPPE), an arylalkylamine analogue of tamoxifen inhibits the binding of histamine to 
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CYP450 (Brandes et al. 2002). DPPE allosterically modified histamine binding to the 
heme moiety of CYP450 enzymes and inhibits platelet aggregation, as well as 
lymphocyte and hematopoietic progenitor proliferation (Labella and Brandes 2000). The 
effect of DPPE on histamine binding was found to be highly complicated and depends on 
the nature of the P450 enzymes. Thus, it inhibits the action of histamine on CYP2D6 and 
CYPlAl, enhances its effect on CYP3A4 and does not affect CYP2B6 (Brandes et al. 
2000). The heme moiety of CYP450 binds to several histamine antagonists (Kishimoto et 
al. 1997, Hamelin et al. 1998), particularly H3R antagonists (thioperamide, clobenproprit 
and ciproxyfan) (Kishimoto et al. 1997). This property explains some effects of these 
antagonists, when used at high doses. Notably, histamine interacts with CYP450 and it 
has been demonstrated that CYP2E1 and CYP3A were upregulated in histidine 
decarboxylase (HDC)-deficient mice (Tamasi et al. 2003). 
2.3.2. Transporters of histamine 
Histamine {2-(lH-imidazol-4-yl) ethanamine} is synthesized in the cytosol and 
requires a specific transport into secretory vesicles where it is sequestered. Vesicular 
monoamine transporters (VMATs) are proteins, which accomplish this specific task for 
several neurotransmitters (Erickson and Varoqui 2000), see Fig. (10). The two subtypes 
of monoamine transporters are VMATl and VMAT2 both of which have been cloned 
and characterized. VMAT2 transports histamine. Vesicular monoamine transporter 2 
(VMAT2) had been cloned from rat and human brain, bovine adrenal medulla and a 
basophilic leukemia cell line. 
The increased VMAT2 expression in IL-3 dependent cell lines was seen with 
enhanced histamine synthesis in response to calcium (Ca^"^)ionophore (Watson et al. 
1999). VMAT2 is responsible for the transport of histamine into secretory granules of 
enterochromaffin-like cells (ECL). The gene expression of VMAT2 was found to be 
modulated by cytokines, either positively (TGF- a) or negatively (IL-1 and TNF-a) 
(Kazumori et al. 2004). VMAT2-deleted granules do not release histamine upon 
activation even though granule cell fusion does still occur (Travis et al. 2000). 
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Figure 10. The non-classical histemine binding sites and their main signaling pathways 
such as DAO: diamine oxidase; HMT: histamine methyl transferase; OCT: organic cation 
transporter; HDC: histidine decarboxylase; CYP 450: cytochrome P450; VMAT: 
vesicular monoamine transporter [Shahid et al. The Open Immunology Journal 2009; 2: 
9-41]. 
The bone marrow-derived mast cells from HDC-deleted mice are completely devoid 
of endogenous histamine but can take up the mediator from histamine-supplemented 
medium and store it in secretory granules (Shahid et al. 2009). Hence, two transporters 
are essential to: 
1. insure the passage across the plasma membrane, 
2. cross the vesicular membrane. 
First transporter has not been identified yet, but the second transporter seems to be 
VMAT-2. The non-neuronal monoamine transporters that actively remove monoamines 
from extracellular space have been described as organic cation transporter-1 (OCT-1), 
(42) 
Chapter 2 Review of Literature 
OCT-2, and extraneuronal monoamine transporter (EMT). EMT was also designated as 
OCT-3. The expression of OCT-1 was found to be restricted to liver, kidney and 
intestine, OCT-2 to brain and kidney, while EMT showed a broad tissue distribution. It 
has been established that OCT-1 cannot transport histamine, compared to OCT-2 and 
EMT for which it is a good substrate (Griindemann et al. 1999). Thus, EMT appeared to 
be a good candidate as histamine transporter in mast cells and basophils, accounting for 
their capacity to take up the mediator from the environment (Shahid et al. 2009). 
2.4. Histamine in Immunomodulation and Allergic Inflammation 
Histamine exerts a very important immunomodulatory effect via HI-, H2-, H3-, 
and H4-receptors (Triggiani et al. 2001, Shahid et al. 2009; Table 3). According to the 
cell differentiation stage and microenvironment influences the receptors expression 
changes. Histamine shows proinflammatory or anti-inflammatory effects, depending on 
the predominance of the type of histamine receptor (HIR, H2R, HSR & H4R) and on the 
experimental system studied. Histamine had proinflammatory activity through the HIR, 
and is involved in the development of various aspects of antigen-specific immune 
response including the maturation of dendritic cells (DCs) and the modulation of the 
balance of type 1 helper (ThI) T cells and type 2 helper (Th2) T cells (Shahid et al. 
2009). Histamine blocks humoral immune responses by means of a specific mechanism 
in which it induce an increase in the proliferation of Thl cells and in the production of 
interferon-y (IFN-y) (Shahid et al. 2009). Histamine also stimulates the release of 
proinflammatory cytokines and lysosomal enzymes from human macrophages and shows 
the capacity to influence the activity of immune cells including mast cells, basophils, 
eosinophils, fibroblasts, lymphocytes, neutrophils, epithelial and endothelial cells. The 
role of histamine in autoimmunity and malignant disease through the HIR was well 
documented (Ma et al. 2002, Akdis and Blaser 2003). Histamine also plays a pivotal role 
in allergic inflammation which is a complex network of cellular events and involves 
redundant mediators and signals. Histamine is released from the granules of mast cells 
and basophils (FceRI^ cells) along with several mediators such as tryptase, leukotrienes, 
prostaglandins and other newly generated mediators (Shahid et al. 2009). Histamine was 
found in relatively large (|ig) quantities per 1 million cells, in contrast to leukotrienes and 
other mediators (which are present in picograms), after allergen challenge in sensitized 
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persons (Shahid et al. 2009). Most of the potent effects of histamine in allergic 
inflammation occur through HlRs (Schneider et al 2002, Akdis and Blaser 2003, 
MacGlashan 2003, Shahid et al. 2009; Table 3), while hypotension, flushing, headache, 
and tachycardia occurred via both the HI- and H2-receptors in the vasculature (Spitaler et 
al. 2002), whereas nasal congestion and cutaneous itch occurs by both the HI- and H3-
receptors (McLeod et al. 1999, Sugimoto et al. 2004). Histamine also acts as a contributor 
to the late allergic response by generating a stimulatory signal for the production of 
cytokines, the expression of cell adhesion molecules and class II antigens (Shahid et al. 
2009). 
2.5. Effect of Histamine in Immune Cells with Respect to Allergic Diseases 
Histamine's classical effects, expressed at the organ level, have been documented 
and were highly emphasized in allergies and autoimmune diseases. Histamine directly or 
indirectly influences the activity of various inflammatory/effector/immunologic cell types 
involved in the pathogenesis of several diseases. Indeed, several studies have suggested 
that histamine receptors (HRs) are expressed on mast cell and basophils; lymphocytes; 
neutrophils; monocytes, macrophages and dendritic cells (DCs); eosinophils; epithelial 
cells; endothelial cells, and therefore modulate the function of these cells in immune 
system (Shahid et al. 2009). 
2.5.1. Mast cells and basophils 
Recent studies shed light on the potent role of histamine in mast cells and 
basophils, both types of cells can themselves be modulated by histamine as they express 
HI-, H2- and H4-receptors (Lippert et al. 2004, Godot et al. 2007). The peritoneal and 
skin mast cells exhibited aberrant granules with very low electron density, in HDC-
deficient' mice, which indicated the drastic decrease in the granule contents including 
granule proteases and sulfated proteoglycans (Ohtsu et al. 2001). 
The critical roles of histamine in cutaneous and systemic anaphylaxis have been 
suggested by using the HDC-deleted mice (Ohtsu et al. 2002, Makabe-Kobayashi et al. 
2002) and it remained a possibility that diminished granule constituents, such as 
proteases, make contribution to the relief of anaphylaxis in the mutant mice. 
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Table 3. Immunopharmacological profiles of histamine receptors. 
Characteristics Histamine HIR Histamine H2R Histamine H3R Histamine H4R 
'General function 
^Function in 
immune 
modulation and 
allergic 
inflammation 
Physiological 
relevance 
Pathophysiological 
relevance 
a,b 
'Antagonists 
Increased pruritus, pain, 
vasodilation, vascular per-
meability, hypotension; 
flushing, headache, 
tachycardia, 
bronchoconstriction, 
stimulation of airways, 
vagal stimulation of 
airway vagal receptors; 
decreased atrio-
ventricular-node 
conduction time. 
Increases release of 
histamine and other 
mediators; increases 
cellular adhesion molecule 
expression and chemotaxis 
of eosinophils and 
neutrophils; increases 
antigen-presenting cell 
capacity, co-stimulatory 
activity on B cells; 
increases cellular 
immunity (Thl), IFN-y, 
autoimmunity. Decreases 
humoral immunity and IgE 
production. 
Cycle of sleeping and 
waking, food intake, 
thermal regulation, 
emotions and aggressive 
behavior, locomotion, 
memory, and learning, 
contraction of smooth 
muscles. 
Allergic reaction. 
Clinically usable 
(Mepyramine, 
chlorpheniramine, 
astemizole, terfenadine, 
loratidine, triprolidine, 
diphenhy 
dramine, cetirizine, desl-
oratidine, fexofenadine) 
Increased gastric acid 
secretion, vascular 
permeability, 
hypotension, flushing, 
headache, tachycardia, 
chronotropic and 
inotropic activity, 
bronchodilatation, mucus 
production (airway). 
Decreased eosinophil 
and neutrophil 
chemotaxis; induction of 
interleukin-lO, 
suppression of 
interleukin-l2by 
dendritic cells; 
development of Th2 or 
tolerance inducing 
dendritic cells; induction 
of humoral immunity; 
suppression of Th2 cells 
and cytokines; indirect 
role in allergy, 
autoimmunity, malignant 
disease, and graft 
rejection. 
Neuroendocrine, gastric 
acid secretion. 
Gastric ulcer 
Clinically usable 
(Cimetidine, zolantidine, 
tiotidine, femotidine, 
nizatidine, and 
ranitidine) 
Prevents excessive 
bronchoconstriction; 
mediates pruritus (no 
mast-cell 
involvement). 
Probably involved in 
control of neurogenic 
inflammation through 
local neuron-mast cell 
feedback loops; 
proinflammatory 
activity; increased 
APC (antigen-
presenting cell) 
capacity. 
Presynaptic 
heteroreceptor; 
decreased histamine, 
dopamine, serotonin, 
noradrenaline and 
acetylcholine release, 
sleep, food intake. 
Cognitive impairment, 
seizure, metabolic 
syndrome? 
Clobenpropit, 
lodophenpropit, 
Thioperamide 
Differentiation of 
myeloblasts and 
promyelocytes. 
Increased Ca^ "^  
flux in human 
eosinophils; 
increased 
eosinophil 
chemotaxis; 
increases IL-16 
production (H2-
receptor also 
involved). 
Chemotaxis. 
Inflammation, 
immune reaction 
JNJ 7777120, 
JNJ10I9I584 
Simon, 2004, "Stark, 2007, (Shahid et al. The Open Immunology Journal 2009; 2: 9-41). 
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How histamine regulates allergic responses by maturation of tissue mast cells 
requires comprehending detailed studies on the effect of absence of histamine on mast 
cell function. Impact of histamine was also demonstrated in the migration of mast cells 
which was mediated exclusively through the H4R (Hofstra et ai. 2003). It has been shown 
that histamine acting through H4Rs can stimulate chemotaxis of murine mast cells in 
vitro (Hofstra et al. 2003) and lead to changes in tissue localization in vivo (Thurmond et 
al. 2004). 
A hematopoietic organ, bone marrow contains certain types of cells which can 
produce histamine in response to IL-3 (Schneider et al. 1999, Shahid et al. 2009). The 
role of IL-3 sensitized histamine synthesis in bone marrow remains to be clarified 
(Shahid et al. 2009). However, a study suggested a unique circuit of newly synthesized 
histamine and its implication in basophil precursors (Schneider et al. 2005). It has been 
documented that bidirectional transport of histamine is facilitated largely through 0CT3 
in the plasma membranes of the FceRI^ c-kit~ bone marrow cells. It had been 
demonstrated that intracellularly stimulated histamine in the 0CT3 deleted cells has 
suppressive impacts on expression of HDC, IL-4, and IL-6. This suggests not only the 
feedback inhibition of histamine synthesis but also the suppression of Th2 cytokine 
production through immature basophils (Griindemann et al. 1999, Tanaka et al. 2003). 
In addition, histamine receptor binding studies with specific receptor antagonists 
have suggested that basophils express predominantly H2R, and these were involved in 
the regulation of IgE-stimulated histamine release, as demonstrated through increased 
histamine release in the presence of anti-IgE and cimetidine (a H2R antagonist) but not in 
the presence of anti-IgE and thioperamide (a H3R antagonist) (Kleine-Tebbe et al. 1990, 
Tedeschi et al. 1991, Bull et al. 1993). H2Rs in mast cells show various effects such as 
inhibition of histamine release and modulation of cytokine production (Lippert et al. 
2000). 
It has been suggested that H3R functions on mast cells but many of these 
properties may be attributed to the H4R as the ligands used were not specifically 
selective. H3R expression was not detected in some types of mast cells (Hofstra et al. 
2003). 
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2.5.2. Lymphocytes 
The expression of histamine receptors (HRs) on the cell surface of immunocompetent 
cells, including lymphocytes (B-cells and T-cells) and their effects mediated by HRs have 
been published in several studies and significantly reviewed (Sachs et al. 2000), see Fig. 
(11). 
It has been concluded that both histamine receptors (HI and H2) are present on 
the lymphocytes but there is only few data available on the functional significance of the 
HIR and the distribution of H2R on lymphocyte subsets. In general, signaling through 
the HIR was associated with enhancement and signaling through the H2R with inhibition 
of lymphocyte responses. It has been suggested by several studies that histamine and its 
derivatives can inhibit the immune response by enhancing the activity of T suppressor 
cells through H2R and natural suppressor cells via HIR (Sansoni et al. 1985, Khan et al. 
1986). 
The impacts of histamine on T helper lymphocytes are differential and complex; 
see in Fig. (11). T lymphocytes, mainly T helper lymphocytes, play a significant role in 
the pathogenesis of atopic asthma. Helper T lymphocytes can be divided into two subsets 
T helper type 1 cells (Thl) and Th2 based on their cytokine profile and distinct functions 
and both the subsets play distinctive roles in the development, initiation and regulation of 
the immune response. Thl cells were found to be responsive in delayed type 
hypersensitivity (DTH) and cytotoxic response, while Th2 cells were involved in allergic 
disease via activating B-lymphocytes and regulating antibody (IgG and IgE) secretion; 
see in Fig. (11). Thl cells secrete important cytokines as IL-2, IFN-y, IL-3 and 
granulocyte monocyte colony stimulating factor (GM-CSF), while Th2 cells secrete 
cytokines such as IL-3, IL-4, IL-5, IL-10, IL-13 and GM-CSF. 
Histamine downregulates the proliferation of Thl cells (which control cytotoxic 
response and DTH) and upregulates the proliferation of Th2 cells (which regulate allergic 
disease and asthma) (Weltman 2000, Shahid et al. 2009). Histamine also regulates the 
development of an allergic state by enhancing the secretion of Th2 cytokines such as IL-
4, IL-5, IL-10 and IL-13 and inhibiting the production of Thl cytokines IL-2, IFN-y and 
monokine IL-12 (Shahid et al. 2009). 
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HR1; Blocking of 
humoral immunity and 
induction of cellular immunity. 
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B-cell modulation: 
(i) direct effect on B-cells 
(HR1 shows co-stimulatory activity) 
(ii) indirect effect via T-cells 
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Figure 11. Histamine regulates monocytes, dendritic cells, T cells and B cells in 
lymphatic organs and subepithelial tissues in allergic inflammation. Monocytes and 
dendritic cells express all four known histamine receptors (HRl, HR2, H3R and HR4). 
HRl and HR2 induce proinflammatory activity and enhanced antigen presenting cell 
capacity, whereas HR2 plays an important suppressive role on monocytes and monocyte-
derived dendritic cells (MDDC) (Shahid et al. The Open Immunology Journal 2009; 2: 9-
41). 
It had been demonstrated in several studies that histamine dose-dependently 
upregulate the secretion of Th2 cytokines (IL-5, IL-10, and IL-13) and downregulate the 
secretion of Thl cytokines (IL-2 and IFN-y) in cloned murine T helper cells (Osna et al. 
2001a, Osnaet al. 2001b, Elliott et al. 2001). 
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It has also been demonstrated that Thl and Th2 cells express distinct surface 
histamine receptor patterns (Thl cells that express predominantly HIR and Th2 cells 
express H2R). Histamine increases Thl-type responses by triggering HIR and negatively 
regulates both Thl and Th2-type responses by H2R as suggested by enhanced release of 
TNF-a and decreased release of IL-4 and IL-13 respectively (Jutel et al. 2001). The 
differential expression of these cells to histamine is a result of the type of intracellular 
signals generated via histamine activation. Notably, HIR signaling involves calcium-
dependent phospholipase stimulation and generation of IP3, while H2R signaling 
involves adenylate cyclase stimulation and cAMP formation (Shahid et al. 2009). 
The receptor binding study of human peripheral blood lymphocytes has suggested 
that histamine trifluoromethyl-toludine (HTMT) derivative lead to a two-phase 
enhancement in intracellular Ca^ "^  and an increase in inositol phosphate (IP3) production. 
The increase in Ca was thoroughly antagonized through high concentrations of 
histamine but not by the classical histamine HI-, H2- or H3- receptor antagonists (Qui et 
al. 1990). These observations demonstrate that HTMT have a specific binding site on 
lymphocytes which is different for three classic histamine receptors. Several functional 
studies demonstrated that histamine primarily modulates T-suppressor activity including 
DTH, cytotoxic T-lymphocyte-mediated target cell killing, cell-mediated lympholysis 
and natural killer activity by H2R signaling (Rocklin 1990). Although, some studies 
suggest that activation of the H2Rs indirectly increases the allergic cascade. Suppressor 
T-cells were found to be more responsive to histamine than T helper cells or cytotoxic T 
cells (Khan et al. 1985). Likewise, the response to histamine in T helper cells and 
cytotoxic T-cells was highly enhanced after mitogenic stimulation (Khan et al. 1985). 
It is more important to note that in humans, histamine suppresses the proliferation 
of mixed T lymphocytes via H2R (Khan and Melmon 1985, Khan and Melmon 1988). 
Further, it had been confirmed that histamine inhibited lipopolysaccharide (LPS)-
stimulated IFN-y-gene expression from human peripheral blood mononuclear cells 
(PBMC) (Horvath et al. 1999). IFN-y cytokine releases human CD4"' T-cell clones, which 
are classified as either ThO, Thl or Th2 based on their cytokines (IL-4 and IFN-y) 
secretion patterns (Lagier et al. 1997). Notably, histamine-induced inhibition of IFN-y 
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secretion was seen in Thl clones but not Th2 clones and the effect was reversed by H2R 
and not HI - or H3-receptor antagonists. 
Histamine has been verified to directly enhance the synthesis of the 
proinflammatory cytokines (IL-lb and IL-6) through lymphocytes, anti-CD23- and anti-
CD28-stimulated release of IL-4 and IL-5 (but not IL-2) or IFN from T lymphocytes can 
be inhibited by terfenadine treatment (Sachs et al. 2000). Similarly, several other studies 
have suggested that histamine leads to synthesis and release of a lymphocyte chemo-
attractant factor (LCF) from H2R bearing lymphocytes and also results in release of two 
different types of lymphocyte migration inhibitory factors (LyMIFs) from only a subset 
of H2R bearing lymphocytes (Center et al. 1983, Berman et al. 1984). 
2.5.3. Neutrophils 
Neutrophils have been demonstrated to express HIR and H2R, and it had been 
suggested that the impacts of histamine on neutrophils are inhibitory through H2R 
(Gespach and Abita 1982, Westcott and Kaliner 1983). In vitro studies showed the 
autologous serum-sensitized chemotaxis of neutrophils both in normal, atopic subjects 
which is abolished by histamine in a dose-dependent manner and this inhibition was more 
effective in atopic individuals (Radermecker and Maldague 1981). It is more important to 
note that incubation of neutrophils from these individuals with cimetidine, but not 
promethazine causes reversal of the histamine-sensitized inhibition of neutrophil 
chemotaxis (Shahid et al. 2009). In vivo study has demonstrated that the histamine 
administration by either inflision and subcutaneous injection or inhalation diminished 
neutrophil chemotaxis in healthy volunteers (Bury et al. 1992). Several studies have 
suggested that histamine inhibits the activation of neutrophils as demonstrated by 
inhibition of fMet-Leu-Phe induced superoxide (0 ) formation, degranulation and 
membrane potential changes acting by H2R signaling (Seligmann et al. 1983, Burde et al. 
1983). 
2.5.4. Monocytes, macrophages and dendritic cells 
The presence of histamine receptors (HIR and H2R) on human monocytes and 
macrophages (Pynaert et al. 1999, Wang et al. 2000) indicates that in allergic disease 
histamine also modulate the activity of these cells. Differentiation of monocytes into 
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macrophages causes switching over from H2R to HIR (Wang et al. 2000). Several other 
recent studies have suggested (investigations which were performed with exogenously 
added histamine) that it has a potential role in modulating maturation and function of 
monocytes and dendritic cells. Activated monocytes and dendritic cells have a significant 
potential role in release of histamine which acts in autocrine and paracrine fashion and 
modifies dendritic cell markers. Histamine was found to inhibit the production of TNF-a 
and IL-12, and to augment the production of IL-10 in response to Toll-like receptor 
ligands by acting on the H2R, in human monocytes (Atkins et al. 1990a, Atkins et al. -
1990b), while, in human monocyte-derived dendritic cells similar inhibition of IL-12 and 
enhancement of IL-IO production was investigated. Recently, H4R involvement in 
suppression of IL-12 was observed (Marmy et al. 1993, Shahid et al. 2009). In the 
Propionibacterium acnes-'pximtd and LPS-stimulated hepatitis model, endogenous 
histamine production via macrophages and Kupffer cells was reported to play a protective 
role through acting on the H2R (Jarjour et al. 1991). This study was performed with 
attention to endogenous histamine synthesis in macrophages and Kupffer cells. 
Furthermore, it has been documented that dendritic cells (DC) are especially antigen-
presenting cells, which mature from monocytic and lymphoid precursors and leads to 
acquisition of DCl and DC2 phenotypes that drives the development of Thl and Th2 
cells, respectively. Histamine potentially participates in functions and activity of DC 
precursors as well as their immature and mature forms. It is important to note that 
immature and mature DCs express all four histamine receptors (Gutzmer et al. 2002, 
Idzko et al. 2002) see in Fig. (11) for more details. Furthermore, in the differentiation 
process of DCl from monocytes, HIR and H3R act as positive stimulants that enhance 
antigen-presentation capacity and proinflammatory cytokine production and also Thl 
priming activity. H2R acts as a suppressive molecule and enhances IL-10 production and 
stimulates IL-10 producing T-lymphocytes (Th2 cells) for antigen-presentation (Mazzoni 
et al. 2001). The suppressive impact of histamine by H2R seems through the regulation of 
ICAM-1 and B7.1 expression facilitating the reduction of innate immune responses 
activated by LPS (Morichika et al. 2003). Indeed, histamine stimulates intracellular Ca 
flux, chemotaxis, and actin polymerization in immature dendritic cells due to activation 
of HIR and H3R subtypes. Notably in maturation of DCs results in loss of these 
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responses. However, histamine dose dependently augments intracellular cAMP levels and 
stimulates IL-10 secretion in maturing dendritic cells, while inhibiting production of IL-
12 through H2R (Mazzoni et al. 2001). Human monocyte-derived DCs express both 
histamine receptors (HIR and H2R) and can stimulate CD86 expression via histamine, 
while human epidermal Langerhans cells express neither HIR nor H2R due to effect of 
TGF-p (Ohtani et al. 2003). 
2.5.5. Eosinophils 
Eosinophils express both histamine HI- and H2-receptors. The effect of histamine 
on eosinophils is stimulatory at lower concentrations. It had been suggested that 
preincubation of eosinophils with 10"^ M or higher concentrations of histamine suppressed 
the chemotactic response of eosinophils to endotoxin-activated serum (C5a) while 
preincubation of eosinophils with a lower concentration of lO'^ M histamine had the 
inverse effect, enhancing the C5a-activated eosinophil chemotaxis. Furthermore, H2R-
and HlR-antagonists respectively, inhibited these impacts. The expression of a novel 
H3R mediates the direct eosinophil chemotactic response towards histamine (Raible et al. 
1994, Shahid et al. 2009). It has also been observed that this receptor seems to have 
similar antagonist binding activities to those reported for the HSR observed in the CNS, 
although it does not bind R-a-methylhistamine or N-a-methylhistamine with similar 
potency as histamine suggesting differences between the activities and function of H3Rs 
expressed in CNS and on the eosinophil. Histamine acting via the HIR also augments 
eosinophil C3b receptor expression (Anwar and Kay 1980), and it was considered as an 
important mechanism that was found to be involved in the amplification of complement-
dependent parasite killing. However, 0.1-50 mM histamine was demonstrated to block 
eosinophil degranulation, as shown by diminished release of C5a-mediated eosinophil 
peroxidase (Ezeamuzie and Philips 2000). It has been suggested that selective H2R 
agonists produced an impact sirailar to that shown by histamine and that cimetidine 
(H2R-antagonist) reversed this inhibitory impact of histamine. Furthermore, in contrast, 
treatment with neither mepyramine (HlR-antagonist) nor thioperamide (H3R-antagonist) 
significantly inhibited the C5a-induced release of eosinophils-peroxidase from 
eosinophils suggesting the significant role of H2R in same respect. An important relation 
between histamine and eosinophil in allergic disease has been documented in vivo in 
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patients with allergic rhinitis undergoing segmental allergen challenge and followed by 
airway sampling via bronchoalveolar lavage (BAL) after 5 min and 48 h (Jarjour at al. 
1997). While in response to in vitro antigen challenge, maximal blood histamine release 
was determined in each patient before segmental bronchoprovocation. The number of 
eosinophils in BAL samples collected after 48 h were significantly enhanced and 
correlated with the maximal basophil histamine release noted for each individual 
suggesting a direct causal relationship between basophilic mediator release and airway 
eosinophilia (Shahid et al. 2009). 
2.5.6. Epithelial cells 
The implications of histamine have been observed in cultured human bronchial 
epithelial cells that demonstrate functionally active HIR and H2R as shown by 
histamine-induced generation of cGMP for HIR and cAMP for H2R, and blockage of 
cGMP release by treatment with pyrilamine and cAMP release by treatment with 
titotidine (Devalia and Davies 1991). Recently, the expression of HIR on cultured human 
ocular and nasal epithelial cells indicates that histamine may potentially influence the 
property of these cells (Sharif et al. 1996, Hamano et al. 1998). It has been demonstrated 
that nasal and bronchial epithelial cells synthesizes and release distinct biologically active 
mediators including cell adhesion molecules, endothelin, cytokines, arachidonic acid 
metabolites, major histocompatibility complex class (MHC) II antigens, neuropeptide 
degrading enzymes and nitric oxide that influence the migration, activation and also 
function of both structural and inflammatory cells involved in the pathophysiology of 
allergic rhinitis and asthma (Devalia et al. 2000a, Devalia et al. 2000b). Notably, the 
implications of histamine on mediator release from human bronchial epithelial cells 
demonstrated that HIR modulation with 2 mM histamine led to induction of cytoplasmic 
phospholipase A2 mRNA, activation of the transcription factor NF-kp, production of 
leukotriene B4, and expression of IL-8 (Aoki et al. 1998). It has been shown that 
histamine-induced enhancement in leukotriene B4 was inhibited by incubation of the 
cells with specific 5-lipoxygenase activating protein inhibitors and Zileuton and 
expression of IL-8 was blocked by diphenhydramine and 5-lipoxygenase activating 
protein inhibitors and Zileuton indicating an important network of histamine-modulated 
inflammatory mechanisms within the airways. Similarly, histamine induced the release of 
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IL-6, IL-8 and GM-CSF from human corneal and conjunctival epithelial cells in a dose-
dependent manner at physiologically or pathologically relevant concentrations and 
several HlR-antagonists, but not H2R-antagonist (ranitidine) or H3R-antagomst 
(thioperamide) blocked this cytokine release (Yanni et al. 1999). Indeed, the role of 
epithelial cells as modulators of inflammation, mainly in allergic diseases has been an 
important subject of much discussion for future prospects (Shahid et al. 2009). 
2.5.7. Endothelial cells 
The contribution of endothelial cells to the pathophysiology of allergic disorder 
has mainly been investigated. The significant effect of histamine on vascular permeability 
has well been demonstrated and is a consequence of HIR signaling that results in the 
contraction of F-actin fibres of the endothelial cytoskeleton and formation of gaps in the 
post capillary venules and extravasation of macromolecules (Burke-Gaffney and 
Hellewell 2000). The functionally potent HIR and/or H2R are expressed on human 
endothelial cells present in distinct tissues (the airway mucosa, eye, skin, brain and 
umbilical vein) (Koizumi and Ohi:awara 1999). Human umbilical vein endothelial cells 
have been the most investigated in mechanistic studies, because of comparatively easier 
and greater access to these cells. Currently, in a recent study it has been suggested that 
histamine itself regulates the expression of histamine receptor (HR) subtypes on 
endothelial cells and influences the overall significant role in inflammatory response in 
allergic disease (Schaefer et al. 1999). It has been documented that the levels of mRNA 
for both the receptors (HIR and H2R) were downregulated by histamine, of which the 
effect on H2R-mRNA was rapid and long lasting, compared with a less pronounced, 
transient and shorter lasting impact on the HlR-mRNA. Furthermore, the H2R-mRNA 
was exclusively downregulated as a resuh of HIR protein activation. Histamine-induced 
receptor signaling on the endothelial cells directly modulates inflammatory changes in 
these cells. Therefore, treatment of human umbilical vein endothelial cell cultures with 
IO'^'M or lO'^ M histamine resulted in the release of lipophilic neutrophil chemoattractant 
activity from endothelial cells, an effect inhibited by cimetidine but not by 
diphenhydramine (Farber et al. 1986). Histamine or HIR- or H2R-agonist stimulated 
adhesion of neutrophils to endothelial cells, participated in activation of phospholipase C, 
guanylate cyclase and nitric oxide synthase isozymes as inhibition of these enzymes with 
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specific inhibitors decreases Ais adhesion (Farber et al. 1986). The impact of histamine 
was found to be mediated by both Hi-receptor and H2-receptor signaling and modulation 
of P-selectin on endothelial cells in the mesentery. Thus, histamine receptors are involved 
in significant implications in the field of histamine research in endothelial cells (Shahid et 
al. 2009). 
2.6. Implication of Histamine on Cytokines Production 
It has been documented that histamine stimulates cytokine synthesis in allergic 
inflammation via two main different mechanisms: 
(a) Direct effects of histamine on cytokine synthesis 
(b) Modulation of cytokine production stimulated by immunologic stimuli 
Histamine differentially modulates IL-4 and IFN-y release from T cells (Lagier et 
al. 1997), inhibits TNF-a (Vannier et al. 1991) and IL-12 synthesis via human monocytes 
(Van der Pouw Kraan 1998), while it directly modulates IL-10 (Sirois et al. 2000) and IL-
18 production from human monocytes (Kohka et al. 2000). In addition, it inhibits IFN-y, 
TNF-a, and IL-12 and enhances IL-IO synthesis in LPS- or mitogen-activated peripheral 
blood mononuclear cells (Carlsson et al. 1985, Van der Pouw Kraan 1998), and increases 
IL-1 stimulated synthesis of IL-6 by monocytes (Vannier and Dinarello 1994). These 
complex impacts of histamine were found to be mediated through the activation of HIR, 
H2R, and H3R on immune cell cytokine synthesis (Cameron et al. 1986, Shahid et al. 
2009). Recently, cloned H4R has been characterized as functionally active to modulate 
cytokines (Shahid et al. 2009). Several investigators have observed that low 
concentrations of histamine [i.e., found in the bronchoalveolar lavage (BAL) fluid of 
patients with bronchial asthma or at other sites of allergic inflammation] (Liu et al. 1990), 
modulates human lung macrophages. The rationale for studying human lung macrophage 
was the high prevalence of macrophages in the human lung parenchyma and in the BAL 
fluid (Triggiani et al. 1997). An important study has been done on macrophages, which 
were purified (approximately 98%) from the lung parenchyma of thoracic surgery. 
Q —7 
Patients were incubated (1 to 18 h) with low doses of histamine (10 to 10 mol/L) that 
was compared to those released in vivo in distinct pathophysiology. It has been observed 
that histamine stimulated the de novo synthesis of IL-6 from macrophages, and these 
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impacts were reproduced via the HIR agonist (6-[2-(4-imidazolyl)ethylamino]-N-(4-
trifluoromethylphenyl) heptane carboxamide) but not by the H2-receptor agonist 
(dimaprit) suggesting that those were HIR mediated events (Shahid et al. 2009). Thus, 
these results are in line with the general investigation that HIR modulation is related with 
intracellular Ca^ "^  influx and demonstrated that this signal transduction pathway is active 
in human macrophages (Ganellin 1992). The HlR-mediated activation of macrophages 
was documented by demonstrating that histamine-induced IL-6 release was blocked in a 
concentration-dependent fashion by enhancing concentrations of the selective HIR-
antagonist (fexofenadine) (Shahid et al. 2009). While the H2R-antagonist (ranitidine) had 
no effect on IL-6 release or Ca^ "^  signal produced by histamine. A more valuable research 
in this field has provided the significant evidence that low concentrations of histamine 
promote exocytosis and IL-6 synthesis by inducing HlRs and activating intracellular 
Ca signaling in macrophages. This investigation enhances the intriguing possibility that, 
via activating macrophage functions, histamine might be implicated in the long-term 
control of inflammation (Shahid et al. 2009). 
2.7. Significance of Histamine in Autoimmunity and in Allergic Diseases 
It is highly significant in field of immunomodulation that endogenous levels of 
histamine influence the repertoire of autoantibodies. Histamine has been observed to 
influence several aspects of the immune response, including antibody production (Shahid 
et al. 2009). It has been characterized that the repertoire of natural autoantibodies in 
histidine decarboxylase (HDC) diminished mice was unable to produce histamine. HDC-
diminished and wild type mice differed in the patterns of reactivity of their 
immunoglobulin-M (IgM) and immunoglobulin-G (IgG) natural autoantibodies (Ohtsu et 
al. 2001, Quintana et al. 2004). The natural autoantibodies in HDC diminished sera 
manifested a larger repertoire of IgM autoantibodies than did the wild type sera 
(Quintana et al. 2004). The self-antigens bound by IgM from HDC diminished mice 
includes structural proteins, enzymes related with cellular metabolism, double-stranded 
DNA and single stranded DNA, and tissue-specific antigens like insulin (Shahid et al. 
2009). It was noted that relatively fewer differences in the natural autoantibodies 
repertoire of IgG autoantibodies of the mice, notably, the HDC diminished sera reacted 
with glutamic acid decarboxylase (GAD) (Quintana et al. 2004), an antigen related with 
(56) 
Chapter 2 Review of Literature 
autoimmune diabetes (Tisch et al. 1993). It has been documented that GAD-specific 
antibodies in HDC diminished mice reflect an enhanced susceptibihty to develop 
autoimmune diabetes. Therefore, this demonstrates that factors not directly associated to 
antigenic activation such as endogenous levels of histamine can influence the natural 
autoantibodies repertoire (Quintana et al. 2004). Thus, disorders of immune system 
characterized by altered levels of endogenous histamine, such as allergies, might be 
reflected as specific alterations in the repertoire of natural autoantibodies (Shahid et al. 
2009). 
2.7.1. Urticaria and angioedema 
Urticaria is the medical word for itchy wheals or hives (pale red swellings of skin 
"wheals" that occur in groups on any part of the skin) and angioedema known as deep 
mucocutaneous swelling often occur together with urticaria. Urticaria is classified, based 
on its temporal evolution, as acute (less than 6 weeks) or chronic (more that 6 weeks). 
Acute urticaria is related with sensitivity to foods, latex, and certain drugs and is often 
immunoglobuIin-E (IgE)-mediated. Chronic urticaria includes the physical urticarias and 
urticarial vasculitis but allergic causes of chronic urticaria were rarely identified. Some 
cases of chronic urticaria have been associated with circulating IgG autoantibodies 
against FcsRIa and autoantibodies against IgE (Hide et al. 1993, Sabroe et al. 1999). The 
frequency of autoantibodies to FcsRIa in chronic urticaria has been estimated 30-50%. 
These autoantibodies to FceRIa found to be fiinctional i.e. they can cause histamine 
release from basophils under in vitro condition, however, evidences increasingly suggests 
that such autoantibodies were also functional in vivo. Other evidences have suggested 
that the serum from many patients with chronic urticaria causes an immediate autologous 
wheal and flare response (i.e. a positive autologous serum skin test) and many of such 
patients have evidence of circulating functional IgG autoantibodies to the high affinity 
IgE receptor (FceRIa). The current mainstream thought is that in such patients the IgG 
autoantibodies causes the visible urticarial skin lesions. It has been documented that in 
chronic urticaria the autoantibodies causing histamine release were predominantly IgGl 
and IgG3. Thus, the presence of these autoantibodies characterizes the so-called chronic 
autoimmune urticaria. A cause-and-effect relation between levels of autoantibodies, 
histamine-releasing factors, and the clinical manifestations of chronic urticaria has still a 
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part of research. However, severe cases often suggest that autoantibodies or circulating 
histamine-releasing factors do have an important role (Grattan et al. 1992). Hereditary 
angioedema is a rare autosomal dominant disorder caused by the absence of the inhibitor 
of the first component of complement (Shahid et al. 2009). 
2.7,2. Allergic rhinitis 
Allergic rhinitis has been characterized by itching, sneezing, rhinorrhea and nasal 
obstruction. Perennial allergic rhinitis can be distinguished from non-allergic, non-
infectious forms of rhinitis [idiopathic (vasomotor) rhinitis, non-allergic rhinitis with 
eosinophilia syndrome, hormonal rhinitis, drug-stimulated rhinitis, and food-induced 
rhinitis]. The treatment of allergic diseases (allergic rhinitis) consists of allergen 
avoidance, anti allergic medication and immunotherapy for specific allergens which is 
known as desensitization or hyposensitization. Recently, the drugs commonly used to 
treat allergic rhinitis are antihistamines (histamine antagonists) and anticholinergic agents 
for the relief of symptoms and corticosteroids to suppress allergic inflammation. HIR-
antagonists (loratadine, cetirizine and fexofenadine) are less sedating and more 
pharmacologically selective than earlier antihistamines. Some HlR-antagonists 
(cetirizine) block allergen-sensitized infiltration of tissue by eosinophils, an influence that 
may be independent of their impacts on HIR (Slater et al. 1999, Shahid et al. 2009). 
2.7.3. Atopic dermatitis 
Atopic dermatitis (AD) or atopic eczema is a chronic relapsing pruritic skin 
disease with a high incidence in the first year of life. AD can persist into childhood, 
symptoms usually remit by puberty. AD is characterized by two phases: 1^ ' phase with 
acute lesions predominated by Th2 cytokines (IL-4, IL-5 and IL-13), 2" phase that is 
associated with eczematous chronic atopic dermatitis lesions by Thl cytokine (INF-y and 
IL-12). Atopic dermatitis can also be present in adults and affects more than 10% of the 
total populafion, with 80-90% of those affected being children under 5 years of age in 
Western population (Williams et al. 1999, Sehra et al. 2008). Atopic dermatitis is often 
regarded as a cutaneous form of atopy; as a resuh, 50-80% of children with AD will 
develop asthma or allergic rhinitis by 5 years of age later in life and the high serous 
concentration of IgE (Di TuUio 2001). This temporal progression of atopic symptoms 
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from atopic dermatitis to allergic sensitization of the skin, food allergy, hay fever 
• (allergic rhinitis) and later airway hyperresponsivness and airway inflammation or 
asthma, has been named the "allergic march" (Gustafsson et al. 2000, Spergel and Paller 
2003). 
In AD, the skin becomes extremely itchy. Scratching leads to redness, swelling, 
cracking, "weeping" clear fluid, and finally crusting and scaling. It is frequently 
perceived as a minor dermatological disorder. However, the high prevalence of this 
condition carries financial and social cost not only for the community, regarding medical 
and hospital cost but also for the patient and the patient's family (Kemp 2003). In AD, 
inflammafion results from interactions of immune cells [T cells (Thl and Th2), dendritic 
cells (langerhans dendritic cells and inflammatory dendrific epidermal cells), mast cells 
and eosinophils] and kerotinocytes. The complex picture of the AD lesion is aggravated 
by environmental and genetic factors that increase the difficulty of understanding the 
mechanisms behind this complex pathology (Sehra et al. 2008, Shahid et al. 2009). 
2.8. Role of Histamine in Malignancies 
Malignant melanoma is a well known life-threatening tumor (with a high rate of 
metastasis and strong malignant potential). Recently, the immune response against 
melanoma was compromised through multiple escape mechanisms of the tumor, which 
have been uncovered partially via thorough immunological and molecular analyses. 
These analyses were documented by gene-expression profiling. It has been suggested that 
melanoma-derived histamine should be included as a significant factor participated in bi-
direcfional interactions between the tumor tissue and infiltrating immune cells. Notably, 
the presence and activity of histamine has been demonstrated to be relevant by directly 
stimulating or suppressing growth of the melanoma (i.e. depending on the local histamine 
receptor balance) and indirectly shifting the local T-cell polarization towards a 
predominance of Th2 cells (Falus et al. 2001, Shahid et al. 2009). 
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2.9. Relation of Histamine-Cytokiine During Hematopoiesis 
Many researchers have reported that exogenous histamine promote the entry of 
colony-forming units-spleen (CFU-S) into cell cycle and showed that this mediator 
stimulated granulocyte precursors, when added during in vitro cultures (Byron 1977, 
Nakaya and Tasaka 1999). Recently, it has been demonstrated that a similar positive 
effect on hematopoietic progenitors was induced by endogenous histamine. Histamine is 
synthesized in response to hematopoietic growth factors (IL-3, GM-CSF and IL-1) 
generated during the immune response. It was probably not needed for maintaining bone 
marrow homeostasis, but involved in inducible hematopoiesis and satisfies the enhanced 
requirements of an efficient host defense. There were several reports in support of a 
positive effect of histamine on granulopoiesis, but side effects of some histamine receptor 
ligands have also been described. Rare cases of agranulocytosis have been observed in 
response to H2-receptor antagonist (cimetidine) and H4R antagonist (clozapine). It 
should be confirmed and re-evaluated by several reports, as regards the significant role of 
various histamine receptors; those expressions are most abundant in bone marrow (Dy 
and Schneider 2004, Shahid et al. 2009). 
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Brief In trod u ction 
Histamine, a biogenic amine, is considered not only a mediator of chronic 
inflammation and hypersensitivity but also a regulator of several essential events in 
the immune response. Histamine regulates dendritic cells, T-lymphocytes, B-
lymphocytes, as well as related antibody isotype responses. Recently, accumulating 
evidences have highlighted the importance of histamine receptors in 
immunomodulation (Banu and Watanabe 1999, Jutel et al. 2001, Ma et al. 2002, 
Shahid et al. 2009). Histamine released from the mast cells and basophils during 
inflammatory reactions can modulate immune response (Banu and Watanabe 1999). 
Its immunosuppressive and immunomodulatory effects on both humoral- and cell-
mediated immune (HI and CMI, respectively) responses have been observed (Rocklin 
and Beer 1983, Moharana et al. 2002). 
Histamine receptors have previously been shown to enhance delayed 
hypersensitivity and antibody mediated immune responses in many pathological 
processes regulating several essential events in allergies and autoimmune diseases in 
experimental animals, especially in knock out mice (either HI- or H2-deficient) 
(Rocklin and Beer 1983, Ma et al. 2002, Quintana et al. 2004). However, studies 
evaluating the role with intact receptors, but blocked by respective 
agonists/antagonists, and especially studying the immunomodulatory profile over a 
span of time are lacking in the existing literature. Moreover, the studies in rabbit 
model are elementary, and the existing studies have demonstrated immunomodulatory 
role studying only single blood samples taken after immunizing the animals. 
The investigations account for an important regulatory mechanism in the 
control of inflammatory functions in immune regulation through effector cells (mast 
cells and basophils)-derived histamine, exogenous histamine and its receptors-
agonist/inverse agonist (histamine antagonist). Histamine receptors (HIR, H2R, H3R 
and H4R) belong to the G-protein-coupled receptor (GPCR) family (Shahid et al. 
2009) however, they trigger different biochemical intracellular events upon activation 
(Thurmond et al. 2008, Shahid et al. 2009). Jutel et al. (2001) investigated that the 
HlR-specific antagonist trlpelennamine inhibit histamine binding in Thl but not in 
Th2 cells and demonstrated predominant HIR expression on Thl cells. Neither H2R-
antagonist (ranitidine) nor H3R-antagonist/H4R-partial agonist (clobenpropit) had any 
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impact on histamine binding to Thl cells. Rather, HlRs and H2Rs are regulated by 
specific cytokines present in the immune system. 
Their study demonstrated the expression of HIR on Thl cells and H2R on Th2 
cells by antibodies generated against HIR and H2R (Jutel et al. 2001). 
Histamine receptors (HIR - H4R) expression, distribution and functional 
characterization such as immunopharmacological, physiological and pathological are 
well documented (Shahid et al. 2008). The data of histamine receptors (HIR and 
H2R) in immune modulation and regulation are elementary in the existing literature 
(Banu and Watanabe 1999, Jutel et al. 2001) however, their distribution and immuno-
functional characterization in several immunological cells are well described (shahid 
et al. 2009). However, the role of histamine receptors (HSR and H4R) in immune 
modulation and regulation is still unclear. 
Therefore, keeping in view the above facts, the present chapter has been 
further sub-divided with the following preliminary findings: 
> 2A. In Vivo Immunomodulation and Immunomodulatory Profile of Histamine 
Receptors 
(i) Role of Histamine on Antibody Profile Generated by Primary-and 
Secondary-Immunization 
(ii) Dose-Dependent Effect of Histamine on Antibody Generation Profile 
> 3.2. In Vivo Immunomodulation and Immunomodulatory Profile of Histamine 
HI Receptors 
> 3.3. In Vivo Immunomodulation and Immunomodulatory Profile of Histamine 
H2 Receptors 
> 3.4. In Vivo Immunomodulation and Immunomodulatory Profile of Histamine 
H3 Receptors 
> 3.5. In Vivo Immunomodulation and Immunomodulatory Profile of Histamine 
H4 Receptors 
> 3.6. In Vivo Immunomodulation and Immunomodulatory Profile of 
Histamine Receptors (HI-, H2-, H3- & H4-): A Comparative Agonists Study 
> 3.7. In Vivo Immunomodulation and Immunomodulatory Profile of Histamine 
Receptors (HI-, H2-, H3- & H4-): A Comparative Antagonists Study 
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Chapter 3.1.1. Role of Histamine on Antibody Profile Generated by 
Primary- and Secondary-Immunization 
3.1.1.1. Brief Summary 
Present study was designed to delineate the immunomodulatory role of histamine on 
antibody generation profile in rabbit system, systemically. The cohort comprised of 
three groups (I, II & III) containing 18 (9 male and 9 female) rabbits each, received 
subcutaneous histamine (100 ngkg"' x b.i.d.) for 10 days (starting from day 1). 
Histamine (100 ftgkg"' x b.i.d.) was given group II and III further for one week 
(starting from day 58) while group-ll received same dose of histamine for another 
week (starting from day 72). They were subsequently immunized at day 3 with 
intravenous injection of SRBC whereas group-II and -III were further immunized 
(secondary immunization) with SRBC at day 72. A IVth-positive control group (n = 
18) received vehicle (sterile distilled water, 1 mlkg"' x b.i.d.) and then immunized at 
day 3 similar to other test groups, while a Vth-negative control group (n = 18) 
remained non-immunized and received only vehicle. Blood samples were collected on 
pre-immunization (pre-I) (day 0), as well as on days 7-, 14-, 21-, 28-, 58-, 65-, 72-, 
79- and 86- post-immunization (post-I). The ELISA and HA both showed similar 
production of Igs, IgM and IgG but evident more in ELISA as compared to HA. 
Results showed that, histamine could influence a detectable antibody response to 
SRBC as early as day 7-post-I, which lasted till day 86- post-I. Primary- and 
secondary-immunization findings showed potential role of histamine on antibody 
generation. All the results were found statistically significant (P<0.05). To conclude, 
our results provide evidence that histamine has a short-term effect (until its presence 
in the body) on antibody class switching and potentially stimulates antibody 
generation titer. 
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3.1.1,2. Materials and methods 
3.1.1.2.1. Experimental design 
To evaluate the systemic antibody response, 90 (45 Male and 45 Female) New 
Zealand adult healthy albino rabbits of either sex (1:1 ratio) weighing 1.0-1.5 kg were 
randomized equally into five treatment groups i.e. 18 rabbits (9 male and 9 female) in 
each group. Four groups were immunized with sheep red blood cells (SRBC). 
Experimental group: Groups (I, II and III) were treated with histamine for 10 days 
(starting from day 1). Group-Il and -III further received histamine respectively for one 
week (starting from day 58) while group-II was again treated with histamine for one 
week (starting from day 72). 
Control group: Group-IV (positive control) received vehicle (sterile distilled water, 1 
mlkg'' X b.i.d.) and immunized while group-V (negative control) remained non-
immunized and received only vehicle (sterile distilled water, 1 mlkg'' x b.i.d.). 
The animals were housed in well-maintained animal facility at central animal 
house, J. N. Medical College, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22 ± 2°C) and were 
allowed free access. They have provided standard laboratory diet including green 
vegetables and tap water during experimentation. All studies were carried out during 
the light cycle and were approved by the Institutional Animal Ethical Committee. 
3.1.1.2.2. Materials 
All materials were obtained from the following manufacturers: Monoclonal-
anti-rabbit-immunoglobulins-horseradish peroxidase (HRP) conjugate and 
monoclonal-anti-rabbit-IgG-HRP conjugate from Sigma (USA), anti-rabbit-IgM-HRP 
conjugate from G Biosciences (Maryland heights, USA), tetramethyl benzidine 
(TMB) and TMB diluent from J. Mitra and Co. (India), Polystyrene MaxiSorp 
microtitre flat bottom ELISA plates from NUNC (Denmark), Glutaraldehyde solution 
from Central Drug House (India), Skimmed milk from Nestle India Ltd. (New Delhi). 
All chemicals were of analytical grade. 
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3.1.1.2.3. Drugs and doses 
Histamine dihydrochloride was purchased from Himedia laboratories Pvt 
Limited, India. Its dose (100 ngkg'') was common in all histamine-treated groups and 
was administered twice a day subcutaneously (s.c). Histamine dose is referred to the 
weight of the salts used. 
3.1.1.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, J. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCI, pH-
7.4) thrice by centrifugation. The cell suspensions were adjusted to the desired 
concentration in terms of hemoglobin, lysis of a 1% SRBC suspension (2 x lo^ 
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franzl (1972). Finally the concentration 
was adjusted to 5% (1 x lO^cells/ml) in PBS for immunization before use. 
3.1.1.2.5. Immunization of rabbits 
The rabbits in experimental groups (I-IV) were immunized at day 3 
intravenously (i.v.) with 1ml of 5% (1 x 10^  cells/ml) sheep red blood cells (SRBC) in 
PBS and again same quantity of SRBC was inoculated via i.v. in group (11 and III) on 
day 72. 
3.1.1.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins prior to immunization (day 0), as well as 
on days 7-, 14-, 21-, 28-, 58-, 65-, 72-, 79- and 86- post-I. Blood samples were kept at 
room temperature for 2 hr and then at 4°C overnight. Blood samples were centrifuged 
for 10 minutes at 580xg, and serum was separated and heated at 56°C for 30 minutes 
to inactivate complement proteins and stored in aliquots with sodium azide as 
preservative at -20°C till further testings. 
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3.1.1.2.7. Serological analysis 
3.1.1.2.7.1. Hemagglutination assay (HA) 
To determine the antibodies response to SREC, a direct hemagglutination 
technique (Haghighi et al. 2005) was used with some modifications in our laboratory. 
Briefly, 100|j,L of PBS was dispensed in each well of a round bottomed 96-well 
microplate. Serum sample (lOO^L) were then added using two-fold serial dilutions 
(1:2, 1:4, 1:8, 1:16, 1:32...) in the wells from columns 2 to 12. The first column (PBS 
only) of wells was considered blank. Then, 100|j,L of 2% sheep red blood cells 
(SRBC) in PBS was added to all wells to make a final volume of 200^1. 
Subsequently, the plates were shaken for 1 minutes and incubated at 37°C for 1 hr, 
and then overnight at A°C to determine agglutination titres. A positive result was 
recorded when at least 50% SRBC agglutination was observed. To measure anti-
SRBC-immunoglobulin-M (IgM) and immunoglobulin-G (IgG), serum sample were 
treated with 0.2M 2-mercaptoethanol (2-ME) for 1 hr at 37°C. This treatment 
inactivates IgM antibody, and as a result, hemagglutination observed after treatment 
with 2-ME is mostly due to the presence of IgG antibody. The difference between 
total antibodies and IgG antibody titres were taken as the titres of IgM antibody. 
3.1.1.2.7.2. ELISA using whole sheep red blood cells (SRBC) 
To determine the SRBC-specific-immunoglobulins (Igs), SRBC-specific-IgM 
and SRBC-specific-IgG response, the whole SRBC-enzyme linked immunosorbent 
assay (ELISA) (Koganei et al. 2007) was carried out on polystryrene plates with some 
modifications. Briefly, polystryrene MaxiSorp immunoplates were coated with SRBC 
suspension [5 x 10 /^100 ^L PBS (10 mM sodium phosphate buffer containing 150 
mM NaCl, pH-7.4)]. The plates were held overnight at 4°C. Each sample was coated 
in duplicate and half of the plate, devoid of antigen coating, served as control. 
Without disturbing the cell layer, 20 ^L of 1.8% glutaraldehyde solution was then 
gently added to plates inoculated with SRBC and the plates were held at 25T for 30 
min. Unbound SRBC were washed four times with 200 [xL of PBS and non-specific 
binding sites were blocked with 1% fat-free milk in PBS for 2 hr at 37T. After 
incubation, the plates were washed four times with 200 i^L of PBS. Each rabbit serum 
diluted 1:100 in PBS (100 uL well'') was adsorbed for 1.5 hr at 37°C, and then 
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remained for overnight incubation at 4°C followed by washing as earlier as possible. 
The secondary antibody, HRP conjugated monoclonal-anti-rabbit-immunoglobulins, 
monoclonal-anti-rabbit-IgM and monoclonal-anti-rabbit-IgG was then added (100 ^ iL 
weir') in respective plates and incubated at STT for 1 hr. The washing stage was 
repeated as before and 100 fiL well"' TMB substrate was added and the plates were 
incubated at 25°C for 1 hr. The enzymatic reaction was stopped by adding 50 |xL well' 
' of 5% H2SO4 The absorbance (A) was determined at 405 nm by an automatic 
ELISA plate reader (Micro scan MS5608A, ECIL, India). Each rabbit serum sample 
was run in duplicate. The control wells were treated similarly but were devoid of 
antigen. Thus, total serum immunoglobulins (Igs), total immunoglobulin-M (IgM) and 
total immunoglobulin G (IgG) profiles (production) were studied in vivo in five 
experimental groups separately and results were expressed as a mean of Atest- control at 
day 0 (pre-immunization) and day 7, 14, 21, 28 and 58 (post-immunization). 
3.1.1.2.8. Statistical analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. A two-tailed (a = 2) probability PO.Q5 
was considered to be statistically significant. Analyses were performed on SPSS for 
windows (version 12.0, Inc., Chicago, IL). 
3.1.1.3. Results 
To assess the effects of histamine on the antibody generation, antibody-
mediated responses to SRBC were analyzed. Total serum immunoglobulins (Igs), 
immunoglobulin-M (IgM) and immunoglobulin-G (IgG) generation profiles were 
studied in vivo in five experimental groups at days 0 [pre-immunization (pre-1)], 7, 14, 
21, 28, 58, 65, 72, 79 and 86 [post-immunization (post-I)]. 
3.1.1.3.1. Total serum anti-Sl^C-immunoglobulins (Igs) production 
The profile of total anti-SRBC- immunoglobulins (Igs) titer was studied by 
whole SRBC-ELISA method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghlghi 
et al. 2005) (Table 1). The ELISA and HA assay both showed similar Igs production 
but evident more in ELISA as opposed to HA. No antibody response was detectea in 
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all experimental groups at day 0 (pre-I). Igs titer in control group showed an initial 
increase on day 7- post-I, which achieved highest peak at day 14- post-I and then 
gradual decrease in anti-SRBC-Igs titer over time (day 21-, 28-, 58-, 65-, 72-, 79- and 
86- post-I). The detailed summary of statistically analyzed Igs production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are shown 
in Fig. 1 and Table 1. Drug treated groups I, II and III showed similar patterns in total 
Igs titer at day 7-, 14-, 2I-, 28- and 58- post-I. However, group II and III showed a 
different pattern of enhanced total Igs titer at the day 65-, 72-, 79-, 86- post-I. 
Primary-immunization (primary-I) study revealed significantly (P< 0.01) enhanced 
total Igs titer in drug-treated groups I, II and III (similar to each other) as compared to 
positive control (group IV) at day 7- post-I. However, group I, II and III showed 
significant decrease (P< 0.01) of total Igs titer as compared to positive control (group 
IV) at day 14- and 21- post-I. At day 28- and 58- post-I, total Igs titer in group I, II 
and III was similar to control group. One week treatment of histamine in group II and 
III (starting from day 58- post-I) showed significantly (P< 0.01) enhanced total Igs 
titer at day 65- and 72- post-I as compared to group I and IV. 
Furthermore, secondary-immunization (secondary-I) study showed that total 
Igs titer in group II (secondary-I with SRBC at day 72- post-I + histamine treatment 
for one week starting from day 72- post-1) was significant (P< 0.01) and enhanced as 
compared to group III (secondary-1 with SRBC at day 72- post-I only) at day 79-
post-I, while both of the groups II and III revealed significant (P< 0.01) enhancement 
of total Igs titer as compared to rest of the study groups (group I and VI) at day 79-
and 86- post-I. No Igs response was noticed in group V (negative control) during 
whole of the study period. 
3.1.1.3.2. Anti-SRBC-immunogiobuIin-M (IgM) production 
Anti-SRBC-IgM was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 2) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgM production but evident more in ELISA as opposed to 
HA. 
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Figure 1. SRBC-specific Immunoglobulins (Igs) production titer in histamine-treated 
rabbits by whole SRBC-ELISA method in duplicate 1:100 diluted sera. The results 
demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect 
of treatments (F=9632.773, DF=4,85; P<0.01) and days (F-31811.33, DF=9,765; 
P<0.01) on SRBC were statistically significant. The interaction (treatments x days) 
effect of (F=8075.988, DF=36,765; P<0.01) these on SRBC were also found to be 
significant. 
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No antibody response was detected in all experimental groups (negative 
control, positive control and drug- treated) at day 0 (pre-I). However there was an 
initial increase and then gradual decrease in anti-SRBC-IgM titer over time in all the 
groups before secondary-I. By day 7- post-I, the IgM titer increased and attained 
highest peak, but by days 14-, 21-, 28-, 58-, 65- and 72- post-I there was a gradual 
decrease in all experimental groups. While at days 79- and 86- post-I, IgM titer 
remained decreased in both groups I and IV, however on secondary-I in groups II and 
III, IgM titer was highest at day 79- post-I, but at day 86- post-I a gradual decrease 
was observed. The detailed summary of statistically analyzed IgM production by two 
way analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are 
shown in Fig. 2 and Table 1. Primary-I study revealed that IgM titer in drug-treated 
groups I, II and III showed significant (P< 0.01) enhancement as compared to group 
IV at day 7- post-I. However, IgM titer in drug-treated groups showed suppression at 
day 14-, 21-, 28- and 58- post-I as compared to group IV. IgM titer at day 65- and 72-
post-I were found similar in groups II and III (both groups were treated with 
histamine for one week starting from day 58- post-I) and found similar to group I and 
IV. However, secondary-I revealed interesting findings in group II and III (group II 
received secondary-I with SRBC at day 72- post-I and treated with histamine for one 
week starting from day 72- post-I, while group III received only secondary-I with 
SRBC) and showed that group II obtained significantly (P< 0.01) high peak of IgM 
titer as compared to group III and also rest of the study groups at day 79- post-I, while 
group III showed significantly (P< 0.01) high IgM titer as compared to group II and 
also rest of the study groups at day 86- post-1. No antibody response was noticed in 
group V (negative control) during whole of the study period. 
3.1.1.3.3. Anti-SRBC-immunoglobulin-G (IgG) production 
Anti-SRBC-IgG was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 3) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgG production but evident more in ELISA as opposed to 
HA. No antibody response was detected in all experimental groups (negative control, 
positive control and drug- treated) at day 0 (pre-I). 
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Figure 2. SRBC-specific Immunoglobulin-M (IgM) production titer in histamine-
treated rabbits by whole SRBC-ELISA method in duphcate l.iOO diluted sera. The 
results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect 
of treatments (F=1488.692, DF=4,85; P<0.01) and days (F=812.006, DF=9,765; 
P<0.01) on SRBC were statistically significant. The interaction (treatments x days) 
effect of (F=138.900, DF=36,765; P<0.01) these on SRBC were also found to be 
significant. 
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Figure 3. SRBC-specific Immunoglobulin-G (IgG) production titer in histamine-
treated rabbits by whole SRBC-ELISA method in dupHcate 1:100 diluted sera. The 
results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect 
of treatments (F=2425.826, DF=4,85; P<0.01) and days (F-3742.816, DF=9,765; 
P<0.01) on SRBC were statistically significant. The interaction (treatments x days) 
effect of (F=650.190, DF=36,765; P<0.01) these on SRBC were also found to be 
significant. 
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Chapter 3.1.1. Role of Histamine on Antibody Profile Generated by 
Primary- and Secondary-Immunization 
The detailed summary of statistically analyzed IgG production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are shown 
in Fig. 3 and Table 1. By day 7- post-I, the IgG titer increased but it attained highest 
peak at day 14- post-I, while by days 21-, 28-, 58-, 65-, 72- and 86- post-I, there was a 
gradual decrease in group IV. However, IgG titer in drug-treated groups (I, II and III) 
revealed significant (P< 0.01) enhancement as compared to group IV at day 7- post-I. 
However, IgG titer in drug-treated groups showed significant (P< 0.01) suppression at 
day 14-, 21-, 28- and 58- post-I as compared to group IV. Furthermore, group I 
showed significant (P< 0.01) suppression of IgG titer as compared to group IV at days 
65-, 72-, 79- and 86- post-I. While, IgG titer in group II and III at day 65- post-I 
attained highest peak, but at day 72- post-1 it showed gradual decrease (both groups 
were treated with histamine for one week starting from day 58- post-I), and were 
found showing significantly (P< 0.01) enhanced IgG titer as compared to group I and 
IV. This warrants further study to elucidate the effect of histamine on IgG production. 
However, secondary-I revealed interesting findings in group II and III (group II 
received secondary-I with SRJ3C at day 72- post-I and treated with histamine for one 
week starting from day 72- post-I, while group III received only secondary-! with 
SRBC) and showed that group II obtained significantly (P< 0.01) high peak of IgG 
titer as compared to group III and also rest of the study groups at day 79- and 86-
post-I. While group III showed significantly (P< 0.01) high IgG titer as compared to 
group I and IV (positive control) at days 79- and 86- post-I. No antibody response was 
noticed in group V (negative control) during whole of the study period. 
3.1.1.4. Discussion 
In the present report, we studied the role of histamine as an 
immunopotentiating agent by the immunomodulatory profile, and demonstrated the 
effect of histamine on antibody generation. We investigated total serum 
immunoglobulins (Igs), IgM and IgG generation profile against SRBC, a T 
lymphocyte-dependent test antigen (Koganei et al. 2007), modulated by endogenous 
histamine (released from effector cells) in positive control (sterile distilled water-
treated)- and histamine treated-experimental groups. According to the document of 
International Conference on Harmonization (ICH) S8 Guideline on Immunotoxicity 
Testing for Pharmaceuticals (adapted by EU in 2005, and by the FDA and MHLW in 
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2006), the evaluation of antibody response to a T-lymphocyte-dependent antigen (e.g., 
SRBC or Keyhole Hmpet hemocyanin) is recommended as one of the most sensitive 
immune tests following chemical exposures (Koganei et al. 2007). The T-lymphocyte-
dependent antibody response assay is a sensitive indicator of immunological integrity. 
When SRBC is used as the particular T-lymphocyte-dependent antigen, this response 
requires the coordinated interaction of various immune system cells (i.e., antigen-
presenting cells, T-lymphocytes and B-lymphocytes) (Benacerraf 1978, Koganei et al. 
2007). Moreover, several studies have demonstrated that the modulation of antibody-
mediated immune response against SRBC following chemical exposures (i.e., 
immunomodulatory and immunosuppressive agents) (Zhang et al. 2005, Bafna and 
Mishra 2005). 
Therefore, we hypothesized the present work to delineate the 
immunomodulatory role of histamine (as they are immunopotentiating agents) against 
SRBC. To provide exact evidence relating our findings to in vivo immunoregulatory 
processes, we used healthy rabbits with and without histamine treatments. Here we 
reveal that histamine-treated rabbits were characterized by a marked deviation of the 
immune response as compared to positive control rabbits. In the present study, we 
showed that the histamine, released from immunological stimuli from effector cells 
(mast cells and basophils) in vivo (Shahid et al. 2009), could influence a detectable 
antibody response to SRBC as early as day 7- post-I, which lasted until day 86- post-I 
in all experimental groups. Histamine, itself is a potent agonist of all four receptors 
(HI-H4) (Jutel et al. 2001, Thurmond et al. 2008, Shahid et al. 2009), which are 
distributed in different parts of body and modulates different biochemical, 
pharmacological and immunological reactions both in vivo and in vitro by the 
activation of signal transduction on releasing the endogenous histamine (Shahid et al. 
2009). It is a well known mechanism that histamine directly affects B-cell antibody 
production as a co-stimulatory receptor on B-cells (Rocklin and Beer 1983, Akdis and 
Blaser 2003, Jutel et al. 2005, Akdis 2006). It must be highlighted here that, to the 
best of our knowledge, none of the earlier reports have shown the anti-SRBC antibody 
profile over a span of study period (86 days), rather all previous reports have studied 
the anti-SRBC antibody concentrations at a single time period by taking single blood 
samples from experimental animals. 
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We demonstrated that the histamine treated-rabbits showed 
immunopotentiating properties by enhancing the anti-SRBC-antibodies (Igs, IgM and 
IgG) titers as compared to positive control. We noticed that histamine stimulates 
antibody titer (Igs and IgG) in group II and III at day 65- post-I when treated with 
histamine for one week (starting from the day 58- post-I) however it showed gradual 
decrease at day 72- post-I. While IgM titer was unaffected and showed similar 
pattern as in group I and group V. These findings showed potential role of histamine 
on antibody generation specially IgG. Secondary-immunization study in group II and 
III, further strengthen our results of histamine role in antibody generation. 
To conclude, our results provide evidence that short-term effect of histamine 
(until its presence in the body) affects antibody class switching and potentially 
stimulates antibody generation titer. To the best of our knowledge, this is the first 
report describing the potential immunoregulatory role of histamine and also the first 
report studying immunomodulatory profile in experimental rabbits over a continued 
study period of 86 days (pre- and post- immunization) against primary- and 
secondary-immunization of SIU3C. 
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3.1.11,1. Brief Summary 
The immunomodulatory role of histamine on antibody generation profile in rabbit was 
delineated in the present dose-dependent histamine study. The cohort comprised of 
three groups (III, IV and V), containing 18 (9 male and 9 female) rabbits each, and 
received histamine subcutaneously 50 ngkg'' x bis in die (b.i.d.), 100 ngkg"' x b.i.d. 
and 200 ngkg"' x b.i.d., respectively for 10 days (starting from day 1). They were 
subsequently immunized at day 3 with intravenous injection of SRBC (1 x IQ^  cells 
ml"'). Group-II (positive control) (n = 18) received vehicle (sterile distilled water, 1 
mikg'' X b.i.d.) and then get immunized at day 3 similarly while group-I (negative 
control) (n = 18) remained non-immunized and received only vehicle (sterile distilled 
water, 1 mlkg"' x b.i.d.). Blood samples were collected on pre-immunization (pre-I) 
(day 0), as well as on days 7-, 14-, 21-, 28- and 58- post-immunization (post-1). The 
ELISA and HA both showed similar production of Igs, IgM and IgG but evident more 
in ELISA as compared to HA. Results showed that, histamine could influence a 
detectable antibody response to SRBC as early as day 7-post-I, which lasted until day 
58- post-I. All the results were found statistically significant (P<0.05). To conclude, 
our results provide evidence that histamine has a short-term effect on antibody 
generation (until its presence in the body), and the antibody generation titer in vivo 
affect by the concentration of histamine. 
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3.1.11.2. Materials and Methods 
3.1.11.2.1. Experimental design 
To evaluate the systemic antibody response, 90 (45 Male and 45 Female) New 
Zealand adult healthy albino rabbits of either sex (1:1 ratio) weighing 1.0-1.5 kg were 
randomized equally into five treatment groups i.e. 18 rabbits (9 male and 9 female) in 
each group. Four groups were immunized with sheep red blood cells (SRBC). 
Experimental group: Groups (III, IV and V) were treated with histamine 10 days 
(starting from day 1). 
Control group: Group-II (positive control) received vehicle (sterile distilled water, 1 
mlkg"' X b.i.d.) and immunized while group-I (negative control) remained non-
immunized and received only vehicle (sterile distilled water, 1 mlkg"' x b.i.d.). 
The animals were housed in well-maintained animal facility at central animal 
house, J. N. Medical College, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22 ± 2°C) and were 
allowed free access. They have provided standard laboratory diet including green 
vegetables and tap water during experimentation. All studies were carried out during 
the light cycle and were approved by the Institutional Animal Ethical Committee. 
3.1.11.2.2. Materials 
All materials were same as used in chapter 3.1.1. 
3.1.11.2.3. Drugs and doses 
Histamine dihydrochloride was purchased from Himedia laboratories Pvt 
Limited, India. Its dose (50 ^gkg'', 100 ngkg' and 200 ngkg"') was in groups III, IV 
and V, respectively, and was administered twice in a day through subcutaneous (s.c.) 
injection. Histamine dose is referred to the weight of the salts used. 
3.1.11.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, J. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH-
7.4) thrice by centrifugation. The cell suspensions were adjusted to the desired 
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concentration in terms of hemoglobin, lysis of a !% SRBC suspension (2 x 10** 
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franz! (1972). Finally the concentration 
was adjusted to 5% (1 x lO'cells/ml) in PBS for immunization before use. 
3.1.11.2.5. Immunization of rabbits 
The rabbits in experimental groups (II-V) were immunized intravenously at 
day 3 (i.v.) with 1ml of 5% (1 x 10^  cells/ml) sheep red blood cells (SRBC) in PBS. 
3.1.11.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins into labelled sterile bottles prior to 
immunization (day 0), as well as on days 7-, 14-, 21-, 28- and 58- post-I. Blood 
samples were kept at room temperature for 2 hr and then at 4°C overnight. Blood 
samples were centrifuged for 10 minutes at 580xg, and serum was separated and 
heated at 56°C for 30 minutes to inactivate complement proteins and stored in aliquots 
containing sodium azide as preservative at -20°C till further testings (Doumal 1972). 
3.1.11.2.7. Serological method 
3.1.11.2.7.1. Hemagglutination assay (HA) 
Same as chapter 3.1.1. 
3.1.11.2.7.2. ELISA using whole sheep red blood ceils (SRBC) 
Same as chapter 3.1.1. 
3.1.11.2.8. Statistical analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. A two-tailed (a = 2) probability P<0.05 
was considered to be statistically significant. Analyses were performed on SPSS for 
windows (version 12.0, Inc., Chicago, IL). 
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3.1.II.3. Results 
To assess the effects of histamine on the antibody generation, antibody-
mediated responses to SRBC were analyzed. Total serum immunoglobulins (Igs), 
immunoglobulin-M (IgM) and immunoglobulin-G (IgG) generation profiles were 
studied in vivo in five experimental groups at days 0 [pre-immunization (pre-I)], 7, 14, 
21, 28 and 58 [post-immunization (post-I)]. 
3.1.II.3.1. Total serum anti-SRBC-immunoglobuIins (Igs) production 
The profile of total anti-SRBiC-immunoglobulins (Igs) titer was studied by whole 
SRBC-ELISA method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghighi et al. 
2005) (Table 1). No antibody response was detected in all experimental groups at day 
0 (pre-1). Igs titer in positive control group showed an initial increase on day 7- post-I, 
then achieved highest peak at day 14- post-I and then gradually decreased in anti-
SRBC-Igs titer over time (day 21-, 28- and 58- post-1) was observed. The detailed 
summary of statistically analyzed Igs production by two way analysis of variance 
(ANOVA) followed by Newman-Keuls post hoc test are shown in Fig. 1 and Table 1. 
Histamine treated groups III, IV and V showed different patterns in total Igs titer at 
day 7-, 14-, 21-, 28- and 58- post-I. All the histamine treated groups (111, IV and V) 
showed enhanced Igs titer at day 7- post-I as compared io positive control (group II). 
While, group V showed significant enhancement of total Igs titer at days 7-, 14-, 21-, 
28- and 58- post-I (P< 0.01) as compared to rest of the groups (11, III and IV). Group 
IV revealed significant (P< 0.01) enhancement of total Igs titer as compared to group 
II and III at day 7- post-I. However, group III revealed significant increase of total Igs 
titer at day 7- post-I as compared to group II. Moreover, total Igs titer at days 14-, 21-, 
28- and 58- post-I in group 111 and IV showed suppression of total Igs titer as 
compared to group II. No Igs response was noticed in group I (negative control) 
during whole of the study period. 
3.1.II.3.2. Anti-SRBC-immunoglobulin-M (IgM) production 
Anti-SRBC-immunoglobulin M (IgM) was determined by whole SRBC-
ELISA method (Koganei et al. 2007) (Fig. 2) and direct HA (Haghighi et al. 2005) 
(Table 1). No IgM response was detected in all experimental groups (negative control, 
positive control and histamine-treated) at day 0 (pre-I). However there was an initial 
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increase and then gradual decrease in anti-SRBC-IgM titer over time in all the groups. 
The detailed summary of statistically analyzed IgM production by two way analysis 
of variance (ANOVA) followed by Newman-Keuls post hoc test are shown in Fig. 2 
and Table 1. By day 7- post-I, the IgM titer increased and attained highest peak, but 
by days 14-, 2I-, 28- and 58- post-I a gradual decrease was observed in all 
experimental groups. Group V showed significant (P< 0.01) enhancement of anti-
SRBC-IgM titer at day 7-, 14-, 2I-, 28-, 58- post-I as compared to all experimental 
groups (II, III and IV). However, group IV showed significant (P< 0.01) enhancement 
(at day 7- post-I) and suppression (at day 14-, 21-, 28- and 58- post-I) of anti-SRBC-
IgM titer as compared to group II. Moreover, group IV revealed significantly (P< 
O.OI) enhanced anti-SRBC-IgM titer at day 7-, 14-, 21- & 28- post-1, while at day 58-
post-I, it showed similar anti-SRBC-IgM titer to group III. Group III revealed 
significant (P< 0.01) suppression of anti-SRBC-IgM titer at day 7-, 14- and 21- post-I 
as compared to group II. However, at day 28- and 58- post-1, anti-SRBC-IgM titer 
was same in group II, III and IV. No IgM response was noticed in group I (negative 
control) during whole of the study period. 
3.1.II.3.3. Anti-SRBC-immunoglobulin-G (IgG) production 
Anti-SRBC-IgG was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 1) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgG production but evident more in ELISA as opposed to 
HA. No IgG response was detected in all experimental groups at day 0 (pre-1). The 
detailed summary of statistically analyzed IgG production by two way analysis of 
variance (ANOVA) followed by Newman-Keuls post hoc test are shown in Fig. 3 and 
Table 1. By day 7- post-1, the IgG titer increased but it attained highest peak at day 
14- post-I; while by days 21-, 28- and 58- post-I, it gradually falls down or maintained 
a plateau in the group II (positive control). However, IgG titer in histamine-treated 
groups (III and IV) revealed significant (P< 0.01) enhancement as compared to group 
II at day 7- post-I. 
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Figure 1. SRBC-specific Immunoglobulins (Igs) production titer in dose dependent 
histamine-treated rabbits by whole SRBC-ELISA method in duplicate 1:100 diluted sera. 
The results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect of 
treatments (F=32722.843, DF=4,85; P<0.01) and days (F=8434.679, DF=5,425; P<0.01) 
on SRBC were statistically significant. The interaction (treatments x days) effect of 
(F=2624.262, DF=20,425; P<0.01) these on SRBC were also found to be significant. 
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Figure 2. SRBC-specific Immunoglobulin-M (IgM) production titer in dose dependent 
histamine-treated rabbits by whole SRBC-ELISA method in dupHcate 1:100 diluted sera. 
The results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect of 
treatments (F=25399.739, DF=4,85; P<0.01) and days (F=5537.344, DF=5,425; P<0.01) 
on SRBC were statistically significant. The interaction (treatments x days) effect of 
(F=l731.587, DF=20,425; P<0.01) these on SRBC were also found to be significant. 
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Figure 3. SRBC-specific Immunoglobulin-G (IgG) production titer in dose dependent 
histamine-treated rabbits by whole SRBC-ELISA method in dupUcate 1:100 diluted sera. 
The results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect of 
treatments (F=38652.635, DF=4,85; P<0.01) and days (F=5664.092, DF-5,425; P<0.01) 
on SRBC were statistically significant. The interaction (treatments x days) effect of 
(F=1748.642, DF=20,425; P<0.01) these on SRBC were also found to be significant. 
(84) 
1/5 
00 
Chapter 3.1. In Vivo Immunomodulation and Immunomodulatory 
Profile of Histamine Receptors 
Chapter 3.1.11. Dose-Dependent Effect of Histamine on Antibody 
Generation Profde 
However, IgG titer in group IV and III showed significant (P< 0.01) suppression 
at day 14-, 21-, 28- and 58- post-I as compared to group II. IgG titer in group III was 
significantly (P< 0.01) suppressed as compared to group IV over a span of whole study 
period. Moreover, group V showed significant (P< 0.01) enhancement of anti-SRBC-IgG 
titer at days 7-, 14-, 21-, 28- and 58- post-I as compared to rest of the experimental group 
(II, III and IV). No IgG response was noticed in group V (negative control) during whole 
ofthe study period. 
3.1.11.4. Discussion 
In the present report, we studied the effect of histamine as an immunopotentiating 
agent via the dose-dependent experimentations in albino rabbits and demonstrated the 
effect of histamine on antibody generation profile. We investigated total serum 
immunoglobulins (Igs), IgM and IgG generation profile against SRBC, a T lymphocyte-
dependent test antigen (Koganei et al. 2007), modulated by endogenous histamine 
(released from effector cells) in positive control (sterile distilled water-treated)- and 
histamine treated-experimental groups. Therefore, we hypothesized the present work to 
delineate the immunomodulatory role of histamine against SRBC. 
Based on the present study, we demonstrate that the histamine, released from 
immunological stimuli from effector cells (mast cells and basophils) in v/vo (Shahid et al. 
2009), could influence a detectable antibody response to SRBC as early as day 7- post-I, 
which lasted till day 58- post-I in all experimental groups. 
We showed that the histamine treated-rabbits showed immunopotentiating 
properties by enhancing the anti-SRBC-antibodies (Igs, IgM and IgG) titers as compared 
to positive control group over span of whole study period. 
In this preliminary study, we noticed immunomodulatory effect of histamine at 
three different doses (50 ^gkg'', 100 i^gkg"' and 200 iigkg''), and observed their outcome 
on antibody generation titer. It was interestingly noticed that 50 |ig histamine-treated 
group affect total Igs and IgG generation titer at day 7- post-I (until histamine remains in 
the body). However, 100 |ig and 200 ^g histamine-treated group at day 7- post-I (until 
(86) 
Chapter 3.1. In Vivo Imniunomodulation and Immunomodulatory 
Profile of Histamine Receptors 
Chapter 3.1.11. Dose-Dependent Effect of Histamine on Antibody 
Generation Profile 
it's presence in the body) enhanced total Igs, IgM and IgG generation titer whereas, on 
further metabolization histamine effect disappeared on the antibody generation profile 
bringing it in the range of control antibody level in 50 fag and 100 |ig histamine-treated 
group, while it disappeared in 200 |ig histamine-treated group. Therefore, on the basis of 
the present study we reached the conclusion that the results obtained due to histamine 
were of short duration which disappeared in later stage of 50 |Lig and 100 \xg histamine-
treated groups due to clearance of these substance from the body in rabbits. 
To conclude, our results provide evidence that antibody generation titer in vivo 
was affected by the concentration of histamine. 
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3.2.1. Brief Summary 
Present study was designed to delineate the immunomodulatory role of histamine Hl-
receptors on antibody generation profile in rabbit system. The cohort comprised of 
three groups (III, IV & V), containing 18 (9 male and 9 female) rabbits each, and 
received subcutaneous histamine (100 ngkg"' x b.i.d.), HI-agonist (HTMT, 10 ngkg"' 
X b.i.d.) and intramuscular HI-antagonist (pheniramine, 10 mgkg'' x b.i.d.), 
respectively for 10 days (starting from day 1). They were subsequently immunized 
with intravenous injection of SRBC at day 3. Group-II (positive control) (n = 18) 
received vehicle (sterile distilled water, 1 mikg'' x b.i.d.) and then immunized in a 
similar manner, while group-1 (negative control) (n = 18) remained non-immunized 
and received only vehicle (sterile distilled water, 1 mIkg'' x b.i.d.). Blood samples 
were collected on pre-immunization (pre-I) (day 0), as well as on days 7-, 14-, 21-, 
28- and 58- post-immunization (post-I). The ELISA and HA both showed similar 
production of anti-SRBC-immunoglobulins (Igs), IgM and IgG but evident more in 
ELISA as compared to HA. Results showed that, histamine could influence a 
detectable antibody response to SRBC as early as day 7-postimmunization (post-I), 
which lasted until day 58- post-I. In vivo immunoregulatory processes showed 
suppression of total anti-SFlBC-Igs, IgM and IgG generation profile in HIR-
antagonist-treated group as compared to positive control-group and HlR-agonist-
group. While HlR-agonist-group showed increased total Igs, IgM and IgG profile as 
compared to positive control, histamine-treated and HlR-antagonist group. All the 
results were found stafistically significant (P<0.05). In conclusion, HlRs 
demonstrated significant role in modulation of immunoglobulins generation profile. 
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3.2.2. Materials and Methods 
3.2,2.1. Experimental design 
To evaluate the systemic antibody response, 90 (45 Male and 45 Female) New 
Zealand adult healthy albino rabbits of either sex (1:1 ratio) weighing 1.0-1.5 kg were 
randomized equally into five treatment groups i.e. 18 rabbits (9 male and 9 female) in 
each group. 
Control group: Group-I (negative control) remained non-immunized and received 
only vehicle (sterile distilled water, 1 mlkg'' x b.i.d.). Group-Il was vehicle (sterile 
distilled water, 1 mlkg' x b.i.d.) treated and immunized as a positive control. 
Experimental group: Group-lII was histamine treated and immunized, group-lV was 
HlR-agonist treated and immunized, and group-V was HlR-antagonist treated and 
immunized. 
The animals were housed in well-maintained animal facility at central animal 
house, J. N. Medical College, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22 ± 2°C) and were 
allowed free access. They have provided standard laboratory diet including green 
vegetables and tap water during experimentation. All studies were carried out during 
the light cycle and were approved by the Institutional Animal Ethical Committee. 
3.2.2.2. Materials 
All materials were same as used in chapter 3.1.1. 
3.2.2.3. Drugs and doses 
In the present study following drugs were used: histamine dihydrochloride 
obtained from Himedia laboratories Pvt Limited, India; HlR-agonist [histamine 
trifluoro-methyl toluidide (HTMT)-dimaleate] kindly donated by Tocris Bioscience, 
Tocris Cookson Ltd., United Kingdom; and Avil® (pheniramine maleate) in injection 
LP. from Unimark Remedies. 
Histamine (lOO^g/kg), HTMT-dimaleate (lOng/kg) were administered twice a 
day subcutaneously (s.c), and pheniramine maleate (lOmg/kg) was administered 
twice a day through intramuscular (i.m.) route; starting from three days prior to 
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immunization till 7 days after immunization. All doses referred to the weight of the 
salts used. 
3.2.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, ,1. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH-
7.4) thrice by centrifugation. The cell suspensions were adjusted to the desired, 
concentration in terms of hemoglobin, lysis of a 1% SRBC suspension (2 x lo* 
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franzl (1972). Finally the concentration 
was adjusted to 5% (1 x 10^  cells/ml) in PBS for immunization before use. 
3.2.2.5. Immunization of rabbits 
The rabbits in all experimental groups (II-V) were immunized intravenously 
with 1ml of 5% (I x 10^  cells/ml) sheep red blood cells (SRBC) in PBS. 
3.2.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins into labelled sterile bottles prior to 
immunization (day 0), as well as on days 7-, 14-, 21-, 28- and 58- after immunization. 
Blood samples were kept at room temperature for 2 hr and then left for overnight at 
4°C. Blood samples were centrifuged for 10 minutes at 580xg, and serum was isolated 
and heated at 56T for 30 minutes to inactivate complement proteins and stored in 
aliquots containing sodium ai^ ide as preservative at -20°C till tested further (Doumal 
1972). 
3.2.2.7. Serological analysis 
3.2.2.7.1. Hemagglutination assay (HA) 
Same as chapter 3.1.1. 
3.2.2.7.2. ELISA using whole SRBC 
Same as chapter 3.1.1. 
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3.2.2.8. Statistical analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. A two-tailed (a = 2) probability P<0.05 
was considered to be statistically significant. Analyses were performed on SPSS for 
windows (version 12.0, Inc., Chicago, IL). 
3.2.3. Results 
To evaluate the effects of histamine HI receptors-agonist and -antagonist on 
the immunomodulation, antibody-mediated responses to SRBC were assessed. Total 
serum immunoglobulins (Igs), total immunoglobulin-M (IgM) and total 
immunoglobulin G (IgG) generation profiles were studied in vivo in five experimental 
groups at days 0 [pre-immunization (pre-I)], 7, 14, 21, 28 and 58 [post-immunization 
(post-I)]. 
3.2.3.1. Profile of total anti-SRBC-immunoglobulins (Igs) production 
The profile of total anti-SRBC-immunoglobulins (Igs) titer was studied by 
whole SRBC-ELISA method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghighi 
et al. 2005) (Table 1). The ELISA and HA assay both showed similar IgG production 
but evident more in ELISA as opposed to HA. No Igs response was detected in all 
experimental groups (control and drug treated) at day 0 (pre-I). There was an initial 
increase and subsequent decrease in total serum Igs titer over a time span of 58 days 
in all the groups. By the day 7- post-I, Igs titer was significantly high, however it 
attained a peak at day 14, and by days 2I-, 28- and 58- post-I there was a gradual 
decrease or a plateau in all experimental groups as compared to histamine-treated 
groups (Fig. 1 and Table I). The detailed summary of statistically analyzed Igs 
production by two way analysis of variance (ANOVA) followed by Newman-Keuls 
post hoc test are shown in Fig. 1 and Table 1. More extensive evaluation revealed that 
anti-SRBC-immunoglobulins (Igs) raised steeply up to 7 days post-I, and there was a 
significant decrease in histaniiine-treated group as compared to all other experimental 
groups. 
HlR-agonist (HTMT dimaleate)-treated rabbits showed significant (P< 0.01) 
enhancement of anti-SRBC-Igs production in contrast to histamine-treated and control 
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rabbits. However, antagonists studies showed different patterns; Jiistamine showed 
initial enhancement and later suppression of anti-SRBC-Igs production profile during 
the whole study as compared to control groups only (significant increase of total 
serum anti-SRBC-Igs level was noticed at day 7- post-I (P< 0.01), and suppression of 
serum anti-SRBC-Igs levels at days 14- and 21- post-I (P< 0.01). While, at days 28-
and 58- post-I the results were more similar to control group. HIR-antagonist 
(pheniramine)-treated rabbits showed significant (P< 0.01) suppression of total serum 
anti-SRBC-Igs level at days 7-, 28- and 58- post-I in comparison to'histamine-treated 
group (P< 0.05), whereas this group demonstrate significant (P< 0.01) enhancement 
of total serum anti-SRBC-Igs levels at days 14- and 21- post-I (Fig. 1). Moreover, 
HIR-antagonist (pheniramine)-treated rabbits showed significant (P<0.01) 
suppression of total anti-SRBC-Igs as opposed to control rabbits during complete 
study period (Fig. 1 and Table 1). No Igs response was noticed in group I (negative 
control) during whole of the study period. 
3.2.3.2. Profile of anti-SRBC-immunoglobulin-M (IgM) production 
Anti-SRBC IgM was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 2) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgG production but evident more in ELISA as opposed to 
HA. No IgM response was observed in all experimental groups (control and drug 
treated) at day 0- pre-I, however there was an initial increase and then gradual 
decrease in serum-IgM titer over time in all the groups. By day 7- post-I, the IgM titer 
increased and attained highest peak, but by days 14-, 21-, 28-, and 58- post-I there 
was a gradual decrease in all experimental groups (except HIR-antagonist 
(pheniramine)-treated, where the highest peak was obtained at day 14- post-I and then 
there was a gradual decrease). The detailed summary of statistically analyzed IgM 
production by two way analysis of variance (ANOVA) followed by Newman-Keuls 
post hoc test are shown in Fig. 2 and Table 1. Anti-SRBC-IgM raised steeply up to 7 
days post-I, and there was a significant decrease in histamine-treated group as 
compared to all other experimental groups. 
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Figure 1. SRBC-specific Immunoglobulins (Igs) production titers in HlR-agonist/-
antagonist-treated rabbits by wboie SRBC-FTJSA in duplicate 1:100 diluted sera. The 
results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect 
of treatments (F-60012.621, DF=4,85; P<0.01) and days (F=56673.656, DF=5,425; 
P<0.01) on SRBC were statistically significant. The interaction (treatments x days) 
effect of (F=l0685.232. DF-20.425; P<0.01) these on SRBC were also found to be 
significant. 
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Figure 2. SRBC-specific Immunoglobulin-M (IgM) production titers in HIR-
agonist/'-antagonist-treated rabbits by wlioie SRBC-ELISA in duplicate 1:100 diluted 
sera. The results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-wav ANOVA followed by Newman-Keuls post hoc test revealed that the effect 
of treatments (F-8235.159, DF=4,85; P<0.01) and days (F=12620.850, DF=5,425; 
P<0.01) on SRBC were statistically significant. The interaction (treatments x days) 
effect of (1=1638.580, DF=20,425; P<0.01) these on SRBC were also found to be 
significant. 
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HlR-agonist (HTMT dimaleate)-treated rabbits showed significant (P< 0.01) 
enhancement of total anti-SRBC-IgM as opposed to ail experimental groups (Fig. 2). 
HlR-antagonist (pheniramine)-treated rabbits showed significant (P< 0.01) 
suppression of total anti-SRBC-IgM as compared to control rabbits and also HIR-
agonist-treated group during span of the study period (refer to Fig. 2 and Table 1). No 
IgM response was noticed in group 1 (negative control) during whole of the study 
period. 
3.2.3.3, Profile of anti-SRBC-immunoglobuIin-G (IgG) production 
The profile of total anti-SRBC-IgG titer was also studied by whole SRBC-ELISA 
method (Koganei et al. 2007) (Fig. 3) and direct HA (Haghighi et al. 2005) (Table 1). 
The observed profiles were similar by ELISA and HA assays. The ELISA and HA 
assay both showed similar IgG production but evident more in ELISA as opposed to 
HA. No IgG response was detected in all experimental groups (control and drug 
treated) at day 0 (pre-I). More extensive evaluation revealed that anti-SRBC-IgG in 
histamine-treated group raised steeply up to 7- days post-I as compared to control and 
HlR-antagonist (pheniramine)-treated, but suppressed as opposed to HlR-agonist 
(HTMT dimaleate)-treated rabbits. By days 14-, 21-, 28- and 58- post-I there was a 
significant decrease in anti-SRBC-IgG levels in histamine-treated as compared to all 
other experimental groups and this was found statistically significant (Fig. 3 and 
Table I). The detailed summary of statistically analyzed IgG production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are shown 
in Fig. 3 and Table 1. HlR-agonist (HTMT dimaleate)-treated rabbits showed 
significant enhancement of anti-SRBC-IgG as opposed to histamine-treated and 
control rabbits (Fig. 3). Furthermore, HlR-antagonist (pheniramine) suppressed 
significantly (P< 0.01) the anti-SRBC-IgG in comparison to control group. By day 7-
post-I, the antibody titer was significantly high, which obtained a peak between days 
14- to 21- post-I, and by day 28- and 58- post-I, it gradually fell down or maintained a 
plateau in all experimental groups except histamine-treated group (Fig. 3). 
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Figure 3, SRBC-specific Immunoglobulin-G (IgG) production titers in HlR-agonist/-
antagonist-treated rabbits by whole SRBC-ELISA in duplicate 1:100 diluted sera. The 
results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect 
of treatments (F=7387.145. DF=4,85; P<0.01) and da>s (F=4812.220, DF=5,425; 
P<0.01) on SRBC were statistically significant. The interaction (treatments x days) 
effect of (F=849.827, DF=20.425; P<0.01) these on SRBC were also found to be 
significant. 
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More extensive evaluation revealed that anti-SRBC-IgG raised steeply up to 21- days 
post-I, and then there was a significant decrease in HlR-antagonist (pheniramine)-
treated group, however, control group (untreated) showed slight increase until 14-
days and finally maintained a plateau. No IgG response was noticed in group I 
(negative control) during whole of the study period. 
3.2.4. Discussion 
In the present study, v/e investigated total serum Igs, IgM and IgG generation 
profile against SRBC, a T lymphocyte-dependent test antigen (Putman et al. 2002, 
Koganei et al. 2007), modulated by endogenous histamine (released from effector 
cells) in control (untreated)-, HlR-agonist (HTMT) treated-, HlR-antagonist 
(pheniramine) treated- and histamine treated-experimental groups. 
To provide exact evidence relating our investigations to in vivo 
immunoregulatory processes, we used healthy rabbits with and without HIR-
agonistsZ-antagonists treatments. Here we demonstrate that HlR-specific agonist/-
specific antagonist-treated rabbits were characterized by a marked deviation of the 
immune response as compared to control rabbits (untreated). 
Based on the results of the present study, we demonstrate that the histamine, 
released from immunological stimuli from effector cells (mast cells and basophils) in 
vivo (Shahid et al. 2009), could influence a detectable antibody response to SRBC. 
Furthermore, our comparative study on in vivo immunoregulatory processes 
demonstrated suppressed generation profile of total anti-SRBC-specific-Igs in HIR-
antagonist-treated group while it showed enhancement in HlR-agonist-treated group 
during the whole study period. These data provide evidence that HI-receptors have 
dominant role in total immunoglobulins (Igs) production. 
Histamine, itself is a potent agonist of all four receptors (HI, H2, H3 & H4) 
(Jutel et al. 2001, Thurmond et al. 2008, Shahid et al. 2009), which directly affects B-
cell antibody production as a co-stimulatory receptor on B-cells (Rocklin and Beer 
1983, Akdis and Blaser 2003, Jutel et al. 2005, Akdis 2006). It has been demonstrated 
in mice also that histamine enhances anti-IgM induced proliferation of B-cells, which 
abolished in HlR-deleted mice. 
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In HlR-deleted mice antibody production against a T cell-independent 
antigen-TNP-Ficoll is decreased (Banu and Watanabe 1999), suggesting an important 
role of HIR signaling in response triggered from B-cell receptors. 
Jutel et al. (2001) showed a different pattern of antibody responses to T cell-
dependent antigens like ovalbumin and demonstrated that HlR-deleted mice produced 
high ovalbumin-specific IgGl and IgE in comparison to wild type mice. 
In the present in vivo study, we demonstrated that the histamine treated-rabbits 
showed immunopotentiating properties by enhancing the anti-SRBC-antibodies levels 
as compared to control group. 
Furthermore, anti-SRBC-IgM profile demonstrated that H1 R-antagonist 
suppresses IgM profile as compared to positive control-group, and on the other hand, 
HlR-agonist enhanced the anti-SRBC-IgM levels as compared to all the 
experimental-group and demonstrate that HI-receptors have role of IgM generation. 
While anti-SRBC-IgG profiles demonstrated that HlR-antagonist-treated group 
suppress the anti-SRBC-IgG levels during complete study as compared to positive 
control-group, while in contrast, HlR-agonist increased IgG profile as compared to 
other experimental-group and further demonstrated that HI-receptors have an 
important role in IgG generation. 
In this preliminary study, we noticed that exogenously added histamine in vivo 
(until its presence in the body) enhanced the antibody generation profile against 
SRBC whereas; on further metabolism its effect disappeared on the antibody 
generation profile bringing it in the range of control antibody level. We also observed 
that HI R-antagonist (until their presence) suppressed the antibody profile, which 
came to normal level (control range) in later phase due to their metabolism. 
Therefore, on the basis of the present study we reached to a conclusion that the results 
obtained due to histamine and HI R-antagonist were of short duration which 
disappeared in latter stage due to clearance of the body from these substance in 
rabbits. Thus, both results (histamine-treated and antagonist-treated) groups, after 
metabolism of drugs, were identical to each other and also similar to control group. 
In the current study, analysis of the results by two serological techniques, 
ELISA and HA, is noteworthy. On comparing the results of HA with ELISA, similar 
conclusions were drawn and hence we suggest that laboratories that still do not have 
facilities for ELISA may at least use HA to perform base line studies on this aspect. 
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To conclude, our results provide evidence that histamine HI-receptors have 
principle role in modulation of immunoglobulins and demonstrate important 
immunomodulatory effects in IgG and IgM generation. To the best of our knowledge, 
this is the first report describing the potential immunoregulatory role of Hl-receptor-
agonistZ-antagonist. 
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3.3.1. Brief Summary 
Present study was designed to delineate tlie immunomodulatory role of histamine H2-
receptors and their role in antibody generation profile in rabbit system. The cohort 
comprised of three groups (III, IV & V), containing 18 (9 male and 9 female) rabbits 
each, and received subcutaneous histamine (100 ^gkg"' x b.i.d.), H2-agonist 
(amthamine, 10 ngkg"' x b.i.d.) and intramuscular H2-antagonist (ranitidine, 10 mgkg' 
' X b.i.d.), respectively for 10 days (starting from day 1). They were subsequently 
immunized with intravenous injection of SRBC at day 3. Group Il-positive control (n 
= 18) received vehicle (sterile distilled water, 1 mlkg'' x b.i.d.) and immunized in a 
similar manner, while group I-negative control (n = 18) remained non-immunized and 
received only vehicle (sterile distilled water, 1 mlkg'' x b.i.d.). Blood samples were 
collected on pre-immunization (pre-I) (day 0), as well as on days 7-, 14-, 21-, 28- and 
58- post-immunization (post-I). The ELISA and HA both showed similar production 
of Igs, IgM and IgG but evident more in ELISA as compared to HA. The results 
demonstrated that the histamine treated-rabbits showed immunopotentiating 
properties by enhancing the anti-SRBC-antibodies levels as compared to control 
group. Furthermore, anti-SRBC-IgM profile showed that H2R-antagonist enhanced 
IgM profile as compared to positive control-group; on the other hand, agonists study 
showed different profile; H2R-agonist enhanced the anti-SRBC-IgM levels in 
comparison to H2R-antagonist-treated group and positive control. While anti-SRBC-
IgG profiles showed that H2R-antagonist-treated group suppress the anti-SRBC-IgG 
levels during complete study as compared to positive control and in contrast, H2R-
agonist increased IgG profile as compared to all experimental-group. All the results 
were found statistically significant (P<0.05). In conclusion, H2Rs demonstrated 
significant role in enhancement of total immunoglobulins (Igs), IgG and IgM 
generation. The findings of this study may have clinical significance and may provide 
the baseline information in future. 
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3.3.2. Materials and Methods 
3.3.2.1. Experimental design 
To evaluate the systemic antibody response, 90 (45 Male and 45 Female) New 
Zealand adult healthy albino rabbits of either sex (1:1 ratio) weighing 1.33±0.28 kg 
were randomized equally into five treatment groups i.e. 18 rabbits (9 male and 9 
female) in each group. 
Control group: Group-I (negative control) remained non-immunized and received 
only vehicle (sterile distilled water, 1 mlkg'' x b.i.d.). Group-II was vehicle (sterile 
distilled water, 1 mlkg'' x b.i.d.) treated and immunized as a positive control. 
Experimental group: Group-Ill was histamine-treated and immunized, group-lV was 
H2R-agonist-treated and immunized, and group-V was H2R-antagonist-treated and 
immunized. 
The animals were housed in well-maintained animal facility at central animal 
house, J. N. Medical College & Hospital, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22±2°C) and were 
allowed for free access to standard laboratory diet including green vegetables and tap 
water until experimentation. All studies were carried out during the light cycle and 
were approved by the Institutional Animal Ethical Committee. 
3.3.2.2. Materials 
All materials were same as used in chapter 3.1.1. 
3.3.2.3. Drugs and Doses 
In the present study following drugs were used: histamine dihydrochloride 
obtained from Himedia laboratories Pvt Limited, India; H2R-agonist (amthamine 
dihydrobromide) kindly donated by Tocris Bioscience, Tocris Cookson Ltd., United 
Kingdom; and Rantac® (ranitidine hydrochloride) in injection LP. by J. B. Chemicals 
and pharmaceuticals, India. All doses referred to weight of the salts used. 
Histamine (100 |ag/kg) and amthamine dihydrobromide (10 ng/kg) were 
administered twice in a day through subcutaneous (s.c.) route, while ranitidine 
hydrochloride (10 mg/kg) was administered intramuscularly (i.m.) twice a day. 
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starting from three days prior to immunization until 7 days after immunization. All 
doses referred to weight of the salts used. 
3.3.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, J. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH-
7.4) thrice by centrifugation. The cell suspensions were adjusted to the desired 
concentration in terms of hemoglobin, lysis of a 1% SRBC suspension (2 x IQ^  
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franzl (1972). Finally the concentration 
was adjusted to 5% (1 x 10^  cells/ml) in PBS for immunization before use. 
3.3.2,5. Immunization of rabbits 
The rabbits in all experimental groups (II-V) were immunized intravenously 
with 1ml of 5% (1 x ]o' cells/ml) sheep red blood cells (SRBC) in PBS. 
3.3.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins into labelled sterile bottles prior to 
immunization (day 0), as well as on days 7-, 14-, 21-, 28- and 58- post-immunization. 
Blood samples were kept at room temperature for 2 hr and then left for overnight at 
4°C. Blood samples were centrifuged for 10 minutes at 580xg and serum was isolated 
and heated at 56°C for 30 minutes to inactivate complement proteins and stored in 
aliquots containing sodium azide as preservative at -20^ till tested further (Doumal 
1972). 
3.3.2.7. Serological analysis 
3,3.2,7.1. Hemagglutination assay (HA) 
Same as chapter 3.1.1. 
3.3.2.7.2, ELISA using whole SRBC 
Same as chapter 3.1.1,. 
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3.3.2.8. Statistical analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. A two-tailed (a = 2) probability P<0.05 
was considered to be statistically significant. Analyses were performed on SPSS for 
windows (version 12.0, Inc., Chicago, IL). 
3.3.3. Results 
To evaluate the effects of histamine H2 receptors-agonist and -antagonist on 
the antibody-mediated immune responses to SRBC were assessed. Total serum 
immunoglobulins (Igs), total immunoglobulin-M (IgM) and total immunoglobulin-G 
(IgG) generation profiles were studied in vivo in five experimental groups at days 0 
[pre-immunization (pre-I)], 7, 14, 21, 28 and 58 [post-immunization (post-I)]. 
3.3.3.1. Profile of total anti-SRBC-immunoglobulins (Igs) production 
The profile of total anti-SRBC-Igs titer was studied by whole SRBC-ELISA 
method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghighi et al. 2005) (Table 1). 
The observed profiles were similar by ELISA and HA assays, however, the results 
were found comparatively more significant by ELISA (P< 0.01) as compared to HA 
(P< 0.05). No anti-SRBC-Igs response was detected in all experimental groups 
(control and drug treated) at day 0 (pre-I). There was an initial increase and 
subsequent decrease in total serum anti-SRBC-Igs titer over a time span of 58 days in 
all the groups and was found statistically significant at each experimental post-I days. 
The detailed summary of statistically analyzed Igs production by two way analysis of 
variance (ANOVA) followed by Newman-Keuls post hoc test are shown in Fig. 1 and 
Table 1. By the day 7- post-I, Igs titer was significantly high, however it obtained a 
peak at day 14, and by days 21-, 28- and 58- post-I there was a gradual decrease or a 
plateau in all experimental groups as compared to histamine-treated groups (Fig. 1 
and Table 1). More extensive evaluation revealed that anti-SRBC-immunoglobulins 
(Igs) raised steeply up to 7 days post-I, and there was a significant decrease in 
histamine-treated group was observed as compared to all other experimental groups. 
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Figure 1. SRBC-specific Immunoglobulins (Igs) production titers in H2R-agonist/-
antagonist-treated rabbits by whole SRBC-RLISA in duplicate 1:100 diluted sera. The 
results demonstrate mean ± s.d. of three experiments each with six rabbits. Two-way 
ANOVA followed by Newman-Keuls post hoc test revealed that the effect of treatments 
(r-56263.064. DF=4.85; P<0.01) and days (F=62327.134, DF=5,425; P<0.01) on SRBC 
were statistically significant. The interaction (treatments x days) effect of (F=9706.625, 
DF-20.425; P<0.01) these on SRBC were also found to be significant. 
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H2R-agonist (amthamine)-treated rabbits showed significant (P< 0.01) enhancement 
in the production of total anti-SRBC-lgs as opposed to histamine-treated and control 
rabbits. However, antagonists studies showed different patterns i.e., histamine showed 
initial enhancement and later suppression of anti-SRBC-lgs production profile during 
the whole study as compared to H2R-antagonist and control groups only (significant 
increase of total serum anti-SRBC-lgs level was noticed at day 7- post-I (P< 0.01), 
and suppression of serum anti-SRBC-lgs levels at days 14- and 21- post-I (P< 0.01 
each for H2R-antagonist and control groups). At days 28- and 58- post-I the results 
were found statistically significant as compared to H2R-antagonist (P< 0.01), 
however these results were found similar to control group. Ranitidine-treated rabbits 
showed slightly different pattern of initial suppression and later enhancement of anti-
SRBC-lgs production profile during the whole study period. Ranitidine significantly 
(P< 0.01) suppressed total serum anti-SRBC-lgs level at days 7- and 14- post-I, and in 
the later period enhanced total serum anti-SRBC-lgs levels at days 21-, 28- and 58-
post-I as compared to control rabbits (Fig. 1 and Table 1). No Igs response was 
noticed in group I (negative control) during whole of the study period. 
3.3.3.2. Profile of anti-SRBC-immunoglobulin-M (IgM) production 
Anti-SRBC-IgM was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 2) and direct HA (Haghighi et al. 2005) (Table 1). No IgM response 
was observed in all experimental groups (control and drug treated) at day 0- pre-I, 
however there was an initial increase and then gradual decrease in serum-IgM titer 
over time in all the groups. The detailed summary of statistically analyzed IgM 
production by two way analysis of variance (ANOVA) followed by Newman-Keuls 
post hoc test are shown in Fig. 2 and Table 1. By day 7- post-I, the IgM titer increased 
and attained highest peak, but by days 14-, 21-, 28-, and 58- post-I there was a gradual 
decrease in all experimental groups (except H2R-antagonist (ranitidine)-treated 
groups, where the highest peak was attained at day 14- post-I and then there was a 
gradual decrease). Anti-SRBC-IgM raised steeply up to 7 days post-I, and there was a 
significant decrease in histamine-treated group as compared to all other experimental 
groups. H2R-agonist (amthamine)-treated rabbits showed significant (P< 0.01) 
enhancement of total anti-SRBC-IgM as opposed to all experimental groups (Fig. 2). 
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Figure 2. SRBC-specific Immunoglobulin-M (IgM) production titers in H2R-agonist/-
antagonist-treated rabbits by whole SRBC-ELISA in duplicate 1:100 diluted sera. The 
results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect of 
treatments (F=l 5611.492, DF=4,85; P<0.01) and days (F=l 5535.230, DF=5.425; P<0.01) 
on SRBC were statistically significant. The interaction (treatments x days) effect of 
(F-2353.508, DF-20.425; P<0.01) these on SRBC were also found to be significant. 
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H2R-antagonist (ranitidine)-treated rabbits showed suppression of anti-SRBC-
IgM level at day 7- post-I, and then enhanced production of anti-SRBC-IgM at days 
14-, 21-, 28- and 58- post-I as compared to control rabbits (P< 0.01). No IgM 
response was noticed in group I (negative control) during whole of the study period 
(refer to Fig. 2 and Table 1). 
3.3.3.3. Profile of anti-SRBC-immunoglobulin-G (IgG) production 
The profile of total anti-SRBC-IgG titer was also studied by whole SRBC-
ELISA method (Koganei et al. 2007) (Fig. 3) and direct HA (Haghighi et a). 2005) 
(Table 1). The ELISA and HA assay both showed similar IgG production but evident 
more in ELISA as opposed to HA. No anti-SRBC-IgG response was detected in all 
experimental groups (control and drug treated) at day 0 (pre-I). More extensive 
evaluation revealed that anti-SIlBC-IgG in histamine-treated group raised steeply up 
to 7- days post-I as compared to control and H2R-antagonist (ranitidine) groups, but 
suppressed as opposed to H2R-agonist (amthamine)-treated rabbits. By days 14-, 21-, 
28- and 58- post-I there was a significant decrease in anti-SRBC-IgG levels in 
histamine-treated group as compared to ail other experimental groups and it was 
found statistically significant (Fig. 3 and Table 1). The detailed summary of 
statistically analyzed IgG production by two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test are shown in Fig. 3 and Table 1. H2R-
agonist (amthamine)-treated rabbits showed significant enhancement of anti-SRBC-
IgG as opposed to histamine-treated and control rabbits (Fig. 3). H2R-antagonist 
(ranitidine) suppressed significantly (P< 0.01) the anti-SRBC-IgG as compared to 
control group. By day 7- post-I, the antibody titers was significantly high, obtained a 
peak between days 14- to 21- post-I, and by day 28- and 58- post-I and then it 
gradually fall down or maintained a plateau in all experimental groups except 
histamine-treated group (Fig. 3). More extensive evaluation revealed that anti-SRBC-
IgG raised steeply up to 14 days post-I, however, the H2R-antagonist (ranitidine)-
treated, and control group (untreated) showed slight increase until 21- days and finally 
maintained a plateau. No IgG response was noticed in group V (negative control) 
during whole of the study period. The detailed results of ELISA and HA, detecting the 
anti-SRBC-IgG are shown in Fig. 3 and Table 1. 
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Figure 3. SRBC-specific Immunoglobulin-G (IgG) production titers in H2R-agonist/-
anlagonist-treated rabbits by whole SRBC-ELISA in duplicate 1:100 diluted sera. The 
results demonstrate mean ± s.d. of three experiments each with six rabbits. 
Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the effect of 
treatments (F=4277.263. DF=4,85; P<0.01) and days (F=4378.292. DF=5,425; P<0.01) 
on SRBC were statistically significant. The interaction (treatments x days) effect of 
(F=624.256, DF-20,425; P<0.01) these on SRBC were also found to be significant. 
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3.3.4. Discussion 
In the present study, we investigated total serum immunoglobulins (Igs), 
immunoglobulin-M (IgM) and immunoglobuIin-G (IgG) generation profile against 
SRBC, a T lymphocyte-dependent test antigen (Putman et al. 2002, Koganei et al. 
2007), modulated by endogenous histamine (released from effector cells) in control 
(untreated)-, H2R-agonist (amthamine) treated-, H2R-antagonist (ranitidine) treated-
and histamine treated-experimentai groups. 
To provide exact evidence relating our investigations to in vivo 
immunoregulatory processes, we used healthy rabbits with and without H2R-agonist/-
antagonist treatments. Here we demonstrate that H2R-specific agonistZ-specific 
antagonist-treated rabbits were characterized by a marked deviation of the immune 
response as compared to control rabbits (untreated). 
Based on the results of the present study, we demonstrate that the histamine 
released from immunological stimuli from effector cells in vivo (Shahid et al. 2009), 
could influence a detectable antibody response to SRBC. Our comparative study on in 
vivo immunomodulatory processes demonstrated that H2R-agonist enhances while 
H2R-antagonist suppresses the anti-SRBC-antibody generation level. Thus, these data 
provide evidence that H2-receptors have role in immunoglobulins production. 
Histamine, itself is a potent agonist of all four receptors (HI, H2, H3 and H4) 
(Jutel et al. 2001, Thurmond et al. 2008, Shahid et al. 2009), which are distributed in 
different parts of body and modulates different biochemical, pharmacological and 
immunological reactions both in vivo and in vitro by activation of signal transduction 
on releasing the endogenous histamine (Shahid et al. 2009). 
It is a known fact that histamine directly affects B-cell antibody production as 
a co-stimulatory receptor on B-cells (Rocklin and Beer 1983, Akdis and Blaser 2003, 
Jutel et al. 2005, Akdis 2006). In the present in vivo study, histamine treated-rabbits 
showed immunopotentiating properties by enhancing the anti-SRBC-antibodles levels 
as compared to control group. 
Furthermore, anti-SRBC-specific-IgM profile demonstrated that H2R-
antagonist suppresses IgM profile (during in early phase treatment period i.e. 
antagonist) as compared to positive control-group, while agonist study showed 
different profile i.e., H2R-agonist enhances the anti-SRBC-IgM levels as compared to 
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H2R-antagonist-treated group and positive control. Tfiese data showed that H2-
receptors have dominant role in IgM generation. 
Anti-SRBC-specific-IgG profile demonstrated that H2R-antagonist-treated 
group suppresses the anti-SRBC-IgG levels as compared to positive control. 
However, H2R-agonist increased IgG profile as compared to all experimental-group. 
These data revealed that H2-receptors have dominant role in enhancement of IgG 
generation. 
In this preliminary study, we noticed that exogenously added histamine in vivo 
(until its presence in the body) enhanced the antibody generation profile against 
SRBC whereas; on further metabolism its effect disappeared on the antibody 
generation profile bringing it in the range of control antibody level. We also observed 
that H2R-antagonist (until their presence) suppressed the antibody profile, which 
came to normal level (control range) in later phase due to their metabolism. 
Therefore, on the basis of the present study we reached to a conclusion that the results 
obtained due to histamine and H2R-antagonist were of short duration which 
disappeared in latter stage due to clearance of the body from these substance in 
rabbits. Thus, both results (histamine-treated and H2R-antagonist-treated) groups, 
after metabolism of drugs, were identical to each other and also similar to control 
group. 
To conclude, our results provide evidence that histamine H2-receptors have 
dominant role in IgM generation and regulate the antibody production. To the best of 
our knowledge, this is the first report describing the potential immunoregulatory role 
of H2-receptor-agonist/-antagonist and also the first report studying the 
immunomodulatory profile in experimental rabbits over a continued study period of 
58 days pre- and post- immunization. 
(112) 
Chapter 3.4. In Vivo Immunomodulation and Immunomodulatory 
Profile of Histamine H3 Receptors 
3.4.1. Brief Summary 
Histamine via its receptors (HI-, H2- & H4-) modulates several immunopathological 
reactions. However, H3-receptor's role is still unclear. Present study was designed to 
delineate the immunomodulatory role of histamine by H3-receptor on antibody 
generation profile in rabbit model. The cohort comprised of three groups (III, IV & 
V), containing 18 (9 male and 9 female) rabbits each and received subcutaneous 
histamine (100^gkg"'xb.i.d.), H3-agonist [R-(-)-a-methylhistamine-dihydrobromide, 
10ngkg"'><b.i.d.], and intramuscular H3-antagonist (iodophenpropit-dihydrobromide, 
lHgkg"'xb.i.d), respectively for 10 days (starting from day 1). They were 
subsequently immunized with intravenous injection of SRBC at day 3. Group-II 
positive-control (n=18) received vehicle (sterile distilled water, lmlkg"'xb.i.d.) 
intramuscularly and immunized in a similar manner, while group-] negative-control 
(n=18) remained non-immunized and received only vehicle (lmlkg"'xb.i.d.). The 
estimation of serum immunoglobulins (Igs), IgM and IgG were done by ELISA and 
Hemagglutination Assay (HA) and observed at day 0 (pre-immunization) and day 7, 
14, 21, 28 and 58 (post-immunization). The ELISA and HA both showed similar 
production of Igs, IgM and IgG but evident more in ELISA as compared to HA. 
Results showed that, histamine could influence a detectable antibody response to 
SRBC as early as day 7-post-I, which lasted until day 58-post-I. Moreover, H3-
receptors by H3R-antagonist showing modulatory activity by enhancing the antibody 
generation levels. In contrast, H3-receptors by H3R-agonist showing modulatory 
activity by suppressing the antibody generation levels. All the results were found 
statistically significant (P< 0.05). In conclusion, histamine through H3-receptors 
modulates antibody generation. The findings of this study may have clinical 
significance and may provide the baseline information in future. 
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3.4.2. Materials and Methods 
3.4.2.1, Experimental design 
To evaluate the systemic antibody response, 90 (45 Male and 45 Female) New 
Zealand adult healthy rabbits of either sex weighing I - 1.5 kg were randomized 
equally into five treatment groups, i.e. 18 rabbits (9 male and 9 female) in each group. 
Each group was immunized with sheep red blood cells (SRBC). 
Control group: Group-I (negative control) remained non-immunized and received 
only vehicle (sterile distilled v/ater, 1 mlkg"' x b.i.d.). Group-II was vehicle (sterile 
distilled water, I mlkg'' x b.i.d.) treated and immunized as a positive control. 
Experimental group: Group-Ill was histamine-treated and immunized, group-IV was 
H3R-agonist-treated and immunized, and group-V was H3R-antagonist-treated and 
immunized. 
The animals were housed in well-maintained animal facility at central animal 
house, J. N. Medical College & Hospital, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22±2°C) and were 
allowed for free access to standard laboratory diet including green vegetables and tap 
water until experimentation. All studies were carried out during the light cycle and 
were approved by the Institutional Animal Ethical Committee. 
3.4.2.2. Materials 
All materials were same as used in chapter 3.1.1. 
3.4.2.3. Drugs and Doses 
In the present study following drugs were used: histamine dihydrochloride 
from Himedia laboratories Pvt Limited, India; H3R-agonist [R-(-)-a-methylhistamine 
dihydrobromide] and H3R-antagonist (iodophenpropit dihydrobromide) kindly 
donated by Tocris Bioscience, Tocris Cookson Ltd., United Kingdom. 
Histamine (100 ng/kg) and [R-(-)-a-methylhistamine dihydrobromide] (10 
Hg/kg) were administered twice a day through subcutaneous (s.c.) route, and 
iodophenpropit dihydrobromide (1 ^g/kg) was administered twice a day through 
intramuscular (i.m.) route; starting from three days prior to immunization until 7 days 
after immunization. All doses referred to the weight of the salts used. 
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3.4.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, J. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH-
7.4) thrice by centrifugation. The cell suspensions were adjusted to the desired 
concentration in terms of hemoglobin, lysis of a 1% SRBC suspension (2 x 10^  
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franzl (1972). Finally the concentration 
was adjusted to 5% (1 x lo'cells/ml) in PBS for immunization before use. 
3.4.2.5. Immunization of rabbits 
The rabbits in all experimental groups (II-V) were immunized intravenously 
via marginal ear vein with 1ml of 5% (1 x lo^ cells/ml) sheep red blood cells (SRBC) 
in PBS. 
3.4.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins into labelled sterile bottles prior to 
immunization (day 0), as well as on days 7-, 14-, 21-, 28- and 58- post-immunization 
(post-I). Blood samples were kept at room temperature for 2 hr and then left overnight 
at 4 ^ . Blood samples were centrifuged for 10 minutes at 580xg, and serum was 
isolated and heated at 56°C for 30 minutes to inactivate complement proteins and 
stored in aliquots, containing sodium azide as preservative, at -20°C till tested further 
(Doumal 1972). 
3.4.2.7. Serological analysis 
3.4.2.7.1. Hemagglutination assay (HA) 
Same as chapter 3.1.1, 
3.4.2.7.2. ELISA using whole SRBC 
Same as chapter 3.1.1. 
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3.4.2.8. Statistical analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. A two-tailed (a = 2) probability P<0.05 
was considered to be statistically significant. Analyses were performed on SPSS for 
windows (version 12.0, Inc., Chicago, IL). 
3.4.3. Results 
To evaluate the effects of histamine H3-receptors-agonist and -antagonist on 
the immunomodulation, antibody-mediated responses to SRBC were assessed. Total 
serum immunoglobulins (Igs), total immunoglobulin-M (IgM) and total 
immunog!obulin-G (IgG) generation profiles were studied in vivo in five experimental 
groups at days 0 [pre-immunization (pre-1)], 7, 14, 21, 28 and 58 [post-immunization 
(post-I)]. 
3.4.3.1. Profile of total anti-SRBC-immunoglobulins (Igs) production 
The profile of total anti-SRBC-immunoglobulins (Igs) titer was studied by 
whole SRBC-ELISA method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghighi 
et al. 2005) (Table 1). The ELISA and HA assay both showed similar Igs production 
but evident more in ELISA as opposed to HA. No anti-SRBC-Igs response was 
detected in all experimental groups (negative control, positive control and drug 
treated) at day 0 (pre-I). There was an initial increase and subsequent decrease in 
serum anti-SRBC-Igs titer over a time span of 58 days in all the groups (Table 1 and 
Fig. 1). The detailed summary of statistically analyzed Igs production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are shown 
in Fig. 1 and Table 1. By the day 7- post-I, antibody titer was high, however it 
obtained a peak at day 14- post-I and by days 21-, 28- and 58- post-I there was a 
gradual decrease or a plateau in positive control group as compared to all drug-treated 
groups (anti-SRBC-Igs raised steeply up to 7 days post-1 and obtained a highest peak, 
however there was a decrease in anti-SRBC-Igs titer at days I4-, 21-, 28- and 58-
post-I in histamine-treated group, H3R-agonist and H3R-antagonist-treated group). 
H3R-agonist [R-(-)-a-methylhistamine dihydrobromidej-treated rabbits showed 
significant (P< 0.01) suppression of anti-SRBC-Igs production as opposed to 
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histamine-treated, HSR-antagonist-treated and positive control rabbits over a time 
span of 58 days. However, histamine and H3R-antagonist studies showed different 
patterns; histamine showed initial enhancement and later suppression of anti-SRBC-
Igs production profile during the whole study as compared to control groups only 
[significant increase of serum anti-SRBC-Igs level was noticed at day 7- post-I (P< 
0.01)], and suppression of serum anti-SRBC-Igs levels at days 14- and 21- post-I (P< 
0.01), while the results were found to be similar to control group at days 28- and 58-
post-I. H3R-antagonist (iodophenpropit dthydrobromide)-treated rabbits showed 
enhancement of anti-SRBC-Igs level at days 7-, and 14- post-I in comparison to 
histamine-treated group [significant (P< 0.01) at day 7- & 14- post-I] and positive 
control group [significant (P< 0.01) at days 7- and 14- post-I], whereas this group 
demonstrate enhancement (as compared to histamine-treated) and suppression (as 
compared to positive control) of serum anti-SRBC-Igs levels at day 21- post-I which 
were found statistically significant (P< 0.01). Moreover, anti-SRBC-Igs levels at days 
28- and 58- post-I were found to be similar in H3R-antagonist, histamine and positive 
control groups. No antibody response was noticed in group I (negative control) during 
whole of the study period (Fig. 1 and Table 1). 
3.4.3.2. Profile of anti-SRBC-immunoglobulin-M (IgM) production 
Anti-SRBC-IgM was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 2) and HA (Haghighi et al. 2005) (Table 1). The ELISA and HA assay 
both showed similar IgM production but evident more in ELISA as opposed to HA. 
No IgM response was observed in all experimental groups at day 0- pre-I, however an 
initial increase and then gradual decrease in serum-IgM titer over time was observed 
in positive control and drug-treated groups. No IgM response was observed in all 
experimental groups at day 0- pre-1, however there was an initial increase and then 
gradual decrease in serum-IgM titer over time in positive control and drug-treated 
groups. The detailed summary of statistically analyzed IgM production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are shown 
in Fig. 2 and Table I. By day 7- post-I, the IgM titer increased and obtained highest 
peak, but by days 14-, 2I-, 28-, and 58- post-I there was a gradual decrease in all 
experimental groups. 
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-Group 1: Negative Control-Total Antibody 
Group 3: Histamine Treated-Total Antibody 
- Group 6: H3R-Antagonist Treated-Total Antibody 
Group 2: Positive Control-Total Antibody 
Group A: l-l3R-Agonist Trested-Total Antibody 
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Figure 1. SRBC-specific Immunoglobulins (Igs) production titers in H3R-agonist''-
antagonist-treated rabbits by whole SRBC-ELISA method in duplicate 1:100 diluted sera. 
The results demonstrate mean ± s.d. of three experiments each with six rabbits. Two-way 
ANOVA followed by Newman-Keuls post hoc test revealed that the effect of treatments 
(F 7188.097. DF-4,85; P<0.01) and days (F=33146.730. DF=5.425; P<0.01) on SRBC 
were statistically significant. The interaction (treatments x days) effect of (F=4088.888, 
DF-20.425; P<0.01) these on SRBC were also found to be significant. 
(118) 
Chapter 3.4. In Vivo Immunomodulation and immunomodulatory 
Profile of Histamine H3 Receptors 
-Group 1: Negative ContnoNgM -o- Group2: Positive Control-!gM Group3; HistamineTreated-IgM 
Group4: H3R-AgonistTreated-lgM -• -Groups: l-BR-AntagonistTreated-IgM 
E 
c 
ir> 
o 
o 
O 
§ 
0.2 
0.19 
0.18 
0.17 
0.16 
0.15 i 
0.14 
0.13 
0.12 
0.11 
0.1 -
0.09 -
0.08 -
0.07 
0.06 -I 
0.05 
0.04 
0.03 ^ 
0.02 
0.01 
0 / 
+ 
7 14 21 
Days (pre and post)-immunization 
28 -i h 58 
Figure 2. SRBC-specific Immunoglobulin-M (IgM) production titers in H3R-agonist/-
antagonist-treated rabbits by whole SRBC-FLISA method in dupUcate 1:100 diluted sera. 
The results demonstrate mean ± s.d. of three experiments each with six rabbits. Two-way 
ANOVA followed b) Ncwman-Kculs post hoc test revealed that the effect of treatments 
(F=3143.902, DF=4,'85; P<0.01) and days (F-9652.705. DF=5,425; P<0.01) on SRBC 
were statistically significant. The interaction (treatments x days) effect of (F=803.867. 
DF"20,425; P<0.01) these on Sf^C were also found to be significant. 
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In histamine-treated group, anti-SRBC-IgM raised steeply up to 7- day post-I 
(significant (P< 0.01) enhancement as compared to positive control and suppression 
as compared to H3R-antagonist-treated group), and there was a significant decrease 
from days 14- to 58- post-I as compared to positive control and H3R-antagonist 
groups. H3R-agonist-treated rabbits showed significant (P< 0.01) suppression of anti-
SRBC-IgM as opposed to all experimental groups. Nonetheless H3R-antagonist-
treated rabbits showed significant (P< 0.01) enhancement of anti-SRBC-IgM as 
compared to histamine-treated [significant (P< 0.01) at days 7-, 14- & 21- post-I] and 
positive control [significant (P< 0.01) at day 7- post-I], whereas this group 
demonstrated significant (P< 0.01) suppression at day 14- post-I and showed further 
enhancement at days 21-, 28- & 58- post-I as opposed to positive control. However, it 
demonstrated similar anti-SRBC-IgM level to histamine-treated group at days 28- and 
58- post-I. No anti-SRBC-IgM response was noficed in group I (negative control) 
during whole of the study period (refer to Fig. 2 and Table 1). 
3.4.3.3. Profile of anti-SRBC-immunoglobuIin-G (IgG) production 
The profile of total anti-SRBC-immunoglobulin-G (IgG) titer was also studied 
by whole SRBC-ELISA method (Koganei et al. 2007) (Fig. 3) and direct HA 
(Haghighi et al. 2005) (Table 1). The ELISA and HA assay both showed similar IgG 
production but evident more in ELISA as opposed to HA. The detailed summary of 
statistically analyzed IgG production by two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test are shown in Fig. 3 and Table 1. No 
antibody response was detected in all the groups at day 0 (pre-1). More extensive 
evaluation revealed that anti-SRBC-IgG in histamine-treated and H3R-antagonist-
treated groups raised steeply up to 7- days post-I as compared to positive control and 
H3R-agonist groups (P< 0.01) (however, H3R-antagonist-treated group showed 
significantly increased IgG level opposed to histamine-treated group). But by days 14-
,21 - , 28- and 58- post-I there was a decrease in anti-SRBC-IgG levels in histamine-
treated group as compared to H3R-antagonist-treated group (significant (P< 0.01) 
decrease at days 14- 21-, 28- & 58- post-I) and positive control group (significant (P< 
0.01) decrease from days 14- to 58- post-1). H3R-agonist-treated rabbits showed 
significant (P< 0.01) suppression of anti-SRBC-IgG as opposed to all other 
experimental groups over a time span of 58 days. 
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• Group 1: Negative ControNgG -o- Group 2: Positive ControHgG Grioup3: HistamineTreated-IgG 
Group i: H3R-AgonistTreated-IgG - • - Group 6: H3R-AntagonistTreated-lgG 
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Figiure 3. SRBC-specific Immunoglobu!in-G (IgG) production titers in HSR-agonist/-
antagonist-treated rabbits by whole SRBC-EIJSA method in dupHcate 1:100 diluted sera. 
The results demonstrate mean ± s.d. of three experiments each with six rabbits. Two-way 
ANOVA followed b> Ncwman-Kculs post hoc test revealed that the effect of treatments 
(F=3140.182. DF=4,85; P<0.01) and days (F-2831.942. DF=5,425; P<0.01) on SRBC 
were statistically significant. The interaction (treatments x days) effect of (F=439.006. 
DF-20.425; P<0.01) these on SRBC were also found to be significant. 
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H3R-antagonist enhanced significantly (P< 0.01) the anti-SRBC-IgG at day 7-
post-I and suppressed (P< 0.01) at day 14- post-I in comparison to positive control group, 
however, it further showed significantly (P< 0.01) enhance anti-SRBC-IgG level at days 
21 - and 28- post-I in comparison to positive control group, while IgG pattern was found 
to be similar to positive control at day 58- post-I. No anti-SRBC-IgG response was 
noticed in group I (negative control) during whole of the study period. 
3.4.4. Discussion 
Histamine is a potent agonist of all four receptors (HI, H2, H3 & H4) (Jutel et al. 
2001, Thurmond et al. 2008, Shahid et al. 2009), which modulates different biochemical, 
pharmacological and immunological reactions both in vivo and in vitro by releasing the 
endogenous histamine (Shahid et al. 2009). It is a well documented mechanism that 
histamine directly affects B-cell antibody production as a co-stimulatory receptor on B-
cells (Rocklin and Beer 1983, Akdis and Blaser 2003, Jutel et al. 2005, Akdis 2006). 
Therefore, in the present study, we investigated total serum Igs, IgM and IgG generation 
profile against SRBC, a T lymphocyte-dependent test antigen (Putman et al. 2002, 
Koganei et al. 2007), modulated by endogenous histamine (released from effector cells) 
in control (untreated)-, H3R-agonist [R-(-)-a-methylhistamine dihydrobromide] treated-, 
H3R-antagonist (iodophenpropit dihydrobromide) treated- and histamine treated-
experimental groups. 
To provide exact evidence relating our investigations to in vivo immunoregulatory 
processes, we used healthy rabbits with and without histamine, H3R-agonist/-antagonist 
treatments. Here we demonstrate that H3R-specific agonistZ-specific antagonist-treated 
rabbits were characterized by a marked deviation of the immune response as compared to 
control rabbits (untreated). Based on the results of the present study, we demonstrate that 
the histamine, released from immunological stimuli from effector cells (mast cells and 
basophils) in vivo (Shahid et al. 2009), could influence a detectable antibody response to 
SRBC. Moreover, the present study on in vivo immunomodulatory processes showed 
suppressed generation profile of total anti-SRBC-specific-Igs, anti-SRBC-specific-IgM 
and anti-SRBC-specific-IgG in H3R-agonist-treated group. In contrast, H3R-antagonist-
treated group demonstrated increased generation profile of total anti-SRBC-Igs, anti-
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SRBC-specific-IgM and anti- SRBC-specific-IgG during whole of the study period. These 
results are in contrast to our previous study of histamine HI- and H2-receptors-
agonists/antagonists (chapter 3.2 and chapter 3.3) and demonstrate that H3-receptors, on 
inhibition by H3R-antagonist show modulatory activity [enhancing the antibody 
generation levels by activating other histamine receptors (HI-, H2-, or H4-) through 
endogenous releasing histamine]. On the other hand, H3-receptors on stimulation by 
H3R-agonist show modulatory activity [suppressing the antibody generation levels by 
decreased activation of other histamine receptors (HI-, H2-, or H4-) through reduced 
endogenous histamine]. These data provide evidence that histamine H3-receptors in 
biological system serve as regulator for other histamine HI-, H2-, or H4-receptors and 
auto-regulator for itself. Therefore, our studies demonstrate that H3-receptors regulate 
biological histamine level and its function in body, and have their role in antibody 
production. 
In this preliminary study, we noticed that exogenously added histamine in vivo 
(until its presence in the body) enhanced the antibody generation profile against SRBC 
whereas, on further metabolism its effect disappeared on the antibody generation profile, 
bringing it in the range of control antibody level as reported in earlier chapters). We 
observed that H3R-antagonist (until its presence) increased the antibody profile, which 
came to normal level (control range) in later phase due to their metabolism. Therefore, on 
the basis of the present study we came to a conclusion that the results obtained due to 
histamine and its antagonist were of short duration which disappeared in later stage due 
to clearance of the body from these substance in rabbits. Thus, both results (histamine-
treated and antagonist-treated) groups, after metabolism of drugs, were identical to each 
other and similar to control group (strengthen our previous reports mentioned in earlier 
chapters). 
To conclude, our results provide evidence that histamine H3-receptors have 
principle role in modulation of antibody (Igs, IgM and IgG) generation. Thus, H3-
receptors have a principle role in auto-regulation of antibody production. To the best of 
our loiowledge, this is the first report describing the potential immunoregulatory role of 
H3-receptor-agonist/-antagonist, studying the immunomodulatory profile in experimental 
rabbits over a continued study period of 58 days pre- and post- immunization. 
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3.5.1. Brief Summary 
Recently accumulating evidences have highlighted histamine role in inflammation 
and immune reaction by histamine H4-receptor, however histamine role via H4-
receptor in immunomodulation is still unclear. The aim of the present hypothesis was 
to investigate the immunomodulatory role of histamine H4-receptor on antibody 
generation profile~in rabbit system. The cohort comprised of four groups (III, IV, V & 
VI), containing 18 (9 male and 9 female) rabbits each, and received subcutaneous 
histamine (100 ngkg"' x b.i.d.), H4-agonist (clobenpropit dihydrobromide, 10 ngkg'' 
X b.i.d.), and intramuscular H4-antagonist (JNJ 7777120, 10 ngkg' x b.i.d) and 
-u DMSO (control group for H4R-antagonist, 1 mlkg') respectively for 10 days (starting 
from day 1). They were subsequently immunized with intravenous injection of SRBC 
at day 3. Group Il-positive control (n = 18) received vehicle (sterile distilled water, 1 
mlkg'' X b.i.d.) and immunized in a similar manner, while group I-negative control (n 
= 18) remained non-immunized and received only vehicle (sterile distilled water, 1 
mlkg'' X b.i.d.). The estimation of serum immunoglobulins (Igs), IgM and IgG were 
done by ELISA and Hemagglutination Assay (HA) and observed at day 0 (pre-
immunization) and day 7, 14, 21, 28 and 58 (post-immunization). The ELISA and 
HA both showed similar production of Igs, IgM and IgG but evident more in ELISA 
as compared to HA. Results showed that, histamine could influence a detectable 
antibody response to SRBC as early as day 7-postimmunization (post-I), which lasts 
until day 58- post-I, whereas H4-receptors on inhibition by H4R-antagonist showing 
modulatory activity of antibody (Igs, IgM and IgG) generation similar to positive 
control. On the other hand H4-receptors on stimulation by H4R-agonist show 
modulatory activity (enhancing the antibody generation levels as compared to H4R-
antagonist and positive control). All the results were found statistically significant 
(P<0.05). To conclude, the present data provide evidence that histamine H4-receptors 
in biological system modulates immunological function and stimulates antibody 
production. 
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3.5.2, Materials and Methods 
3.5.2.1. Experimental design 
To evaluate the systemic antibody response, 108 (54 Male and 54 Female) 
New Zealand adult healthy rabbits of either sex weighing 1.36±0.24 kg were 
randomized equally into six treatment groups, i.e. 18 rabbits (9 male and 9 female) in 
each group. Each group was immunized with sheep red blood cells (SRBC). 
Control group: Group-I (negative control) remained non-immunized and received 
only vehicle (sterile distilled water, 1 mikg"' x b.i.d.). Group-ll was vehicle (sterile 
distilled water, 1 mlkg"' x b.i.d.) treated and immunized as a positive control. 
Experimental group: Group-Ill was histamine-treated and immunized, group-IV was 
H4R-agonist-treated and immunized, group-V was H4R-antagonist-treated and 
immunized, and Group-VI DMSO-treated (control group for H4R-antagonist, 1 mlkg" 
The animals were housed in well-maintained animal facility at central animal 
house, J. N. Medical College & Hospital, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22±2°C) and were 
allowed free access to standard laboratory diet including green vegetables and tap 
water until experimentation. All studies were carried out during the light cycle and 
were approved by the Institutional Animal Ethical Committee. 
3.5.2.2. Materials 
All materials were same as used in chapter 3.1.1. 
3.5.2.3. Drugs and doses 
Following drugs were used: histamine dihydrochloride from Himedia 
laboratories Pvt Limited, India; H4R-agonist (clobenpropit dihydrobromide) kindly 
donated by Tocris Bioscience, Tocris Cookson Ltd., United Kingdom; and H4R-
antagonist (JNJ 7777120) purchased from Sigma (USA). 
Histamine (100 ng/kg) and clobenpropit dihydrobromide (10 ng/kg) were 
administered twice in a day through subcutaneous (s.c.) route, and JNJ 7777120 (10 
\ig/kg) was administered twice in a day through intramuscular (i.m.) route; starting 
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from three days prior to immunization until 7 days after immunization. All doses 
referred to the weight of the salts used. 
3.5.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, J. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH-
7.4) thrice by centrifugation. The cell suspensions were adjusted to the desired 
concentration in terms of hemoglobin, lysis of a 1% SRBC suspension (2 x 10^  
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franzl (1972). Finally the concentration 
was adjusted to 5% (1 x 10^  cells/ml) in PBS for immunization before use. 
3.5.2.5. Immunization of rabbits 
The rabbits in all experimental groups (II-V) were immunized intravenously 
via marginal ear vein with Iml of 5% (1 x 10^  cells/ml) sheep red blood cells (SRBC) 
in PBS. 
3.5.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins into labelled sterile bottles prior to 
immunization (day 0), as well as on days 7-, 14-, 21-, 28- and 58- post-immunization. 
Blood samples were kept at room temperature for 2 hr and then left overnight at 4°C 
overnight. Blood samples were centrifuged for 10 minutes at 580xg, and serum was 
isolated and heated at 56°C for 30 minutes to inactivate complement proteins and 
stored in aliquots, containing sodium azide as preservative, at -20°C till tested further 
(Doumal 1972). 
3.5.2.7. Serological analysis 
3.5.2.7.1. Hemagglutination assay (HA) 
Same as chapter 3.1.1. 
3.5.2.7.2. ELISA using whole SRBC 
Same as chapter 3.1.1. 
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3.5.2,8. Statistical analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. A two-tailed (a = 2) probability P<0.05 
was considered to be statistically significant. Analyses were performed on SPSS for 
windows (version 12.0, Inc., Chicago, IL). 
3.5.3. Results 
To evaluate the effects of histamine H4 receptors-agonist and -antagonist on 
the immunomodulation, antibody-mediated responses to SRBC were assessed. Total 
serum immunoglobulins (Igs), total immunoglobulin-M (IgM) and total 
immunoglobulin-G (IgG) generation profiles were studied in vivo in six experimental 
groups at days 0 [pre-immunization (pre-I)], 7, 14, 21, 28 and 58 [post-immunization 
(post-I)]. 
3.5.3.1. Profile of total anti-SRBC-immunoglobulins (Igs) production 
The profile of total anti-SRBC-immunoglobulins (Igs) titer was studied by 
whole SRBC-ELISA method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghighi 
et al. 2005) (Table 1). The ELISA and HA assay both showed similar Igs production 
but evident more in ELISA as opposed to HA. No antibody response was detected in 
all experimental groups (control and drug treated) at day 0 (pre-I). There was an 
initial increase and subsequent decrease in total serum Igs titer over a time span of 58 
days in all the groups, and was found statistically significant at each experimental 
post-I days. The detailed summary of statistically analyzed Igs production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are shown 
in Fig. 1 and Table 1. By the day 7- post-I, anti-SRBC-Igs titer was significantly high, 
however it obtained a peak at day 14-, and by days 21-, 28- and 58- post-I there was a 
gradual decrease or a plateau was observed in positive control and DMSO-treated as 
compared to H4R-agonist-treated, H4R-antagonist-treated and histamine-treated 
groups (Fig. 1 and Table 1). More extensive evaluation revealed that anti-SRBC-
immunoglobulins (Igs) raised steeply up to 7 days post-I, and there was a significant 
(P< 0.01) decrease in H4R-agonist-treated and histamine-treated group as compared 
to all other experimental groups. While anti-SRBC-Igs increased gradually at days 7-
(128) 
Chapter 3.5. In Vivo Immunomodulation and Immunomodulatory 
Profile of Histamine H4 Receptors 
and 14- post-1 and attained a high pealc at day 21- and by days 28- and 58- post-I there 
was a gradual decrease as compared to other experimental groups. 
Histamine showed initial enhancement and later suppression of anti-SRBC-Igs 
production profile during the whole study as compared to H4R-antagonist, positive 
control group and DMSO-treated groups (significant increase of total serum anti-
SRBC-Igs level was noticed at day 7- post-I (P< 0.01), and suppression of serum anti-
SRBC-Igs levels at days 14- and 21- post-I (P< 0.01 each for H4R-antagonist, 
positive control and DMSO-treated groups). At days 28- and 58- post-I the results 
were found statistically significant with H4R-antagonist (P< 0.01); however these 
results were found to similar to positive control and DMSO-treated groups. DMSO-
treated group served as control group for H4R-antagonist (JNJ 7777120) and showed 
similar pattern as that of anti-SRBC-Igs generation profile to positive control. 
H4R-agonist-treated group showed significant (P< 0.01) enhanced anti-SRBC-
Igs profile as opposed to positive control, DMSO-treated, H4R-antagonist-treated and 
histamine-treated groups. However, H4R-antagonist studies showed similar anti-
SRBC-Igs level as that of positive control and DMSO-treated at day 7- post-I, 
however it showed significant (P< 0.01) suppression as compared to histamine-treated 
group. While at day 14- post-I, it showed suppressed Igs level as compared to positive 
control group, and significant (P< 0.01) enhancement as compared to histamine-
treated group. Furthennore, H4R-antagonist treated group showed significant (P< 
0.01) enhancement of Igs generation level at day 21-, 28-, 58- post-I as compared to 
positive control, DMSO-treated and histamine-treated groups. No Igs response was 
noticed in group I (negative control) during whole study period (Fig. 1 and Table 1). 
3.5.3.2. Profile of total anti-SRBC-immunoglobulin-M (IgM) 
Anti-SRBC-IgM was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 2) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgM production but evident more in ELISA as opposed to 
HA. No IgM response was observed in all experimental groups at day 0- pre-I, 
however there was an initial increase and then gradual decrease in serum-IgM titer 
over time in positive control, DMSO-treated, drug-treated groups. The detailed 
summary of statistically analyzed IgM production by two way analysis of variance 
(ANOVA) followed by Newman-Keuls post hoc test are shown in Fig. 2 and Table 1. 
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Figure 1. SRBC-specific Immunoglobulins (Igs) production titers in H4R-
agonist/antagonist-treated rabbits by whole SRBC-ELISA method in duplicate 1:100 
diluted sera. The results demonstrate mean ± s.d. of three experiments each with six 
rabbits. Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the 
effect of treatments (F-13309.637. Dr=5.102; P<0.01) and days (F=89815.206, 
DF=5.510; P<0.01) on SRBC were statistically significant. The interaction (treatments x 
days) effect of (F=9480.445, DF=25,510; P<0.01) these on SRBC were also found to be 
significant. 
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By day 7- post-I, the JgM titer increased and attained highest peak, but by days 14-, 
21-, 28-, and 58- post-I there was a gradual decrease in positive control, DMSO-
Ireated, histamiine-treated and H4R-agonist-treated groups. While, by the day 7- post-
1, antibody titer gradually increases and attained a peak at day 14, and by days 21-, 
28- and 58- post-I, a gradual decrease in H4R-antagonist-treated group was observed 
(Fig. 2 and Table 1). DMSO-treated group showed similar pattern of anti-SRBC-IgM 
generation profile to positive control group over a time span of 58 days. 
In histamine-treated group, anti-SRBC-IgM raised steeply up to 7- day post-I 
[significant (P< 0.01) and shows as compared to positive control, DMSO-treated and 
H4R-antagonist], but there was a significant (P< 0.01) decrease at days 14- and 21-
post-I as compared to positive control, DMSO-treated and H4R-antagonist-treated 
group while at day 28- post-I, it was found to be significantly (P< 0.01) suppressed as 
compared to H4R-antagonist, however at day 58- post-I, it showed similar anti-
SRBC-IgM level as that of positive control, DMSO-treated and H4R-antagonist 
groups. 
H4R-agonist-treated group showed significant (P< 0.01) enhancement of anti-
SRBC-IgM-generation profile as compared to positive control, DMSO-treated, H4R-
antagonist-treated and histamine-treated groups. While H4R-antagonist-treated group 
showed similar IgM profile to positive control and DMSO-treated but significant (P< 
0.01) suppression was observed as compared to histamine-treated group. Furthermore, 
H4R-antagonist-treated group demonstrated significantly (P< 0.01) enhanced anfi-
SRBC-IgM levels at days 14-, 21-, 28- post-I, however similar IgM production levels 
at day 58- post-I was observed, to positive control, DMSO-treated and histamine-
treated groups. No antibody response was noticed in group I (negative control) during 
whole of the study period (Fig. 2 and Table 1). 
3.5.3.3. Profile of total anti-SRBC-immunoglobulin-G (IgG) 
The profile of total anti-SRBC-IgG titer was studied by whole SRBC-ELISA 
method (Koganei et al. 2007) (Fig. 3) and direct HA (Haghighi et al. 2005) (Table 1). 
The ELISA and HA assay both showed similar IgG production but evident more in 
ELISA as opposed to HA. The detailed summary of statistically analyzed IgG 
production by two way analysis of variance (ANOVA) followed by Newman-Keuls 
post hoc test are shown in Fig. 3 and Table 1. 
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Figure 2. SRBC-speciflc Immunoglobulin-M (IgM) production titers in H4R-
agoniSt/antagonist-treated rabbits by whole SRBC-ELISA method in duplicate 1:100 
diluted sera. The results demonstrate mean ± s.d. of three experiments each with six 
rabbits. Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the 
effect of treatments (F-5844.533, DF-5,102; P<0.G1) and days (F-21533.286. 
DF=5,510; P<0.01) on SRBC were statistically significant. The interaction (treatments x 
days) effect of (F=2151.403, DF=25,510; P<0.01) these on SRBC were also found to be 
sigaificant. 
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Figure 3. SRBC-speciflc Immunoglobulin-G (IgG) production titers in H4R-
agonist/antagonist-treated rabbits by whole SRBC-ELISA method in duplicate 1:100 
diluted sera. The results demonstrate mean ± s.d. of three experiments each with six 
rabbits. Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the 
effect of treatments (F=5463.127, DF-5,102; P<0.01) and days (F-5888.457, DF-5,510; 
P<0.01) on SRBC were statistically significant. The interaction (treatments x days) 
effect of (F=581.692. DF=25.510; P<0.01) these on SRBC were also found to be 
significant. 
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No IgG response was detected in all experimental groups at day 0 (pre-I). More 
extensive evaluation revealed that anti-SRBC-IgG in histamine-treated group and 
H4R-agonist group raised steeply up to 7- days post-I. But by days 14-, 21-, 28- and 
.58- post-I there was a decrease or a plateau in anti-SRBC-IgG generation levels. 
While in positive control and DMSO-treated groups, anti-SRBC-IgG generation titer 
was gradually enhanced and attained a high peak at day 14- post-I and by days 21-, 
28- and 58- post-I, a plateau was observed. However, in H4R-antagonist group anti-
SRBC-IgG titer gradually increase up to 28- post-I and then decrease or maintained a 
plateau at day 58- post-I. H4R-agonist-treated group showed enhancement of anti-
SRBC-IgG generation profile as compared to all the experimental groups over a time 
span of 58 days. While H4R-antagonist study revealed suppression or similar IgG 
production levels to positive control and DMSO-treated groups at day 7- and 14- post-
I, and significant (P< 0.01) suppression as compared to histamine-treated at day 7-
post-I of anti-SRBC-IgG level. However, this group further showed significant (P< 
0.01) enhancement of anti-SRBC-IgG level at days 21-, 28- and 58- post-I as 
compared to DMSO-treated and positive control groups, and it also showed 
significant (P< 0.01) enhancement of anti-SRBC-IgG level at day 14-, 21-, 28- and 
58- post-I as compared to histamine-treated group only. No anti-SRBC-IgG response 
was noticed in group I (negative control) over a time span of 58 days (refer to Fig. 3 
and Table I). 
3.5.4. Discussion 
In the present study, we investigated total serum Igs, IgM and IgG generation profile 
against SRBC, a T lymphocyte-dependent test antigen (Putman et al. 2002, Koganei 
et al. 2007), modulated by endogenous histamine in control (untreated)-, H4R- agonist 
(clobenpropit dihydrobromide) treated-, H4R-antagonist (JNJ 7777120) treated-, 
DMSO-treated and histamine treated-experimental groups. Histamine stimulates its 
all four receptors (H1-H4), and modulates different physiological and pathological 
reactions both in vivo and in vitro by releasing the endogenous histamine (Jutel et al. 
2001, Thurmond et al. 2008, Shahid et al. 2009). 
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In immunological reaction, it directly affects B-ceii antibody production as a 
co-stimulatory receptor on B-cells (Rocklin and Beer 1983, Akdis and Blaser 2003, 
Jute! et ai. 2005, Akdis 2006). To provide exact evidence relating our investigations to 
in vivo immunoregulatory processes, we used healthy rabbits with and without 
histamine, H4R-agonist/-antagonist and DMSO treatments. Here we demonstrate that 
H4R-agonist/-antagonist-treated rabbits were characterized by a marked deviation of 
the immune response as compared to positive control (untreated), DMSO and 
histamine-treated rabbits. 
In the present study, we demonstrate that the histamine, released from 
immunological stimuli from effector cells in vivo (Shahid et al. 2009), could influence 
a detectable antibody response to SRBC (same results as observed in previous 
chapters). Moreover, the present study on in vivo immunomodulatory processes 
showed enhanced generation profile of total anti-SRBC-Igs, anti-SRBC-IgM and anti-
SRBC-IgG in H4R-agonist-treated group. In contrast, H4R-antagonist-treated group 
demonstrated initially suppressed and then later enhanced profde of total anti-SRBC-
Igs, anti-SRBC-IgM and anti-SRBC-IgG over the time span of present study. 
These results demonstrate that H4-receptors on inhibition by H4R-antagonist 
show modulatory activity of antibody (immunoglobulins (Igs), IgM and IgG) 
generation similar to positive control. On the other hand, H4-receptors on stimulation 
by H4R-agonist also show modulatory activity (enhancing the antibody generation 
levels as compared to H4R-antagonist and positive control). These data provide 
evidence that histamine H4-receptors in biological system modulates immunological 
function and stimulates antibody production. 
In this preliminary study, exogenously added histamine in vivo (until its 
presence in the body) enhanced the antibody generation profile against SRBC 
whereas; on further metabolism its effect disappeared on the antibody generation 
profile bringing it in the range of control antibody level (reported as earlier chapters). 
H4R-antagonist (until their presence) showed normal level of antibody profile, which 
was similar to control range whereas, on further metabolism its effect appeared as 
modulator and enhanced the antibody generation profile, which came to normal level 
(control range) at day 58- post-I (in later phase). 
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To conclude, our results provide evidence that histamine H4-receptors have 
principle role in modulation of antibody (Igs, IgM and IgG) generation. To the best of 
our knowledge, this is the first report describing the potential immunoregulatory role 
of H4-receptor-agonist/-antagonist studying the immunomodulatory profile in 
experimental rabbits over a continued study period of 58 days pre- and post-
immunization. 
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3.6.1. Brief Summary 
Present study was designed to delineate the immunomodulatory role of histamine HI, 
H2, H3 and H4-receptors and their role on antibody generation profile in rabbit 
system. The cohort comprised of seven groups (Group-1 negative control, Group-II 
positive control and Group III-VII HRs-agonist-treated) containing 18 (9 male and 9 
female) rabbits each. Group-I remained non-immunized and received only vehicle 
(sterile distilled water, 1 mlkg"' x b.i.d.). Group-II received vehicle (1 mlkg'') while 
Groups III-VII (HRs-agonists-treated) received subcutaneous histamine (100 jigkg'' x 
b.i.d.) and HIR-agonist (HTMT dimaleate), H2R-agonist (amthamine 
dihydrobromide), H3R-agonist [R-(-)-a-methylhistamine dihydrobromide] and H4R-
agonist (clobenpropit dihydrobromide) each in a dose of 10 ^gkg'' x b.i.d., 
respectively for 10 days (starting from day 1). They were subsequently immunized 
with intravenous injection of SRBC at day 3. The estimation of serum 
immunoglobulins (Igs), IgM and IgG were done by ELISA and Hemagglutination 
Assay (HA) and observed at day 0 (pre-immunization) and day 7, 14, 21, 28 and 58 
(post-immunization). The ELISA and HA both showed similar production of Igs, 
IgM and IgG but evident more in ELISA as compared to HA. Results showed that, 
histamine and HRs (HIR, H2R, H3R & H4R)-agonists could influence a detectable 
antibody response to SRBC as early as day 7-postimmunization (post-I), which lasted 
until day 58- post-I. All the results were found statistically significant (P<0.05). To 
conclude, our results provide evidence that HRs (HIR, H2R and H4R) have important 
role in modulation of antibody generation, in which HIR have dominant role, while 
H2R and H4R play similar role of immune modulation. On the other hand, H3R have 
dominant suppressive role and regulates other histamine receptors (HI, H2 and H4) in 
immuno-biological system. To the best of our knowledge, this is the first report 
describing the potential comparative immunoregulatory role of HI-, H2-, H3- and H4-
receptors-agonists. 
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3.6.2. Materials and Methods 
3.6,2.1. Experimental design 
To evaluate the systemic antibody response, 126 (63 Male and 63 Female) 
New Zealand adult healthy rabbits of either sex weighing 1.36±0.24 kg were 
randomized equally into seven treatment groups, i.e. 18 rabbits (9 male and 9 female) 
in each group. 
Control group: Group-I (negative control) remained non-immunized and received 
only vehicle (sterile distilled water, 1 mlkg"' x b.i.d.). Group-II was vehicle (sterile 
distilled water, 1 mlkg"' x b.i.d.)-treated and immunized as a positive control. 
Experimental group: Group-Ill was histamine-treated and immunized, group-IV was 
HlR-agonist-treated and immunized, Group-V was H2R-agonist-treated and 
immunized. Group-VI was H3R-agonist-treated and immunized and Group-VII was 
H4R-agonist-treated and immunized. 
The animals v/ere housed in well-maintained animal facility at central animal 
house, J. N. Medical College & Hospital, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22±2°C) and were 
allowed free access to standard laboratory diet including green vegetables and tap 
water until experimentation. Ail studies were carried out during the light cycle and 
were approved by the Institutional Animal Ethical Committee. 
3.6.2.2. Materials 
All materials were same as used in chapter 3.1.1. 
3.6.2.3. Drugs and doses 
Following drugs were used: histamine dihydrochloride obtained from Himedia 
laboratories Pvt Limited, India; HlR-agonist (Histamine Trifluoro-Methyl Toluidide 
(HTMT-dimaleate), H2R-agonist (amthamine dihydrobromide), H3R-agonist [R-(-)-
a-methylhistamine dihydrobromide] and H4R-agonist (clobenpropit dihydrobromide) 
which were kindly donated by Tocris Bioscience, Tocris Cookson Ltd., United 
Kingdom. 
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Histamine dihydrochloride (100 figkg"') and other agonists [HTMT-dimaleate, 
amthamine dihydrobromide, R-(-)-a-methylhistamine dihydrobromide, 
clobenpropit dihydrobromide] (10 Hgkg') were administered subcutaneously (s.c.) 
twice a day for 10 subsequent days. All doses were referred to the weight of the salts 
used. 
3.6.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, J. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCl, pH-
7.4) thrice by centrifugation. The cell suspensions were adjusted to the desired 
concentration in terms of hemoglobin, lysis of a 1% SRBC suspension (2 x lo^ 
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franz! (1972). Finally the concentration 
was adjusted to 5% (1 x 10^cells/ml) in PBS for immunization before use. 
3.6.2.5. Immunization of rabbits 
The rabbits in all experimental groups (Il-V) were immunized intravenously 
via marginal ear vein with 1ml of 5% (1 x lO' cells/ml) sheep red blood ceils (SRBC) 
in PBS. 
3.6.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins into labeled sterile bottles prior to 
immunization (day 0), as well as on days 7-, 14-, 21-, 28- and 58- post-immunization. 
Blood samples were kept at room temperature for 2 hr and then left for overnight at 
4°C. Blood samples were centrifuged for 10 minutes at 580xg, and serum was isolated 
and heated at 56T for 30 minutes to inactivate complement proteins and stored in 
aliquots containing sodium azide as preservative at -20^ till tested further (Doumal 
1972). 
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3.6.2.7. Serological analysis 
3.6.2.7.1. Hemagglutination assay (HA) 
Same as chapter 3.1.1. 
3.6.2.7.2. ELISA using whole SRBC 
Same as chapter 3.1.1. 
3.6.2.8. Statistical analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuls post hoc test. A two-tailed (« = 2) probability P<0.05 
was considered to be statistically significant. Analyses were performed on SPSS for 
windows (version 12.0, Inc., Chicago, IL). 
3.6.3. Results 
To evaluate the effects of histamine-receptors-agonist on the 
immunomodulation, antibody-mediated responses to SRBC were assessed. Total 
serum immunoglobulins (Igs), total immunoglobulin-M (IgM) and total 
immunoglobulin G (IgG) generation profiles were studied in vivo in seven 
experimental groups at days 0 [pre-immunization (pre-I)], 7, 14, 21, 28 and 58 [post-
immunization (post-I)]. 
3.6.3.1. Profile of total anti-SRBC-immunoglobulins (Igs) production 
The profile of total anti-SRBC-immunoglobulins (Igs) titer was studied by 
whole SRBC-ELISA method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghighi 
et al. 2005) (Table 1). The ELISA and HA assay both shov/ed similar Igs production 
but evident more in ELISA as opposed to HA. No anti-SRBC-lgs response was 
detected in all experimental groups (negative control, positive control and drug 
treated) at day 0 (pre-I). There was an initial increase and subsequent decrease in total 
serum Igs titer over the span of 58 days in all the groups, and was found statistically 
significant at each experimental post-I days. The detailed summary of statistically 
analyzed Igs production by two way analysis of variance (ANOVA) followed by 
Newman-Keuls post hoc test are shown in Fig. 1 and Table 1. By day 7- post-I, the 
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anti-SRBC-immunoglobuIins (Igs) titer increased and attained highest peak, but by 
days 14-, 21-, 28-, and 58- post-I there was a gradual decrease in all experimental 
groups (except HlR-agonist-treated and positive control (untreated) groups, where the 
highest peak was attained at day 14- post-1 and then there was a gradual decrease). 
More extensive evaluation revealed that anti-SRBC-Igs raised steeply up to 7 
days post-I, and there was a significant (P< 0.01) decrease in histamine-treated group 
at days 14- and 21- post-I as compared to positive control group, while this group 
showed similar antibody titer near to positive control at days 28- and 58- post-I. 
However, HlR-agonist (HTMT)-treated, H2R-agonist (amthamine)-treated 
and H4R-agonist (clobenpropit)-treated rabbits showed significant (P< 0.01) 
enhancement of total anti-SRBC-Igs production as opposed to histamine-treated, 
positive control and H3R-agonist [R-(-)-a-methylhistamine]-treated rabbits. HlR-
agonist (HTMT)-treated rabbits showed initially significant (P< 0.01) suppression at 
day 7 post-I and later significant (P< 0.01) enhancement of anti-SRBC-Igs production 
level at days 14-, 21-, 28- and 58- post-1 as opposed to H2R-agonist (amthamine)-
treated and H4R-agonist (ciobenpropit)-treated rabbits, and demonstrated increase of 
Igs titer significantly lower than observed in H2R- and H4R-agonists-treated group 
(Fig. 1 and Table 1). Anti-SRBC-Igs generation levels at each experimental post-I 
days was observed similar in H2R-agonist- and H4R-agonist-treated groups. On the 
other hand, H3R-agonist [R-(-)-a-methylhistamine]-treated group showed significant 
(P< 0.01) suppression of anti-SRBC-Igs production level at days 7-, 14-, 21-, 28- and 
58- post-1 as compared to H1R-, H2R- and H4R-agonists, while it showed significant 
(P< 0.01) suppression of total serum anti-SRBC-Igs level as compared to histamine-
treated and untreated (positive control) groups over the span of 58 days. No anti-
SRBC-Igs response was noticed in group I (negative control) during whole of the 
study period (Fig. I and Table 1). 
3.6.3.2. Profile of anti-SRBC-immunoglobulin-M (IgM) production 
Anti-SRBC-lgM was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 2) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgM production but evident more in ELISA as opposed to 
HA. No anti-SRBC-IgM response was observed in all experimental groups (negative 
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control, positive control and drug treated) at day 0- pre-1, however there was an initial 
increase and then gradual decrease in serum-IgM titer over time in all the groups. The 
detailed sumnnary of statistically analyzed IgM production by two way analysis of 
variance (ANOVA) followed by Newman-Keuls post hoc test are shown in Fig. 2 and 
Table 1. Anti-SRBC-IgM raised steeply up to 7 days post-I, and by days 14-, 21-, 28-
and 58- post-I there was a decrease in histamine-treated and H1R-, H2R-, H3R- & 
H4R-agonists-treated groups as compared to positive control group. In histamine-
treated group, anti-SRBC-lgM raised steeply up to 7- day post-I [significant (P< 0.01) 
enhancement as compared to positive control and H3R-agonist-treated group], and 
also the enhancement of IgM of this group was seen at days I4-, 21-, 28- and 58-
post-I as compared to H3R-agonist-treated group, while there was a significant (P< 
0.01) decrease at days 14- and 21- post-I as compared to positive control group 
whereas at days 28- and 58- post-1, it showed similarity to positive control's anti-
SRBC-lgM level. The total anti-SRBC-lgM generation titer of HIR-agonist-, H2R-
agonist- and H4R-agonist-treated rabbits showed significant (P< 0.01) enhancement 
as opposed to H3R-agonist-treated, histamine-treated and positive control rabbits 
(Fig. 2). Moreover, H2R-agonist-treated rabbits showed similar anti-SRBC-lgM 
generation titer to H4R-agonist-treated rabbits at each experimental post-I days. 
While, HlR-agonist-treated group showed significant (P< 0.01) suppression of anti-
SRBC-lgM production titer as compared to H2R-agonist- and H4R-agonist-treated 
groups at days 7-, 14-, 21-, 28- post-I, however this group showed enhancement at 
day 58- post-I as compared to H2R-agonist- and H4R-agonist-treated rabbits. No anti-
SRBC-lgM response was noticed in group I (negative control) during whole of the 
study period (Fig. 2 and Table 1). 
Profile of anti-SRBC-immunogiobuIin-G (IgG) production 
Anti-SRBC-IgG was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 3) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgG production but evident more in ELISA as opposed to 
HA. The detailed summary of statistically analyzed IgG production by two way 
analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are shown 
in Fig. 3 and Table 1. 
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Figure 1. SRBC-specific Immunoglobulins (Igs) production titers in H1R-, H2R-. 
H3R- & H4R-agonist-treated rabbits by whole SRBC-ELISA method in duplicate 
1:100 diluted sera. The results demonstrate mean ± s.d. of three experiments each 
with six rabbits. Two-way ANOVA followed by Newman-Kculs post hoc test 
revealed that the effect of treatments (F=40968.340. DF=6.119: P<0.01) and days 
(F=l23866.4, DF=5,595; P<0.01) on SRBC were statistically significant. The 
interaction (treatments x days) effect of (F=10015.733, DF-30,595; P<0.01) these on 
SRBC were also found to be significant. 
(144) 
Chapter 3.6. In Vivo tminunomodulation and Immunomodulatory 
Profile of Histamine Receptors (HI-, H2-, H3- & H4-): 
A Comparative Agonists Study 
—•—Group 1: Negative Control-IgM —•—Group2: Positive ControMgM 
^•,— Group4:H1R-AgonistTr«ated-lflM - * Groups: H2R-AgonistTreated-lgM -
—<^ GroupT: H4R-AgonistTreated-)gM 
-:—Group 3: Histamine Treat*d-lgM 
-•—Group6: H3R-Agoni5tTreated-lgM 
04 1 
0.35 
E 
c 
in 
o 
Q 
O 
(/I 
c 
0) 
« 
- * • ' 
a. 
O 
0.25 
0.15 -
0.05 
14 21 
Days (pre and post)-<mmunization 
28 i h 58 
Figure 2. SRBC-specific Immunoglobulin-M (IgM) production titers in H1R-, H2R-, 
H3R- & H4R-agonist-treated rabbits by whole SRBC-ELISA method in dupUcate 
1:100 diluted sera. The results demonstrate mean ± s.d. of three experiments each 
with six rabbits. Two-way ANOVA followed by Ncwman-Kculs post hoc test 
revealed that the effect of treatments (F=8975.923, DF=6.119; P<0.01) and days 
(F=40509.989, DF=5,595; P<0.01) on SRBC were statistically significant. The 
interaction (treatments >: days) effect of (F=3038.703, DF=30,595; P<0.01) these on 
SRBC were also found to be significant. 
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Figure 3. SRBC-specific Immunoglobulin-G (IgG) production titers in H1R-. H2R-. 
H3R- & H4R-agonist-treated rabbits by whole SRBC-ELISA method in duplicate 
1:100 diluted sera. The results demonstrate mean ± s.d. of three experiments each 
with six rabbits. Two-way ANOVA followed by Ncwman-Kculs post hoc test 
revealed that the effect of treatments (F=8363.643, DF=6,119; P<0.01) and days 
(F=l 1101.804, DF=5,595; P<0.01) on SRBC were statistically significant. The 
interaction (treatments x days) effect of (F=903.632, DF=30,595; P<0.01) these on 
SRBC were also found to be significant. 
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No anti-SRBC-IgG response was observed in all experimental groups (negative 
control, positive control and HRs-agonists-treated) at day 0- pre-I; however there was 
an initial increase and then gradual decrease in serum-IgG titer over the time period in 
all the groups. Anti-SRBC-IgG generation profile raised steeply up to 7 days post-I, 
and by days 14-, 21-, 28- and 58- post-I a decrease in histamine-treated group was 
observed as compared to all other experimental groups. In histamine-treated group, 
anti-SRBC-IgG raised steeply up to 7- day post-I [significant (P< 0.01) enhancement 
as compared to positive control and H3R-agonist-treated group], and also the 
significant (P< 0.01) enhancement ofIgG of this group was seen at days 14-, 21-, 28-
and 58- post-I as compared to H3R-agonist-treated group, while there was a 
significant (P< 0.01) decrease in IgG generation titer at days 14-, 21-, 28- and 58-
post-I as compared to positive control group. The total anti-SRBC-IgG generation 
titer of HlR-agonist-, H2R-agonist- and H4R-agonist-treated rabbits showed 
enhancement as opposed to positive control, H3R-agonist- and histamine-treated 
rabbits over the time span of 58 days (Fig. 3). Furthermore, H2R-agonist-treated 
rabbits showed similar anti-SRBC-IgG generation titer to that of H4R-agonist-treated 
rabbits at each experimental post-I days. While, HlR-agonist-treated group showed 
significant (P< 0.01) suppression of anti-SRBC-IgM generation titer at days 7- post-I, 
while it showed significant (P< O.OI) enhancement at 14-, 21-, 28- and 58- post-I as 
compared to H2R-agonist- and H4R-agonist-treated groups. No anti-SRBC-IgG 
response was noticed in group I (negative control) during whole study period (Fig. 3 
and Table 1). 
Discussion 
The present study investigated total serum Igs, IgM and IgG generation profile 
against SRBC (a T cell-dependent test antigen) (Putman et al. 2002, Koganei et al. 
2007) in negative control (untreated) and treated groups [positive control (treated with 
sterile distilled water)-, HlR-agonist (HTMT)-, H2R-agonist (amthamine)-, H3R-
agonist [R-(-)-a-methylhistamine]-, H4R-agonist (clobenpropit)- and histamine 
treated-experimental groups] in healthy rabbits. Here we demonstrate that H1R-, 
H2R-, H3R- & H4R- agonists-treated rabbits were characterized by a marked 
deviation of the immune response as compared to positive control rabbits. The results 
of the present study demonstrate that the histamine, released from immunological 
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stimuli from effector cells in vivo (Shahid et al. 2009), could influence a detectable 
antibody response to SRBC (same results were observed in previous study). 
It must be emphasized here that to the best of our knowledge, none of the 
earlier reports have demonstrated the comparative study of anti-SRBC-
immunoglobulins (Igs), IgM and IgG profile modulated by histamine and histamine 
receptors (HlR-H4R)-agonists over a span of study period of 58 days. 
Histamine has been documented the agonist of histamine receptors (Jutel et al. 
2001, Thurmond et al. 2008, Shahid et al. 2009). Histamine receptors are distributed 
in all parts of body and modulate several reactions both in vivo and in vitro, by 
activation after releasing the histamine (Shahid et al. 2009). Histamine also modulates 
immunological reactions and directly affects B-cell antibody production as a co-
stimulatory receptor on B-cells (Rocklin and Beer 1983, Akdis and Blaser 2003, Jutel 
et al. 2005, Akdis 2006). It is also being documented in mice that histamine enhances 
anti-IgM induced proliferation of B-ceils, which abolished in HIR deleted mice. In 
HlR-deleted mice antibody production against a T cell-independent antigen-TNP-
Ficoll is decreased (Banu and Watanabe 1999), suggesting an important role of HIR 
signaling in response triggered from B-cell receptors. Jutel et al. (2001) showed a 
different pattern of antibody responses to T cell-dependent antigens like ovalbumin 
and demonstrated that HlR-deleted mice produced high ovalbumin-specific IgGl and 
IgE as compared to wild type mice. 
Keeping in view the above facts, especially the paucity of literature (i.e., 
immunomodulatory role of histamine HI-, H2-, H3- and H4-receptors), defining the 
correlation of histamine receptors-agonists in immune regulation & modulation and 
the fragmentary literature of histamine receptors (HIR, H2R, H3R and H4R) 
describing existing immunomodulatory role of histamine and histamine receptors in 
vivo system, the present study was proposed. This study demonstrated that the 
histamine treated-rabbits showed immunopotentiating properties by enhancing the 
anti-SRBC-antibodies (Igs, IgM & IgG) levels as compared to positive control group 
over a span of study period of 58 days (hence strengthen our previous histamine 
findings documented in earlier chapters). 
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Furthermore, our comparative HI-, H2-, H3- & H4-agonists study on in vivo 
immunoregulatory processes demonstrated enhanced generation profile of anti-
SRBC-Igs, IgM and IgG in HlR-agonist-, H2R-agonist- and H4R-agonist-treated 
rabbits while it showed suppression in H3R-agonist-treated rabbits as compared to 
positive control rabbits during the whole study period. 
In this preliminary study, we noticed that exogenously added histamine in vivo 
(until its presence in the body) enhanced the antibody generation -profile against 
SRBC whereas; on further metabolism its effect disappeared on the antibody 
generation profile bringing it in the range of control's antibody level. But it was 
disappeared in HlR-H4R-agonists study. 
Therefore, on the basis of the present study we reached to a conclusion that the 
result obtained due to histamine was of short duration which disappeared in latter 
stage due to clearance of these substance in the body of rabbits. This was disappeared 
in specific-agonists studies. 
Thus, the histamine-treated results and HlR-H4R-agonists-treated results, 
after metabolism of drugs, were different with each other, however histamine results 
was similar to control group. 
To conclude, our results provide evidence that histamine receptors (HIR, 
H2R and H4R) have important role in modulation of antibody generation, among 
which HIR have dominant role, while H2R and H4R play similar role of immune 
modulation. On the other hand, H3R have dominant suppressive role and regulates 
other histamine receptors (HI, H2 and H4) in immuno-biological system. To the best 
of our knowledge, this is the first report describing the potential comparadve 
immunoregulatory role of HI-, H2-, H3- and H4- receptors-agonists. 
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3.7.1. Brief Summary 
Present study was designed to delineate the immunomodulatory role of histamine HI, 
H2, H3 and H4-receptors on antibody generation profile in rabbit system. The cohort 
comprised of eight groups (Group-I negative control, Group-II positive control. Group 
III-VII HRs-antagonist-treated and Group-VIII DMSO-treated) containing 18 (9 male 
and 9 female) rabbits each. Group-I remained non-immunized and received only 
vehicle (sterile distilled water, 1 mlkg'' x b.i.d.). Group-II received vehicle (1 mlkg"' x 
b.i.d.) while Groups III-VII (drug-treated) received subcutaneous histamine (100 
)agkg'' X b.i.d.), and intramuscular HlR-antagonist (pheniramine maleate, 10 mgkg'' 
X b.i.d.), H2R-antagonist (ranitidine hydrochloride, 10 mgkg"' x b.i.d.), H3R-
antagonist (iodophenpropit dihydrobromide, 1 |igkg"' x b.i.d.) and H4R-antagonist 
(JNJ 7777120, 10 ngkg"' x b.i.d.), and Group-VIII DMSO (control group for H4R-
antagonist, 1 mlkg"'), respectively for 10 days (starting from day 1). They were 
subsequently immunized with intravenous injection of SRBC at day 3. The estimation 
of serum Igs, IgM and IgG were done by ELISA and HA, and observed at day 0 (pre-
immunization) and day 7, 14, 21, 28 and 58 (post-immunization). The ELISA and 
HA both showed similar production of Igs, IgM and IgG but evident more in ELISA 
as compared to HA. Results showed that histamine and HRs (H1R-, H2R-, H3R- & 
H4R)-antagonists could influence a detectable antibody response to SRBC as early as 
day 7-postimmunization (post-I), which lasted until day 58- post-I. The results were 
found statistically significant (P<0.05). To conclude, our results provide evidence that 
HRs have important role in modulation of antibody generation, in which HIR have 
dominant role, while H2R and H4R play significant role in immune modulation (HIR 
revealed more marked modulatory role as compared to H4R). On the other hand, H3R 
have dominant modulatory role in inverse direction, therefore this receptor has 
regulatory role and regulates other histamine receptors (HI, H2 and H4) in immuno-
biological system. 
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3.7.2. Materials and Methods 
3.7.2.1. Experimental design 
To evaluate the systemic antibody response, 144 (72 Male and 72 Female) 
New Zealand adult healthy rabbits of either sex weighing 1.63±0.36 kg were 
randomized equally into eight treatment groups, i.e. 18 rabbits (9 male and 9 female) 
in each group. 
Control group: Group-I (negative control) remained non-immunized and received 
only vehicle (sterile distilled water, 1 mlkg'' x b.i.d.). Group-II was vehicle (sterile 
distilled water, I mlkg"' x b.i.d.) treated and immunized as a positive control. 
Experimental group: Group-Ill was histamine-treated and immunized, group-IV was 
HlR-antagonist-treated and immunized. Group-V was H2R-antagonist-treated and 
immunized, Group-VI was H3R-antagonist-treated and immunized, Group-VII was 
H4R-antagonist-treated and immunized, and Group-VIII was DMSO-treated and 
immunized. 
The animals were housed in well-maintained animal facility at central animal 
house, J. N. Medical College & Hospital, Aligarh Muslim University, Aligarh, in the 
Bioresources unit under a 12 hr light/dark cycle, temperature (22±2°C) and were 
allowed free access to standard laboratory diet including green vegetables and tap 
water until experimentation. Each animal was used only once. All studies were carried 
out during the light cycle and were approved by the Institutional Animal Ethical 
Committee. 
3.7.2.2. Materials 
All materials were same as used in chapter 3.1.1. 
3.7.2.3. Drugs and Doses 
Following drugs were used: histamine dihydrochloride from Himedia 
laboratories Pvt Limited, India; HlR-antagonist: Avil® (pheniramine maleate) in 
injection LP. by Unimark Remedies, India and H2R-antagonist: Rantac® (ranitidine 
hydrochloride) in injection LP. by J. B. Chemicals and Pharmaceuticals, India; H3R-
antagonist (iodophenpropit dihydrobromide) was kindly donated by Tocris 
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Bioscience, Tocris Cookson Ltd., United Kingdom; and H4R-antagonist (JNJ 
7777120) from Sigma (USA). 
Histamine (100 ngkg"' x b.i.d.), and pheniramine maleate (10 mgkg'' x b.i.d.), 
ranitidine hydrochloride (10 mgkg'' x b.i.d.), iodophenpropit dihydrobromide (1 
Hgkg"' X b.i.d.) and JNJ 7777120 (10 i^gkg"' x b.i.d.) and DMSO (1 mlkg'). All doses 
were referred to the weight of the salts used. 
3.7.2.4. Antigen 
Sheep blood diluted 1:1 in sterile Alsevier's solution was obtained from 
Department of Microbiology, J. N. Medical College & Hospital, A.M.U., Aligarh, and 
washed with PBS (10 mM sodium phosphate buffer containing 150 mM NaCI, pH-
7.4) thrice by centrifugation. The ceil suspensions were adjusted to the desired 
concentration in terms of hemoglobin, lysis of a 1% SRBC suspension (2 x lo^ 
cells/ml) with 14 volumes of 0.1% Na2C03 develops an optical density of 0.135 at 
541 nm in a spectrophotometer (Systronics, UV visible double beam 
spectrophotometer-2101, India), as described Franzl (1972). Finally the concentration 
was adjusted to 5% (1 x 10^  cells/ml) in PBS for immunization before use. 
3.7.2.5. Immunization of rabbits 
The rabbits in all experimental groups (II-V) were immunized intravenously 
via marginal ear vein with 1ml of 5% (1 x ]0^ cells/ml) sheep red blood cells (SRBC) 
in PBS. 
3.7.2.6. Sample collection 
To determine the systemic antibody response, blood samples were collected 
from rabbits through the marginal ear veins into labelled sterile bottles prior to 
immunization (day 0), as well as on days 7-, 14-, 21-, 28- and 58- post-immunization. 
Blood samples were kept at room temperature for 2 hr and then at 4°C overnight. 
Blood samples were centrifuged for 10 minutes at 580xg, and serum was isolated and 
heated at 56°C for 30 minutes to inactivate complement proteins and stored in aliquots 
containing sodium azide as preservative at -20°C till tested further (Doumal 1972). 
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3.7.2.7. Serological analysis 
3.7.2.7.1. Hemagglutination assay (HA) 
Same as chapter 3.1.1. 
3.7.2.7.2. ELISA using whole SRBC 
Same as chapter 3.1.1. 
3.7.2.8. Statistical Analysis 
Data were summarized as Mean ± SD. Groups were compared by using 
repeated measures (subjects within groups) two way analysis of variance (ANOVA) 
followed by Newman-Keuis post hoc test. A two-tailed {a = 2) probability P<0.05 
was considered to be statistically significant. Analyses were performed on SPSS for 
v/indows (version 12.0, Inc., Chicago, IL). 
3.7.3. Results 
To evaluate the effects of histamine-receptors-antagonist on the 
immunomodulation, antibody-mediated responses to SRBC were assessed. Total 
serum immunoglobulins (Igs), total immunoglobulin-M (IgM) and total 
immunoglobulin-G (IgG) generation profiles were studied in vivo in eight 
experimental groups at days 0 (pre-I), 7, 14, 21, 28 and 58 (post-I). 
3.7.3.1. Profile of total anti-SRBC-immunoglobulins (Igs) production 
The profile of total anti-SRBC-Igs titer was studied by whole SRBC-ELISA 
method (Koganei et al. 2007) (Fig. 1) and direct HA (Haghighi et al. 2005) (Table 1). 
The ELISA and HA assay both showed similar Igs production but evident more in 
ELISA as opposed to HA. No anti-SRBC-Igs response was detected in all 
experimental groups (negative control, positive control and drug treated) at day 0 
(pre-I). There was an initial increase and subsequent decrease in total serum Igs titer 
over a time span of 58 days in all the groups. The detailed summary of statistically 
analyzed Igs production by two way analysis of variance (ANOVA) followed by 
Newman-Keuls post hoc test are shown in Fig. I and Table I. By the day 7- post-I, 
anti-SRBC-Igs titer was significantly high, however it obtained a peak at day 14-, and 
by days 21-, 28- and 58- post-I there was a gradual decrease or a plateau in all 
experimental groups as compared to histamine-treated and H3R-antagonist-treated 
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groups (Fig. 1 and Table 1). More extensive evaluation revealed that anti-SRBC-Igs 
raised steeply up to 7 days post-I, and there was a decrease in histamine-treated and 
H3R-antagonist-treated groups as compared to all other experimental groups. 
Histamine-treated group showed initial suppression (P< 0.01) (as opposed to 
H3R-antagonist-treated group) and enhancement (P< O.OI) (as compared to HIR-
/H2R-/H4R-antagonists-treated, positive control and DMSO-treated groups) of anti-
SRBC-Igs generation titer at day 7- post-I, and later suppression was observed in the 
anti-SRBC-Igs production titer during the whole study as compared to all the 
experimental groups at days 14-, 21-, 28- & 58- post-I except HlR-antagonist-treated 
group (histamine showed enhanced Igs generation titer at days 28- and 58- post-I). 
H3R-antagonist-treated group showed significant (P< 0.01) enhancement of 
total anti-SRBC-Igs at days 7- and 14- post-I as compared to all the experimental 
groups, while it showed significant (P< 0.01) suppression as compared to H2R-
antagonist- and H4R-antagonist-treated groups at days 21-, 28- & 58- post-I (whereas 
significant suppression was noticed as compared to positive control & DMSO-treated 
at day 21- post-I). This group further demonstrated significant (P< 0.01) enhancement 
as opposed to HlR-antagonist-treated and histamine-treated at days 2I-, 28- & 58-
post-I, and also positive control & DMSO-treated groups at days 28- and 58- post-I. 
The anti-SRBC-Igs generation titer in H4R-antagonist-treated group showed 
significant suppression (P< 0.01) as compared to H3R-antagonist- & histamine-
treated groups; however it showed similarity to DMSO-treated and positive control 
group at day 7- post-I. Furthermore, this group showed significant (P< 0.01) 
enhancement as opposed to H2R-antagonist- and HlR-antagonist-treated groups at 
days 7- post-I. At day 14- post-I, H4R-antagonist showed further suppression of anti-
SRBC-Igs generation titer as opposed to H3R-antagonist-treated, positive control and 
DMSO-treated while it demonstrated enhanced Igs titer as compared to HIR-
antagonist-, H2R-antagonist- and histamine-treated groups. Furthermore, this group 
showed enhancement of anti-SRBC-Igs generation titer as opposed to all the 
experimental groups at days 21-, 28- and 58- post-I. H4R-antagonist- and H2R-
antagonist-treated groups demonstrated similar profile of anti-SRBC-Igs generation 
titer; however H4R-antagonist-treated group showed enhanced profile as opposed to 
H2R-antagonist-treated group (Kindly refer to Fig. 1 and Table 1 for statistical 
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analysis). Moreover, HlR-antagonist-treated rabbits sliowed suppression of anti-
SRBC-Igs level at days 7-, 14-, 21-, 28- and 58- post-I in comparison to all the 
experimental groups (P< 0.01) except histamine-treated group (whereas this group 
demonstrated enhancement of total serum anti-SRBC-Igs levels at days 14- and 21-
post-I which were found statistically significant). HlR-antagonist-treated rabbits 
showed significant (P< 0.01) suppression of total anti-SRBC-Igs as opposed to that of 
H2R-/H3R-/H4R-antagonists-treated groups and positive control rabbits (Fig. 1 and 
Table 1). 
3.7.3.2. Profile of anti-SRBC-immunoglobulin-M (IgM) production 
Anti-SRBC-IgM was determined by whole SRBC-ELISA method (Koganei et 
al. 2007) (Fig. 2) and direct HA (Haghighi et al. 2005) (Table 1). The ELISA and HA 
assay both showed similar IgM production but evident more in ELISA as opposed to 
HA. No anti-SRBC-IgM response was observed in all experimental groups (negative 
control, positive control and HRs-antagonist-treated) at day 0- pre-I; however there 
was an initial increase and then gradual decrease in serum-IgM titer over time in all 
the groups. The detailed summary of statistically analyzed IgM production by two 
way analysis of variance (ANOVA) followed by Newman-Keuls post hoc test are 
shown in Fig. 2 and Table I. By day 7- post-I, the IgM titer increased and obtained 
highest peak, but by days 14-, 21-, 28-, and 58- post-I there was a gradual decrease in 
all experimental groups (except HlR-antagonist-treated, H2R-antagonist-treated and 
H3R-antagonist-treated groups, where the highest peak was obtained at day 14- post-I 
and then there was a gradual decrease). 
Histamine-treated group showed initial suppression (as opposed to H3R-
antagonist-treated group) and enhancement (as compared to H1R-/H2R-/H4R-
antagonists -treated, positive control and DMSO-treated groups) of anti-SRBC-IgM 
generation titer at day 7- post-I, and later suppression was noticed in the anti-SRBC-
IgM production titer during the whole study as compared to all the experimental 
groups at days 14-, 21-, 28- & 58- post-1 except HlR-antagonist- and DMSO-treated 
group (histamine showed significant enhanced IgM generation titer at days 28- and 
58- post-I as compared to HlR-antagonist-treated group, while histamine showed 
similar IgM production level to DMSO-treated group at days 28- and 58-post-I). 
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Figure 1. SRBC-spccific Immunoglobulins (Igs) production titers in II1R-. H2R-, U3R-
& H4R-antagonist-treated rabbits by whole SRBC-ELISA method in duplicate 1:100 
diluted sera. The resuhs demonstrate mean ± s.d. of three experiments each with six 
rabbits. Two-way ANOVA followed by Newman-Keuls post hoc test revealed that the 
effect of treatments (F=3608.816, DF=7,136; P<0.01) and days (F=72124.468, 
DF=5,680; P<0.01) on SRBC were statistically significant. The interaction (treatments x 
days) effect of (F=3896.230, DF=35,680; P<0.01) these on SRBC were also found to be 
significant. 
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Figure 2. SRBC-specific Immunoglobulin-M (IgM) production titers in H1R-. H2R-. 
H3R- & H4R-antagonist-treated rabbits by whole SRBC-ELISA method in dupHcate 
1:100 diluted sera. The results demonstrate mean ± s.d. of three experiments each with 
six rabbits. Two-way ANOVA followed by Newman-Keuls post hoc test revealed that 
the effect of treatments (F=2167.238. DF=7J36; P<0.01) and days (F=16405.067. 
DF=5,680; P<0.01) on SRBC were statistically significant. The interaction (treatments x 
days) effect of (F=642.525, DF=35,680; P<0.01) these on SRBC were also found to be 
significant. 
(158) 
Chapter 3.7. In Vivo Iitimunomodulation and Immunomodulatory 
Profile of Histamine Receptors (HI-. H2-, H3- & H4-): 
A Comparative Antagonists Study 
H3R-antagonist-treated group showed significant (P< 0.01) enhancement of total anti-
SRBC-IgM at days 7- post-I as compared to all the experimental groups, while it 
showed significant (P< 0.01) suppression as compared to H4R-antagonist-treated 
groups at days 14-, 21-, 28- & 58- post-I and also showed significant (P< 0.01) 
suppression as compared to H2R-antagonist-treated group at days 14-, 21- & 28-post-
I. H3R-antagonist group also showed suppression as compared to positive control 
group at day 14- post-I. This group demonstrated significant (P< 0.01) enhancement 
as opposed to H1 R-antagonist-tfeated and histamine-treated at days 14-, 21-, 28- & 
58- post-I, and also positive control & DMSO-treated groups at days 21-, 28- & 58-
post-I. 
The anti-SRBC-IgM generation titer in H4R-antagonist-treated group showed 
suppression as compared to positive control & DMSO-treated and also significant 
suppression (P< 0.01) as compared to H3R-antagonist- & histamine-treated groups. 
Furthermore, this group showed significant (P< 0.01) enhancement as opposed to 
H2R-/HlR-antagonist-treated groups at days 7- post-I. Moreover at day 14-, 21-, 28-
& 58- post-I, H4R-antagonist further showed significant (P< 0.01) enhancement of 
anti-SRBC-IgM generation titer as opposed to all the experimental groups (Fig. 2). 
H4R-antagonist- and H2R-antagonist-treated groups demonstrated similar profile of 
anti-SRBC-IgM generation titer; however H4R-antagonist-treated group showed 
enhanced profile as opposed to H2R-antagonist-treated group. 
Moreover, HlR-antagonist-treated rabbits showed suppression of anti-SRBC-
IgM level at days 7-, 14-, 21-, 28- and 58- post-1 in comparison to all the experimental 
groups except histamine-treated group (this group demonstrated enhancement of total 
serum anti-SRBC-IgM level at days 14- and 21- post-I which were found statistically 
significant). HlR-antagonist-treated rabbits showed significant (P< 0.01) suppression 
of total anti-SRBC-IgM as opposed to that of H2R-/H3R-/H4R-antagonists-treated 
and positive control rabbits (Fig. 2 and Table 1). 
3.7,3.3. Profile of anti-SRBC-immunoglobuIin-G (IgG) production 
The profile of total anti-SRBC-IgG titer was also studied by whole SRBC-
ELISA method (Koganei et al. 2007) (Fig. 3) and direct HA (Haghighi et al. 2005) 
(Table 1). The ELISA and HA assay both showed similar IgG production but evident 
more in ELISA as opposed to HA. 
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Figure 3. SRBC-specific Immunoglobulin-G (IgG) production titers in H1R-, H2R-, 
H3R- & H4R-antagonist-treated rabbits by whole SRBC-ELISA method in duplicate 
1:100 diluted sera. The results demonstrate mean ± s.d. of three experiments each with 
six rabbits. Two-way ANOVA followed by Newman-Keuls post hoc test revealed that 
the effect of treatments (F=2425.731. DF=7.136; P<0.01) and days (F=8166.595. 
DF=5,680; P<0.01) on SRBC were statistically significant. The interaction (treatments x 
days) effect of (F-507.794, DF=35,680; P<0.01) these on SRBC were also found to be 
significant. 
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The detailed summary of statistically analyzed IgG production by two way analysis of 
variance (ANOVA) followed by Newman-Keuls post hoc test are shown in Fig. 3 and 
Table 1. More extensive evaluation revealed that anti-SRBC-IgG in histamine-treated 
groups raised steeply up to 7- days post-I as compared to positive control, DMSO-treated 
and HlR-/H2R-/H4R-antagonists groups, however showed suppression as opposed to 
H3R-antagonist-treated rabbits. 
By days 14-, 21-, 28- and 58- post-I there was a significant (P< 0.01) decrease in 
anti-SRBC-IgG levels in histamine-treated as compared to all other experimental groups 
except HlR-antagonist-treated (whereas it showed enhancement of IgG as opposed to 
HlR-antagonist-treated at day 14- post-I) and this was found statistically significant (Fig. 
3 and Table 1). H3R-antagonist-treated group showed significant (P< 0.01) enhancement 
of total anti-SRBC-IgG at days 7- post-I as compared to all the experimental groups, 
while it showed significant (P< 0.01) suppression as compared to H4R-/H2R-antagonists-
treated groups, positive control and DMSO-treated groups and also showed significant 
(P< 0.01) enhancement as compared to HlR-antagonist- & histamine-treated groups at 
days 14- post-I. This group further demonstrated enhancement as opposed to all the 
experimental groups except H4R-antagonist-treated group (whereas it showed suppressed 
IgG level) at days 21-, 28- & 58- post-I). The anti-SRBC-IgG generation titer in H4R-
antagonist-treated group showed significant suppression as compared to histamine- & 
H3R-antagonist-treated groups. However, it showed similar IgG production level near to 
positive control & DMSO-treated and also HlR-/H2R-antagonists-treated groups at day 
7- post-I. H4R-antagonist-treated group further demonstrated similar IgG generation titer 
near to positive control & DMSO-treated, while it showed significant (P< 0.01) 
enhancement as compared to histamine- & H3R/HlR-antagonist-treated groups at day 
14- post-I. Moreover at day 21-, 28- & 58- post-I, H4R-antagonist further showed 
significant (P< 0.01) enhancement of anti-SRBC-IgG generation titer as opposed to all 
the experimental groups (Fig. 2). 
H2R-antagonist-treated and H4R-antagonist-treated rabbits showed similar anti-
SRBC-IgG generation titer at days 7- & 14- post-I, while on further analysis, H2R-
antagonist-treated group showed significant enhancement as compared to histamine-
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treated & HlR-antagonist-treated group and also demonstrated significant suppression as 
compared to H4R-antagonist-, H3R-antagonist-treated & positive control groups at days 
21-, 28- & 58- post-I (Fig. 2 and Table 1). 
HlR-antagonist-treated rabbits showed significant (P< 0.01) suppression of anti-
SRBC-IgG level at days 7-, I4-, 21-, 28- and 58- post-I in comparison to all the 
experimental groups except histamine-treated group and demonstrated enhancement of 
total serum anti-SRBC-IgG level at days 21-, 28- «& 58- post-I (Fig. 2 and Table 1). 
3.7.4. Discussion 
Histamine receptors are distributed in all parts of body and modulate several 
physiological and pathological reactions both in vivo and in vitro by the activation on 
releasing the histamine (Shahid et al. 2009) and also it has been well documented that 
histamine shows the agonist properties of their receptors (HIR, H2R, H3R & H4R) (Jutel 
et al. 2001, Thurmond et al. 2008, Shahid et al. 2009). Histamine also modulates 
immunological reactions and directly affects B-cell antibody production as a co-
stimulatory receptor on B-cells (Rocklin and Beer 1983, Akdis and Blaser 2003, Jutel et 
al. 2005, Akdis 2006). It is also being documented in mice that histamine enhances anti-
IgM induced proliferation of B-cells, which abolished in HIR deleted mice. In HIR-
deleted mice antibody production against a T cell-independent antigen-TNP-Ficoll is 
decreased (Banu and Watanabe 1999), suggesting an important role of HIR signaling in 
response triggered from B cell receptors. Jutel et al. (2001) showed a different pattern of 
antibody responses to T cell-dependent antigens like ovalbumin and demonstrated that 
HlR-deleted mice produced high ovalbumin-specific IgGl and IgE in comparison to wild 
type mice. 
Keeping in view the above facts, especially the paucity of literature (i.e., 
immunomodulatory role of histamine HI-, H2-, H3- and H4-receptors), defining the co-
relation of histamine receptors-antagonists in immune regulation & modulation and the 
fragmentary literature of histamine receptors (HIR, H2R, H3R and H4R) describing 
existing immunomodulatory role of histamine and histamine receptors in vivo system, the 
present study was proposed. 
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Therefore, the comparative study explored total serum anti-SRBC-Igs, IgM and 
IgG generation profile against SRBC (a T cell-dependent test antigen) (Putman et al. 
2002, Koganei et al. 2007) in negative control (untreated) and treated groups (positive 
control [treated with sterile distilled water]-, HlR-antagonist (pheniramine)-, H2R-
antagonist (ranitidine)-, H3R-antagonist (iodophenpropit)-, H4R-antagonist (JNJ 
7777120), histamine treated-, DMSO-treated-experimental groups) in healthy albino 
rabbits. The study reveals that H1R-, H2R-, H3R- & H4R-antagonists-treated rabbits 
were characterized by a marked deviation of the immune response as compared to control 
rabbits. 
The results of the present study demonstrate that the histamine, released from 
immunological stimuli from effector cells in vivo (Shahid et al. 2009), could influence a 
detectable antibody response to SRBC (same results were observed in previous study, 
strengthen previous results of histamine). 
It must be emphasized here that to the best of our knowledge, none of the earlier 
reports have demonstrated the comparative study of anti-SRBC-antibody (total 
immunoglobulins (Igs), IgM and IgG) profile modulated by histamine and histamine 
receptors (HIR, H2R, H3R & H4R)-antagonists over a span of study period of 58 days. 
This study showed that the histamine treated-rabbits showed immunopotentiating 
properties by enhancing the anti-SRBC-antibodies levels as compared to positive control 
group (strengthen our previous histamine findings documented in earlier chapters). 
The comparative study, until the presence of HI-, H2-, H3- & H4-antagonists in 
the body, in vivo immunoregulatory processes demonstrated enhanced generation profile 
of anti-SRBC-antibody (total-anti-SRBC-Igs, IgM and IgG) in H3R-antagonist-treated 
rabbits as compared to positive control rabbits, while H4R-antagonist, H2R-antagonist-
and HlR-antagonist-treated rabbits revealed suppressed generation profile of total-anti-
SRBC-Igs, IgM and IgG as compared to positive control rabbits. Whereas, on further 
metabolism of antagonists in the body showed enhanced anti-SRBC-Igs, IgM and IgG 
generation profile in H4R-, H3R- & H2R-antagonists-treated rabbits (H4R- showed more 
marked immune modulation as compared to H3R- & H2R-) as compared to positive 
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control rabbits. HlR-antagonist-treated rabbits showed suppressed antibody generation 
profile overall the study period as compared to other experimental groups. 
Furthermore, the effect of histamine & H1R-H4R antagonists were disappeared 
on the antibody generation profile bringing them in the range of control antibody level at 
the final phase of study due to complete metabolism. 
To conclude, our results provide evidence that histamine receptors (HIR, H2R 
HSR & H4R) have important role in modulation of antibody generation, in which HIR 
have dominant role, while H2R and H4R play significant role of immune modulation 
(H2R revealed more marked modulation role as compared to H4R). 
On the other hand, H3R have dominant modulatory role in opposite direction, 
therefore this receptor have regulatory role and regulates other histamine receptors (HI, 
H2 and H4) in immuno-biological system. To the best of our knowledge, this is the first 
report describing the potential comparative immunomodulatory and immunoregulatory 
role of HI-, H2-, H3- and H4- receptors. 
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Brief Introduction 
Histamine, a well-known bioactive monoamine, originally considered as a 
mediator of immediate hypersensitivity, plays an important role in inflammatory and 
allergic responses. Its biological pleiotropic effects are mediated by four subtypes of 
histamine receptors (HIR, H2R, H3R and H4R) (Shahid et al. 2009). These receptors 
have been important drug targets for many years. Their physiological and pathological 
relevance such as cell proliferation, differentiation, hematopoiesis, embryonic 
development, regeneration, wound healing, aminergic neurotransmission and 
numerous brain functions (sleep/nociception, food intake and aggressive behavior), 
secretion of pituitary hormones, regulation of gastrointestinal and circulatory 
functions, cardiovascular system (vasodilation and blood pressure reduction), as well 
as inflammatory reactions, modulation of the immune response, endocrine function 
and homeostasis have been documented (Shahid et al. 2009). However, the 
information regarding exact role of histamine receptors (HRs) in liver's functions and 
structure is still limited. 
As a very active site of metabolism, the liver is especially susceptible to 
histamine and histamine receptors-agonists/antagonists. A recent study showed that 
the histamine H2R pathway plays a useful role in treatment of endotoxin-induced 
hepatic injury and related inflammatory disorders (Masaki et al. 2005), and it was also 
reported earlier that histamine protects against early alcohol-induced liver injury in 
rats via same pathway (Homyak et at. 2003). A previous study on H2R-antagonists 
(cimetidine and ranitidine) has already shown inhibitory effect on liver regeneration, 
while famotidine (a H2R-antagonist) has been reported not to inhibit liver 
regeneration (Kanashima and Kobayashi 1989). Luyendyk et al. (2003) demonstrated 
that modest inflammation causes the emergence of liver as a target for ranitidine 
toxicity in rats and suggested its role for inflammation in idiosyncratic reactions to 
ranitidine. A recent study with impromidine (H2R-agonist) in rats and dogs 
demonstrated that impromidine had no serious toxicological effects at lower dose. 
However, in dogs, at the higher doses minor pathological changes were observed in 
liver (Lesli et al. 1982). 
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The data of H1R-, H2R-, H3R- and H4R-receptors-agonists/-antagonists on 
the effects of hepatic functions and hepatotoxicity are elementary in the existing 
literature in contrast to studies on their uses in various pathological conditions. 
This prompted us to look for induction of hepatotoxicity (if any) by HIR, H2R, H3R 
and H4R -agonistsZ-antagonists (used in this immunomodulatory study). 
Therefore, keeping in view the above facts the present chapter was further 
sub-divided with the following preliminary findings and we demonstrated here 
notable hepatotoxicity due to these agonists/antagonists in albino rabbits by using 
histopathological and biochemical methods. 
> 4.1. Hepatotoxicity by Histamine Receptors (HI, H2, H3 & H4)-Agonists in 
Rabbits: A Histopathological & Biochemical Study 
> 4.2. Hepatotoxicity by Histamine Receptors (HI, H2, H3 & H4)-Antagonists in 
Rabbits: A Histopathological & Biochemical Study 
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4.1.1. Brief Summary 
Since in vivo studies looking for toxicological impact of histamine receptors-
agonists in experimental models are fragmentary, the present study was designed to 
delineate the histopathological and biochemical changes in livers of rabbits treated 
with histamine receptors (HIR, H2R, HSR and H4R)-agonists. The cohort comprised 
of six groups (Group I control and Group II-VI treated) containing five rabbits in each 
group. Control-group received vehicle (sterile distilled water) and treated groups 
received subcutaneous histamine (100 ngkg'' x b.i.d.), and HlR-agonist (HTMT 
dimaleate), H2R-agonist (amthamine dihydrobromide), H3R-agonist (R-(-)-a-
methylhistamine dihydrobromide) and H4R-agonist (clobenpropit dihydrobromide) 
each in a dose of 10 |J.gkg'' x b.i.d. Hepatotoxicity due to these agonists was analyzed 
by using histopathological and biochemical methods. Rabbits treated with drugs in 
group II to VI showed significant elevated levels of serum enzymes (alanine 
transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase and 
bilirubin) (P< 0.05). Histopathological examination revealed hepatic congestion (by 
histamine and H2R-agonist), centrilobular necrosis (by HlR-agonist), increasing 
degree of binuclearity (in H4R-agonist) and rather unusual multinuclearity (in H2R-
and H3R-agonist) of hepatocytes, and Kupffer cell prominence (in H4R-agonist) 
constituted the hallmark of the injuries produced by short-term treatment of histamine 
and its agonists as compared to control group. These results provide evidence that 
histamine receptors on induction via their specific-agonist produce specific pattern of 
hepatic congestion, hepatocyte necrosis and polyploidy, and Kupffer cell prominence. 
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4.1.2. Materials and Methods 
4.1.2.1. Experimental design 
To evaluate the histopathological changes, 30 New Zealand adult healthy 
albino rabbits of either sex weighing 1.29 ± 0.21 kg were divided into six groups. 
Each group contained five rabbits. 
Control group: Group-I was vehicle-treated (Vehicle is sterile distilled water). 
Experimental group: Group-II was histamine-treated; group-Ill was HlR-agonist-
treated; group-IV was H2R-agonist-treated; group-V was H3R-agonist-treated; and 
group-VI was H4R-agonist-treated. 
They were housed in well-maintained animal facility at Central Animal House 
of J. N. Medical College, Aligarh Muslim University, Aligarh, in the Bioresources 
unit under a 12 hr light/dark cycle, temperature (22±2°C) and were fed on standard 
laboratory diet including fresh green vegetables and clean tap water. All studies were 
carried out during the light cycle and were approved by the Institutional Animal 
Ethical Committee. 
4.1.2.2. Drugs 
In the present study, following drugs were used: histamine dihydrochloride 
from Himedia laboratories Pvt Limited, India; HlR-agonist (histamine trifluoro-
methyl toluidide (HTMT-dimaleate), H2R-agonist (amthamine dihydrobromide), 
H3R-agonist (R-(-)-a-methylhistamine dihydrobromide) and H4R-agonist 
(clobenpropit dihydrobromide) which were kindly donated by Tocris Bioscience, 
Tocris Cookson Ltd., United Kingdom. All doses were referred to the weight of the 
salts used. 
4.1.2.3. Dose 
Histamine dihydrochloride (lOO^g/kg) and other agonists (HTMT-dimaleate, 
amthamine dihydrobromide, R-(-)-a-methylhistamine dihydrobromide, clobenpropit 
dihydrobromide) (lOfig/kg) were administered subcutaneously (s.c.) twice a day for 
10 subsequent days. 
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4.1.2.4. Sample collection and analysis methods 
4.1.2.4.1. Blood sample collection and biochemical analysis 
To determine biochemical levels for liver function test (LFT), blood samples 
were collected from rabbits through the marginal ear veins into labeled sterile bottles 
at day 0 prior to drug treatment, as well as on day 3 (the day during drug treatment) 
and day 10 (the day after last day of drug administration). Blood samples were kept at 
room temperature for 2 hr and then overnight at 4°C. Blood samples were centrifuged 
for 10 minutes at 580xg, and serum was separated and stored in aliquots, with sodium 
azide as a preservative at -20°C till tested further (Doumai 1972). Serum levels of 
liver enzymes, including aspartate aminotransferase (AST) and alanine amino 
transferase (ALT), alkaline phosphatase and bilirubin, were determined using an 
automatic analyzer (Transasia XL 300, Germany). 
4.1.2.4.2. Liver sample collection and histopathological analysis 
For histopathological examination, albino rabbits in each group were 
sacrificed by high dose ether anesthesia, after completion of drug treatments. Animals 
were immediately perfused with 10% buffered formalin. Whole liver was taken out 
and photographed with digital camera (Olympus-SP-560UZ-Indonesia). 5 mm to 1 
cm blocks of liver were processed for paraffin embedding. 10 |xm thick paraffin 
sections were stained with Haematoxylin and eosin and were examined under light 
microscope (Olympus-BX 40-Japan). Observations were recorded in sample 
photomicrographs taken at X200, X400 and XI000. 
4.1.2.5. Statistical analysis 
Liver function tests (LFT) of the experimental rabbits in each group were presented as 
mean ± s.d. Significance of differences from control values were determined with the 
paired Student's / test using SPSS 12.0 for windows, Inc., Chicago, IL. In all analysis, 
P< 0.05 was considered as statistically significant. 
4.1.3. Results 
To evaluate the toxicological effects of specific histamine receptors-agonists 
in rabbits, both histopathological and biochemical assays were assessed. 
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4.1.3.1. Biochemical examination 
Rabbits of control group (sterile distilled water-treated) showed no significant 
increase in ALT, AST, alkaline phosphate and bilirubin levels. While rabbits in group 
II to VI had increased serum levels of these enzymes at days 3- and 10- post-drug 
treatment compared to control group (P< 0.05 for each drug treated group) (Table I). 
However, serum study of day- 0 (prior to drug-treatment and vehicle-treatment in 
groups II - VI and group I, respectively) showed no significant changes in the enzyme 
levels and demonstrated normal condition of liver in all experimental rabbits. 
4.1.3.2. Histopathological examination 
On gross examination, the size of the liver of the rabbits from control and 
experimental group appeared very much alike. In general, the color of liver from 
control and histamine treated looked dark and alike, those of HIR- and H2R-agonist 
groups were lighter and those from HSR- and H4R-agonist were pale. On increasing 
magnification, images of liver revealed some interesting pattern of the hepatic 
lobules. In all groups except H2R-agonist-treated, they appeared as characteristic 
regular hexagons. In H2R-agonist group, it was distorted and appeared as cluster of 
beans. In H4R-agonist group, it was found that each hexagon was subdivided by 
triradiate and cruciform grooves into minor lobules. 
Under light microscope, group-I (control-group) showed normal lobular 
architecture, hepatocyte laminae and patent sinusoids without congestion and 
hepatocytes appeared normal with only occasional hepatocytes being binucleated 
(Figure lA). There was no apparent sign of necrosis, fibrosis or periportal 
lymphocytic infiltration. 
In rabbits of group-II, treated with histamine dihydrochloride the contour of 
hepatocyte laminae and portal tract appeared normal but sinusoids were found to be 
congested. There was a noticeable increase in the binuclearity of hepatocytes as 
compared to control group (kindly refer to Figure lA & B). Although occasionally, 
but focal necrosis of hepatic cells was also noticed. Thus, generalized congestion, 
focal necrosis and increased incidence of binuclearity, as compared to control group, 
were observed (Figure lA & B). 
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Figure 1. Photomicrographs of livers: (A) Control rabbits. In the 
perivenular region the hepatocytes, cords, sinusoid normal. Binuclearity 
(t) is not very common. X400. (B) Histamine-treated rabbits. 
Architecture is maintained. Portal venule and sinusoids show congestion 
with mild infiltration in the portal tract. Many binucleated hepatocytes 
(It) are also seen. X400. 
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Figure 2. Photomicrographs of livers: (A) HlR-agonist-treated rabbits. 
Centrilobular necrosis seen in the right half of the field with spillover of 
bile pigment (*). X400. (B) H2R-agonist-treated rabbits. Marked 
periportal congestion in the right and lower half of the field (*) with 
infiltration in the periportal tissue (j). X200. 
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Figure 3. Photomicrographs of Hvers: (A) H3R-agonist-treated rabbits 
shows binucleated (B), muUinucleated (M) hepatocytes and Kupffer 
cell (K). XI000. (B) H4R-agonist-treated rabbits showing binucleated 
hepatocytes (B) and Kupffer cells (K). XI000. 
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Group-Ill, HlR-agonist (HTMT-dimaleate)-treated rabbits revealed 
centrilobular necrosis of hepatic cells and moderate increase in the hepatic 
macrophages. While, increased binuclearity of hepatocytes was also noticed in this 
group as compared to control group (Figure lA and 2A) and the sinusoid were less 
congested as compared to histamine-treated group. 
In group-IV, H2R-agonist (amthamine dihydrobromide)-treated rabbits, there 
was marked periportal congestion (Figure 2B) as compared to control as well as with 
the rest of the groups. Portal tract showed mild infiltration (Figure 2B). Focal 
necrosis, and increased binuclearity were obvious with occasional but unusual 
polyploidal multinucleated (4 nuclei) hepatocytes very similar to those seen in group-
V were also noticed. 
Group-V-treated with H3R-agonist (R-(-)-a-methylhistamine dihydrobromide) 
showed focal necrosis, moderate prominence in the Kupffer cells (KCs) in association 
with necrotic debris. There was marked nuclear heterogeneity among hepatocytes in 
terms of their size and number. In addition to increased incidence of binucleated 
hepatocytes, occasional but unusual polyploidal multinucleated hepatocytes were also 
noticed (Figure 3A), a feature that was also noticed in group-IV. 
Group-Vl H4R-agonist (clobenpropit dihydrobromide)-treated rabbits 
revealed in addition to focal necrosis, marked increase in the binuclearity of 
hepatocytes (>60%) as compared to group-II histamine-treated (Figure IB and 3B) 
and other drug-treated groups. One of the remarkable features of this group was 
prominence of hepatic macrophages or Kupffer cells (KCs). At certain locations, the 
hepatocytes were found to be arranged in the form of compact sheet with ill-defined 
sinusoids warranting further study. 
4,1.4. Discussion 
We demonstrated here that short-term treatment by histamine and histamine 
receptors-agonists cause increase in the serum levels of ALT, AST, alkaline 
phosphatase and bilirubin, as well as necrotic changes in hepatocytes, which are 
biochemical and histological parameters of liver damage, respectively (Kraly et al. 
1996, Thapa and Walia 2007). To provide evidence relating our investigations to in 
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vivo toxicological studies, we used healthy rabbits treated with histamine and 
histamine receptors (H1R-, H2R-, H3R- and H4R-)-agonists. Here we report that 
histamine and histamine receptors (H1R-, H2R-, H3R- and H4R-)-specific agonist 
treated rabbits were characterized by marlied histological changes as compared to 
control rabbits. It must be emphasized here that, to the best of our knowledge, none of 
the earlier reports have demonstrated the biochemical and histopathological studies on 
HIR-agonist (HTMT-dimaieate), H2R-agonist (amthamine dihydrobromide), H3R-
agonist (R-(-)-a-methylhistamine dihydrobromide) and H4R-agonist (clobenpropit 
dihydrobromide) which we have used in this study. 
The elevation of serum levels of ALT, AST, alkaline phosphatase and 
bilirubin indicate increased rates of hepatocyte apoptosis and necrosis (Masaki et al. 
2005, Thapa and Walia 2007). Liver apoptosis and necrosis developes in a stepwise 
fashion, first step being apoptosis which is caused by various humoral factors 
(Galanos et al. 1979, Lehmann et al. 1987, Leist et al. 1995, Masaki et al. 2005), and 
the second step is focal necrosis which is induced by the accumulated 
polymorphonuclear cells and lymphomononuclear cells (Galanos et al. 1979, 
Lehmann et al. 1987, Leist et al. 1995). Finally, massive necrosis appears to be caused 
by intra-hepatic macrophages and neutrophils (Galanos et a!. 1979, Lehmann et al. 
1987, Leist et al. 1995). In our study, the liver in the histamine receptors-agonists-
treated groups (III-VI) appeared pale in color as compared to the reddish brown color 
of the controls and histamine treated group. The surface features of hepatic lobules in 
the magnified digital images revealed marked distortion (from hexagonal in control) 
in H4R-agonist treated group possibly due to specific pattern of congestion, 
infiltration and necrosis. Histological findings in all drug-treated rabbits showed quite 
specific pattern of degenerative changes in livers. Since histamine is involved in 
lymphocyte proliferation and neutrophil chemotaxis and infiltration, the possibility 
exists that histamine prevents liver injury by affecting the late stage of hepatic cell 
damage, which includes necrosis, induced by inflammatory cells (Masaki et al. 2005). 
However, the present study demonstrates that short-term treatments of histamine 
group showed focal necrosis, generalized congestion of sinusoids and marked 
hepatocyte binuclearity while hepatocyte contour and portal tract appeared normal. 
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Liver, an organ of vital importance, was found to be markedly damaged by 
histamine receptors (H1R-, H2R-, H3R- and H4R-)-agonists in the present 
investigation on rabbits. The damage caused by short-term exposure to histamine and 
HRs-agonists appeared to be quite specific for each of the agonist. In general, 
increased incidence of hepatocyte polyploidy (bi-and multinucleated), frequent 
occurrence of Kupflfer cells (KCs), variable grades of necrosis, congestion and 
lymphocytic infiltration constituted the hallmark of injuries produced by the histamine 
and HRs-agonists. Binuclearity of hepatocyte was most remarkable in H4R-agonist 
treated group while occurrence of multinucleated (4 nuclei) hepatocyte was noticed in 
H2R- and H3R-agonists treated rabbits. KCs were most pronounced in H4R-agonist 
treated rabbits. Serum enzymes ALT and AST leakage from hepatocytes and their 
marked elevations have been observed in cases of hepatitis, neonatal hepatitis, 
ischaemic, and autoimmune toxicity (Thapa and Walia 2007). AST and ALT levels 
were significantly increased in all drug-rabbits on lO"^  day as compared to their own 
control pre-treatment readings (P< 0.05) and demonstrated the increased rates of liver 
degeneration in group-Il to group-Vl with the corresponding values of respective 
days, which support our histopathological findings in all drug-treated groups 
compared to control group. Furthermore, increased alkaline phosphatase and bilirubin 
levels in all drug-treated groups as compared to control group (P< 0.05) also support 
liver degeneration and sustain our histological findings of liver damage in all the 
drug-treated experimental groups. 
Polyploidy of hepatocytes and prominence of KCs were among the remarkable 
histopathological changes produced by HRs-agonists. However, certain degree of 
binuclearity (about 10%) and polyploidy in hepatocytes are considered normal 
(Guidotti et al. 2003), but in the present study it has been noticed that histamine and 
almost all HRs-agonists results in increased incidence of binuclearity (most marked 
with H4R-agonist) and in certain cases multinuclearity (up to 4 nuclei) of hepatocytes. 
Though the biological significance of hepatic polyploidy remains unclear, it is 
believed that binuclear status may constitute an intermediate step before the 
mononuclear 4n status is achieved (Guidotti et al. 2003). On one hand polyploidy is 
considered to be a general physiological process indicating terminal differentiation 
and senescence or a strategy of cell growth which enables an increase in metabolic 
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output, cell mass, cell size and thus constituting an alternative to cell division. On the 
other hand, tetraploid to octoploid hepatocytes with one-or-two nuclei are believed to 
be due to the cleavage failure (Sigal et al. 1999). Postraumatic hepatic regeneration is 
associated with cell proliferation, hypertrophy, polyploidization and partial 
hepatectomy, hence causes accumulation of polyploid hepatocytes with prolonged 
depletion of diploid hepatocytes (Sigal et ai. 1999). It is also believed that 
polyploidization may affect the expression profile of specific gene, and thus provide 
protection against the dominant expression of mutant onco-genes - a safety measure 
that might be helpful for an organ heavily engaged in drug detoxification (Sigal et al. 
1999). Thus, polyploidization of hepatocyte having single large nucleus or with two 
nuclei has been described in many conditions but not in association with 
multinucleated hepatocyte. Therefore, the state of polyploidization of hepatocyte 
bearing multiple nuclei assumes special significance. In addition, observing such 
condition both in H2R- and H3R-agonists treated groups, suggests some kind of 
functional similarity between the H2R- and H3R-agonists. Therefore, in the present 
study, it remains to be elucidated as to whether the multinucleated and polyploidal 
condition of hepatocyte is a regenerative response to necrosis, protective mechanism 
against oncogenesis or an alternate measure of boosting function during stressful 
conditions. 
Kupffer cells (KCs) are resident macrophages of the liver. They play an 
important role in its normal physiology and homeostasis as well as participate in the 
acute and chronic responses of the liver to toxic compounds (Vbra and Modriansky 
2002). The primary functions of KCs include phagocytosis, processing of ingested 
material, antigen presentation and secretion of biologically active products (Vbra and 
Modriansky 2002). In the present study, both histamine and most of HRs-agonists 
treated liver showed mild increase in their frequency. However, H4R-agonist treated 
liver was characterized by marked increase in the prominence of KCs in association 
with pronounced polyploidy (binuclearity) of hepatocytes- feature akin to 'liver cell 
unrest' which is believed to be common in many severe illness affecting the entire 
body. Erythrophagocytosis by KCs is said to promote oxidative stress, inflammation 
and fibrosis (Otogawa et al. 2007). Activation of KCs by toxic agents results in the 
release of an array of inflammatory mediators, growth factors, and reactive oxygen 
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species (Roberts et al. 2007). Many of the cytokines may induce hepatocyte cell 
proliferation and may thus enhance clonal expansion of preneoplastic cells leading to 
neoplasia (Roberts et al. 2007). They have an enormous endotoxin eliminating 
capacity (Prins et al. 2005) and play an important role in both liver damage and 
regeneration (Baier et al. 2005). Also, they have the same preferences as do spleen 
cells for certain types of tumor cells. Metastasizing tumor cells are less sensitive than 
their non-metastasizing counterparts (Maker et al. 1986). In the present study it 
remains to be resolved as to whether the prominence of KCs in association with 
marked binuclearity of hepatocytes represents a protective phenomenon against 
harmful agents or it is idiosyncratic response which might produce undesirable 
effects. 
In summary, the histopathological examination of liver revealed that short-
term treatment by histamine and its receptors-agonist produce differential patterns of 
heptotoxicity in terms of hepatic congestion (histamine and H2R-agonist), 
centrilobular necrosis (HlR-agonist), binucleated (H4R-agonist) and multinucleated 
hepatocytes (H2R- and H3R-agonist), and prominent KCs (H4R-agonist) as compared 
to control group. In conclusion, these results suggest that histamine receptors on 
induction via their specific-agonist produce differential pattern of hepatotoxicity 
warranting further studies. 
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4.2.1. Brief Summary 
The present study was designed to delineate the hepatotoxicological roles of 
histamine receptors (HIR, H2R, H3R & H4R)-antagonist in vivo which is elementary 
in existing literature. The cohort comprised of seven groups (Group I control, Group 
II-VI drug-treated and Group VII DMSO-treated) containing five rabbits each. Group 
I was sterile distilled water (1 mlkg'' x b.i.d.)-treated, Group II histamine-treated (100 
Hgkg"' X b.i.d.), group III HlR-antagonist-treated (pheniramine maleate, 10 mgkg'' x 
b.i.d.), Group IV H2R-antagonist-treated (ranitidine hydrochloride, 10 mgkg"' x 
b.i.d.). Group V H3R-antagonist-treated (iodophenpropit dihydrobromide, I ngkg'' x 
b.i.d.). Group VI H4R-antagonist-treated (JNJ 7777120, 10 ngkg"' x b.i.d.), and 
Group VII DMSO-treated (1 mlkg"' x b.i.d.), respectively for 10 days (starting from 
day 1). Hepatotoxicity due to these histamine receptors-antagonists analyzed by using 
histopathological and biochemical methods. Rabbits treated with drugs in group II to 
VI had significant (P< 0.05) elevated levels of serum enzymes (alanine transaminase 
(ALT), aspartate transaminase (AST), alkaline phosphatase and bilirubin). 
Histopathological examination showed maintained hepatic lobular architecture, portal 
triad, hepatic cords and sinusoids in histamine and DMSO-treated groups a kin to 
control. The notable findings included increased binuclearity in HIR, trinuclearity in 
H2R, oxyphilic clusters of hepatocytes in HSR and moderate centrilobular necrosis in 
H3R and H4R-antagonist-treated groups without obvious lymphocytic infiltration and 
Kupffer cell prominence. In conclusion, HRs-antagonist appears moderately 
hepatotoxic which is expressed in terms of altered serum enzyme levels and almost 
non-inflammatory hepatocellular damage. 
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4.2.2. Materials and methods 
4,2.2.1. Experimental design 
To evaluate the biochemical and histopathological changes, 35 New Zealand 
adult healthy albino rabbits of either sex weighing 1.19 ± 0.31 kg were randomly 
divided into seven experimental groups. Each group contained five rabbits. 
Control group: Group I was vehicle-treated (sterile distilled water, 1 mlkg"' x b.i.d.). 
Experimental group: Group II histamine-treated, group III HlR-antagonist-treated, 
Group IV H2R-antagonist-treated, Group V H3R-antagonist-treated, Group VI H4R-
antagonist-treated, and Group VII DMSO-treated (served as control for H4R-
antagonist-treated group).They were housed in well-maintained animal facility at 
Central Animal House of J. N. Medical College, Aligarh Muslim University, Aligarh, 
in the Bioresources unit under a 12hr light/dark cycle, temperature (22±2°C) and were 
fed on standard laboratory diet including fresh green vegetables and clean tap water. 
All studies were carried out during the light cycle and were approved by the 
Institutional Animal Ethical Committee. 
4.2.2.2. Drugs 
In the present study, following drugs were used: histamine dihydrochloride 
from Himedia laboratories Pvt Limited, India; Avil® (pheniramine maleate) in 
injection LP. by Unimark Remedies, India; and Rantac® (ranitidine hydrochloride) in 
injection LP. by J. B. Chemicals and Pharmaceuticals, India; H3R-antagonist 
(iodophenpropit dihydrobromide) was kindly donated by Tocris Bioscience, Tocris 
Cookson Ltd., United Kingdom; H4R-antagonist (JNJ 7777120) from Sigma (USA); 
and dimethyl sulfoxide (DMSO) from Qualigens fine chemicals, India. All doses were 
referred to the weight of the salts used. 
4.2.2.3. Doses 
Histamine dihydrochloride (100 ng/kg) was administered twice a day 
subcutaneously (s.c.) while H1R-, H2R-, H3R- & H4R-antagonists (pheniramine 
maleate, 10 mg/kg; ranitidine hydrochloride, 10 mg/kg; iodophenpropit 
dihydrobromide, 1 ^g/kg; and JNJ 7777120, 10 ^g/kg; respectively); and DMSO, 1 
ml/kg were administered intramuscularly (i.m.) twice a day for 10 subsequent days. 
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4.2.2.4. Sample collection and analysis methods 
4.2.2.4.1. Blood sample collection and biochemical analysis 
To determine biochemical levels for liver function test (LFT), blood samples 
were collected from rabbits through the marginal ear veins into labeled sterile bottles 
at day 0 prior to drug treatment, as well as on day 10 (the day after last day of drug 
administration). Blood samples were kept at room temperature for 2hr and then at 4°C 
overnight. Blood samples were centrifuged for 10 minutes at 580xg, and serum was 
separated and stored at -20°C (Doumal 1972). Serum levels of liver enzymes, 
including aspartate aminotransferase (AST) and alanine amino transferase (ALT), 
alkaline phosphatase and bilirubin (total bilirubin, direct bilirubin and indirect 
bilirubin), were determined using an automatic analyzer (Transasia XL 300, 
Germany). 
4.2.2.4.2. Liver sample collection and histopathological analysis 
For histopathological examination, albino rabbits in each group were 
sacrificed by high dose ether anesthesia after completion of drug treatments. Animals 
were immediately perfused with 10% buffered formalin. Whole liver was taken out 
and photographed with digital camera (Olympus-SP-560UZ-lndonesia) and 
subsequently liver was immersed in the same fixative for one week 10 mm x 5 mm x 
3 mm blocks of liver were processed for paraffin embedding. 10 fim thick paraffin 
sections were stained with Haematoxyiin and eosin, and were examined under light 
microscope (Olympus-BX 40-Japan). Observations were recorded in sample 
photomicrographs taken at X400 and XI000. 
4.2.2.5. Statistical analysis 
Liver function tests (LFT) of the experimental rabbits in each group were 
presented as mean ± s.d. Significance of differences from control values were 
determined with the paired Student's / test using SPSS 12.0 for windows, Inc., 
Chicago, IL. In all analysis, P< 0.05 was considered as statistically significant. 
4.2.3. Results 
To evaluate the toxicological effects of specific histamine receptors-antagonist 
in rabbits both histopathological and biochemical assays were assessed. 
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4.2.3.1. Biochemical examination 
Liver function test in terms of serum enzyme profile and bilirubin of different 
groups as mentioned in Table-1 may be summarized as: i). Serum levels of both ALT 
and AST showed significant (P< 0.05) increase in all drug treated groups except 
histamine treated and H4R treated groups, ii). Serum ALP showed significant (P< 
0.05) elevation in all drug treated groups, iii). Total serum bilirubin was significantly 
(P< 0.05) elevated in all except in H4R treated group, iv). Serum enzyme levels in 
DMSO treated group was comparable to that of control. 
4.2.3.2. Histopathological examination 
Gross: Livers from Histamine, DMSO and H4R-antagonist treated groups were 
darker, hyperemic and in their magnified images showed maintained regular 
hexagonal external lobular architecture. HIR- and H3R-antagonist treated groups 
appeared normal in size, color and texture and maintained hexagonal lobular 
structure. H2R-antagonist treated group had paler liver and moderate distortion in 
hepatic lobular architecture. 
Microscopic: As compared to control (group I), the histamine-treated (group II) had 
obviously congested and dilated sinusoids and central veins, moderately increased 
binuclearity of hepatocytes and occasional focal necrosis but had intact laminae and 
occasional centrilobular architecture (Fig. 4A, B). In the HlR-antagonist-treated 
(group III) though central lobular necrosis could be spotted but in general hepatic 
architecture, hepatic cord and sinusoids remained only mildly affected. However, 
presence of binuclear hepatocytes was very obvious (Fig. 4C). H2R-antagonist-treated 
(group IV) in addition to having increased incidence of binuclear hepatocytes also had 
quite frequent trinuclear hepatocytes. Oxyphilic hepatocytes clusters extending across 
the hepatic cords were also noticed. Though Kupffer cells could be identified easily 
under higher magnification they were neither numerous nor associated with 
inflammatory cells (Fig. 4D1 & D2). 
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Figure 1. Photomicrographs from control group (A) showing intact hepatic laminae, 
hepatocytes, minimal blood inside sinusoids and no lymphocytic infiltration; histamine 
treated group (B) had dilated and congested sinusoids with sporadic focal necrosis (in the 
right half of field) and bile pigments; HlR-antagonist group (C) showed centrilobular 
necrosis (lower half of field) and binuclearity among hepatocytes; and H2R-antagonist 
group (Di) with trinucleate hepatocyte and Kupffer cell in the central field as well as (D2) 
with Kupffer cell in the midfield in the vicinity of necrotic cell). Haematoxylin and eosin 
stain; A, B, C x 400 and Di & D2 x 1000. 
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Figure 2. Photomicrographs from H3R-antagonist (A and B) showing focal necrosis with 
eosinophilic hepatocytes clusters. Many hepatocytes appear to fuse (in B right upper 
field) and give the appearance of large multinucleated hepatocytes; DMSO-treated (C) 
with hepatic lobular and laminar structure is maintained without frank necrosis or 
infiltration but mildly swollen hepatocytes and dilated sinusoids; and H4R-antagonist (D) 
had centrilobular necrosis (left half of field). Haematoxylin and eosin stain; x 400. 
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H3R-antagonist-treated (group V) had both focal and centrilobular necrosis and 
oxyphilic heptocyte clusters akin to H2R-antagonist-treated group, either extending along 
a hejjatic cord or expanding across them. Multinucleate appearance of hepatocytes was a 
peculiar feature of this group wherein many hepatocytes appeared fused (Fig. 5 A and B). 
DMSO-treated (group VII) had maintained hepatic architecture but hepatocytes looked 
fluffy and sinusoid dilated without congestion, infiltration or significant hepatic injury 
(Fig. 5C). H4R-antagonist-treated (group VI) had focal to centrilobular necrosis. In the 
unaffected areas the hepatic lobular structure, portal triad, hepatic cords and sinusoids 
remained intact which were not associated with inflammatory cells (Fig. 5D). 
4.2.4. Discussion 
Hepatotoxic short term study of HRs-antagonist, liver is a very active site of drug 
metabolism especially susceptible to histamine and both HRs-agonists/antagonists. A 
recent study showed that the histamine H2R pathway plays a useful role in treatment of 
endotoxin-induced hepatic injury and related inflammatory disorders and this was also 
reported earlier that histamine protects against early alcohol-induced liver injury in rats 
via same pathway. A previous study on H2R-antagonists (cimetidine and ranitidine) has 
already shown inhibitory effect on liver regeneration, while famotidine (a H2R-
antagonist) has been reported not to inhibit liver regeneration. Luyendyk et al. (2003) 
demonstrated that modest inflammation causes the emergence of liver as a target for 
ranitidine toxicity in rats and suggested a role for inflammation in idiosyncratic reactions 
to ranitidine. The present study demonstrates that short-term treatments of H2R-
antagonist group showed focal necrosis, increase hepatocyte binuclearity as well as 
frequent occurrence of trinucleate hepatocytes with maintained hepatic lobular 
architecture and hepatocyte contour. 
Liver, an organ of vital importance, was markedly damaged by histamine receptors 
(H1R-, H2R-, H3R- and H4R-)-agonists on rabbits (Tripathi et al. 2009). The damage 
caused by short-term exposure to histamine and HRs-agonists appeared quite specific for 
each of the agonist. In general, increased incidence of hepatocyte polyploidy (bi-and 
muhinucleated), frequent occurrence of Kupffer cells (KCs), variable grades of necrosis, 
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congestion and lymphocytic infiltration constituted the hallmark of injuries produced by 
the histamine and HRs-agonists. Binuclearity of hepatocyte was most remarkable in 
H4R-agonist treated group while occurrence of multinucleated (4 nuclei) hepatocyte was 
noticed in H2R- and H3R-agonists treated rabbits. In the present study, binuclear cells are 
marked in HlR-antagonist group and trinuclear cells are frequent in H2R-antagonist 
treated groups. In our previous study KCs were most pronounced in H4R-agonist treated 
rabbits. In the present study though the KCs could be located in certain groups (H2R-
antagonist) they were not pronounced. Oxyphilic hepatocyte clusters noticed in the 
present (mainly H2R and H3R-antagonist group) study may be representing 
surviving/regenerating hepatocytes. The DMSO-treated group which served as control 
against H4R-antagonist did not show obvious hepatic damage and hence could be 
considered as reasonably safe vehicle for H4R-antagonist. Thus it can be stated that the 
damage noticed in H4R-antagonits-treated group is by the antagonist agent and not by the 
vehicle used. Thus as compared to HRs-agonist (Tripathi et al. 2009), neither congestion 
and infiltration nor KC prominence was noticed in any of HRs-antagonist-treated 
samples. 
It has been demonstrated that abnormalities in liver function tests (LFTs) are 
elevated levels of static biochemical tests, including ALT, AST, alkaline phosphatase and 
bilimbin. Serum enzymes ALT and AST leakage from hepatocytes "and their marked 
elevations have been documented in cases of hepatitis, neonatal hepatitis, ischaemic and 
autoimmune toxicity (Thapa and Walia 2007). The biochemical analysis of present study 
revealed H3R-antagonist was found to be hepatotoxic as shown by statistically significant 
elevated levels of ALT and AST. HIR- and H2R-antagonist-treated groups showed 
statistically significant elevation of ALT and AST levels falling within the higher limit of 
control. H4R-antagonist and DMSO-treated groups showed similarity of ALT and AST 
levels as control. However, contrary to other groups, histamine group showed significant 
suppression of ALT level as compared to all other experimental groups. Previous studies 
have shown that cellular injury in the liver causes release of ALT (Thapa and Walia 
2007; Yokoyama et al. 2007). However, there is no data available on suppressive effect 
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of ALT in existing literature. Yokoyama et al. (2007) demonstrated that the elevation of 
endogenous histamine by amodiaquine (a histamine A'^  methyhransferase inhibitor) play a 
protective role through the regulation of TNF-a production in endotoxin-induced hepatic 
injury in mice. When liver cells die or are damaged, the ALT spill out causing the blood 
level to rise; that is why the ALT level in the blood are considered good indicators of 
liver cell damage. Histamine causes regeneration (Shahid et al. 2009) and protects liver 
against early alcohol-induced liver injury (Homyak et al. 2003). Imoto et al. (1985) 
showed predominance of histamine HlRs on liver plasma membrane and demonstrated 
that histamine and its receptor play some role in liver function. Thus, we have put 
forwarded a conclusion indicating suppression of ALT level by exogenous histamine in 
vivo system i.e., elevation of histamine in exogenous environment of cell may thus play a 
protective role of liver and provide stability to plasma cell membrane (warranting further 
stud}') of liver cells. Significantly elevated levels of alkaline phosphatase and total 
bilinibin in most of the experimental groups in the present study though generally 
indicated liver degeneration, these are not as specific as ALT and AST for liver damage 
(Thapa and Walia 2007). 
Polyploidy of hepatocytes and prominence of KCs were among the remarkable 
histopathological changes produced by HRs-agonists (Tripathi et al. 2009). Certain 
degn;e of binuclearity (about 10%) and polyploidy in hepatocytes are considered normal 
(Guidotti et al. 2003). In the present study, it has been noticed that HRs-antagonists result 
into increased incidence of binuclearity (HIR), trinuclearity (H2R-antagonist), 
multinuclearity (H3R-antagonist) of hepatocytes. Though the biological significance of 
hepatic polyploidy remains unclear, and it is believed that binuclear status may constitute 
an intermediate step before the mononuclear 4n status is achieved (Guidotti et al. 2003). 
On one hand, polyploidy is considered to be a general physiological process indicating 
terminal differentiation and senescence or a strategy of cell growth which enables an 
increase in metabolic output, cell mass, cell size and thus constituting an alternative to 
cell division. On the other hand, tetraploid to octoploid hepatocytes with one-or-two 
nuclei are believe to be due to the cleavage failure (Sigal et al. 1999). Postraumatic 
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hepatic regeneration is associated with cell proliferation, hypertrophy, polyploidization 
and partial hepatectomy causes accumulation of polyploid hepatocytes with prolonged 
depletion of diploid hepatocytes (Sigal et al. 1999). It is also believed that 
polyploidization may affect the expression profile of specific gene and thus provide 
protection against the dominant expression of mutant onco-genes-a safety measure that 
might be helpful for an organ heavily engaged in drug detoxification (Sigal et al. 1999). 
Thus, polyploidization of hepatocyte having single large nucleus or with two nuclei has 
been described in many conditions but not in association with multinucleated hepatocyte. 
Therefore, the state of polyploidization of hepatocyte bearing multiple nuclei assumes 
special significance. Therefore, in the present study, it remains to be elucidated as to 
whether the multinucleated and polyploidal condition of hepatocyte is a regenerative 
response to necrosis, protective mechanism against oncogenesis or else an alternate 
measure of boosfing function during stressful condifions. 
Kupffer Cells (KCs) are resident macrophages of the liver. The primary functions of 
KCs include phagocytosis, processing of ingested material, antigen presentation and 
secretion of biologically active products (Vbra and Modriansky 2002). In the present 
study, though necrosis is evident in various grades (focal to centrilobular) but 
interestingly neither Kupffer cell prominence nor lymphocytic infiltration could be 
noticed. Thus the histopathological findings in this respect differ from those noticed in 
HRs-agonist study (Tripathi et al. 2009). 
In summary, Short-term treatment by histamine receptors-antagonists produced 
different patterns and intensities of hepatotoxicity in terms of hepatocellular necrosis and 
hepatocyte polyploidy congruent with biochemical alteration in the blood but had 
minimal effects on hepatic congestion, inflammatory cells infiltration or Kupffer ceil 
prominence. 
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Chapter 5 Summary and Conclusion 
Histamine, the product of histidine decarboxylation, is an evolutionary 
conserved signaling molecule. It acts as a powerful stimulant of gastric acid secretion, 
neurotransmission, bronchocontriction, vasodilation, and immune modulation. 
Histamine plays a central role in innate and acquired immunity: in allergy and 
inflammation, closely associated with mast cell functions, in immunomodulation 
regulating T-cell and B-cell function. Histamine synthesis, signaling, and function is 
controlled by a variety of immune signals and in turn, modulates antibody and 
cytokine networks and flinction. Histamine modulates its function via four receptors 
(HIR, H2R, HSR and H4R). All these four receptors are members of the 7-
transmembrane (heptahelical) spanning family of G protein-coupled receptors, and are 
expressed on various histamine responsive target tissues and cells and suggest an 
important critical role of histamine in immune regulation, allergic disorder and 
autoimmunity. Histamine can selectively recruit the major effector cells into tissue 
sites and affect their maturation, activation, polarization, and other functions leading 
to chronic inflammation. Histamine also regulates dendritic cells, T-cells and B-cells, 
as well as related antibody isotype responses. Histamine modulates antibody 
production. It directly affects B-cell antibody production as co-stimulatory receptor 
on B-cells. Histamine HIR- and H2R-deficient mice have an imbalance in ThIArh2 
cell function and a lower susceptibility to develop autoimmunity. Histamine HIR 
predominantly expressed on Thl cells may block humoral immune responses by 
enhancing Thl type cytokine IFN-y. In contrast, through histamine H2R, histamine 
enhances humoral immune responses. Allergen-specific IgE production is 
differentially regulated in histamine HIR and H2R-deficient mice. Histamine HIR-
deleted mice show increased allergen-specific IgE production, whereas histamine 
H2R-deleted mice show suppressed IgE production. In contrast, more sever 
autoimmune diseases are observed in mice lacking H3R, the receptor confined to the 
CNS. H4R on immune cells regulate cell migration and allergic responses in the 
periphery. Thus, humoral immune role of histamine in immunomodulation by 
histamine HI- and H2-receptors is documented (however it seems preliminary in 
nature), while its role by histamine H3- and H4-receptors are still unclear or 
elementary. However, the studies evaluating the role with receptors intact, but 
blocked by respective agonists/antagonists, and especially studying the 
immunomodulatory profile over a span of time are lacking in the existing literature. 
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Moreover, the studies in rabbit model are elementary, and the existing studies 
(histamine HI- and H2-receptors) have demonstrated the immunomodulatory role 
studying only single blood samples taken after Immunizing the animal. Therefore, the 
present study has been planned to fulfill the requirement of histamine role in immune 
modulation and regulation through histamine HI-, H2-, H3- & H4-receptors against 
sheep red blood cells (SRBC) (a T-cell dependent antigen) and has been presented in 
two parts. 
In the first part of study we have delineated the histamine role in immune 
modulation and regulation. To study the humoral immune aspects of histamine in 
immunomodulation, the present part of study is divided into seven chapters. In the 
first chapter we have studied in vivo immunomodulation and immunomodulatory 
profile of histamine receptors. Furthermore, on the basis of histamine dose, 
immunization schedule and time factor, this section has been presented in two sub-
chapters: (i) role of histamine on antibody profile generated by primary- and 
secondary-immunization and (ii) dose-dependent effect of histamine on antibody 
generation profile. In the first sub-chapter we have demonstrated potential role of 
histamine on antibody (total immunoglobulins (Igs), immunoglobulin-M and 
immunoglobulin-G) generation. These results have provided evidence that histamine 
has a short-term effect (until its presence in the body) on humoral immune system and 
affects B-cell for antibody class switching and potentially modulates antibody (Igs, 
IgM & IgG) generation titer. Secondary-immunization study has provided support to 
primary-immunization results of histamine role in antibody generation. In the second 
sub-chapter we have studied dose-dependent effect of histamine on antibody 
generation profile, and evaluated the antibody (Igs, IgM & IgG) generation titer in 
vivo affected by the concentration of histamine. 
In the second chapter we have studied in vivo immunomodulation and 
immunomodulatory profile of histamine HI-receptors and demonstrated that the 
histamine treated-rabbits showed immunopotentiating properties by enhancing the 
anti-SRBC-anfibodies levels as compared to control group (strengthen the previous 
findings of chapter first). HlR-antagonist-treated group suppressed the anti-SRBC-
IgM profile as compared to positive control group, on the other hand HIR-agonist-
treated group enhanced the anti-SRBC-IgM levels as compared to all experimental 
groups and demonstrated that Hl-receptors have role of IgM generation. While anti-
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SRBC-IgG profiles showed that HlR-antagonist-treated group suppressed the anti-
SRBC-IgG levels during complete study as compared to positive control group, while 
in contrast, HlR-agonist increased anti-SRBC-IgG profile as compared to other 
experimental group and further illustrated that HI-receptors have an important role in 
IgG generation. In this study, we noticed that exogenously added histamine in vivo 
(until its presence in the body) enhanced the antibody generation profile against 
SRBC whereas; on fiarther metabolism its effect disappeared on the antibody 
generation profile bringing it in the range of control antibody level. We also observed 
that HlR-antagonist (until their presence) suppressed the antibody profile, which 
came to normal level (control range) in later phase due to their metabolism. 
Therefore, on the basis of the present study we reached to a conclusion that the results 
obtained due to histamine and HlR-antagonist were of short duration which 
disappeared in latter stage due to clearance of the body from these substance in 
rabbits. The results of both groups (histamine-treated and antagonist-treated) after 
metabolism of drugs were identical to each other and also similar to control group. 
Thus, histamine Hi-receptors showed principle role in modulation of 
immunoglobulins and demonstrate important immunomodulatory effects in IgG and 
IgM generation. 
In the third chapter we have evaluated in vivo immunomodulation and 
immunomodulatory profile of histamine H2 receptors and showed that H2R-
antagonist-treated group enhanced IgM profile as compared to positive control-group, 
while agonists study showed different profile i.e., H2R-agonist-treated group 
enhanced the anti-SRBC-IgM levels as compared to H2R-antagonist-treated group 
and positive control. These data showed that H2-receptors have dominant role in IgM 
generation. While anti-SRBC-lgG profiles revealed that H2R-antagonist-treated group 
suppresses the anti-SRBC-IgG level during complete study as compared to positive 
control, and in contrast, H2R-agonist increased IgG profile as compared to all 
experimental groups and showed that H2-receptors have dominant modulatory role in 
IgG generation. In this study, we noticed that H2R-antagonist (until their presence) 
suppressed the antibody profile, which came to normal level (control range) in later 
phase due to their metabolism. Therefore, on the basis of the present study we reached 
to a conclusion that the results obtained due to H2R-antagonist were of short duration 
which disappeared in later stage due to clearance of the body from these substance in 
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rabbits. Thus, the result of H2R-antagonist-treated group, after metabolism of drug 
was similar to control group. This study provided evidence that histamine H2-
receptors have dominant role in IgM generation. 
In the fourth chapter we have studied in vivo immunomodulation and 
immunomodulatory profile of histamine H3-receptors and demonstrated suppressed 
generation profile of total anti-SRBC-lgs, anti-SRBC-IgM and anti-SRBC-IgG in 
H3R-agonist-treated group. In contrast, H3R-antagonist-treated group demonstrated 
increased generation profile of total anti-SRBC-lgs, anti-SRBC-IgM and anti-SRBC-
IgG during whole of the study period. These results are contrast to our previous study 
of histamine HI- and H2-receptors-agonists/antagonists (chapter 2 and 3) and 
demonstrated that H3-receptors on inhibition by H3R-antagonist showing modulatory 
activity (enhancing the antibody generation levels). On the other hand H3-receptors 
on stimulation by H3R-agonist showing modulatory activity (suppressing the 
antibody generation levels). These data provide evidence that histamine H3-receptors 
in biological system serve as regulator for other histamine HI-, H2-, or H4-receptors 
and auto-regulator for itself. Therefore, present study exhibits that H3-receptors 
regulate biological histamine level and its function in the body, and modulate 
histamine role in antibody production. In this study, we noticed again that 
exogenously added histamine in vivo (until its presence in the body) enhanced the 
antibody generation profile against SRBC whereas; on further metabolism its effect 
disappeared on the antibody generation profile bringing it in the range of control 
antibody level (strengthen previous histamine results of chapters I, 2 and 3). 
Furthermore, H3R-antagonist (until their presence) increased the antibody profile, 
which came to normal level (control range) in later phase due to their metabolism. 
The present results provided evidence that histamine through histamine H3-receptors 
have important role in modulation of total immunoglobulins (Igs, IgM and IgG) 
generation. 
In the fifth chapter we have evaluated in vivo immunomodulation and 
immunomodulatory profile of histamine H4-receptors and showed enhanced 
generafion profile of total anti-SRBC-lgs, anfi-SRBC-IgM and anti-SRBC-IgG in 
H4R-agonist-treated group. In contrast, H4R-antagonist-treated group revealed 
initially suppressed and then later enhanced the profile of total anti-SRBC-lgs, anti-
SRBC-IgM and anti-SRBC-IgG throughout the study. These results demonstrated that 
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H4-receptors by H4R-antagonist-treatment showing similar profile of antibody (Igs, 
IgM and IgG) generation as positive control group. On the other hand H4R-agonist-
treatment showing modulatory activity (enhancing the antibody generation levels) as 
compared to other experimental groups. These data provided evidence that histamine 
through histamine H4-receptor modulates immunological function and stimulates 
antibody production in vivo biological system. Again in this study, exogenously added 
histamine in vivo (until its presence in the body) enhanced the antibody generation 
profile against SRBC whereas; on further metabolism its effect disappeared (showed 
same findings of histamine as chapter 1-4). H4R-antagonist (until their presence) 
showed normal level of antibody profile, which was similar to control range whereas; 
on further metabolism its effect appeared as modulator and enhanced the antibody 
generation profile, which came to normal level (control range) at the last experimental 
day (in later phase). The conclusion of present study provided evidence that histamine 
H4-receptors have role in modulation of Igs, IgM and IgG generation. 
In the sixth chapter we have studied in vivo immunomodulation and 
immunomodulatory profile of histamine receptors (HI-, H2-, H3- & H4-): a 
comparative agonists study and demonstrated that enhanced generation profile of anti-
SRBC-antibody (anti-SRBC-Igs, IgM and IgG) in HIR-agonist-, H2R-agonist- and 
H4R-agonist-treated rabbits, while it showed suppression in H3R-agonist-treated 
rabbits as compared to positive control rabbits during the whole study period (same 
results were analyzed in chapter 2 - 5). Further we noticed that exogenously added 
histamine in vivo (until its presence in the body) enhanced the antibody generation 
profile against SRBC on 7"^  day post-I whereas; in later stages its effect disappeared 
on the antibody generation profile bringing it in the range of control antibody level 
(same as chapter 1 - 5). The conclusion of the present comparative study has provided 
evidence that histamine receptors (HIR, H2R and H4R) on stimulation have 
important role in modulation by enhancing the antibody generation, in which HIR 
have dominant role in immune modulation as compared to H2R and H4R. On the 
other hand, H3R on stimulation have dominant immune suppressive role and regulates 
other histamine receptors (HI, H2 and H4) in immune system. 
In seventh chapter we have evaluated in vivo immunomodulafion and 
immunomodulatory profile of histamine receptors (HI-, H2-, H3- & H4-): a 
comparative antagonists study and showed that the histamine treated-rabbits 
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illustrated immunopotentiating properties by enhancing the anti-SRBC-antibodies 
levels as compared to positive control group (strengthen our previous histamine 
findings documented in earlier chapters) and the comparative study of HI-, H2-, H3-
& H4-antagonists-treated groups demonstrated enhanced generation profile of anti-
SRBC-Igs, IgM and IgG in H3R-antagonist-treated rabbits as compared to positive 
control rabbits, while H4R-antagonist, H2R-antagonist- and HlR-antagonist-treated 
rabbits revealed suppressed generation profile of anti-SRBC-Igs, IgM and IgG as 
compared to positive control rabbits (until the presence in the body). Whereas, on 
further metabolism of antagonists in the body showed enhanced anti-SRBC-Igs, IgM 
and IgG generation profile in H4R- & H2R-antagonists-treated rabbits (H4R- showed 
more marked immune modulation as compared to H2R-) as compared to positive 
control rabbits. HlR-antagonist-treated rabbits showed suppressed antibody 
generation profile throughout the study period as compared to other experimental 
groups. The conclusion of the present study has provided evidence that histamine 
receptors (HIR, H2R, HSR & H4R) have important role in modulation of antibody 
generation, in which HIR have dominant immune enhancing role as compared to 
H2R and H4R (H2R revealed more marked immune enhancing role as compared to 
H4R). On the other hand, H3R have dominant immune modulatory role in 
suppressing the antibody generation. Therefore, H3R have regulatory role and 
regulates other histamine receptors (HI, H2 and H4) in immune system. 
In the second part of study we have delineated toxicological effects of 
histamine receptors (HI, H2, H3 & H4)-agonists/antagonist used in the present 
immunomodulation study. To study the toxicological effects of HRs-
agonists/antagonist, the present part of study is divided into two chapters: (i) 
Hepatotoxicity by histamine receptors (HI, H2, H3 & H4)-agonists in rabbits: a 
histopathological & biochemical study, and (ii) Hepatotoxicity by histamine receptors 
(HI, H2, H3 & H4)-antagonists in rabbits: a histopathological & biochemical study. 
In the first toxicological chapter we have demonstrated that AST and ALT 
levels were significantly increased in all drug-treated groups as compared to control 
and showed the increased rates of liver degeneration in histamine and HRs-agonists-
treated groups, which support hepatotoxic findings in all drug-treated groups 
compared to control group. Furthermore, increased alkaline phosphatase and bilirubin 
levels in all drug-treated groups as compared to control group also support liver 
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degeneration and sustain our histological findings of liver damage. The 
histopathoiogical study of liver revealed that short-term treatment by histamine and its 
receptors-agonist produce differential patterns of heptotoxicity in terms of hepatic 
congestion {histamine and H2R-agonist), centrilobular necrosis (HlR-agonist), 
binucleated (H4R-agonist) and multinucleated hepatocytes (H2R- and H3R-agonist), 
and prominent KCs (H4R-agonist) as compared to control group. Thus, the 
conclusion of these results suggests that histamine receptors on induction via their 
-specific-agonist produce differential pattern of hepatotoxicity warranting further 
studies. 
In the second toxicological chapter we have demonstrated the maintained 
hepatic lobular architecture, portal triad, hepatic cords and sinusoids in control, 
histamine and DMSO-treated groups. The notable findings included increased 
binuclearity in HIR, trinuclearity in H2R, oxyphilic clusters of hepatocytes in H3R, 
and moderate centrilobular necrosis in HSR and H4R-antagonist-treated groups 
without obvious lymphocytic infiltration and Kupffer cell prominence. Thus, the 
conclusion of present study revealed that short-term treatment by histamine receptors-
antagonists produce different patterns and intensities of hepatotoxicity in terms of 
hepatocellular necrosis and hepatocyte polyploidy congruent with biochemical 
alteration in the blood but had minimal effects on hepatic congestion, inflammatory 
cells infiltration or Kupffer cell prominence. 
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Hepatotoxicity Due to Histamine Trifluoro-Methyl Toluidide, Amthamine, 
R-(-)-a-Metliyl Histamine and Clobenpropit (HlR-H4R-Agonists, 
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Abstract: Problem statement: Since in vivo studies looking for toxicological impact of histamine 
receptors-agonists in experimental models are fragmentary, the present study was designed to delineate 
the histopathological and biochemical changes in livers of rabbits treated with histamine receptors 
(HlR-H4R)-agonists. Approach: The cohort comprised of six groups (Group I control and Group II-
VI treated) containing five rabbits each. Control-group received vehicle (sterile distilled water) and 
treated, groups received subcutaneous histamine (100 ng kg"' x b.i.d.) and HlR-agonist (HTMT 
dimaleate), H2R-agonist (amthamine dihydrobromide), H3R-agonist (R-(-)-a-methylhistamine 
dihydrobromide) and H4R-agonist (clobenpropit dihydrobromide) each in a dose of 10 pig kg"' x b.i.d. 
Hepatotoxicity due to these agonists analyzed by using histopathological and biochemical methods. 
Results: Rabbits treated with drugs in group II-VI had significant elevated levels of serum enzymes 
(alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and 
bilirubin) (p<0.05). Histopathological examination revealed hepatic congestion (by histamine and 
H2R-agonist), centrilobular necrosis (HlR-agonist), increasing degree of binuclearity (in H4R-agonist) 
and rather unusual multinuclearity (in H2R-and H3R-agonist) of hepatocytes and Kupffer cell 
prominence (in H4R-agonist) constituted the hallmark of the injuries produced by short-term treatment 
by histamine and its agonists as compared to control group. Conclusion: These results provided 
evidence that histamine receptors on induction via their specific-agonist produce specific pattern of 
hepatic congestion, hepatocyte necrosis and polyploidy and Kupffer cell prominence. 
Key words: Histamine, histamine receptors-agonists, liver histopathoiogy, hepatotoxicity, polypoidy, 
kupffer cells 
INTRODUCTION physiological and pathological relevance such as cell 
proliferation, differentiation, hematopoiesis, embryonic 
Histamine, a well-known bioactive monoamine, development, regeneration, wound healing, aminergic 
originally considered as a mediator of immediate neurotransmission and numerous brain functions 
hypersensitivity, plays an important role in (sleep/nociception, food intake and aggressive 
inflammatory and allergic responses. Its biological behavior), secretion of pituitary hormones, regulation of 
pleiotropic effects are mediated by four subtypes of gastrointestinal and circulatory functions, 
histamine receptors (HIR, H2R, H3R and H4R) cardiovascular system (vasodilation and blood pressure 
(Shahid et ai, 2009). These receptors have been reduction), as well as inflammatory reactions, 
important drug targets for many years. Their modulation of the immune response, endocrine function 
Correspondirg Author: M. Shahid, Department of Medical Microbiology, JN Medical College and Hospital, AMU, Aligarh, 
UP, India Tci:+91-571-2720382 Fax:+91-571-2721776 
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with Haema':oxylin and cosin and were examined under 
light microscope (Olympus-BX 40-Japan). 
Observations were recorded in sample 
photomicrographs lakcn a( X200, X400 and XI000^ 
Statistical analysis: Liver Function Tests (LFT) of the 
experimental rabbits in each group were presented as 
mean ± SD. Significance of differences from control 
values were determined with the paired Student's t lest 
using SPSS 12.0 for windows. Inc., Chicago, IL. In all 
analysis, p<0.05 was considered as statistically 
significant. 
RESULTS 
To evaluate the toxicological effects of specific 
histamine receptors-agonists in rabbits both 
histopathological and biochemical assays were 
assessed. 
Biochemical examination: Rabbits of control group 
(sterile distilled water-treated) had no significanl 
increase in ALT, AST, alkaline phosphate and bilirubin 
levels. While rabbits in group It to VI had increased 
serum levels of these enzymes at days 3- and 10- post-
drug treatment compared with control group (p<0.05 
for each drug treated group) (Table 1). However, serum 
study of day 0 (prior to drug-treatment and vehicle-
treatment in groups II-VI and group I, respectively) 
showed no significant changes in the enzyme levels and 
demonstrated normal condition of liver in all 
experimental rabbits. 
Histopatholoj;ical examination: On gross 
examination, the size of the liver of the rabbits from 
control and experimental group appeared ven,' much 
alike. In general, the color of liver fi'om control and 
histamine treated looked dark and alike, those of HIR-
and H2R-agonis( groups were lighter and those from 
H3R- and H4R-agonist were paler. Images of liver on 
zoom revealed some interesting pattern of the hepatic 
lobules. In all groups except H2R-agonist-treated, they 
appeared as characteristic regular hexagons. In H2R-
agonist group, it was distorted and appeared as cluster 
of beans. In H4R-agonist group, each hexagon was 
subdivided by triradiate and cruciform grooves into 
minor lobules. 
Under light microscope, group-I (control-group) 
showed normal lobular architecture, hepatocyte laminae 
and patent sinusoids without congestion and 
hepatocytcs appeared normal with only occdsional 
hcpatocytcs being binucleated (Fig. 1). There was no 
apparent sign of necrosis, fibrosis or periportal 
lymphocytic infiltration. 
In rabbits of group-Il treated with histamine 
dihydrochloridc the contour of hepatocj'te laminae and 
portal tract appeared normal but sinusoids were 
congested. There was a noticeable increase in the 
binuclearity of hcpatocytes as compared to control 
group (Fig. 1 and 2). Focal necrosis of hepatic cells was 
also occasionally noticed. Thus, generalized congestion 
and focal necrosis and increase incidence of 
binuclearity as compared to control group were 
observed (Fig. 1 and 2). 
Group-Ill HlR-agonist (HTMT-dimaleate)-treated 
rabbits revealed ccntrilobular necrosis of hepatic cells, 
moderate increase in the hepatic macrophages. While 
increased binuclearity of hepatocytcs was also noticed 
in this group as compared to control group (Fig. 1 and 
3), the sinusoid were less congested as compared to 
histamine-treated group. 
Tabic I: Effects ordnig-lrcatmcnts on li\or function lest (ALT. .\.ST. alkaline pho.sphatasc and bilirubin scrum levels) 
l-.xperimental .Xl.'l'CIL 1/'l(day) AST' ( I f I,"') (day) Alkaline phosphate'(IT'L"') (d^y) Bilirabin'(mg 1. ((day'l 
groups — 
(11-5) () 3rd imh 0 3rd IO(h 0 3rtl 10th 0 3rd 10th 
fhoup I 4.9(W).3 4.')7i0.()l 5.()()±().1 4,25±().25 4.27±0.()7 i j s l o j 6.9Zi:().02 6,90±0.l 6.W±0.1 (l.()89±0.09') ().09()±0.002 0.087±0.007 
(Control) 
(dvupll 4.91,L(14 ' P . M I - . I 'zi.Ml-.iLi 4.24±(l.l 'l5,.^OxU.3 'iiS..!!!!! h.hy±0.1 '27.2(l±0.2 •4S.9II1] ().()S6±0.()()(> 'o.lKJiO.OOi •u.54<)i-U,()2 
(Histamine 
-treated) 
(IroupIII 4.88lO.(IS '34.U()xl.!< •4I,8II-(>,S 4.29:T0.2 ' 3 4 . 8 0 » I ';1S3)(I±I).2 6,79i().4 '3I.I)0±2,5 '38.0(h().« 0,085*0.0« '0,280±0.01 •().5U)-i().()2 
(lllllagonisl 
-heated) 
riroupIV 4,9()±<).9 '42.7(fa2 '3.^,0(1-0.5 4.32i0.02 '34.I0±1 '30.201-0.2 6.SSi0.4 '35,()()±2..'> ''37.0O>0.8 0.08S±0.00S -0.310*0.01 '().420±0.()2 
(H2R-agonisi 
-treated) 
riioajr \ 4'),!:U,ir 4.220,1 .l(i,40j(i,4 .13,.sO-3-,S t , ' ) M 1 . : j4.70il),: ,^40!il,4 0,()S7iO,007 (l,241)±0,02 0.610:0,03 
(ll3R-agonist 
4rcated) 
(iroupVI 4 , 8 9 J 1 '40,20-2 '35,IOiO,l 4.30-il.l '32.IO±0,l '38.101,3,3 6.8(i±(),0(i '5812,7 '62,50i:2,5 0.()85±0.()05 ''0.2IOi0.02 %,3(X)±().()5 
(li4R-agonis 
treated) __^ 
': Results demonstrate mean ± SD of five cxpeiimental rabbits in each group. Significance of differences (p<0.05) were analyzed by paired 
student's t test. \ p<(1.05 compared with control values of respective d;iy. ALT: Alanine aminotransferase, AST: Aspartate aminotransferase 
3 
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Fig. 6: H4R-agonist-treated group showing binucleated 
hcpatocytcs (B) and Kupffcr cells (K). XiOOO 
DISCUSSION 
We deiTionstrated here that short-term treatment by 
histamine and histamine receptors-agonists causes 
mcreasc in the serum levels of ALT, AST, alkaline 
phosphatase and bilirubin, as well as necrotic changes 
in hepatoc>tes, which are biochemical and histological 
parameters of liver damage, respectively (Thapa and 
Walia, 2007; Kral> i7 .//., 1996), To provide evidence 
relating our investigations to In vivo toxicological 
studies, we used healthy rabbits treated with histamine 
and hislumiiie receptors (H1R-, H2R-, H3R- and H4R-
)-agonists. Here wc report that histamine and histamine 
receptors (H1R-, H2R-, H3R- and H4R-)-specific 
agonist trcai.cd rabbits were characterized by marked 
histological changes as compared to control rabbits. It 
must be emphasized here that, to the best of our 
knowledge, none of the earlier reports have 
demonstrated the biochemical and histopathological 
studies on HlR-agonist (HTMT-dimaleate), H2R-
,-jgonisl (amthaniine dihydrobroniide), IDR-agonisi (R 
(-)-a-methyl histamine dihydrobromide) and H4R-
jgonisl (^lobciipropii dih)drobruinide) \shich \sc used 
in this study 
The cle\'ation of scrum levels of AIT, AST, alkaline 
phosphatase and bilirubin, indicate increased rates of 
hepatoeyte apoptosis and necrosis (Masaki et al., 2005; 
Thapa and Walia. 200'') Liver apoptosis and necrosis 
develop in a stepwise fashion. The first step is 
apoptosis, which is caused by various humoral factors 
(Masaki et al.. 200,5; Galanos el ai. 1979; Lcist et al.. 
1995; Lehmann, 1987), The second step is focal 
necrosis, which is induced by the accumulated 
polymorphonuclear cells and lymphomononuclear cells 
(Galanos et al., 1979; Leist et al., 1995; Lehmann, 
1987). FinaTy, massive necrosis appears to be caused 
by intra-hcpatic macrophages and neutrophils 
(Galanos et al., 1979; Leist et al., 1995; Lehmann, 
1987). In our study, the liver in the histamine receptors-
agonisls-lrcated groups (III-VT) appeared pale in color 
as compared to the reddish brown color of the controls 
and histamine treated group. The surface features of 
hepatic lobules in the zoomed digital images revealed 
marked distortion (from hexagonal in control) in H4R-
agonist treated group possibly due to specific pattern of 
congestion, infiltration and necrosis. Histological 
findings in all drug-treated rabbits showed quite 
specific pattern of degenerafive changes in livers. Since 
histamine is involved in lymphocyte proliferation and 
neutrophil chemotaxis and infiltration, the possibility 
exists that histamine prevents liver injury by affecting 
the late stage of hepatic cell damage, which includes 
necrosis, induced by inflammatory cells (Masaki et al.. 
2005), However, the present study demonstrates that 
short-term treatments of histamine group showed focal 
necrosis. generahVed congestion of sinusoids and 
marked hepatoeyte binuclearity while hepatoeyte 
contour and portal tract appeared normal. 
Liver, an organ of vital importance, was markedly 
damaged by histamine receptors (H1R-, H2R-, H3R-
and H4R-)-agonists in the present investigation on 
rabbits. The damage caused b> shorl-term exposure to 
histamine and HRs-agonists appeared to be quite 
specific for each of the agonist. In general, increased 
incidence of hepatoeyte polyploidy (bi-and 
multinucleated), frequent occurrence of Kupffer Cells 
(KCs), varied grades of necrosis, congestion and 
lymphocytic infiltration constituted the hallmark of 
injuries produced by the histamine and HRs-agonists. 
Binuclearity of hepatoeyte was most remarkable in 
H4R-agonisl treated group while occurrence of 
multinucleated (4 nuclei) hepatoeyte was noticed in 
H2R- and H3R-agonists treated rabbits. KCs were most 
pronounced in H4R-agonist treated rabbits. Scrum 
enzymes ALT and AST leakage from hepatocytes and 
their marked elevations have been shown in cases of 
hepatitis, neonatal hepatitis, ischaemie and autoimmune 
toxicity (Thapa and Walia, 2007). AST and ALT levels 
were significantly increased in all drug-treated groups 
as compared to control (p<0.05) and demonstrated the 
increased rates of liver degeneration in group-II to 
group-VI with the corresponding values of respective 
days, which support our histopathological findings in 
all dnig-treated groups compared to control group. 
Furthermore, increased alkaline phosphatase and 
bilirubin levels in all drug-treated groups as compared 
to control group (p<0.05) also support liver 
degeneration and sustain our histological findings of 
liver damage in all the drug-treated experimental 
groups. 
Polyploidy of hepatocytes and prominence of KCs 
were among the remarkable histopathological changes 
produced by HRs-agonists, Certain degree of 
Am. Med J. 6<l!: 1-7.2010 
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Objective: To deiineate iminuriom<idulalor\ role ol histamine on anldtody generation profile in 
ral)ljil in ifie fire.senl dose-de|iendenl hislamine sludv. Methods: The cohort eonipri.sed (j( three 
groups (III, l \ and V). eonlaining six raJJjils each, anil received suhculaneous hislamine 50 (ig/ 
kgxliis in die (li.i.d.), 100 ^Ig/kgxh.i.d. and 200 (ig/kgxli.i.d.. respectively for 10 days (slarling 
fniin the Isl iia\). The) were sulisequenlh immunized on the 3rd day with intravenous injc( tion 
of shee|) hlood cell (SUHC) (IxlO cells/mL). Group II (positive control) (n=6) received vehicle ' 
(sterile distilled water) and immunized at dav 3 similarK while group I (negative control) (n=6) 
remained non-immunized and received only vehicle. Ml experimentations were performed in 
Iriiilicate. Blood samples were collected on pre-innnunization (pre-I j (day Oj, as well as on 
days 7 - , 14- . 2 1 - , 2 8 - and 5 8 - post-immunization (post-I). Immunological parameters |lolal 
immunoglobulins (Igs), IgM and lg(; | were analvze<l liv enzvme linked immunosorhent assay 
(KI.ISA) technique. Results: Histamine could influence a deleclalile antihody response to >\iH(. 
as earlv as day 7-pos l - l , which husteii until day 5 8 - post-1. Tlie results were found statistically 
.•,ig]iificanl (/'< 0.05). ConclU-Sion: Our results provide evidence that hislamine has a short term 
effect <m antibody generation (until its presence in the body), and the antibody generation titer in 
vivo were affected bv the concentration of histamine. 
1. Introduction 
2-(imidazol-4-ylJ rlhylamine is k.tiov\'n as hislamine (a 
|jioj;fiiic aniiiii-j, pioijaljl) one ol tiu' niosL sliitlird niuiccLile 
in l)i()l()gi(;al .syslcm lo conimunicalf among cells in dillerent 
hiological activities throngii ililfcrcntial t'X])rcssioti ol four 
types ol histamine receptors (HIR, H2R, H3R and H4R) on 
secretion hy effer-tfir cells (ma.st cells and basophil.s) through 
various immunological or non-immunological stimuliMI. 
Iminunosiippressive and irnmiinomodulatorv effects ol 
histamine on lioth humoral- and cell-mediated immune 
responses have been ol)served|2..i|. Histamine mediates 
immediate-type hypersensitivity with increased vascular 
permeability, smooth muscle contraction, vasodilatation, 
flushing, mucus secretion, and pruritusH.Sl, and also have 
been shown to enhance d(dayed hypersensitivity anrl 
antibody mediated immune responseslfe-si. lis broadest 
s()et:lrum of aclivilies have been identified by hislauiine 
receptors in various [)hysiologieal and pathological 
(•(niditioiis iiK'luding the cell proliferation, differeiitiatioii, 
heinatopoiesis, embryonic develo])nienl, regeneration, 
wound healing, aminergic neurotransmission and niinieious 
brain functions, secretion ol pituitary hormones, regulation 
of gastrointestinal and circnlaton' functions, cardiovascular 
system, as well as inflammatory reactions, mf>dulation ol the 
immune response, energy of endf>crine and homeostasisMI. 
However, studies evaluating the role of histamine, 
especially studying the immunomodulatory profile over a 
span ol time are lacking in the existing literature. 
The present study was therefore designed to delineate the 
dose-dependent effect of histamine in immunomodulation 
sp<>ciallv the immunoglobulins [total immunoglobulins (Igs), 
IgG and TgM] generation profile over a period of 58 days in 
labbil model. 
•(:nrr(-s|i(iii(|pni-c In: Dr. M. Slialiiil, Ml). Plil), l.i-i-lurt-r. DeparlmenI of Meiliciil 
\1i,n.l.uii..)i\. JN Mi'.iicl Coilit?.- A llcjhpildl, -AMI., \li);arl,. iV. hiilia. 
IVl: +91 -571 -2721 ).182. (X)9411 S()25."!6 
Fax:+91-571-2721776 
1-iiiail; slialii(isatiajC"'valHM).(i).ii). (lnjiiilii!hhalii(112.K"'Vdlton,r(ijii 
2, Materials and methods 
2.1 .Experimental design 
i'ailji, Jaiiriuil ,,i Tiopi, at Mi'dt, i 3 
(lf!;M) and immunoglohulin-G (IgC) generation [jroliles were 
>lu<Jie<l i/i uv/i in fiu- r\[)rriMicntal groups (in llin-c M-paralc 
ex|)erinientation.s) at day.s 0 [pre-immunization (pre-1)], 7, 
14. 21. 28 and .'iS Iposl-irrimiinizalion (post-[)|. 
.•?. 1.Total senim <>nti-SRBC-(intiho(h jmxbirlinn 
The profile of total anti-.SRBr',-anti}x)dy titer was studied 
hy whole SRBC-ELISA methodlioi (Figure 1). No antilMxly 
response was deteeted in anv experimental groups at day 0 
(f)re-I). In po.sitive control group antibody titer showed an 
initial increasi' on dav 7 - post-I, which achieved highest 
peak at day 14- post-1 and then a gradual decrease in anti-
SHHC antibody titer over time fday 21 , 28 and 58 
|){)st-l). Histamine treated groufis III, IV and V showed 
different [)alterns in Iota! antil)ody titer at dav 7- , 14-, 
2 1 - , 2 8 - and 5 8 - posl-l. All the histamine treated grouf)s 
(III, IV and V) showed enhanced antibody titer at day 7 -
post-1 as compared to positive control (grouj) III. While 
group \ showed significant enhancement of total antilwdy 
tiler at days 7- , I4- , 2 1 - . 28 - and 58 - post-f (P< 0.0001) 
as com|)ared to rest ol the groups (II. Ill and IV). Group IV 
revealed signillcant {/''<0.05) enhancement of total antiliody 
titer as co/n/jared to group 11. while it .showed in.significant 
etiihance<l total antibody liter as compared to group III, at 
day 7 - post-1. Howcv(-r, grouj) 111 revealed insignificant 
increased total antibody titer al day 7 - post-I as com|)are(l 
to group 11. MoreoviT. total antibody titer at days 14-, 2 1 - , 
28 - anil 58 - post-1 in group HI and IV showed insignilicanl 
suppressed tola! antibodv titer as com()ared to gioup II. \ o 
antibody response was nitticed in group I (negative control) 
during whole of the study period. 
Figure 1. SRIiC-specilic iriiinunof;i(il)iiliri.s (lj<s) [iroducliun in rulihil.-. 
hv whole SKIiC-Kl.LSA mcllKJti in duplicate 1 : IfX) dilnted sera. 
X2..hill SRUr-IiiMjniductum 
Anli-SHBC-lgM was determined by whole .SHBC-ELISA 
metho(i|H)| (Figure 2). No antibody response was detected in 
any experimental group (negative control, [)ositive control or 
histamine-lreated) at day 0 (pre-l). However, there wa.s an 
initial increase and then gradual decrease in anli-SKBC-
IgVI titer inei lime In all the groups. B\ da\ 7 - ],)OSt-l, 
the IgM liter increased and obtained highest [leak, but by 
days 14-, 2 1 - . 2 8 - and 5 8 - [xist-l there was a gradual 
decrease in all experimental groups, (/roup V showed 
significant (/'<0.000l) enhancement of anli-SRBC-lg.M 
titer at day 1-. 14-, 2 1 - , 28- , 58 - post-I as compared to 
other exjierimental groups (II, Hi and IV). However, group 
iV showed insignificant enhance/nenf (al day 7 po>l 1) and 
suppression (at day 14-, 2 1 - , 28 - and 5 8 - post-1) of anti-
SRRC IgM titer as compared to group 11. Moreover, group 
IV revealed significant enhanced anti-SRBC-IgM liter at 
day 7 - post-I. while at day 14-. 2 I - , 28 - and 5 8 - posl-I. 
it showed insignificant difference of anti-SRBC-IgM titer 
to group III. Group III revealed significant suppression of 
anti-SRBC-IgM titer at day 7 - , 14- and 2 1 - post-1 as 
comjiared to group II. However, at dav 28 - and 5 8 - f>ost-I. 
anti-SRBC-IgM titer was same in group II. Ill and IV. No 
antibody response was noticed in group I (negative control) 
during whole of the study period. 
Figure 2. SRBC-spe<Mf'ii' immunofilohulin-M (Ij^ M) producliiin in 
rai)l)it.> h\ wluiie SRBC-F.LlbA iiieliiud in dii[ilicalc I • lUO diluted 
sera. 
iJ.Anti-SRBC IgC, prodiwtion 
Anti-SRBC-Ig(i was determined by whole S R B O 
FJ.ISV methodM"! (Figure 3). No antibody resfxinse was 
detected in any experimental groups at day 0 (pre-l). 
By day 7 - post-I, the lg(i liter increased but it obtained 
highest peak at day 14- posl-l, while by days 2 1 - , 2 8 -
and 5 8 - post-I il gradually fell down or maintained a 
plateau in the group II (positive control). However. lg(; 
liter in hislamine-trealed groups (III and IV) revealed 
significant (P<0.05) enhancement as comf)ared to group 11 
at day 7 - post-1. However, IgG titer in group IV showed 
insignificant suppression, while, in group III it was 
significantly (/V0.05) suppressed, at day 14-, 2 1 - , 28 - and 
5 8 - post-I as compared to group II. Ig(i liter in group III 
was insignificantly sujipressed to the IgG titer of group IV 
over a sj)an of stuily period. Moreover, grouj) V showed high 
significant (F<O.OOOI) eiiiiancement of aiiti-SRBC-IgC 
liter al days 7- , 14-, 2 1 - , 28 - and 58 - post-I as compared 
to rest of the experimental group (II, III and IV). No antibody 
response was noticed in group \ (negative control) during 
whole of the study period. 
4. Discussion 
In ihe present reporl, we studied the effect ol hislaminc 
as an immuno|)Olenlialing agent via the dose-dependent 
experimentations in albino rabbits and demonslraled 
the effect of histamine on antibody generation jirofile. 
, /'.,.;/;, i,„nu,h.fn-iu,,,i M^.ii, 
<l<n-arboxvlase jjciie ctiauges the repertoire ol natural autoantibodies.,/ 
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Immunil) 1972 ;6 :469-82 . 
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EFFECT OF HISTAMINE ON ANTIBODY GENERATION 
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ABSTRACT 
Present study was designed to delineate the immunomodulatory role of histamine on antibody 
generation profile in the rabbit system. The cohort comprised of three groups (I, II and III), containing 
si>: rabbits each, and received subcutaneous histamine (100 ng kg' x b.i.d.) for 10 days (starting from 
day 1). Group-Il and -III further received histamine (100 ng kg' x b.i.d.) for one week (starting from 
day 58) while group-II was again treated with same dose of histamine for one week (starting from 
day 72). They were subsequently immunized at day 3 with intravenous injection of SRBC whereas 
group-II and -III were further secondary immunized with SRBC at day 72. A IVth-positive-control-
group (n = 6) received vehicle (sterile distilled water) and immunized at day 3 similarly with a Vth-
negative-control-group (n = 6) remained non-immunized and received only vehicle. All 
experimentations were performed in triplicate. Blood samples were collected on pre-immunization 
(pj-e-I) (day 0), as well as on days 7-, 14-, 21-, 28-, 58-, 65-, 72-, 79- and 86- post-immunization (post-I). 
Histamine could influence a detectable antibody response to SRBC as early as day 7-post-I, which 
lasted until day 86- post-I. The results were found statistically significant (P< 0.05) when assessed by 
whole SRBC-ELISA method. Primary- and secondary-immunization findings showed potential role 
of histamine on antibody generation. To conclude, our results provide evidence that histamine has a 
short-term effect (whenever it is present in the body) and affects B-cell for antibody class switching 
and potentially stimulates antibody generation titer. 
Keywords: Histamine, immunomodulation, T-cell dependent antibody response, humoral immune 
response, SRBC. 
INTRODUCTION 
Histamine (2-(im!dazol-4-yl) ethylamine) is a 
biogenic amine, probabh' one of the most important 
phlogistic ancient mediator, and even one of the 
most intensely studied molecule in biological 
systems \\hich have been using histamine to 
communicate among cells'''. Histamine stimulates 
different biological activities through differential 
expression of four types of histamine receptors 
(HIR, H2R, HSR and H4R) on secretion by effector 
cells (mast cells and basophils) through various 
immunological or non-immunological stimuli"'. 
Histamine mediates broadest spechum of activities 
via histaminergic receptors in various physiological 
and pathological conditions including the cell 
proliferation, differentiation, hematopoiesis, 
embryonic development, regeneration, wound 
healing, aminergic neurotransmission and numerous 
brain functions (sleep/nociception, food intake and 
aggressive behavior), secretion of pituitary hormones, 
regulation of gastrointestinal and circulatory 
functions, cardiovascular system (vasodilatation and 
blood pressure reduction), as well as inflammatory 
reactions, modulation of the immune response, 
energy of endocrine and homeostasis'". Histamine 
also regulates lymphocytes (T-cells and B-cells), as 
well as related antibody isotype responses'". 
Immunosuppressive and immunomodulatory 
Coiresponding author' (Received on Aug. 13. 2009) 
effects of histamine on both humoral- and cell-mediated 
immune (HI and CMI, respectively) responses have been 
observed''". Histamine mediates immediate-type 
hypersensitivity with increased vascular permeability, 
smooth muscle contraction, vasodilatation, flushing, 
mucus secretion, and pruritus'"', and also have been 
shown to enhance delayed hypersensitivity and antibody 
mediated immune responses in many pathological 
processes regulating several essential events in allergies 
and autoimmune diseases in experimental animals, 
especially in genetically modified mice""''*". 
However, studies evaluatine the role of histamine, 
especially studying the immunomodulatory profile 
over a span of time are lacking in the existing literature. 
Moreover, the studies in rabbit model are elementary, 
and the existing studies have demonstrated 
immunomodulatory role studying only single blood 
samples taken after immunizing the animals. 
The present study was therefore designed to 
study the immunomodulatory effects of histamine 
on the immunoglobulins (total immunoglobulins 
(Igs), IgG and IgM) profiles over a period of 86 
days in rabbit model. 
MATERIALS AND METHODS 
Experimental design 
To evaluate the systemic antibody response. 
New Zealand adult healthy albino rabbits of either 
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sex (1:1 ratio) weighing 1.0-1.5 kg were divided into 
five treatment ;^roups. Each group contained six 
rabbits. Four gi'oups were immunized with sheep 
red blood cells (SRBC). 
Experimental group: Groups (I, II and III) treated 
with histamine respectively for 10 days (starting 
from day 1). Giroup-II and -III further received 
histamine respectively for one week (starting from 
day 58) while group-II was again treated with 
histamine for on(? week (starting from day 72). 
Control group: Group-IV (positive control) received 
vehicle (sterile distilled water) and immunized 
while group-V (negative control) remained non-
immunized and received only vehicle. 
They were housed in well-maintained animal 
facility at Central Animal House, J. N. Medical 
College, Aligarh Muslim University, Aligarh, in 
the Bioresources unit under a 12h light/dark cycle, 
temperature (22±2°C) and were allowed free 
access to standard laboratory diet including green 
vegetables and tap water until experimentation. 
All studies were i:arried out during the light cycle 
and were approved by the Institutional Animal 
Ethical Committee. 
MATERIALS 
All materials were obtained from the following 
manufacturers; Monoclonal-anti-rabbi t-
immunoglobulins-horseradish peroxidase (HRP) 
conjugate and monoclonal-anti-rabbit-lgG-HRP 
conjugate from Sigma (USA), anti-rabbit-IgM-HRP 
conjugate from G Biosciences from Maryland 
heights (USA), tetramethyl beiTzidine (TMB) and 
TMB diluent from J. Mitra and Co. (India), 
Polystyrene MaxiSorp microtitre flat bottom 
ELISA plates from NUNC (Denmark), 
Glutaraldehyde solution from Central Drug House 
(India), Skimmed milk from Nestle India Ltd. 
(New Delhi). All chemicals were of analytical grade. 
DRUG AND DOSE 
Histamine dihydrochloride was purchased 
from Himedia laboratories Pvt Limited, India. Its 
dose (100)ig/kg) was common in all histamine-
treated groups and was administered twice in a 
day through subcutaneous (s.c.) injection. 
Histamine dose is referred to the weight of the 
salts used. 
ANTIGEN 
Sheep blood diluted 1:1 in sterile Alsevier's 
solution was obtained from Department of 
Microbiology, J. N. Medical College, A.M.U., 
Aligarh, and washed with PBS (10 mM sodium 
phosphate buffer containing 150 mM Nacl, pH-7.4) 
thrice, and finally the concentration was adjusted 
to 5% (1 X 10' cells/ml) in PBS for immunization 
before use. 
IMMUNIZATION OF RABBITS 
The rabbits in experimental groups (TIV) were 
immunized at day 3 intravenously (i.v.) with 1ml 
of 5% (1 X 10' cells/ml) sheep red blood cells 
(SRBC) in PBS and again inoculated same quantity 
of SRBC via i.v. in group (II and III) on day 72. 
SAMPLE COLLECTION 
To determine the systemic antibody response, 
blood samples were collected from rabbits through 
the marginal ear veins prior to immunization 
(day 0), as well as on days 7-, 14-, 21-, 28-, 58-, 65-, 
72-, 79- and 86- post-I. Blood samples were kept at 
room temperature for 2h and then at 4°C overnight. 
Blood samples were centrifuged for 10 minutes at 
580 xg, and serum was separated and heated at 
56°C for 30 minutes to inactivate complement 
proteins and stored in aliquots containing sodium 
azide as preservative at -20°C till further testings. 
SEROLOGICAL ANALYSES 
ELISA using whole sheep red blood cells (SRBC) 
To determine the SRBC- specific-
immunoglobulins (Igs), SRBC-specific-lgM and 
SRBC-specific-lgG response, the whole SRBC-
enzyme linked immunosorbent assay (ELISA)' was 
also carried out on polystryrene plates with some 
modifications. Briefly, polystryrene MaxiSorp 
immunoplates were coated with SRBC suspension 
(5 X lO'/lOO pL PBS [10 mM sodium phosphate 
buffer containing 150 mM Nacl, pH-7.4]). The plates 
were held overnight at 4"C. Each sample was 
coated in duplicate and half of the plates served as 
control devoid of antigen coating. Without 
disturbing the cell layer, 20 pL of 1.8% glutaraldehyde 
solution was then gently added to plates inoculated 
with SRBC and the plates were held at 25°C for 30 
min. Unbound SRBC was washed four times with 
200 ]iL of PBS and non-specific binding sites were 
blocked with 1% fat-free milk in PBS for 2 hr at 37°C. 
After incubation, the plates were washed four times 
with 200 pL of PBS. Each rabbit serum diluted 1:100 
in PBS (100 pL well') was adsorbed for 1.5 hr at 37°C, 
and then overnight at 4°C followed by washing as 
earlier. The secondary antibody, HRP conjugated 
monoclonal-anti-rabbit-immunoglobulins, 
monoclonal-anti-rabbit-lgM and monoclonal-anti-
rabbit-lgC was then added (100 pL well') in 
respective plates and incubated at 37''C for 1 hr. 
The washing stage was repeated as before and 100 
pL well"' TMB substrate was added and the plates 
were incubated at 25^ for 1 hr. The enzymatic 
reaction was stopped by adding 50 pL well'' of 5% 
HBO, The absorbance (A) was determined at 405 
nm on an automatic ELISA plate reader (Micro 
scan MS5608A, ECIL, India). Each rabbit serum 
sample was run in duplicate. The control wells 
were treated similarly but were devoid of antigen. 
(27) 
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Results we^re expressed as a mean of A,js, „„,„,. 
STATIST][CAL ANALYSIS 
Data were presented as mean ± s.d. of triplicate 
experiments. Significance of differences from control 
values were determined with the paired student's 
t-test (SPSiS 12.0 for windows, Inc., Chicago, IL). 
Statistical significance was concluded at P< 0.05. 
RESULTS 
To assess the effects of histamine on the 
antibody gieneration, antibody-mediated responses 
to SRBC were analyzed. Total serum 
immunoglobulins, immunoglobulin-M (IgM) and 
immunoglobulin-G (IgG) generation profiles were 
studied in vivo in five experimental groups (in 
three separate experimentations) at days 0 [pre-
immunizatjon (pre-I)], 7, 14, 21, 28, 58, 65, 72, 79 
and 86 [post-immunization (post-I)]. 
Total serum anti-SRBC-antibody production 
The profile of total anti-SRBC-antibody titer 
was studied by whole SRBC-ELISA method'" (Fig, 1). 
— Group l-Kittamitt* Tr*3ted-ToUI Antibody 
Group lll-HisUmtne Trailod * Booster Ag-Total Anlibtxly 
— Group V-N*gativ« Control-Total Antibody 
' Group il-Hlstamine * Booster Ag & histamins Traatad-Total Antibody 
— Group IV-Positive Control-Total Antibody 
V.. . 
Days (pre and post).immunizatior> 
Figure 1. SRBC-specific Immunoglobulins (Igs) production in rabbits 
by whole SRBCELIS.A method" in duplicate 1:100 diluted sera. The 
results demonstra:e mean ± s.d. of three experiments each with six rabbits. 
No antibody response was detected in all 
experimental groups at day 0 (pre-1). Antibody 
titer in control group showed an initial increase 
on day 7- post-I, which achieved highest peak at 
day 14- post-I and then gradual decrease in anti-
SRBC-IgM titer over time (day 21-, 28-, 58-, 65-, 
72-, 79- and 86- post-I). Drug treated groups I, II 
and III shov/ed similar patterns in total antibody 
titer at day 7-, 14-, 21-, 28- and 58- post-I. However, 
group II and III showed a different pattern of 
enhanced total antibody titer at tiie day 65-, 72-, 
79-, 86- post-I. Primary-immunization (primary-I) 
study revea.ed significantly (P< 0.05) enhanced 
total antibody titer in drug-treated groups I, II and 
111 (similar to each other) as compared to positive 
control (group IV) at day 7- post-I. However, group 
I, II and III showed significant decrease (P< 0.05) 
of total antibody titer as compared to positive 
control (group IV) at day 14- and 21- post-I. At day 
28- and 58- post-I, total antibody titer in group I, II 
and III was similar to control group. One week 
treatment of histamine in group II and III (starting 
from day 58- post-I) showed significantly (P< 0.05) 
enhanced total antibody titer at day 65- and 72-
post-I as compared to group I and IV. Furthermore, 
Secondary-immunization (secondary-I) study 
showed that total antibody titer in group II 
(secondary-I with SRBC at day 72- post-I + histamine 
treatment for one week starting from day 72- post-I) 
was significant (P< 0.5) enhanced as compared to 
group III (secondary-I with SRBC at day 72- post-I 
only), while both of the groups II and III revealed 
significant (P< 0.05) enhancement of total antibody 
titer as compared to rest of the study groups (group 
I and VI) at day 79- and 86- post-I. No antibody 
response was noticed in group V (negative control) 
during whole of the study period. 
Anti-SRBC-IgM production 
Anti-SRBC-IgM was determined by whole 
SRBC-ELISA method"' (Fig. 2). No antibody response 
: 0.16 
I 0.14 
I 0.12 
I OM 
f" 0.04 
0.02 
/K 
—*— Group {-Histamine Treated-IgM 
- • ' Group Ili-Histamine Treated + Booster Ag-IgM 
—0— Group V-Negative ControMgM 
--0- - Group ll-Kistamine -•' Booster Ag & histamine Trealed-4gM 
Group IV-PosHive ControMgM ^. 
/ \ -*.., 
' 1 
• ^ • i ^ . 
• ^ . . 
""4-.^.. 
==-^ -.^ ^ 
Days (pre and post}-Jmniuniz3tion 
Figure 2. SRBC-specific Immunoglobulin-M (IgM) production in 
rabbits by whole SRBC-ELISA method'" in duplicate 1:100 diluted 
sera. The results demonstrate mean ± s.d. of three experiments each 
with six rabbits. 
was detected in all experimental groups (negative 
control, positive control and drug- treated) at day 
0 (pre-I). However there was an initial increase and 
then gradual decrease in anti-SRBC-IgM titer over 
time in all the groups before secondary-I. By day 
7- post-1, the IgM titer increased and obtained 
highest peak, but by days 14-, 21-, 28-, 58-, 65- and 
72- post-I there was a gradual decrease in all 
experimental groups. While at days 79- and 86-
post-I, IgM titer remained gradually decrease in 
both groups I and IV, however on secondary-I in 
groups II and III, IgM titer was highest at day 79-
post-1, but at day 86- post-I there was a gradual 
decrease. Primary-I study revealed that IgM titer 
in drug-treated groups I, II and III showed 
significant (P< 0.05) enhancement as compared to 
group IV at day 7- post-I. However, IgM titer in 
drug-treated groups showed suppression at day 
14-, 21-, 28- and 58- post-I as compared to group 
IV. IgM titer at day 65- and 72- post-I were found 
similar in groups II and III (both groups were 
treated with histamine for one week starting from 
(7P.) 
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day 58- post-I) and found similar to group I and 
IV. However, secondary-I revealed interesting 
findings in group II and III (group II received 
secondary-I with SRBC at day 72- post-I and 
treated with histaraine for one week starting from 
day 72- post-I, v/hile group III received only 
secondary-I with I5RBC) and showed that group 
II obtained significantly (P< 0.05) high peak of IgM 
titer as compared l:o group III and also rest of the 
study groups at clay 79- post-I, while group III 
showed significantly (P< 0.05) high IgM titer as 
compared to group II and also rest of the study 
groups at day 86- post-I. No antibody response 
was noticed in group V (negative control) during 
whole of the study period. 
Anti-SRBC IgG Production 
Anti-SRBC-IgG was determined by whole 
SRBC-ELISA metho(i'"(Fig. 3). No antibody response 
p"' 
i 0.: 
I 
5 «•• 
0 • 
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Figure 3. SRBC-specific Immunoglobulin-G (IgG) production in 
rabbits by whole SRBC-ELISA method" in duplicate 1:100 diluted 
sera. The results demonstrate mean ± s.d. of three experiments each 
with six rabbits. 
was detected in all experimental groups (negative 
control, positive control and drug- treated) at day 
0 (pre-I). By day 7- post-1, the IgG titer increased 
but it obtained highest peak at day 14- post-1, 
while by days 21-, 28-, 58-, 65-, 72- and 86- post-I 
there was a gradual (decrease in group IV. However, 
IgG titer in drug-treated groups (1, II and III) 
revealed significant (P< 0.05) enhancement as 
compared to group IV at day 7- post-1. However, 
IgG titer in drug-treated groups showed significant 
(P< 0.05) suppression at day 14-, 21-, 28- and 58-
post-I as compared to group IV. Furthermore, group 
1 showed significant (P< 0.05) suppression of IgG 
titer as compared to group IV at days 65-, 72-, 79-
and 86- post-I. While, IgG titer in group II and III 
at day 65- post-I obtained highest peak, but at day 
72- post-1 it showed gradual decrease (both groups 
were treated with histamine for one week starting 
from day 58- post-I), and were found showing 
significantly (P< 0.05) enhanced IgG titer as 
compared to group 1 and IV. This warrants further 
study to elucidate the effect of histamine on IgG 
production. However, secondary-I revealed 
interesting findings in group II and III (group II 
received secondary-I with SRBC at day 72- post-I 
and treated with histamine for one week starting 
from day 72- post-I, while group III received only 
secondary-I with SRBC) and showed that group 
II obtained significantly (P< 0,05) high peak of IgG 
titer as compared to group III and also rest of the 
study groups at day 79- and 86- post-I. While group 
III showed significantly (P< 0.05) high IgG titer as 
compared to group I and IV (positive control) at 
days 79- and 86- post-I. No antibody response was 
noticed in group V (negative control) during whole 
of the study period. 
DISCUSSION 
In the present report, we shidied the role of 
histamine as an immunopotentiating agents via the 
enhancement and inhibition on immunomodulatory 
profile, and demonstrated the effect of histamine 
on antibody generation. We investigated total serum 
immunoglobulins, IgM and IgG generation profile 
against SRBC, a T lymphocyte-dependent test 
antigen'", modulated by endogenous histamine 
(released from effector cells) in positive control 
(sterile distilled water-treated)- and histamine treated 
-experimental groups. According to the document of 
International Conference on Harmonization (ICH) 
S8 Guideline on Immunotoxicity Testing for 
Pharmaceuticals (adapted by EU in 2005, and by the 
FDA and MHLW in 2006), the evaluation of antibody 
response to a T-lymphocyte-dependent antigen (e.g., 
SRBC or Keyhole limpet hemocyanin) is recommended 
as one of the most sensitive immune tests following 
chemical exposures'". The T-lymphocyte-dependent 
antibody response assay is a sensitive indicator of 
immunological integrity. When SRBC is used as the 
particular T-lymphocyte-dependent antigen, this 
response requires the coordinated interaction of 
various immune system cells (i.e., antigen-presenting 
cells, T-lymphocytes and B-lymphocytes)"'"'. Moreover, 
several studies have demonstrated that the 
modulation of antibody-mediated immune response 
against SRBC following chemical exposures (i.e., 
immunomodulatory and immunosuppressive 
agents)'"'"'. Therefore, we hypothesized the present 
work to delineate the immunomodulatory role of 
histamine (as thev are immunopotentiating agents) 
against SRBC. 
To provide exact evidence relating our 
findings to in vivo immunoregulatory processes, 
we used healthy rabbits with and without histamine 
treatments. Here we reveal that histamine-treated 
rabbits were characterized bv a marked deviation 
of the immune response as compared to positive 
control rabbits. 
Based on the present studv, we demonstrate 
that the histamine, released from immunological 
stimuli from effector cells (mast cells and basophils) 
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in vivo'", could influence a detectable antibody 
response to SRBC as early as day 7- post-I, which 
lasted until day 86- post-I in all experimental 
groups. Histamine, itself is a potent agonist of all 
four receptors (H1-H4)'"'"', which are distributed 
in different parts of body and modulates different 
biochemical, pharmacological and immunological 
reactions both in vivo and in vitro by the activation 
of signal transduction on releasing the endogenous 
histamine'". It is a published mechanism that 
histamine dir(?ctly effects B-cell antibody production 
as a co-stimulatory receptor on B-cells'"'^. It must be 
highlighted here that, to the best of our knowledge, 
none of the earlier reports have shown the anti-SRBC 
antibody profile over a span of study period (86 days) 
(except our (?arlier report on immunomodulatory 
profile during a study period of 28 days)""', rather all 
previous reports have studied the anti-SRBC antibody 
concentrations at a single time period taking single 
blood samples from experimental animals. We 
demonstrated that the histamine treated-rabbits 
showed immunopotentiating properties by enhancing 
the anti-SRBC-antibodies (total antibody, IgM and 
IgG) titers and also by suppressing anti-SRBC-
antibodies (total antibody, IgM and IgG) titers as 
compared to ]30sitive control over a span of study 
period. We noticed that histamine stimulates antibody 
titer (total immunoglobulins and IgG) in group II and 
III at day 65- post-1 when treated with histamine for 
one week (starting from the day 58- post-I) however 
it showed gradual decrease at day 72- post-1. While 
IgM titer was unaffected and showed similar pattern 
to group I and group V. These findings showed 
potential role of histamine on antibody generation 
specially IgG, warranting further studies on role of 
histamine in immunoglobulin class switching. 
Secondary-immunization study in group II and 111, 
further strengthen our results of histamine role in 
antibody generation. 
To conclude, our results provide evidence 
that short-term effect of histamine (whenever it is 
present in the body) affects B-cell for antibody 
class switching and potentially stimulates antibody 
generation titer. This study would definitely 
stimulate for active discussions and warrants 
further researches on this important aspect 
including histamine-role on antibody generation 
mechanism in immune regulation. To the best of 
our knowledge, this is the first report describing 
the potential immunoregulatory role of histamine 
and also the first report studying immunomodulatorv 
profile in experimental rabbits over a continued 
study period of 86 days (pre- and post- immunization) 
against primarv'- and secondary-immunization of SRBC. 
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ABBREVIATIONS 
b.i.d. 
SRBC = 
HIR = 
H2R = 
H3R = 
H4R = 
pre-I 
post-I = 
s.c. 
PBS = 
Primary-I 
Secondary 
= Bis in die 
= Sheep Red Blood Cells 
Histamine Receptor Type 1 
Histamine Receptor Type 2 
Histamine Receptor Type 3 
Histamine Receptor Type 4 
Pre-Immunization 
Post-Immunization 
Subcutaneous 
Phosphate buffer saline 
= Primary-Immunization 
'-I = Secondary-Immunization 
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Abiitracf: Histamine, a biological amine, is considered as a principle mediator of many pathological processes regulating 
several essential events in allergies and autoimmune diseases. It stimulates different biological activities through differen-
tial expression of four types of histamine receptors (HIR, H2R, H3R and H4R) on secretion by effector cells (mast cells 
and basophils) through various immunological or non-immunological stimuli. Since H4R has been discovered very re-
cenl:ly and there is paucity of comprehensive literature covering new histamine receptors, their antagonists/agonists, and 
role in immune regulation and immunomodulation, we tried to update the current aspects and fill the gap in existing litera-
ture. This review will highlight the biological and pharmacological characterization of histamine, histamine receptors, 
their antagonists/agonists, and implications in immune regulation and immunomodulation. 
Keywords: Histamine, histamine receptors, H4-receptor, antagonists, agonists, immunomodulation. 
I. INTRODUCTION 
In historical evolution, histamine (biogenic amine) is 
probably one of the most important phlogistic ancient media-
tor, and even one of the most intensely studied molecules in 
biological systems which have been using histamine, 
catecholamines and other chemical mediators to communi-
cate among cells [1]. Histamine was synthesized in 1907 and 
characterized in 1910 as a substance ("beta-l") [2], owing to 
its significant competence to constrict guinea pig ileum, and 
its cogent vasodepressor action. However, it took 17 years to 
demonstrate its presence in normal tissues [3]. The relation 
between histamine and anaphylactic reactions was made 
rapidly in 1929, and was identified as a mediator of anaphy-
lactic reactions in 1932 [4, 5], whereas its connection to mast 
cells was not made until 1952 [6], and also its connection to 
basophils in 1972 [7]. The search for compounds being po-
tent to neutralize the pathological effects of histamine began 
at the Pasteur Institute in Paris during the 1930s, and these 
compounds were found to partially block the effects of his-
tamine based on the ethylenediamine structure. The first an-
tihistamine compound was the adrenolytic benzodioxan, 
piperoxan (933F), reported by Ungar, Parrot and Bovet in 
1937 and was shown to block the effect of histamine on the 
guinea-pig ileum [8J. It followed shortly by the report of 
Bovet and Staub [9] that structurally related to aryl ethers 
such as the thymol ether (929F) [8]. The latter antihistamine 
compound proved to be highly toxic for clinical develop-
ment; however, the replacement of ether oxygen by an amino 
group led to the search of aniline ethylene diamine 
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derivatives. For this noble research on antihistamines and 
curare, Bovet was awarded the Nobel Prize in 1957 [8]. It 
was being documented that histamine played an important 
role as a mediator of allergic reactions indicated by a series 
of compounds with antihistamine activity which protected 
guinea pigs from anaphylaxis. However, the clinical use of 
these compounds in humans was precluded due to their tox-
icity [9]. The first antihistamine, Antergan (phenben-
zamine, RP 2339) was being used in humans [10], but this 
compound was subsequently replaced by Neoantergan™ 
(mepyramine, pyrilamine, RP 2786), which is still in use to 
counteract the uncomfortable effects of histamine release in 
the skin. Many other antihistamines such as diphenhy-
dramine (Benadryf ), tripelennamine, chlorpheniramine and 
promethazine are also used in similar manner to counteract 
the adverse effects of histamine [8], Subsequently, after 
1945, these antihistamines were widely used in the treatment 
of various allergic diseases such as hay fever, urticaria, and 
allergic rhinitis. However, the side effects were not uncom-
mon and the sedation was a drawback to their use. A very 
few side effects were put to their good use; therefore, some 
antihistamines such as cyclizine (Marzine ) and diphenhy-
dramine in the form of its 8-chlorotheophyllinate (Drama-
mine ) are being used as an antiemetics for travel sickness 
[8]. By 1950 there were only 20 coinpounds clinically avail-
able to block the effects of histamine [1], but advances in 
histamine receptors (HRs) ligands have ever attracted many 
researchers for pharmaceutical developments and are still 
highly topical [11], 
Histamine (2-(imidazol-4-yl) ethylamine) is one of the 
monoamines and was coined after the Greek word for tissue 
histos, with the broadest spectrum of activities in various 
physiological and pathological conditions including the cell 
proliferation, differentiation, hematopoiesis, embryonic de-
velopment, regeneration, wound healing, aminergic neuro-
1874-2262/09 2009 Benfham Open 
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transmission and numerous brain functions (sieep/noci-
ception, food intake and aggressive behavior), secretion of 
pituitary hormones, regulation of gastrointestinal and circu-
latory functions, cardiovascular system (vasodilatation and 
blood pressure reduction), as well as inflammatory reactions, 
modulation of the immune response, energy of endocrine 
and homeostasis [1, 12-18]. It is being documented by sev-
eral studies which highlighted the evidence of histamine that 
it elicits immune-modulatory and pro-inflammatory effects 
by the differential expression of histamine receptors (HIR, 
H2R, HSR, and H4R) that is easily modulated the diverse 
effects of histamine on immune regulation and distinct intra-
cellular signals. All these four receptors are members of the 
7-transmembrane (heptahelical) spanning family of recep-
tors, are G protein-coupled (GPCR), are expressed on vari-
ous histamine responsive target tissues and cells and suggest 
an important critical role of histamine in immunomodulation 
and allergic diseases [1,8, 11-14]. 
In the present review, we will discuss biology of hista-
mine including synthesis, regulation and metabolism; hista-
mine receptors including HI-, H2-, H3-, and H4-receptors 
and their cellular distribution, functional characterization, 
structural biology, and signaling mechanisms; non-classical 
histamine-binding sites such as cytochrome P450; and his-
tamine transporters; as well as immune regulation by hista-
mine in immune-modulation and allergic inflammation; ef-
fects of histamine in immune cells in respect to allergic dis-
eases; implication of histamine on cytokines production; 
significance of histamine in autoimmunity and allergic dis-
eases and also in malignancies; and finally the relation of 
histamine-cytokine during hematopoiesis. 
II. BIOLOGY OF HISTAMINE 
Histamine exhibits two main important basic functionali-
ties such as primary aliphatic amine (pKai 9.4) and imidazole 
(pKa2 5.8). These make the monocation with different 
tautomers; the preferred form at physiologic pH value (96%) 
with a minor dicationic fraction (3%) and a very small 
amount of the neutral form [19]. The nomenclature for his-
tamine positions may be highly significant for histamine 
biology including synthesis, regulation, metabolism, and also 
histamine derivatives (Fig. 1). 
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Fig. (1). Specific nomenclature for histamine positions. 
A. Synthesis of Histamine 
Histamine was first identified as an autocoid having po-
tent vasoactive properties. It is a low molecular weight 
amine synthesized from L-histidine exclusively by L-
histidine decarboxylase (HDC) (E.G. 4.1.1.22 or E.G. 
4.1.1.26), which is dependent on the cofactor pyridoxal-5'-
phosphate to a putative binding site (TFNPSKW) on the pro-
tein. Histamine cannot be generated by another enzymatic 
pathway [8, 14]. Histidine decarboxylase (HDC) is an en-
zyme that is expressed in various cells through out the body, 
including central nervous system, neurons, gastric-mucosa. 
parietal cells, mast cells(~3 pg/cell histamine), and baso-
phils(~l pg/cell histamine). Histamine has an important role 
in human health, and exerting its diverse biologic effects by 
4 types of receptors [1, 13, 20-22]. Histamine is also pro-
duced by enterochromaffm-like cells (ECL) in the stomach 
and plays an important role in secretion of gastric acid [14]. 
Only basophils and mast cells can store the amine in specific 
granules, in the hematopoietic system, where histamine is 
closely associated with anionic proteoglycans heparin (in 
mast cells) and chondroitin-4-sulfate (in basophils). In this 
specific form, histamine can be released in large amounts 
during degranulation in response to various immunological 
(immunoglobulin E, or cytokines) or non-immunological 
(compound 48/80, calcium ionophore, mastoparin, substance 
P, opioids, or hypo-osmolar solutions) stimuli [14]. Hista-
mine synthesis in Golgi apparatus can be inhibited by a-
fluoromethylhistidin [23]. 
Recently, many myeloid and lymphoid cell types that do 
not store histamine show more HDG activity and are capable 
of synthesis of high amounts of histamine [24]. This so 
called "neo synthesized histamine," has been shown in vari-
ous cells, including hematopoietic progenitors, macrophages, 
neutrophils, platelets, dendritic cells (DCs) and T cells [14, 
25-28]. Histamine synthesis in non-mast cells was first con-
firmed using W/y^ mice, which genetically lack mature mast 
cells, upon stimulation with a phorbol ester [29]. HDG activ-
ity is demonstrated in vitro through cytokines, such as IL-I, 
lL-3, IL-12, IL- 18, GM-CSF, macrophage-colony stimulat-
ing factor, TNF-a, and calcium ionophore [30, 31]. Histidine 
decarboxylase (HDC) activity has been modulated in condi-
tions such as LPS stimulation, infiammation, infection, and 
graft rejection, in vivo [32]. 
It is being demonstrated that the generation of HDC-
knockout mice provides histamine-free system and it is more 
beneficial to study the role of endogenous histamine in a 
broad range of normal and disease processes. Such mice 
demonstrate diminished numbers of mast cells and signifi-
cantly decreased granule content, which suggests that hista-
mine might affect the production of mast cell granule pro-
teins [33]. In a recent study, interleukin-3 (IL-3)-dependent 
bone marrow derived mast cells (BMMCs) have been found 
to be activated by certain immunoglobulin-E (IgE) clones in 
absence of specific antigen, leading to their survival, cyto-
kine secretion, histamine production, adhesion, and migra-
tion [34]. In addition to this study, Tanaka et al. [35] has 
shown a drastic and transient induction of HDG (~ 200-fold 
in activity) in BMMCs stimulated by IgE alone, which was 
found much higher than that upon antigen stimulation. Thus, 
this induction resulted in the increase in stored histamine. 
Another study suggested that the anti-apoptic effects of 
monomeric IgE on BMMCs were mediated by interleukin-3 
(IL-3) in an autocrine fashion [36]. Although Schneider e/a/. 
[30] found the potential role of IL-3 to induce HDG in bone 
marrow cells, it is clearly indicated that monomeric IgE-
induced histamine synthesis may not be mediated through 
IL-3 [36]. Since stimulation of histamine synthesis occurs 
upon IgE-mediated antigen induction, and this remains con-
troversial if these two modes of FceRI activation share a 
common signal transduction pathway. However, many recent 
studies have demonstrated the qualitative differences be-
tween both modes: such as monomeric IgE-induced Ga "^  
influx is mediated by a distinct channel from that activated 
Histamine Receptors in Immunomoilulntion Tlie Open Immunology Journal, 2009, Volume 2 11 
upon antigen stimulation [37], and protein icinase C beta-Il 
(PKCpiI) plays a significant role in monomeric IgE-induced 
histamine synthesis in mast cells, but not upon antigen 
stimulation [38]. Since, only small levels of increase in his-
tamine synthesis were found by monomeric IgE both in puri-
fied rat peritoneal mast cells and in vitro maturated BMMCs, 
inducing effects of monomeric IgE on mast cells may be 
limited to imrfiature mast cells [37]. However, Tanaka and 
Ichikawa [39] has suggested that monomeric IgE-induced 
histamine synthesis exacerbates the symptoms of chronic 
allergy, while drastic increases in the levels of serum IgE are 
often observed in such diseases. 
B. Regulation of Histamine 
Histamine is synthesized only by HDC enzyme. There-
fore, histamine regulation is dependent on the gene of HDC 
enzyme, which is expressed in the cells throughout the body. 
It has been shown that complementary deoxyribonucleic 
acids (cDNAs) of HDC enzyme have been isolated from 
mouse mastocytoma, fetal rat liver, erythroleukemia cells 
and human bcisophil leukemia cells. Based on structural stud-
ies, mouse and human genes are composed of 12 exons 
spanning nearly 24 kb. The 2.4 kb single transcript is pro-
duced by mouse gene, whereas two splice variants of 3.4 kb 
and 2.4 kb exist in humans, and latter encode the functional 
HDC [40]. HDC gene is found on chromosome 2 in mice 
and chromosome 15 in human and their expression is con-
trolled by lineage-specific transcription factors. These factors 
interact with a promoter region consisting of GC box, four 
GATA consensus sequences, a c-Myb-binding motif and 
four CACC boxes [41]. It has been demonstrated in several 
studies that the HDC transcription is regulated by various 
factors in gastric cancer cells such as gastrin, oxidative stress 
and phorbol l!2-myristate 13-acetate (PMA), through a Ras-
independent, pLaf-dependent mechanism, MAP kinase/ERK 
and a protein kinase C (PKC) pathways functioning on three 
overlapping cisacting elements (GASRE 1, GAS-RE 2 and 
GAS-RE3) known as gastrin response elements [42, 43]. The 
negative control on HDC expression in gastric epithelial cell 
line is exerted by expression of the transcription factors 
GATA-4 and GATA-6 [44]. It is well known that the expres-
sion of HDC in basophils and mast cells seems to be a con-
sequence of the state of CpG methylation in the promoter 
region [45]. Many studies on the mast cell line HMCl and 
the pluripotent hematopoietic cell line UT7DI have demon-
strated that HDC-gene expression is subject to post-
transcriptional control. Therefore, the chromosomal configu-
ration and methylation of the HDC-promoter is likely to ac-
count for its cell-specific expression [46, 47]. It has also 
been reported that PMA stimulates a strong increase in HDC 
activity in UT7D1, which is affected by actinomycin D, and 
that is not paralleled by enhanced HDC mRNA expression. 
Similar effect was noted in cell lines (HEL and CMK) with 
megakaryocyte/basophil differentiation potential [48]. In 
addition to this effect, a mechanism that accounts for the 
strong enhancement of HDC activity in ECL cells in re-
sponse to gastrin is explained by a translation control of 
HDC expression [49]. Two essential mechanisms of transla-
tional control have been explained in hematopoietic cells: (i) 
a rapamycin dependent pathaway that is linked to phosphoi-
nositide 3-kin;ise (PI3K), FRAP/mTOR and phosphoryla-
tion/dephosphcrylation of repressor of translation 4E-
binding protein (4E-Bps) and (ii) ERK- and p38-dependent 
pathway that control the 4E-BP expression by the induction 
of Egr-I [50]. The multiple carboxy-truncated isoforms are 
formed due to post-translational processing of HDC gene; 
the gene is initially translated 73-74 kDa protein in mam-
mals, and originally it was assumed that enzymes purified 
from native sources corresponded to a dimer of two proc-
essed isoforms of 53 and 55 kDa. According to Fleming and 
Wang [51], the biosynthesis of histamine involves primarily 
the 55 kDa isoform and it is being acknowledged that many 
other isoforms generated from 74 kDa primary translation 
product can also be active. It is also being documented that 
enhancing the histidine decarboxylase activity might cause 
reduction in messenger RNA (mRNA) degradation by amino 
acid carboxyl-terminal PEST domains [52]. Here is a need to 
completely understand the negative feed back regulation of 
histidine decarboxylase activity that differs from one cell 
type to another. This activity has been shown in AGS-B cells 
that over expression of the HDC protein inhibited histidine 
decarboxylase promoter activity by down regulation of ERK 
signals [53]. 
However, in gastrin-stimulated ECL cells, this type of 
feed back mechanism was not observed. It was also demon-
strated that in the hematopoietic cells, as well as in the stom-
ach, negative feed back signals could be produced through 
high cytosolic histamine concentration [50]. Histamine reup-
take mechanism comparable to that of the other aminergic 
neurotransmitters has not been observed [54]. 
C. Metabolism of Histamine 
It is noteworthy that only a small amount of released his-
tamine (2 to 3%) is excreted unchanged. The remaining his-
tamine (more than 97%) is controlled via two major path-
ways for the metabolizing enzymes: histamine A -^
methyltransferase (HMT) (EC 2.1.1.8) and diamine oxidase 
(DAO) (ECl.4.3.6) before excretion [23, 55]. Histamine yV-
methyltransferase metabolizes the majority of histamine (50 
to 80%) to A'-methyl histamine, which is further metabolized 
to the primary urinary metabolite A/-methylimidazole acetic 
acid by monoamine oxidase. Diamine oxidase metabolizes 
the histamine (15 to 30%) to imidazole acetic acid [20]. The 
study of the former pathway was greatly facilitated by the 
availability of a potent and highly specific inhibitor of dia-
mine oxidase, aminoguanidine. HMT appears to be the most 
important enzyme contributing to the degradation of hista-
mine in the airways, because blockers of HMT (such as SKF 
91488) increase the bronchoconstricting action of histamine 
in vitro and in vivo, whereas diamine oxidase inhibition re-
mained uneffected [56]. HMT is expressed in airway epithe-
lial cells and may therefore be responsible for the local me-
tabolism of histamine released from airway mast cells. Me-
chanical removal of airway epithelium enhances the bron-
choconstriction response to histamine in vitro [57-59]; this 
might be the result, in part, of loss of the metabolizing en-
zyme. Furthermore, experimental viral infections resulted in 
reduced epithelial HMT activity in association with in-
creased responsiveness to inhaled histamine [60]. The half-
life of pharmacologically active doses of histamine is less 
than lOs in the rat and 20-30s in the dog. In earlier studies, 
histamine levels were measured by bioassay, but subse-
quently fluorometric and radio-enzymatic techniques were 
employed [8]. 
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III. HISTAMIINE RECEPTORS 
Histamine is an important biogenic amine and lias multi-
pie effects that are mediated through specific surface recep-
tors on specific target ceils. Four types of histamine recep-
tors have now been identified. In 1966, histamine receptors 
were first differentiated into HI and H2 [61], and it was re-
ported that some responses to histamine were inhibited by 
low doses of mepyramine (pyrilamine), whereas others were 
unsympathetic. In 1999, a third histamine receptor subtype 
was cloned and termed as H3 [22j. Subsequently in 2000, the 
fourth histamine receptor subtype was reported which was 
termed as H4 [21 ] and introduced a significant chapter in the 
story of histamine effects. 
A. Histamine H 1-Receptor 
1. Cellular Distribution and Functional Characterization 
In different mammalian tissues, the study of the distribu-
tion of histamine HI-receptors (HlRs) has been significantly 
helped by the development of specific radioligands for this 
subtype. In 1997, [3H]mepyramJne a selective radioligand 
was developed (Table 1) [62], and since then it has been 
used to identify Hl-receptors in a wide variety of tissues 
such as gastrointestinal tract, central nervous system, air-
ways and vascular smooth muscle cells, mammalian brain, 
hepatocytes, nerve cells, endothelial cells, chondrocytes, 
monocytes, neutrophils, dendritic cells, T and B lymphocytes 
(Table 2), the cardiovascular system and genitourinary sys-
tem, endothelial cells and adrenal medulla in which Hl-
receptor mediates different biological properties of allergic 
responses such as typical immediate responses of allergic 
reaction type I li^e redness, itching and swelling ("triple re-
sponse"). In many pathological processes of allergy, includ-
ing allergenic rhinitis, atopic dermatitis, conjunctivitis, urti-
caria, asthma, and anaphylaxis, Hl-receptors are involved. 
The receptors also mediate bronchoconstriction and en-
hanced vascular permeability in the lung [17, 63-65]. It has 
been noticed that [3H]mepyramine binds to secondary non-
Hl-receptor sites in various tissues and cells [66-70]. In ad-
dition to [3H]mepyramine, which predominantly binds to a 
protein homologous with debrisoquine 4-hydroxylase cyto-
chrome P450 in rat liver [71], this nonspecific binding can 
be blocked by quinine. This investigation led to the demon-
stration that quinine may be used to block binding to other 
lower affinity sites [72], and it was thus proved that all sec-
ondary binding sites for [3H]mepyramine were not sensitive 
to inhibition through quinine [69]. Many researchers have 
shown that a 38 to 40 kDa protein was isolated from 
DDTlMF-2 cells, that binds HIR antagonists with specific 
KD values in the i^M range, but that was not sensitive to in-
hibition through quinine and also that DDTl MF-2 cells pos-
sess [3H]mepyramine binding sites which have the charac-
teristics of histamine Hl-receptors (i.e., KQ values in the nM 
range) to mediate functional responses, and those were pro-
duced by HIR activation [69, 73, 74]. Other radioligands 
that have been demonstrated to study histamine Hl-receptors 
are [3H]mianserin, [3H]doxepin, [125I]iodobolpyramine, 
[1251] iodoazidophenpyramine, and [3H](l)-N-methyl-4-
methyldiphenhydramine [75-80]. [1251]Iodobolpyramine has 
been successfully used for autoradiographic localization of 
HIRs in the brain of guinea pig, whereas, it was used with 
lower success for localization in rat brain (Table 1) [78, 81]. 
Slow dissociation of [3H]mepyramine from HIRs has been 
shown at low temperature (i.e., 4°C) and this denotes that 
[3H]mepyramine can also be used for autoradiography (Ta-
xable 1. Characterization of Histamine Receptors Agonist, Antagonist and Radioligand 
Receptor 
Subtypes Agonists with Potency Antagonists with Potency 
Radioligands with Equilibrium Constant 
for Dissociation (Kd) 
HI 
Histamine(lOO)'''', Dimethylliistaprodifcn 
(243)', Methylhistaprodifen (340)", Histamine-
trifluorometliyltoluidine (HTMT)', 
2-(3-trifluoromelhy)pheny)) histamine (128)''', 
2-Thiazolylethylamine (26)", 
2-Pyridylethylamine (6)" 
Mepyramine (pA; 9.4)', 
( j^-Chlorpheniramine (pA2 9.4)', (-)-
Chlor-pheniramine (PA26.7)', Trans-
triprolidine (pAj 10.0)', Temelastine 
(pA: 9.5)', Promethazine (pA; 8.9)", 
Diphenhydramine (pA2 9.0)', Tripelen-
namine (pA:8.5)', Chlotpromazine (pA: 
8.9)" 
['H]-Mepyramine (Kd O.SnM: guinea-pig 
brain, ileum)"', 
['"'l]-lodobolpyramine (Kd 0.0 InM, guinea-
pig brain)', ['"'l]-lodoazidophen-pyramine 
(Kd O.OInM, guinea-pig cerebellum)"'' 
H2 
Histamine(lOO)"- , 
Ai-pTOmidine(10230)"\lmpromidine(4810)" 
', Sopromidine (740)" \ Amthamine (150)" ^  
Dmiaprit(71)", 
4-Methylhistamine(43)"' 
Cimetidine (PA26.I)", Ranitidine (pAi 
6.7)', Famotidine (pAi?.8)', Zolanti-
dine (pA:7.6)', Mifentidine (pA27.6)', 
Titotidine (pA2 7.8)", lodoaminopotenti-
dme(pA:8.6)" 
['H]-Tiotidine (25nM)"', ['-*I]-lodoamino-
potentidine(Kd0.3nM)"'', 
['•'l]-lodoazido-potentidine(Kd lOnM)''' 
(all guinea-pig brain membrains) 
H3 
H4 
Hislamine(lOO)"', 
Imetit(6200)"', 
lmrnepip(2457)'', 
R-a-methylhistamine (1550) '•' 
•Thioperamide (pA2 8.4)', lodophen-
propit(pA2 9.6)', 
•Clobenpropit(pA29.9)', Ciproxifan 
(pA:9.3)', lmpentamine(pA28.4)', 
GRl"74737(pA2 8.1)''', Impromidine 
(PA2 7.2)' 
[^ H]-R-u-methylhistamine (Kd O.SnM)"', 
['H]-N"-methylhistamine (Kd 2.0nM)''', 
["'l]-Iodophenpropit (Kd 0.3nm)'', ["'ij-
lodoproxyfan (Kd 0.065nM)'\ 
[3H1-GR168320 (Kd 0.1 nM)"-" (all rat cere-
bral cortical membranes in Tris buffer) 
lmetit(pA2 8.6)', 
Imnepip (pA2 8)', 
*Clobenpropit(pA27.9, partial agoni.st)", 
4-Methylhistamine (pA2 7.3)° 
JNJ 10191584 (7.6)', *Thioperamide 
(7.6)' None to date 
[II", 23', 221']; 'These iiompounds act as agonist/antagonist for different histamine receptors at variable potencies. 
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Characteristics H|-Receptor Ha-Receptor Hj-Receptor Hj-Receptor 
• 'Receptor described, 
human gene cloned (years) 
•Receptor proteins in hu-
man 
•'Chromosomal location in 
human 
'Equilibrium constant for 
dissociation (Kd) 
'Receptor expression 
"Gene Structure 
"G-protein coupling 
•'Activated intracellular 
signals (principal signaling 
effector molecules) 
1966, 1993 
487 amino acids, 56 kD 
3p25,3pl4-21 
-lOnmol/L 
Widespread, including neu-
rons, smooth muscle (e.g., 
airways, vascular), and other 
types of cells.* 
Intronless 
Guq/11 
Ca-'T, cGMP, NF-KB, 
PLCT, phospholipase A2, 
and D, cAMP, NOS 
1972, 1991 
359 amino acids, 40 kD 
5,5q35.3 
- 30 nmol/L 
Widespread, including 
gastric mucosa parietal 
cells, smooth-muscle, heart, 
and other types of cells.* 
Intronless 
Gas 
cAMPt, Ca'*,protein kinese 
C, c-fos, phos- pholipase C 
1983,1999 
445 amino acids,70 kD; 
splice variants 
20, 20q 13.33 
~10nmol/L 
High expression in hista-
minergic neurons, low ex-
pression elsewhere. 
Three introns 
Gi/o 
Ca"*T, MAP kinaset; 
inhibition of cAMPJ-
1994,2000 
390 amino acids 
I8qll.2 
20-40 nmol/L 
High expression in bone 
marrow and peripheral 
hematopoietic cells, low 
expression elsewhere. 
Two introns 
Gi/o 
Ca-'T, MAP kinase?; 
Inhibition of cAMPi 
Abbreviations: cAMP = cyclic adenosine monophosphate, cGMP = cyclic guanosine monophosphate, MAP 
oxide synthase, PLC = phospholipase C. 
*Other types of cells: epithelial, endothelial cells, neutrophils, eosinophils, monocytes, dendritic cells, T-cells, 
•(399],'[l],! 14]. 
= mitogen-activated protein, NF-KB = nuclear factor-KB, NOS = nitric 
B cells, hepatocyles, and chondrocytes. 
ble 1) [82, 83], [125I]lodoazidophenpyramine (Table 1) is a 
very potent HI-receptor antagotiist that can bind irreversibly 
to Hl-receptors following irradiation with ultraviolet light 
[19]. The existence of HlRs in !he living human brain has 
been proved by specific ligands [ilC]Mepyramine and 
[llCjdoxepin [84, 85]. HIRs have widely been studied in 
blood vessels [86-88], and also in smooth muscles [61, 88, 
89]. In smooth muscles, such as the guinea pig ileum, which 
freely generate muscle action potentials, modulation of ac-
tion-potential discharge by low concentrations of histamine 
is an important mechanism by which tension is increased 
[90] and there is evidence that the contractile response to 
histamine is produced by inositol 1, 4, 5-triphosphate-
induced mobilization of intracellular calcium (Ca^*) [91, 92]. 
Its further effects have been seen in non excitable smooth 
muscles including airways and vascular smooth muscles, and 
the contractile HIR stimulation initially involve mobilization 
of calcium (Ca^*) from intracellular stores such as inositol 
phospholipids hydrolysis [93-96]. HI-receptor stimulation 
causes various cellular responses in vascular endothelial cells 
such as: it is responsible for changes in vascular permeability 
as a result of endothelial cell contraction [97, 98]; in synthe-
sis of prostacyclin [99, 100]; in platelet-activating factor 
synthesis [99]; in release of Von Willebrand factor [101], 
and in nitric oxide release [102]. 
The study of HIR on human T lymphocytes has been 
characterized by use of [125i]iodobolpyramine [103] (see 
also Table 1) and is shown to increase (Ca^^)i [104]. It is 
being documented that HlR-deficient mice display both 
strong systemic T cell and efficient B cell responses to anti-
gen [105]. The relationship of HIRs to adrenal medulla 
which elicit the release of catecholamines has been estab-
lished many years ago [106-108]. Thus, histamine can stimu-
late the release of both adrenaline and noradrenaline [108], 
and also induce phosphorylation of the catecholamine bio-
synthesis enzyme tyrosine hydroxylase by a mechanism 
which mediates release of intracellular calcium from cultured 
bovine adrenal chromaffin cells [109]. 
The effects of histamine are also seen to elicit the release 
of leucine- and methionine- enkephalin [110]. Furthermore, 
many investigators have demonstrated a marked increase in 
mRNA-encoding proenkephalin A after prolonged exposure 
to histamine [110, 111]. Its negative inotropic effects have 
been observed in human atrial myocardium and also in 
guinea pig ventricle [112,113]. 
Genovese et al. [113] suggested that the negative 
inotropic response of histamine in human myocardium is 
associated with inhibitory effects on heart rate. This can be 
unmasked when the positive responses of histamine on the 
heart rate, and force of contraction (due to histamine H2-
receptors) are mediated through conjoint administration of 
adenosine or adenosine AI-receptor agonists. However, his-
tamine produces a positive inotropic effect in guinea pig left 
atria and rabbit papillary muscle by a specific mechanism 
which is not related with a rise in adenosine 3c, 5c-cyclic 
monophosphate (cAMP) levels [90, 114, 115]. It is being 
documented that the distribution of HIRs in mammalian 
brain with higher densities are found in neocortex, hippo-
campus, nucleus accumbent, thalamus, and posterior hypo-
thalamus [90, 116], however, cerebellum and basal ganglia 
denotes lower densities [76, 85, 117]. The distribution of 
HIRs in rat and guinea pig is very similar to each other [78, 
82, 83, 118], HI-receptor binding sites and mRNA levels 
were overlapped in most areas of brain except in hippocam-
pus and cerebellum in which the inconsistency is mostly to 
reflect the presence of exuberance HIRs in dendrites of py-
ramidal and Purkinje cells [119]. The activation of HIR in-
hibits the firing and hyperpolarization in hippocampal neu-
rons [120] and also an apamine sensitive outward current in 
olfactory bulb intemeurons [121], and these effects are 
mostly generated by intracellular Ca^ "^  release. However, 
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HIR excite various notable factors such as vegetative gan-
glia [122], hypothalamic supraoptic [23], brainstem [123], 
thalamic [124], tjid human cortical neurons [125] through a 
block of potassium conductance. 
The functional characterization of HIR has benefited 
from the use of many potent and specific antagonists (see 
Tables 1 and 3) [63, 126]. HI-receptor antagonists are the 
oldest therapeutic tools of the modern medicine due to their 
sedative side effects, and the anti-allergic drugs which were 
developed initially, have now been abandoned. Indeed, Hl-
receptor involves the distiTrbance of circadian rhythms and 
locomotor activities as well as the impairment of the ex-
ploratory behavior by histamine in the brain, and this is why 
so-called "non-sedating" HI antagonists which cannot cross 
the blood-brain barrier have been designed. HI-receptor 
agonists are not readily available because they enhance 
rather than prevsnt the onset of allergic pathologies. His-
taprodifens are very potent H1R agonists and are more effec-
tive than histamine in activating HIR [127]. Some anti-
inflammatory effects of HIR antagonists at high doses could 
be non-specific because of histamine and other inflammatory 
mediators like leukotriene and platelet activating factors re-
leased from ba^jophils in response to certain HlRs antago-
nists [1, 14]. Bordetellaperlusis-'mduced histamine sensitiza-
tion (Bphs) controls Bordetella pertussis toxin (PTX)-
induced vasoactive amine sensitization elicited by histamine 
(VAASH) and has an established role in autoimmunity. The 
congenic mapping links Bphs to the histamine H, receptor 
gene (Hrhl/HlR) and that HjR differs at three amino acid 
residues in VAASH-susceptible and -resistant mice. Hrhl-/-
mice are protected from VAASH, which can be restored by 
genetic complementation with a susceptible Bphs/Hrhl al-
lele, and experimental allergic encephalomyelitis and auto-
immune orchitis due to immune deviation. Thus, natural al-
leles of Hrhl control both the autoimmune T cells and vascu-
lar responses regulated by histamine after PTX sensitization. 
The exact mechanism through which this effect occurs re-
mains unclear and its clinical relevance is still uncertain 
[128]. The chemical structure of specific HlR-antagonists 
and agonists are .shown in Figs. (2,3). 
2. Structural Biology of Receptor 
H, receptors have been cloned from cows, rats, guinea 
pigs and also from humans. The HI receptor contains 486, 
488 or 487 amino acids in rat, mouse and humans, respec-
tively. It contains the typical properties of G protein coupled 
receptor (GPCR), namely, seven transmembrane domains of 
20-25 amino acids predicted to form an a-helice which spans 
the plasma membrane and an extra cellular NH: terminal 
domain with gly:osylation site. HIR is encoded by a single 
exon gene that is located on the distal short arm of chromo-
some 3p25 in humans see in Fig. (2) and chromosome 6 in 
mice. Histamine binds to aspartate residues in the transmem-
brane domain 3 of the HI-receptor, and to asparagine + ly-
sine residues within the transmembrane domain 5 [14]. 
Its structural studies done by photoaffinity binding prop-
erties using [125I];odoazidophenpyramine (Table 1) and 
subsequent sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDSi-PAGE) analysis demonstrated that the HI-
receptor protein (molecular weight 56 kDa) is found under 
reducing conditions in the brain of rat, guinea pig, and 
mouse [79, 118, 129]. Similar studies have also been done 
by using photoaffinity ligand [3H] azidobenzamide in bovine 
adrenal medullar membranes and found labeled peptides in 
the size range 53 to 58 kDa [130]. In guinea pig heart, the 
specifically labeled HIR with [I25I]iodoazidophenpyramine 
was found to contain substantially higher molecular weight, 
while there was no obvious difference in the characteristics 
of the HIR in tissues (Table 1) [13!]. In 1991, HIR was 
cloned from the bovine adrenal medulla by expression clon-
ing in the Xenopus oocyte system. Interestingly, 491 amino 
acid protein with a calculated molecular weight of 56 kDa 
was represented by the deduced amino acid sequence [130]; 
this protein has the seven transmembrane domains expected 
of a G-protein coupled receptor (GPCR) and contains N-
terminal glycosylation sites. The main feature of the pro-
posed HIR structure is the very large 3"' intracellular loop 
with 212 amino acids and relatively short intracellular C 
terminal tail with 17 amino acids. The availability of the 
bovine sequence and lack of introns has enabled the Hl-
receptor to be cloned from several species including rat 
[132], guinea pig [129, 133], mouse [134], and human [135, 
136]. The human HI-receptor gene has now been localized 
to chromosome 3 bands 3pl4-p21 (Table 2). These clones 
should be regarded as true species homologues of the Hl-
receptor, while there are notable variations amongst them in 
some antagonist potencies [23]. Nevertheless, it is clear that 
the stereoisomers of chlorpheniramine show marked differ-
ences between species. For example, the guinea pig Hl-
receptor has a KD of 0.9 nM for (l)-chlorpheniramine, 
whereas for the rat HI-receptor, the value is nearly 8 nM 
[23]. Similar variations for chlorpheniramine and other com-
pounds (mepyramine and triprolidine) have been shown in 
guinea pig and rat brain, respectively [23, 67, 89]. On this 
basis the species differences may explain why compound 
[I25I]iodobolpyramine can label guinea pig CNS Hl-
receptors, but it is unable to identify HIRs in the brain of rat 
[78, 81]. In brain membranes of both guinea pig and rat the 
native Hl-receptor protein has been solubilized [137, 138], 
and the solubilized receptor retains similar differences in Hl-
antagonist potency for (l)-chlorpheniramine as that detected 
in membranes [137]. It is important to note that mepyramine 
seems to be potent antagonist of the recombinant rat HI-
receptor (i.e. expressed in C6 cells) than of the native hista-
mine Hl-receptor in the brain membrane of rat [23, 67, 132]. 
In addition, the recombinant studies performed in rat C6 
cells [132] are complicated by the presence of a low level of 
endogenous histamine Hl-receptors (HIRs) [139], but in the 
functional studies in untransfected C6 cells, a high affinity 
for mepyramine (KD 51 nM) has been deduced [23, 139]. 
The amino acid sequence alignment of the cloned histamine 
HI- and H2-receptors led to the suggestion that the third and 
fifth transmembrane domains (TM3 and TM5 respectively) 
of receptor proteins are responsible for histamine binding 
[140, 141]. In third transmembrane (TM3) of the human Hl-
receptor, Aspartate (107) that is conserved in entire aminer-
gic receptors, has appeared to be essential for the histamine 
binding, and also Hl-receptor antagonists to the Hl-receptor 
[142]. In Hl-receptor, the amino acid residues corresponding 
to Asparagine (198) and Threonine (194) are in correspond-
ing positions in 5"" transmembrane domain (TM5) of the 
human Hl-receptor, while the substitution of an Alanine for 
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Threonine (194) did not influence the binding properties of tution of Alanine (198) for Asparagine (198) decreased ago-
either agonist or antagonist [142, 143]. However, the substi- nist affinity, while the affinity of antagonist remained un-
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changed [142, 143]. Similar results iiave been seen in the 
mutations to the corresponding residues Threonine (203) and 
Asparagine (207) in the guinea pig-HlR sequence [144]. In 
addition to these mutations 2-methyihistamine is affected by 
the Asparagine (207) Alanine mutation, and HI-selective 
agonists 2-thia2,C'lyiethylamine, 2-pyridylethylamine, and 2-
(3-bromopheny!) histamine are much less influenced through 
this mutation [144, 145]. This suggested that Asparagine 
(207) interacts with the Nt-nitrogen of histamine imidazole 
ring. 
However, it has been shown that Lysine (200) interacts 
with the Np-nitirogen of histamine ring, and that it is impor-
tant for the activation of the HIR by histamine and the 
nonimidazole agonist, 2-pyridylethylamine [63]. Further-
more, Leurs et al. [70] has demonstrated that the Lysine 
(200) Alanine mutation did not alter the binding affinity of 
2-pyridylethylamine to HIR of guinea pig. Thus, the studies 
on the organization, genomic structure and promoter func-
tion of the human HIR revealed a 5.8 kb intron in the 50 
flanking region of this gene, different binding sites for vari-
ous transcription factors, and the absence of TATA and 
CAAT sequences at the appropriate locations [146]. 
3. Signaling Mechanisms 
Hl-receptor is a Gaq/11-coupled protein with a very 
large third intracellular loop and a relatively short C-terminal 
tail see in Fig. (4). The main signal induced by ligand bind-
ing is the activation of phospholipase C-generating inositol 
1, 4, 5-triphosphate and 1, 2-diacylglycerol (DAC) leading to 
increased cytosolic Ca^ "^ . The enhanced intracellular Ca^ ^ 
levels appear to account for the different pharmacological 
properties promoted through the receptor including nitric 
oxide (NO) production, liberation of arachidonic acid from 
phospholipids, contraction of smooth muscles, dilatation of 
arterioles and capillaries, vascular permeability in vessels as 
well as stimulation of afferent neurons, and increased cAMP, 
and also cGMP levels [64, 147] (see also Table 2). This re-
ceptor also stimulates nuclear factor kappa B (NFKB) by 
Gaq/11 and Gpv upon binding of agonist, while stimulation 
of NFKB occurs only via G|3y leading to (pro)inflammatory 
mediators [70, 89, 148]. The number of tissues and cell types 
in which a HIF'-mediated signals increases in either inositol 
phosphate accumulation or intracellular calcium mobilization 
has been described extensively and further details are pro-
vided in several comprehensive reviews [89, 149, 150]. In 
Chinese hamster ovary (CHO) cells Ca^ ^ mobilization and 
[3H]inositol phosphate accumulation has been observed due 
to stimulation by histamine when CHO cells are transfected 
with HlR-complementary deoxyribonucleic acid (cDNA) of 
the human, bovine, and guinea pig [150, 151]. It is worth 
demonstrating that in some tissues histamine can stimulate 
inositol phospholipid hydrolysis independently of HlRs. 
Thus, in the longitudinal smooth muscle of guinea pig ileum 
and neonatal rat brain [92, 152], a component can be identi-
fied in response to histamine that is resistant to inhibition by 
HlR-antagonists. It is yet to be established whether these 
effects are due to "tyramine-like" effects of histamine on 
neurotransmitter release or direct effects of histamine on the 
associated G-proteins [153, 154]. In addition to well known 
effects on the inositol phospholipid signal transduction sys-
tems, several other signal transduction pathways can lead to 
stimulation of HIR and it seems to be secondary to changes 
in intracellular Ca^"^concentration or protein kinase C (PKC) 
activation. Thus, nitric oxide synthase activity (via a 
Ca^Vcalmodulin-dependent pathway), and subsequent stimu-
lation of soluble guanylyl cyclase in a wide variety of vari-
ous cell types can be activated by histamine [155-158]. The 
HIR can stimulate the arachidonic acid release and arachi-
donic acid metabolites synthesis such as prostacyclin and 
thromboxane [150, 159]. It is being interestingly demon-
strated that the histamine-stimulated release of arachidonic 
acid is partially inhibited (~ 40%) by pertussis toxin, when 
CHO-Kl cells transfected with the guinea pig HIR and the 
same response is also shown in HeLa cell possessing a native 
HIR to resist pertussis toxin treatment [150]. The substantial 
changes in the intracellular levels of cAMP can be produced 
by Hl-receptor activation, but in most tissues, HIR activa-
tion does not stimulate adenylyl cyclase directly, and acts for 
the amplification of cAMP effects to histamine H2-, adeno-
sine A2-, and also vasoactive intestinal polypeptide receptors 
[160-162]. The role of both intracellular Ca^ * ions and pro-
tein kinase C has been demonstrated in various cases in this 
augmentation response [161]. HIR stimulation can also lead 
to both cAMP responses and to an increasement of forskolin-
activated cAMP formation when CHO cells are transfected 
with the bovine or guinea pig HIR [ 150, 163]. 
B. Histamine H2-Receptor 
/. Cellular Distribution and Functional Characterization 
The H2R is located on chromosome 5 in humans. Similar 
to what has been demonstrated for HIR, the histamine binds 
to transmembrane (TM) domains 3 (aspartate) and TM 5 
(threonine and aspartate). The short 3' intra-cellular loop 
and the long C-terminal tail make a suitable feature of H2R 
subtype, and the rat N-terminal extracellular tail has N-
linked glycosylation sites [164]. Similar to HIR, H2R is ex-
pressed in different cell types (Table 2). It has been docu-
mented that H2R is mostly involved in suppressive activities 
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of histamine, while positive effects are mediated through 
HIR. It was quite clear that the activation of H2R regulates 
various functions of iiistaminc including heart contraction, 
gastric acid secretion, cell proliferation, differentiation and 
immune response, it has been demonstrated that H2R an-
tagonists, such as /olantidinc, is active in the treatment of 
stomach and duodenal ulcers and it strongly suggests that the 
clinical potency relates to the antagonistic effect of these 
drugs on the secretion of stomach acids [11]. 
Hill [89] designed a study to map the distribution of 
H2Rs by using radiolabeled H2R-antagonists, and achieved 
more affinity/ with [3H] titotidine (Table 1) for the H2R in 
guinea pig brain, lung parenchyma, and CH0-K.1 cells trans-
fected with the human H2-receptor cDNA [165-167J, but it 
was not successful in the studies of rat brain [168]. The most 
successful H2R-radioligand is [125l]iodoaminopotenti-dine, 
which has high affinity (KQ 50.3 nM) for the H2R in brain 
membranes (Table 1) [129, 169-171] and also in CHO-Kl 
cells expressing the cloned rat H2R [171]. This compound 
has also been used for autoradiographic mapping of H2Rs in 
the brain of mammal [131, 170]. [125I]iodo-
aminopotentidine is also the most successful H2R-radio-
ligand (Table 1), which was used to map the distribution of 
H2Rs in human brain with highest densities in the basal gan-
glia, hippocampus, amygdale, and cerebral cortex, and also 
lowest densities were identified in cerebellum and hypo-
thalamus [170|. In guinea pig brain, a similar distribution has 
been observed [129]. Irreversible labeling has also been suc-
cessfully seen by [125l]iodoazidopotentidine (Table 1) [129, 
169]. H2R-stimulated cyclic AMP accumulation or adenylyl 
cyclase activity in Fig. (4) has been shown in various tissues 
including gastric cells, cardie tissue and brain [IG.'i. 172. 
173] and gastric cells [174]. The potent effect of H2Rs have 
been demonstrated on gastric acid secretion and the inhibi-
tion of this secretory process through H2R antagonists had 
provided regulatory evidence for physiological role of his-
tamine in gastric acid secretion [175, 176]. In cardiac tissues 
of most animal species, high concentrations of histamine 
were present which can mediate positive chronotropic and 
inotropic impacts on atrial or ventricular tissues by H2R 
stimulation [177, 178]. Also H2R-mediated smooth muscle 
relaxation has been documented in vascular smooth muscle, 
uterine muscle and in airways [179-183]. Hill [89] had dem-
onstrated that the effects of H2Rs can inhibit a variety of 
functions within the immune system. H2Rs have been shown 
to negatively regulate the release of histamine on basophils 
and mast cells [184, 185]. The inhibition of antibody synthe-
sis, T-cell proliferation, cell-mediated cytolysis, and cyto-
kine production were the increasing evidence of H2Rs on 
lymphocytes [186-189]. The chemical structure of specific 
H2R-antagonist and -agonists are shown in Figs. (5,6). 
2. Structural Biology of Receptor 
The structural studies of H2R have been demonstrated 
using [1251]iodoazidopotentidine and sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) and it 
was suggested that the H2R in guinea pig hippocampus and 
striatum has a molecular weight of 59 kDa [129]. However, 
comparison with the calculated molecular weights (40.2 to 
40.5 kDa) for the cloned H2Rs indicates that the native H2R 
in the brain of guinea pig was glycosylated. It was highly 
significant with the proposal that entire cloned H2R proteins 
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possess N-glycosylation sites in tlie N-terminus region [190-
192]. Fulcushima et a!. [193] has suggested tliat removal of 
these glycosylation sites by site-directed mutagenesis 
showed that N-glycosylation of the H2R is not essential for 
cell surface localization, ligand binding, or coupling via Gs 
to adenylyl cyclase. Gantz and colleagues for the first time 
successfully cloned H2R using the polymerase chain reac-
tion to amplify a partial length H2R sequence from canine 
gastric parietal cDNA using degenerate oligonucleotide 
primers and this sequence was then used to identify a full 
length H2R clone following screening of a canine genomic 
library [167]. Following this cloning, many researchers have 
cloned the rat, human, guinea pig, and mouse H2Rs [167, 
191, 192, 194]. T.iese intronless gene (DNA) sequences en-
code 359 amino acids for canine, human, guinea pig or 358 
amino acids for rat receptor protein which has the general 
properties of a G-protein-coupled receptor (GPCR) (Table 
2). The radioligand binding studies using [1251]iodoamino-
potentidine were attempted to show the expression of rat and 
human H2R proteins in CHO cells and revealed the expected 
pharmacological specificity as shown in Table 1 [150. 171]. 
Chromosomal mapping studies have demonstrated that the 
H2R gene was localized to human chromosome 5 [192]. 
Birdsall [140] has compared H2R sequence with other bio-
genic amine G-protein coupled receptors (G.PCRs), and 
demonstrated that an aspartate in transmembrane (TM) do-
main 3 and an aspartate and threonine residue in TM 5 were 
N N N 
H H H 
lodoaminopotentidine 
NH, 
more responsible for histamine binding. Replacement of as-
partate (98) with asparagine residue in the canine H2R pro-
vides significant results in a receptor that does not bind the 
titotidine, an antagonist, and hence does not stimulate cyclic 
adenosine monophosphate (cAMP) accumulation in hista-
mine response [195]. On changing the aspirate (186) residue 
of TM 5 to an alanine residue there occurs complete loss of 
the antagonist titotidine binding without affecting the EC 50 
for cAMP formation in response to histamine stimulation. 
Other change was observed on changing the threonine (190) 
residue to an alanine residue, resulted in a lower KD for ti-
totidine antagonist and also a reduction in both the histamine 
EC 50 value and maximal cAMP response [195]. Mutation 
of Aspirate (186) and Glycine (187) residue in the canine 
histamine H2-receptor to Alanine (186) and Serine (187) 
residue produces a bifunctional receptor, which can be acti-
vated through adrenaline, and inhibited via both cimetidine 
and propranolol [196]. Thus, these results indicate that 
pharmacological specificity of the H2R resides in only lim-
ited key amino acid residues. 
3. Signaling Mechanisms 
H2R is coupled both to adenylate cyclase and to phos-
phoinositide second messenger systems via separate GTP-
dependent mechanisms. Receptor binding stimulates activa-
tion of c-Fos, c-Jun, protein kinase C (PKC) and 
p70S6kinase [14, 89, 145, 174] see in Fig. (4). Histamine 
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was proved to be a highly potent stimulant of cAMP accu-
mulation in various cells, and H2R-depcndent impacts of 
histamine were predominantly mediated through cAMP [14, 
174], particularly those of central nervous system (CNS) 
origin [23]. Thus, H2R-mediated impacts on cAMP accumu-
lation have been well documented and had been demon-
strated in brain slices, gastric mucosa, fat cells, cardiac myo-
cytes, vascular smooth muscle, basophils and neutrophils 
[23, 172, 197-199]. In addition, H2R-mediated cAMP accu-
mulation hac, been observed in Chinese hamster ovary 
(CHO) cells transfected with the rat, canine, or human H2R 
cDNA [167, 190, 193, 200]. In both brain and cardiac mus-
cle membranes, the direct stimulation of adenylyl cyclase 
activity in cell free preparations had been detected [201, 
202]. 
However, Hill [89] had suggested that the caution is re-
quired regarding the interpretation of receptor characteriza-
tion studies using histamine-stimulated adenylyl cyclase ac-
tivity alone. A most striking feature of studies of H2R-
stimulated adenylyl cyclase activity in membrane prepara-
tions was the potent antagonism demonstrated with certain 
neuroleptics and antidepressants [204], In intact cellular sys-
tems, most of the neuroleptics and antidepressants were ap-
proximately 2 orders of magnitude weaker as antagonists of 
histamine-stimulated cAMP accumulation [203, 205]. One 
highly potential explanation of these variations resides 
within the buffer systems used for the cell-free adenylyl cy-
clase assays, and some differences in potency of some anti-
depressants and neuroleptics have been demonstrated when 
membrane binding of H2Rs has been evaluated using 
[125I]iodoaminopotentidine (Table 1). However, the varia-
tions observed in the Ki values deduced from studies of 
ligand binding in different buffers are not as large as the 
variations in KB values obtained from functional studies. For 
example, in the case of amitriptyline, no difference was ob-
served in binding affinity in Krebs and Tris buffers [206]. In 
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addition to Gs-coupling to adenylyl cyclase, H2Rs are cou-
pled to other signaling systems also. For example, H2R 
stimulation has been demonstrated to enhance the intracellu-
lar free concentration of calcium (Ca^*) ions in gastric parie-
tal cells [207, 208]. In some cell systems, Gaq coupling to 
PLC and intracellular Ca'* had been demonstrated (Table 2). 
In HL-60 cells, a similar calcium (Ca^*) response to H2R 
stimulation had been demonstrated [209], and similar case 
was observed in hepatoma-derived cells transfected with the 
canine H2Rs cDNA [210]. Therefore, the influence on 
[Ca^ *]i was accompanied by both an increase in inositol 
trisphosphate accumulation and a stimulation of cAMP ac-
cumulation in these latter cells [210]. It was interesting to 
note that in these cells the H2R-stimulated calcium and 
inositol trisphosphate responses were both inhibited by chol-
era toxin treatment, whereas cholera toxin produced the ex-
pected increase in cAMP levels [208, 210]. H2Rs release 
Ca^ * from intracellular calcium stores in single parietal cells 
[211] and no effect of H2R agonists was observed on intra-
cellular calcium levels or inositol phosphate accumulation in 
CHO cells transfected with the H2R of human [144]. Thus, 
the effect of H2R stimulation on intracellular Ca^ * signaling 
may be highly cell-specitlc. 
The stimulation of H2R produces both inhibition of P2u-
receptor-mediated arachidonic acid release and an increase in 
cAMP accumulation in CHO cells transfected with the rat 
H2R [ 171 ]. However, Traiffort etal. [171] had demonstrated 
that the effect on phospholipase A2 activity (i.e., arachidonic 
acid release) was not mimicked by forskolin, PGEl, or 8-
bromo-cAMP, suggesting a mechanism of activation that is 
independent of cAMP-mediated protein kinase A activity. 
However, inhibitory effects of H2R stimulation were ob-
served on phospholipase A2 activity in CHO cells trans-
fected with the human H2R [200]. Thus, these cAMP-
independent effects might depend on the level of receptor 
expression or subtle differences between clonal cell lines. 
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C. Histamine H3-Receptor 
/. Cellular Distribution and Functional Characterization 
The function of histamine as neurotransmitter has been 
proved with the discovery of the H3R. It was mainly in-
volved in brain functions, also the peripheral effect of hista-
mine on mast cells via H3Rs, which mainly involves the 
nervous system, and might be connected to a local neuron-
mast cell interaction [212]. Its involvement in cognition, 
sleep-wake status, energy homeostatic regulation and in-
flammation had attracted many pharmaceutical researches 
for numerous, so far unmet, therapeutic approaches in differ-
ent peripheral, but mainly central diseases [213, 214]. A re-
cent study had reported that it is presynaptically located as 
autoreceptor controlling the synthesis and release of hista-
mine [215]. It was observed that H3-autoreceptor activation 
stimulates the negative feedback mechanism that reduces 
central histaminergic activity [216]. H3R's heterogeneity in 
binding and its fimctional studies has well been documented, 
and suggested more than one H3R subtype. This assumption 
had been confirmed by demonstration of several H3R vari-
ants, generated from the complex H3R gene by alternative 
splicing. The three functional isoforms have been found in 
the rat, and they all vary in length of the 3"* intracellular 
loop, their distinct central nervous system (CNS) localiza-
tion, and differential coupling to adenylate cyclase and 
MAPK signaling:. Similar results in case of humans were 
obtained [217-219]. 
Thus, numerous isoforms are found in different species 
and different tissues leading to the assumption that signaling 
fine-tuning may be controlled via receptor oligomerization 
or formation of isoforms [220]. 
H3R is anatomically localized primarily to the CNS with 
prominent expression in basal ganglia, cortex hippocampus 
and striatal area. In the periphery, H3R can be found with 
low density in gastrointestinal, bronchial and cardiovascular 
system [221]. The high apparent affinity of R-(a)-
methylhistamine for the H3R has enabled the use of this 
compound as a radiolabeled probe (Table 1) [222]. In rat 
cerebral cortical membranes, this compound (R-(a)-
methylhistamine) has been used to identify a single binding 
site, and which in phosphate buffer has the important phar-
macological characteristics of the H3R [222, 223]. In rat 
brain membranes, [3H]R-(a)-methyIhistamine binds with 
high affinity (KD 50.3 nM), although its binding capacity is 
low (~ 30 fmol/mg protein) [222]. It was significantly nota-
ble that the autoradiographic studies with [3H]R-(a)-
methylhistamine have described the presence of specific 
thioperamide-inhibitable binding in several rat brain regions, 
especially cerebral cortex, striatum, hippocampus, olfactory 
nucleus, and the bed nuclei of the stna terminalis, which 
receive ascending histaminergic projections from the mag-
nocellular nuclei of the posterior hypothalamus [222, 224]. 
In human brain and the brain of nonhuman primates, the 
H3Rs have also been visualized [225]. H3R binding has also 
been characterized using [3H]R-(a)-methylhistamine in 
guinea pig lung [222], guinea pig cerebral cortical mem-
branes [226], guinea pig intestine and guinea pig pancreas 
[227]. Na-methylhistamine as a radiolabeled probe had 
proved successful for the H3R (Table 1). The relative agonist 
activity of Na-methylhistamine (with respect to histamine) 
was significantly similar for all three histamine receptor 
(HRs) subtypes, but the binding affinity of histamine and 
Na-methylhistamine for the H3R was several orders of mag-
nitude higher than for either HI- or H2-receptors [23, 131]. 
Na-methylhistamine can identify high-affinity H3R sites in 
both rat [228, 230] and guinea pig [227] brain. The binding 
of H3-receptor-agonists to H3Rs in brain tissues was found 
to be regulated by guanine nucleotides, implying its relation 
to heterotrimeric G-proteins [222, 223, 228, 229]. Also the 
binding of H3R agonists appears to be more sensitive to sev-
eral cations. For example magnesium (Mg^*) and sodium 
(Na*) ions inhibit [3H]R-(a)-methylhistamine binding in 
guinea pig and rat brain [226], and the presence of calcium 
(Ca^*) ions has been shown to reveal heterogeneity of ago-
nist binding [223]. It is important to note that the inhibitory 
effect of sodium (Na^*) ions on agonist binding means higher 
Bmax values that were usually obtained in sodium-free Tris 
buffers compared with the Na/K phosphate buffers [228]. 
The multiple histamine H3R subtypes exist in rat brain 
(termed H3A and HJB) on the basis of [^H]N°-
methylhistamine binding in rat cerebral cortical membranes 
in 50 mM Tris buffer (Table 1) [230]. Based on these condi-
tions, the selective histamine H3-antagonist thioperamide 
can discriminate two affinity-binding states [230]. However, 
Heterogeneity of thioperamide binding was sodium (Na^*) 
ions concentration dependent or depends on guanine nucleo-
tides within the incubation medium [228]. Thus, in the pres-
ence of 100 mM sodium chloride, thioperamide binding con-
forms to a single binding isotherm [228], and H3R can exist 
in different conformations for which thioperamide, but not 
agonists or other H3R-antagonists (clobenpropit) can dis-
criminate. This suggests that the equilibrium between these 
conformations is altered by guanine nucleotides or sodium 
(Na^ "") ions [228]. If this speculation is correct, it is likely 
that the different binding sites represented resting, active, or 
G-protein-coupled conformations of the H3R. Furthermore, 
if thioperamide preferentially binds to uncoupled receptors, 
then this compound should exhibit negative efficacy in func-
tional assays. Radiolabeled H3R antagonists [125I]iodo-
phenpropit, has been used to label histamine H3Rs in rat 
brain membranes (Table 1) [231]. The inhibition curves for 
iodophenpropit and thioperamide were consistent with inter-
action with a single binding site, but H3R agonists were 
found to be able to discriminate both high- [4 nM for R-(a)-
methylhistamine] and low- [0.2 mM for R-(a)-methyl-
histamine] affinity binding sites [231]. [^H]GR16820 and 
['^'l]iodoproxyfan have been proved useful as high-affinity 
radiolabeled H3R-antagonists [232, 233]. In rat striatum, in 
the lUPHAR classification of histamine receptors 267 pres-
ence of guanine nucleotides such as guanosine 590- (3-
thiotriphosphate) (GTPgS), 40% of the binding sites exhib-
ited a 40-fold lower affinity for H3-agonists, providing fur-
ther evidence for a potential linkage of H3Rs to G-proteins. 
In rat brain membranes, [^H]thioperamide and [ 'H]5-
methylthioperamide, both have been used to label H3R 
[234]. However, [^H]thioperamide was shown to bind addi-
tionally to low affinity, high-capacity, non H3R sites [234]. 
The localization of H3Rs had come out from functional stud-
ies, primarily involving inhibition of neurotransmitter re-
lease. The H3R was first characterized as an auto receptor 
regulating histamine synthesis and release from rat cerebral 
hippocampus, cortex, and striatum [222, 235]. In human 
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cerebral cortex, the H3R-mediated inhibition of histamine 
release has also been demonstrated [235]. Differences in the 
distribution of H3R binding sites and the levels of histidine 
decarbox>ia;;e (an index of histaminergic nerve terminals) 
suggested at an early stage that H3Rs were not confined to 
histamine-containing neurons within the mammalian CNS 
[222, 236]. It has been documented by the observations that 
H3Rs can regulate neurotransmitter release in mammalian 
brain as serotonergic, noradrenergic, cholinergic, and dopa-
minergic [237-240]. H3R activation inhibits the firing of the 
histamine-neurons in the posterior hypothalamus by a 
mechanism different from auto-receptor functions found on 
other aminergic nuclei, and presumably a block of Ca^ * cur-
rent [241]. H3Rs were found to regulate the release of sym-
pathetic neurotransmitters in guinea pig mesenteric artery 
[242], human saphenous vein [243], guinea pig atria [244, 
245], and human heart [246]. 
An important inhibitory effect of H3R activation on re-
lease of neuropeptides (tachykinins or calcitonin gene-
related peptide) from sensory C fibers has been investigated 
from airways [247], meninges [248], skin [249], and heart 
[250]. The modulation of acetylcholine, capsaicin, and sub-
stance P effects by H3Rs in isolated perfused rabbit lungs 
has also been reported [251]. There was evidence that H3R 
activation can inhibit the release of neurotransmitters from 
nonadrenergic- noncholinergic nerves in guinea pig bronchi-
oles [252] and ileum [253]. In guinea pig ileum, the H3R-
antagonists betahistine and phenylbutanoylhistamine were 
much less potent as inhibitors of H3R-mediated effects on 
nonadrenergic-noncholinergic transmission than they were 
as antagonists, of histamine release in rat cerebral cortex 
[253]. 
A similar low potency has been investigated for betahis-
tine and phenylbutanoyi histamine antagonists for antago-
nism of H3R-mediated [^H]acetylcholine release from rat 
entorhinal correx [239], and antagonism of H3R-mediated 5-
hydroxytryptafiiine release from porcine enterochromaffln 
cells [254]. These investigations provide possible support for 
the existence of distinct H3R subtypes and it had been shown 
that phenylbutanoylhistamine can inhibit ["'H] acetylcholine 
release from rat entorhinal cortex slices, and synaptosomes 
by a nonhistamine receptor mechanism [255]. Therefore, the 
potency of phenylbutanoylhistamine as H3R-antagonist in 
those preparations can be highly underestimated because of 
the additional nonspecific activities of the drug [255], The 
inhibitory effect of H3-receptor stimulation on 5-HT release 
from porcine enterochromaffin cells in strips of small intes-
tine [254] provides evidence for H3-receptors regulating 
secretory mechanisms in non-neuronal cells. Hence, it can be 
concluded that H3R may be present in gastric mast cells or 
enterochromaffin cells and exert an inhibitory effect on his-
tamine release and gastric acid secretion. In conscious dogs, 
H3R activation had been observed to inhibit gastric acid se-
cretion [256], and in isolated rabbit fundic mucosal cells. An 
autoregulation of histamine synthesis by H3R had also been 
investigated [257]. It had been demonstrated that H3R re-
laxes rabbit middle cerebral artery by an endothelium-
dependent pathway involving both nitric oxide and prosta-
noid release [258, 259]. H3-receptor stimulation can activate 
adrenocorticotropic hormone release from the pituitary cell 
line AtT-20 [260]. Therefore, H3R provides constitutive 
properties, which means part of the receptor population 
spontaneously undergoes allosteric transition leading to a 
conformation, to which G protein can bind [261, 262], and 
also H3R-knock out mice manifest an obese phenotype 
(characterized through increased body weight, food intake, 
adiposity, and reduced energy expenditure). Recently, it has 
been observed that H3R express insulin and leptin resistance 
as well as a diminution of the energy homeostasis-associated 
genes UCPI and UCP3 [263]. The chemical structure of spe-
cific H3R-antagonists and -agonists are shown in Figs. (7, 
8). 
2. Structural Biology of Receptor 
The H3-receptor is also G protein-coupled (GPCR) and 
had been cloned [22]. Its gene consists of 4 exons spanning 
5.5 kb on chromosome 20 (20ql3.33) in humans (Table 2). 
Structural studies of H3R are very limited and there are only 
few reports on its purification studies. By using 
['H]histamine as a radioligand, the solubilization of a H3R 
protein from bovine whole brain has been reported and then 
Size-exclusion chromatography has revealed an apparent 
molecular mass of 220 kDa [229]. However, because the 
solubilized receptor retained its guanine nucleotide sensitiv-
ity and it is likely that the molecular mass of 220 kDa repre-
sents a complex of receptor, G-protein, and digitonin [229]. 
Cherifi et al. [264] have reported the solubilization (with 
Triton X-IOO) and purification of the H3-receptor protein 
from the human gastric tumoral cell line HGT-1. After gel 
filtration and sepharose-thioperamide affinity chromatogra-
phy, protein has been purified with a molecular mass of ap-
proximately 70 kDa (see Table 2). 
3. Signaling Mechanisms 
The signal mechanisms used by the H3R remain largely 
subject to hypothesis, but there is increasing evidence to 
suggest that this receptor belongs to the G-protein-coupIed 
receptors (Gi/o) (Table 2), and its activation leads to inhibi-
tion of cAMP formation, accumulation of Ca^ * and stimula-
tion of mitogen-activated protein kinase (MARK) pathway 
[212], see Fig. (4). This evidence had been obtained from 
ligand-binding studies that involve the modulation by gua-
nine nucleotides of H3R-agonist binding [223, 226, 228-230] 
and H3R-agonist inhibition of H3R-antagonist binding [231, 
233, 265]. The direct evidence for a functional H3R-G-
protein linkage came from studies of [ 'S]GTPgS binding to 
rat cerebral cortical membranes [266]. In rat cerebral cortical 
membranes, the presence of HI R- and H2R-antagonists (0.1 
mM mepyramine and 10 mM titotidine), and both R-(a)-
methylhistamine and N-(a)-methylhistamine generated a 
concentration dependent stimulation of [35S]GTPgS binding 
(EC50 = 0.4 and 0.2 nM) [266]. Notably, this response was 
inhibited via pretreatment of membranes with pertussis 
toxin, and implying a direct coupling to a Gi or Go protein 
[266], The evidence of pertussis toxin-sensitive G-proteins in 
the response to H3R stimulation came from studies of H3R 
signaling in human and guinea pig heart [244, 246]. H3R-
activation appeared to lead to an inhibition of N-type Ca^^ 
channels responsible for voltage dependent release of 
noradrenaline in human and guinea pig heart [244, 246], but 
several investigations have failed to demonstrate an inhibi-
tion of adenylyl cyclase activity in different tissues and cells 
[264, 267] which might suggest that H3Rs couple to Go pro-
teins. 
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D. Histamine H4-Receptor 
/. Cellular Distribution and Functional Characterization 
The discover/ of the H4-receptor adds a new chapter to 
the histamine story. The H4R is preferentially expressed in 
intestinal tissue, spleen, thymus, medullary cells, bone mar-
row and peripheral hematopoietic cells, including eosino-
phils, basophils, mast cells, T lymphocytes, leukocytes and 
dendritic cells. However, moderate positive signals have also 
been detected in brain, spleen, thymus, small intestine, co-
lon, heart, liver and lung. Although first expression studies 
demonstrated the absence of H4Rs in the central nervous 
system (CNS), but in situ hybridization studies suggested 
evidence for their human brain localization in low density. 
The relatively restricted expression of the H4R provides an 
important role in inflammation, hematopoiesis and immunity 
by the regulation of H4R expression via stimuli such as IFN, 
TNF-a and IL-6, IL-IO, and IL-13. Basophils and mast cells 
express H4R-mRNA. The H4R mediates chemotaxis of mast 
cells and eosinop^hils as well as control cytokine release from 
dendritic cells and T cells. It was demonstrated that the H4R 
is participated, along with the H2R, in the control of lL-16 
release from human lymphocytes. It had also been hypothe-
sized that H4R selective antagonist might be useful in help-
ing to treat anti-inflammatory potency in models of asthma, 
arthritis, colitis and pruritis. Antagonists, such as JNJ 
7777120, have also been shown to be effective in various 
model of inflammation. Up to now, very little is known 
^NHz 
^^>H 
HN N CH3 
(R)-a-Methylhistamine 
about the biological functions of H4R. There are few reports 
in the literature, providing evidence for chemotactic activity 
in mast cells and eosinophils or control of IL-16 production 
by CD8* lymphocytes. It suggests an important role of H4R 
in the regulation of immune function and offers novel thera-
peutic potentials for histamine receptor ligands in allergic 
and inflammatory diseases [268-280]. A recent study showed 
the role of H4R in mast cell, eosinophil, and T cell function, 
as well as the effects of its antagonist, JNJ 7777120, in a 
mouse peritonitis model pointing to a more general role for 
H4R in inflammation. Selective H4R antagonists like JNJ 
7777120 shows potential role in treatment of inflammation 
in humans. In many diseases such as allergic rhinitis, asthma, 
and rheumatoid arthritis, conditions where eosinophils and 
mast cells are involved, H4R antagonists have therapeutic 
utility [281]. The discovery of H4R and its emerging role in 
inflammation had spurred new interest for the functions of 
histamine in inflammation, allergy and autoimmune diseases. 
Early results in animal models suggest that H4R antagonists 
may have utility in treating various conditions in humans, in 
particular, in diseases in which histamine is known to be 
present and in which HIR antagonists are not clinically ef-
fective [282]. Obviously, a better functional characterization 
of H4R benefits from the exploitation of new, specific tools, 
such as the recently developed potent and selective non-
imidazol H4R antagonist [281]. It can be expected that the 
role of H4R will be more important in autoimmune disor-
ders, allergic conditions and nociceptive responses in the 
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near future. The chemical structure of specific H4R-
antagonists and -agonists are shown in Fig. (9). 
2. Structural biology of Receptor 
The human H4-receptor gene was mapped to chromo-
some 18ql 1.2 which encodes a 390 amino acid and also re-
lated to seven transmembrane G-protein coupled receptor. It 
shares 37-43% homology (58% in transmembrane regions) 
with the H3-receptor and a similar genomic structure. The 
H4R gene spans more than 21 kbp and contains three exons, 
separated by tv/o large introns (>7 kb) (Table 1) with large 
interspecies variations from 65-72% homology in sequences. 
Analysis of the 5' flanking region did not reveal the canoni-
cal TATA or CAAT-boxes. The promoter region contains 
several putative regulatory elements involved in proinflam-
matory cytokine signaling pathways. H4Rs are coupled to 
Gi/o, which initiates various transduction pathways such as 
inhibition of forskolin-induced cAMP formation, enhanced 
calcium influx and MARK activation. In accordance with the 
homology between the two receptors, several H3R-agonists 
and antagonists were recognized by the H4R, although with 
different affinities. It has been observed that H3R-agonist R-
a-methyl histamine acts on H4R with several hundred times 
less potency. Similar effect has been seen with thioperamide, 
the classical H3R antagonist which also behave like a H4R 
antagonist (Table 1), though with a much lower affinity and 
clobenpropit, also a H3R antagonist, which exerts agonistic 
activity on H4R [Table 1; 21,273,274, 283-286]. 
Albeit histamine binding to H4R is ver)' similar to that 
reported for the other histamine receptors (it shows the im-
portance of the Asp 94 residue in transmembrane region 
(TM) 3 and the Glu 182 residue in the TM 5) however, some 
differences exist and these were exploited to design specific 
tools. Mouse, rat and guinea pig H4Rs have been cloned and 
characterized and were found to be only 68, 69, and 65% 
homologous respectively to their human counterpart. These 
studies have revealed substantial pharmacological variations 
between species, with higher affinity of histamine for human 
and guinea pig receptors than for their rat and mouse equiva-
lents [287]. 
3. Signaling Mechanisms 
The signal mechanisms used by the H4R remain highly 
subject to the G-protein-coupled receptors (Gi/o), and its 
activation leads to an inhibition of adenylyl cyclase and 
downstream of cAMP responsive elements (CRE) as well as 
activation of mitogen-activated protein kinase (MAPK) and 
phospholipase C with Ca"^ mobilization (Table 2); see Fig. 
(4). 
IV. HISTAMINE: NON-CLASSICAL BINDING SITES 
A. Cytochrome P450 
The human cytochrome P450 (CYP450) superfamily 
comprises 57 genes encoding heme-containing enzymes, 
which are found in the liver as well as in extrahepatic tissues 
(adrenals, and peripheral blood leukocytes), where they can 
be stimulated by various stimuli [288, 289] (Fig. 10). They 
are not only involved in metabolism of large number of for-
eign substances, but also play an important role in diverse 
physiological processes [generation, transformation or inac-
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tivation of endogenous ligands (steroids and lipids)], which 
are involved in cell regulation [290]. 
Binding of histamine to CYP450 had been shown by 
Branders, who proposed a second messenger role for intra-
cellular histamine via this binding site. This hypothesis was 
mainly based on a finding that N, N diethyl-2-(4-
(phenylmethyl)phenoxy) ethanamine (DPPE), an arylalky-
lamine analogue of tamoxifen inhibits the binding of hista-
mine to CYP450 [291]. DPPE allosterically modii^ hista-
mine binding to the heme moiety of CYP450 enzymes and 
inhibited platelet aggregation, as well as lymphocyte and 
hematopoietic progenitor proliferation [292, 293]. The effect 
of DPPE on histamine binding was found to be highly com-
plicated and depends on the nature of the P450 enzymes. 
Thus, it inhibits the action of histamine on CYP2D6 and 
CYPlAl, which enhances its effect on CYP3A4 and does 
not affect CYP2B6 [294]. The heme moiety of CYP450 
binds to several histamine antagonists [295, 296], particu-
larly H3R antagonists (thioperamide, clobenproprit and 
ciproxyfan) [297]. This property explains some effects of 
these antagonists, when used at high doses. Notably, hista-
mine interacts with CYP450 and it has been demonstrated 
that CYP2E1 and CYP3A were upregulated in histidine de-
carboxylase (HDC)-deficient mice [298]. 
B. Transporters of Histamine 
Histamine (2-(lH-imidazol-4-yl) ethanamine) is synthe-
sized in the cytosol and requires a specific transport into se-
cretory vesicules where it is sequestered. Vesicular mono-
amine transporters (VMATs) are proteins, which accomplish 
this specific task for several neurotransmitters [299] (Fig. 
10). The two subtypes of monoamine transporters are 
VMATl and VMAT2 (that have been cloned and character-
ized) but VMAT2 can transport histamine. Vesicular mono-
amine transporter 2 (VMAT2) had been cloned from rat and 
human brain, bovine adrenal medulla and a basophilic leu-
kemia cell line. When histamine biosynthesis was enhanced 
then its expression was found to be up regulated by several 
stimuli. The increased VMAT2 expression in IL-3-
dependent cell lines was enhanced with enhanced histamine 
synthesis in response to calcium (Ca^')ionophore [300]. 
VMAT2 is responsible for the transport of histamine into 
secretory granules of enterochromaffm-like (ECL) cells. The 
gene expression of VIVIAT2 was found to be modulated x\a 
cytokines, either positively (TGFa) or negatively (IL-1 and 
TNF-a) [301]. VMAT2-deleted granules do not release his-
tamine upon activation, even though granule cell fusion does 
still occur [302]. The bone marrow-derived mast cells from 
histidine decarboxylase (HDC)-deleted mice are completely 
devoid of endogenous histamine but can take up the media-
tor from histamine-supplemented medium and store it in 
secretory granules. Hence, two transporters are essential to: 
1. insure the passage across the plasma membrane, and 
2. cross the vesicular membrane. 
First transporter has not been identified yet, but the sec-
ond transporter seems to be vesicular monoamine transporter 
2 (VMAT2). The non-neuronal monoamine transporters that 
actively remove monoamines from extracellular space have 
been described as organic cation transporter 1 (OCTl), 
0CT2, and extraneuronal monoamine transporter (EMT). 
EMT was also designated as 0CT3. The expression of OCTl 
was found to be restricted to liver, kidney and intestine, 
0CT2 in brain and kidney, while EMT showed a broad tis-
sue distribution. It has been established that OCTl cannot 
transport histamine, conversely to 0CT2 and EMT for which -» 
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it is a good substrate [303]. Thus, EMT appeared to be a 
good candidate as histamine transporter in mast cells and 
basophils, accounting for their capacity to take up the media-
tor from the environment. 
V. IMMUNE REGULATION BY HISTAMINE IN IM-
MUNOMODULATION AND ALLERGIC INFLAM-
MATION 
Histamine exerts a very important immunomodulatory 
effect Mia HI-, H2-, H3-, and H4-receptors [1, 20, 128, 188, 
189, 270, 304; Table 3]. According to the cell differentiation 
stage and microenvironment influences, the receptors ex-
pression changes. Histamine shows proinflammatory or anti-
inflammatory effects, depending on the predominance of the 
type of histamine receptor (HIR, H2R, H3R & H4R) and on 
the experimental system studied. Histamine had proinflam-
matory activit)' through the HIR, and is involved in the de-
velopment of various aspects of antigen-specific immune 
response including the maturation of dendritic cells (DCs) 
and the modulation of the balance of type I helper (Thl) T 
cells and type 2 helper (Th2) T cells. Histamine blocks hu-
moral immune responses by means of a specific mechanism 
in which it induce an increase in the proliferation of Thl 
cells and in the production of interferon y (IFN- y). Hista-
mine also stimulates the release of proinflammator>' cytoki-
nes and lysosomal enzymes from human macrophages and 
shows the capacity to influence the activity of immune cells 
including mast cells, basophils, eosinophils, fibroblasts, 
lymphocytes, neutrophils, epithelial and endothelial cells. 
The role of histamine in autoimmunit}' and malignant disease 
through the HIR is well documented [20, 128]. Histamine 
also plays a pivotal role in allergic inflammation which is a 
complex network of cellular events and involves redundant 
mediators and signals. Histamine is released from the gran-
ules of mast cells and basophils (FceRr cells) along with 
several mediators such as tryptase, leukotrienes, prostagland-
ins, and other newly generated mediators. Histamine was 
found in relatively large (pg) quantities per 1 million cells, in 
contrast to leukotrienes and other mediators (which are pre-
sent in picograms), after allergen challenge in sensitized per-
sons. Most of the potent effects of histamine in allergic in-
flammation occur through HlRs [1, 13, 20; Table 3], while 
hypotension, Hushing, headache, and tachycardia occur both 
by the HI- and H2-receptors in the vasculature [305]. 
Whereas, nasal congestion and cutaneous itch occurs both by 
the HI- and H3- receptors [306, 307]. Histamine also acts as 
a contributor to the late allergic response by generating a 
stimulatory signal for the production of cytokines, the ex-
pression of cell adhesion molecules and class II antigens. 
VI. EFFECT OF HISTAMINE IN IMMUNE CELLS 
WITH RESPECT TO ALLERGIC DISEASES 
Histamine's classical effects, expressed at the organ 
level, have been documented and were highly emphasized in 
allergies and autoimmune diseases. Histamine directly or 
indirectly influences the activity of various inflamma-
tory/effector/immunologic cell types involved in the patho-
genesis of se\'eral diseases. Indeed, several studies have sug-
gested that histamine receptors (HRs) are expressed on mast 
cell and basophils; lymphocytes; neutrophils; monocytes, 
macrophages and dendritic cells (DCs); eosinophils; epithe-
lial cells; endothelial cells, and therefore modulate the func-
tion of these cells in immune system. 
A. Mast Cells and Basophils 
Recent studies shed light on the potent role of histamine 
in mast cells and basophils, both types of cells can them-
selves be modulated by histamine as they express HI-, H2-
and H4-receptors [271, 308, 309]. The peritoneal and skin 
mast cells exhibited aberrant granules with very low electron 
density, in HDC-deficient mice, which indicated the drastic 
decrease in the granule contents including granule proteases 
and sulfated proteoglycans [310]. The critical roles of hista-
mine in cutaneous and systemic anaphylaxis have been sug-
gested by using the HDC-deleted mice [311, 312] and it re-
mained a possibility that diminished granule constituents, 
such as proteases, make contribution to the relief of anaphy-
laxis in the mutant mice. How histamine regulates allergic 
responses by maturation of tissue mast cells requires to com-
prehend detailed studies on the effect of absence of hista-
mine on mast cell function. Impact of histamine was also 
demonstrated in the migration of mast cells which was medi-
ated exclusively through the H4R [271]. It has been shown 
that histamine acting through H4Rs can stimulate chemo-
taxis of murine mast cells in vitro [271] and lead to changes 
in tissue localization in vivo [281]. A hematopoietic organ, 
bone marrow, contains certain types of cells which can pro-
duce histamine in response to IL-3 [30, 313]. The role of IL-
3 -sensitized histamine synthesis in bone marrow remains to 
be clarified [39], however, a study suggested a unique circuit 
of newly synthesized histamine and its implication in baso-
phil precursors [314]. It has been documented that bidirec-
tional transport of histamine is facilitated largely through 
organic cation transporter 3 (0CT3) in the plasma mem-
branes of the FcsRr, c-kit~ bone marrow cells. It had been 
demonstrated that intracellularly stimulated histamine in the 
organic cation transporter 3 (0CT3)-deleted cells has sup-
pressive impacts on expression of HDC, IL-4, and IL-6. This 
suggests not only the feedback inhibition of histamine syn-
thesis but also the suppression of Th2 cytokine production 
through immature basophils [303, 315]. In addition, hista-
mine receptor binding studies with specific receptor antago-
nists have suggested that basophils express predominantly 
H2R, and these were involved in the regulation of IgE-
stimulated histamine release, as demonstrated through in-
creased histamine release in the presence of anti-IgE and 
cimetidine (a H2R antagonist) but not in the presence of anti-
IgE and thioperamide (a H3R antagonist) [316-318]. H2Rs 
in mast cells show various effects such as inhibition of his-
tamine release and modulation of cytokine production [319]. 
It has been suggested that H3R functions on mast cells but 
many of these properties may be attributed to the H4R as the 
ligands used were not specifically selective. HSR expression 
was not detected in some types of mast cells [271], 
B. Lymphocytes 
The expression of histamine receptors (HRs) on the cell 
surface of immunocompetent cells, including lymphocytes 
(B-cells and T-cells) and their effects mediated by receptors 
(HRs) have been published in several studies and signifi-
cantly reviewed [320] (Fig. 11). It has been concluded that 
both histamine receptors (HI and H2) are present on the 
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Table 3. Immunopharmacological Profiles of Histamine Receptor Subtypes 
Shahidetal. 
Characteristics Histamine HI R Histamine H2R Histamine H3R Histamine H4R 
"General function 
'Function in immune 
modulation and alli;rgic 
inflammation 
Physiological relevance 
Pathophysiological rele-
vance 
Antagonists 
Increased pruritus, pain, 
vasodilation, vascular per-
meability, hypotension; flush-
ing, headache, tachycardia, 
bronchoconstriction, stimula-
tion of airways, vagal stimu-
lation of airway vagal recep-
tors, decreased atrio-
ventricular-node conduction 
time. 
Increases release of histamine 
and other mediators; in-
creases cellular adhesion 
molecule expression and 
chemotaxis of eosinophils 
and neutrophils; increases 
antigen-presenting cell capac-
ity, co-stimulatory activity on 
B cells; increases cellular 
immunity (Thl), IFN-y, 
autoimmunity. Decreases 
humoral immunity and IgE 
production. 
Cycle of sleeping and wak-
ing, food intake, thermal 
regulation, emotions and 
aggressive behavior, locomo-
tion, memory, and learning, 
contraction of smooth mus-
cles. 
Allergic reaction. 
Clinically usable 
(Mepyramine, chlor-
pheniramine, astemizole, 
terfenadine, loratidine, 
triprolidine, diphenhy 
dramine, cetirizine, desl-
oratidine, fexofenadine) 
Increased gastric acid secre-
tion, vascular permeability, 
hypotension, flushing, head-
ache, tachycardia, chro-
notropic and inotropic activ-
ity, bronchodilatation, mu-
cus production (airway). 
Decreased eosinophil and 
neutrophil chemotaxis; 
induction of interleukin-IO, 
suppression of interleukin-
12 by dendritic cells; 
development of Th2 or 
tolerance inducing dendritic 
cells; induction of humoral 
immunity; suppression of 
Th2 cells and cytokines; 
indirect role in allergy, 
autoimmunity, malignant 
disease, and graft rejection. 
Neuroendocrine, gastric acid 
secretion. 
Gastric ulcer. 
Clinically usable (Ci-
metidine, zolantidine, 
tiotidine, femotidine, 
nizatidine, and ranitidine) 
Prevents excessive 
bronchoconstriction; 
mediates pruritus (no 
mast-cell involvement). 
Differentiation of mye-
loblasts and promyelo-
cytes. 
Probably involved in control 
of neurogenic inflammation 
through local neuron-mast 
cell feedback loops; proin-
flammatory activity; in-
creased APC (antigen-
presenhng cell) capacity. 
Presynaptic heteroreceptor; 
decreased histamine, dopa-
mine, serotonin, noradrena-
line and acetylcholine release, 
sleep, food intake. 
Cognitive impairment, sei-
zure, metabolic syndrome'' 
Clobenpropit, lodophenpro-
Thioperamide 
Increased Ca"' flux in 
human eosinophils; 
increased eosinophil 
chemotaxis, increases 
lL-16 production (H2-
receptor also involved). 
Chemotaxis. 
Inflammation, immune 
reaction 
JNJ 7777120, 
JNJ 10191584 
|399',22r]. 
lymphocytes but there is only few data available on the func-
tional significance of the HI R and the distribution of H2R on 
lymphocyte subsets in general, signaling through the HIR 
was associated with enhancement and signaling through the 
H2R with inhibition of lymphocyte responses. It has been 
suggested by several studies that histamine and its deriva-
tives can inhibit the immune response by enhancing the ac-
tivity of T suppressor cells through H2R and natural sup-
pressor cells via HIR [321, 322]. The impacts of histamine 
on T helper lympiiocytes are differential and complex; see in 
Fig. (11). T lymphocytes, mainly T helper lymphocytes, play 
a significant role in the pathogenesis of atopic asthma. 
Helper T lymphcicytes can be divided into two subsets (T 
helper type 1 cells (Thl) and Th2) based on their cytokine 
profile and distinct functions and both the subsets play dis-
tinctive roles in the development, initiation, and regulation of 
the immune response. Thl cells were found to be responsive 
in delayed type hypersensitivity (DTH) and cytotoxic re-
sponse, while Th2 cells were involved in allergic disease via 
activating B-lymphocytes and regulating antibody (IgG and 
IgE) secretion; see in Fig. (11). Thl cells secrete important 
cytokines as interleukin (IL)-2, IFN-y, IL-3, and granulocyte 
monocyte colony stimulating factor (GM-CSF), while Th2 
cells secrete cytokines such as IL-3, IL-4, IL-5, IL-IO, IL-13, 
and GM-CSF. Histamine downregulates the proliferation of 
Thl cells (which control cytotoxic response and delayed-
type hypersensitivity) and upregulates the proliferation of 
Th2 cells (which regulate allergic disease and asthma) [323]. 
Histamine also regulates the development of an allergic 
state by enhancing the secretion of Th2 cytokines such as IL-
4, IL-5, IL-10 and lL-13 and by inhibiting the production of 
Thl cytokines IL-2 and IFN-y and monokine IL-12 [324-
330]. It had been demonstrated in several studies that hista-
mine dose-dependently upregulate the secretion of Th2 cyto-
kines (IL-5, IL-10, and IL-13) and down regulate the secre-
tion of Thl cytokines (IL-2 and IFN-y) in cloned murine T 
helper cells [327-329]. It has also been demonstrated that 
Thl and Th2 cells express distinct surface histamine receptor 
(HR) patterns (Thl cells that express predominantly HIR 
and Th2 cells express H2R). Histamine increases Thl-type 
responses by triggering HIR and negatively regulates both 
Thl and Th2-type responses by H2R as suggested by en-
hanced release of tumour necrosis factor (TNF)-a and de-
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creased rciea.sc uf ititerleukin {iL)-4 and iL-13, respectively 
[331]. The differential expression of these cells to histamine 
is a result of the t\pc of intracellular signals generated via 
histamine activation. Notably, HIR signaling involves cal-
cium-dependent phospholipase stimulation and generation of 
IP3, while H2R signaling involves adenylate cyclase stimu-
lation and cAMP formation. 
The receptor binding study of human peripheral blood 
lymphocytes has suggested that histamine trifluoromethyl-
toludine (HTMT) derivative lead to a two-phase enhance-
ment in intracellular calcium (Ca") and an increase in inosi-
tol phosphate (1P3) production. The increase in calcium 
(Ca"') was thoroughly antagonized through high concentra-
tions of histamine but not by the classical histamine HI-, 
H2- or H3- receptor antagonists [332]. These observations 
demonstrate that HTMT have a specific binding site on lym-
phocytes, which is different for three classic histamine re-
ceptors. Several functional studies demonstrated that hista-
mine primarily modulates T-suppressor activity including 
delayed type hypersensitivity (DTH), cytotoxic T-
lymphocyte-rnediated target cell killing, cell-mediated lym-
pholysis. and natural killer activity by H2R signaling [333]. 
Although, some studies suggest that activation of the H2Rs 
indirectly increases the allergic cascade. Suppressor T-cells 
were found to be more responsive to histamine than T helper 
cells or cytotoxic T cells [334]. Likewise, the response to 
histamine in T helper cells and cytotoxic T-cells was highly 
enhanced aft;r mitogenic stimulation [334]. It is more im-
portant to note that in humans, histamine suppresses the pro-
liferation of mixed T i)mpliocytcs via H2R [335, 336]. Fur-
ther, it had been confirmed that histamine inhibited lipopoly-
saccharidc (LPS)-stimulatcd IFN-y-gene expression from 
human peripheral blood mononuclear cells (PBMC) [337]. 
IFN-y cytokine releases human CD4+T-cell clones, which 
are classified as either ThO, Th I or Th2 based on their cyto-
kines (11-4 and IFN-y) secretion patterns [338]. Notably. 
histamine-induced inhibition of IFN-y secretion was seen in 
Th 1 clones but not Th2 clones and the effect was reversed by 
H2R and not HI- or H3-receptor antagonists. Histamine has 
been demonstrated to directly enhance the synthesis of the 
proinflammatory cytokines (IL-lb and IL-6) through lym-
phocytes, anti-CD23- and anti-CD28-stimulated release of 
IL-4 and IL-5 (but not IL-2) or IFN from T lymphocytes can 
be inhibited by terfenadine treatment [320]. Similarly, sev-
eral other studies have suggested that histamine leads to syn-
thesis and release of a lymphocyte chemo-attractant factor 
(LCF) from H2R bearing lymphocytes and also results in 
release of two different types of lymphocyte migration in-
hibitory factors (LyMlFs) from only a subset of H2R bearing 
lymphocytes [339, 340]. 
C. Neutrophils 
Neutrophils have been demonstrated to express H1R and 
H2R [341, 342], and it had been suggested that the impacts 
of histamine on neutrophils are inhibitory via H2R. In vitro 
studies showed the autologous serum-sensitized chemotaxis 
of neutrophils both in normal, atopic subjects which is abol-
ished by histamine in a dose-dependent manner, and this 
inhibition was more effective in atopic individuals [343]. It 
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is more important to note tliat incubation of neutrophils from 
these individuals with cimetidine, but not promethazine, 
causes reversal of the histamine-sensitized inhibition of neu-
trophil chemotaxis. In vivo study has demonstrated that the 
histamine administration by either infusion and subcutaneous 
injection or inhalation diminished neutrophil chemotaxis in 
healthy volunteers [344], Several studies have suggested that 
histamine inhibits the activation of neutrophils as demon-
strated by inhibition of fMet-Leu-Phe induced superoxide 
(0^~) formation, degranulation and membrane potential 
changes acting by H2R signaling [345,346]. 
D. Monocytes, Macrophases and Dendritic Cells 
The presence of histamine receptors (HIR and H2R) on 
human monocytes and macrophages [347, 348] indicates that 
in allergic disease histamine also modulate the activity of 
these cells. Differentiation of monocytes into macrophages 
causes switching over from H2R to HIR [347]. Several other 
recent studies have suggested (investigations which were 
performed with exogenously added histamine) that it has a 
potential role in modulating maturation and function of 
monocytes, and dendritic cells. Activated monocytes and 
dendritic cells have a significant potential role in release of 
histamine, which acts in autocrine and paracrine fashion and 
modifies dendritic cell markers. Histamine was found to in-
hibit the production of TNF-a and IL-12, and to augment the 
production of IL-10 in response to Toll-like receptor ligands 
by acting on the H2R, in human monocytes [24, 89, 349, 
350], while, in human monocyte-derived dendritic cells simi-
lar inhibition of lL-12 and enhancement of IL-10 production 
was investigated. Recently, H4R involvement in suppression 
of IL-12 was observed [351]. In the P. acnes-prmeA and 
LPS-stimulated hepatitis model, endogenous histamine pro-
duction via macrcphages and Kupffer cells was reported to 
play a protective role through acting on the H2R [352]. This 
study was performed with attention to endogenous histamine 
synthesis in macrophages and Kupffer cells. Furthermore, it 
has been documented that dendritic cells (DC) are especially 
antigen-presenting cells, which mature from monocytic and 
lymphoid precursors and leads to acquisition of dendritic cell 
(DC) I and DC2 phenotypes that drives the development of 
Thl and Th2 cells, respectively. Histamine potentially par-
ticipates in functions and activity of DC precursors as well as 
their immature and mature forms. It is important to note that 
immature and mature dendritic cells (DCs) express all four 
histamine receptors [270, 353, 354] see in Fig. (U) for more 
details. Furthermore, in the differentiation process of DCl 
from monocytes, HIR and H3R act as positive stimulants 
that enhance antigen-presentation capacity and proinflamma-
tory cytokine production and also Thl priming activity. H2R 
acts as a suppressive molecule and enhances IL-10 produc-
tion, and stimulates IL-10 producing T-lymphocytes (Th2 
cells) for antigen-presen*ation [355], The suppressive impact 
of histamine by H2R seems through the regulation of ICAM-
1 and B7.1 expression facilitating the reduction of innate 
immune responses activated by LPS [356]. Indeed, histamine 
stimulates intracellular Ca^ "^  flux, chemotaxis, and actin po-
lymerization in immature dendritic cells due to activation of 
HIR and H3R subtypes. Notably, in maturation of dendritic 
cells (DCs) result;; in loss of these responses. However, his-
tamine dose deper.dently augments intracellular cAMP levels 
and stimulates IL-10 secretion in maturing dendritic cells. 
while inhibiting production of IL-12 through H2R [355]. 
Human monocyte-derived dendritic cells express both hista-
mine receptors (HIR and H2R) and can stimulate CD86 ex-
pression via histamine, while human epidermal Langerhans 
cells express neither HIR nor H2R due to effect of trans-
forming growth factor (TGF)-(3 [357]. 
E. Eosinophils 
Eosinophils express both histamine HI- and H2-
receptors. The effect of histamine on eosinophils is stimula-
tory at lower concentrations. It had been suggested that pre-
incubation of eosinophils with I0"^ M or higher concentra-
tions of histamine suppressed the chemotactic response of 
eosinophils to endotoxin-activated serum (C5a) while prein-
cubation of eosinophils with a lower concentration of IO"*M 
histamine had the inverse effect, enhancing the C5a-
activated eosinophil chemotaxis. Furthermore, H2R- and 
HIR-antagonists, respectively, inhibited these impacts. The 
expression of a novel H3R mediates the direct eosinophil 
chemotactic response towards histamine [358]. It has also 
been observed that this receptor seems to have similar an-
tagonist binding activities to those reported for the H3R ob-
served in the CNS, although it does not bind R-a-
methylhistamine or N-a-methylhistamine with similar po-
tency as histamine suggesting differences between the activi-
ties and function of H3Rs expressed in CNS and on the eosi-
nophil. Histamine acting via the HIR also augments eosino-
phil C3b receptor expression [359], and it was considered as 
an important mechanism that was found to be involved in the 
amplification of complement-dependent parasite killing. 
However, 0.1-50 mM histamine was demonstrated to block 
eosinophil degranulation, as shown by diminished release of 
C5a-mediated eosinophil peroxidase [360]. It has been sug-
gested that selective H2R agonists produced an impact simi-
lar to that shown by histamine and that cimetidine (H2R-
antagonist) reversed this inhibitory impact of histamine. Fur-
thermore, in contrast, treatment with neither mepyramine 
(H1 R-antagonist) nor thioperamide (H3R-antagonist) sig-
nificantly inhibited the C5a-induced release of eosinophil 
peroxidase from eosinophils suggesting the significant role 
of H2R in same respect. An important relation between his-
tamine and eosinophil in allergic disease has been docu-
mented in vivo in patients with allergic rhinitis undergoing 
segmental allergen challenge, and followed by airway sam-
pling via bronchoalveolar lavage (BAL) after 5 min and 48 h 
[361]. While, in response to in vitro antigen challenge, 
maximal blood histamine release was determined in each 
patient before segmental bronchoprovocation. The number 
of eosinophils in BAL samples collected after 48 h were sig-
nificantly enhanced and correlated with the maximal baso-
phil histamine release noted for each individual suggesting a 
direct causal relationship between basophilic mediator re-
lease and airway eosinophilia. 
F. Epitlielial Cells 
The implications of histamine have been observed in 
cultured human bronchial epithelial cells that demonstrate 
functionally active HIR and H2R as demonstrated by hista-
mine-induced generation of cGMP for HIR and cAMP for 
H2R and blockage of cGMP release by treatment with pyri-
lamine and cAMP release by treatment with titotidine [362]. 
Recently, the expression of HI-receptor on cultured human 
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ocular and nasal epithelial cells indicates that histamine may 
potently influence the property of these cells [363, 364]. It 
has been demonstrated that nasal and bronchial epithelial 
cells synthesizes and release distinct biologically active me-
diators including cell adhesion molecules, endothelin, cyto-
kines, arachidonic acid metabolites, major histocompatibility 
complex class (MHC) II antigens, neuropeptide degrading 
enzymes and nitric oxide that influence the migration, activa-
tion and also function of both structural and inflammatory 
cells involved in the pathophysiology of allergic rhinitis and 
asthma [365, 366]. Notably, the implications of histamine on 
mediator release from human bronchial epithelial cells dem-
onstrated that HIR modulation with 2 mM histamine led to 
induction of cytoplasmic phospholipase A2 mRNA, activa-
tion of the transcription factor NF-kp, production of leukot-
riene B4, and expression of IL-8 [367]. It has been shown 
that histamine-induced enhancement in leukotriene B4 was 
inhibited by incubation of the cells with specific 5-
lipoxygenase activating protein inhibitors and Zileuton and 
expression of IL-8 was blocked by diphenhydramine, and 5-
lipoxygenase activating protein inhibitors and Zileuton indi-
cating an important network of histamine-modulated in-
flammatory mechanisms within the airways. Similarly, his-
tamine induced the release of lL-6, IL-8 and GM-CSF from 
human corneal and conjunctival epithelial cells in a dose-
dependent manner at physiologically or pathologically rele-
vant concentrations and several HIR-antagonists, but not 
H2R-antagonist (ranitidine) or H3R-antagonist (thiopera-
mide) blocked this cytokine release [368]. Indeed, the role of 
epithelial cells as modulators of inflammation, mainly in 
allergic diseases has been an important subject of much dis-
cussion for future prospects. 
G. Endothelial Cells 
The contribution of endothelial cells to the pathophysiol-
ogy of allergic disorder has mainly been investigated. The 
significant effect of histamine on vascular permeability has 
well been demonstrated and is a consequence of HI R signal-
ing that results in the contraction of F-actin fibres of the en-
dothelial cytoskeleton and formation of gaps in the post cap-
illary venules and extravasation of macromolecules [369]. 
The functionally potent HIR and/or H2R is expressed on 
human endothelial cells present in distinct tissues (the airway 
mucosa, eye, ;;kin, brain and umbilical vein) [370]. Human 
umbilical vein endothelial cells have been the most investi-
gated in mechanistic studies, because of comparatively easier 
and greater acc;ess to these cells. Currently, in a recent study 
it has been suggested that histamine itself regulates the ex-
pression of histamine receptor (HR) subtypes on endothelial 
cells and influences the overall significant role in inflamma-
tory response in allergic disease [371]. It has been docu-
mented that the levels of mRNA for both the receptors (HIR 
and H2R) were down regulated by histamine, of which the 
effect on H2R-mRNA was rapid and long lasting, compared 
with a less pronounced, transient and shorter lasting impact 
on the HlR-mRNA. Furthermore, the H2R-mRNA was ex-
clusively down regulated as a result of HIR protein activa-
tion. Histamine-induced receptor signaling on the endothelial 
cells directly modulates inflammatory changes in these cells. 
Therefore, treatment of human umbilical vein endothelial 
cell cultures vvith IO''*M or lO'^ M histamine resulted in the 
release of lipophilic neutrophil chemoattractant activity from 
endothelial cells, an effect inhibited by cimetidine but not by 
diphenhydramine [372]. Histamine or HIR- or H2R-agonist 
stimulated adhesion of neutrophils to endothelial cells, par-
ticipated in activation of phospholipase C, guanylate cyclase 
and nitric oxide synthase isozymes, since inhibition of^  these 
enzymes with specific inhibitors decreases this adhesion 
[372]. The impact of histamine was found to be mediated by 
both HI-receptor and H2-receptor signaling and modulation 
of P-selectin on endothelial cells in the mesentery. Thus, 
histamine receptors are involved in significant implications 
in the field of histamine research in endothelial cells. 
VII. IMPLICATION OF HISTAMINE ON CYTOKI-
NES PRODUCTION 
It has been documented that histamine stimulates cyto-
kine synthesis in allergic inflammation via two main differ-
ent mechanisms: 
(a) Direct effects of histamine on cytokine synthesis and 
(b) Modulation of cytokine production stimulated by 
immunologic stimuli. 
Histamine differentially modulates IL-4 and IFN-y re-
lease from T cells [338], inhibits TNF-a [373] and IL-12 
synthesis via human monocytes [374] while it directly modu-
lates IL-IO [330] and IL-I8 production from human mono-
cytes [375]. In addition, it inhibits IFN-y, TNF-a, and IL-12 
and enhances IL-IO synthesis in LPS- or mitogen-activated, 
peripheral blood mononuclear cells [374,376], and increases 
IL-I stimulated synthesis of IL-6 by monocytes [377]. These 
complex impacts of histamine were found to be mediated 
through the activation of HIR [378], H2R [374], and H3R on 
immune cell cytokine synthesis [330]. Recently, cloned H4R 
has been characterized as functionally active to modulate 
cytokines [274, 284, 285]. Several investigators have ob-
served that low concentrations of histamine [i.e., found in the 
bronchoalveolar lavage (BAL) fluid of patients with bron-
chial asthma or at other sites of allergic inflammation] [352, 
379], modulates human lung macrophages. The rationale for 
studying human lung macrophage was the high prevalence of 
macrophages in the human lung parenchyma and in the BAL 
fluid [380]. An important study has been done on macro-
phages, which were purified (approximately 98%) from the 
lung parenchyma of thoracic surgery. Patients were incu-
bated (1 to 18 h) with low doses of histamine (10"' to 10"' 
mol/L) that was compared to those released In vivo in dis-
tinct pathophysiology. It has been observed that histamine 
stimulated the de novo synthesis of IL-6 from macrophages 
[304], and these impacts were reproduced via the HIR ago-
nist (6-[2-(4-imidazolyl)ethylamino]-N-(4-trifluoromethyl-
phenyl) heptane carboxamide) but not by the H2-receptor 
agonist (dimaprit) suggesting that those were HIR mediated 
events [304]. Thus, these results are in line with the general 
investigation that HIR modulation is related with intracellu-
lar Ca^ ^ influx and demonstrated that this signal transduction 
pathway is active in human macrophages [381]. The HIR-
mediated activation of macrophages was documented by 
demonstrating that histamine-induced IL-6 release was 
blocked in a concentration-dependent fashion by enhancing 
concentrations of the selective H1 R-antagonist (fexofena-
dine) [304]. While the H2R-antagonist (ranitidine) had no 
effect on IL-6 release or Ca^ * signal produced by histamine. 
A more valuable research in this field has provided the sig-
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nificant evidence that low concentrations of iiistamine pro-
mote exocytosi;; and IL-6 syntliesis by inducing HlRs and 
activating intracellular Ca^ * signaling in macrophages. This 
investigation enhances the intriguing possibility that, via 
activating macrophage functions, histamine might be impli-
cated in the long-term control of inflammation. 
VIII. SIGNIFICANCE OF HISTAMINE IN AUTOIM-
MUNITY AND IN ALLERGIC DISEASES 
It is highly significant in field of immunomodulation that 
endogenous levels of histamine influence the repertoire of 
autoantibodies. Histamine has been observed to influence 
several aspects of the immune response, including antibody 
production [12, 13, 189]. It has been characterized that the 
repertoire of natural autoantibodies in histidine decarboxy-
lase (HDC) diminished mice [33] was unable to produce 
histamine. HDC-diminished and wild type mice differed in 
the patterns of reactivity of their immunoglobulin-M (IgM) 
and immunoglobulin-G (IgG) natural autoantibodies [382]. 
The natural autoantibodies in HDC diminished sera mani-
fested a larger r(;pertoire of IgM autoantibodies than did the 
wild type sera [382]. The self-antigens bound by IgM from 
HDC diminished mice includes structural proteins, enzymes 
related with cellular metabolism, double-stranded DNA and 
single stranded DNA, and tissue-specific antigens like insu-
lin [382]. It was noted that relatively fewer differences in the 
natural autoantibodies repertoire of IgG autoantibodies of the 
mice, notably, the HDC diminished sera reacted with glu-
tamic acid decarboxylase (GAD) [382], an antigen related 
with autoimmune diabetes [383]. It has been documented 
that GAD-specific antibodies in HDC diminished mice re-
flect an enhanced susceptibility to develop autoimmune dia-
betes. Therefore, this demonstrates that factors not directly 
associated to antigenic activation such as endogenous levels 
of histamine can influence the natural autoantibodies reper-
toire [382]. Thus, disorders of immune system characterized 
by altered levels of endogenous histamine, such as allergies, 
might be reflected as specific alterations in the repertoire of 
natural autoantibodies. 
A. Urticaria and Angioedema 
Urticaria is the medical word for itchy wheals or hives 
(pale red swellings of skin "wheals" that occur in groups on 
any part of the skin) and angioedema known as deep muco-
cutaneous swelling often occur together with urticaria. Urti-
caria is classified, based on its temporal evolution, as acute 
(less than 6 weelcs) or chronic (more that 6 weeks). Acute 
urticaria is related with sensitivity to foods, latex, and certain 
drugs and is of^ en immunoglobulin-E (IgE)-mediated. 
Chronic urticaria includes the physical urticarias and urticar-
ial vasculitis but allergic causes of chronic urticaria were 
rarely identified. Some cases of chronic urticaria have been 
associated with circulating IgG autoantibodies against 
FceRIa [384] and autoantibodies against IgE [385]. The fre-
quency of autoantibodies to FcsRIa in chronic urticaria has 
been estimated 30-50%. These autoantibodies to FccRIa 
found to be functional i.e. they can cause histamine release 
from basophils under in vitro condition, however, evidences 
increasingly suggests that such autoantibodies were also 
functional in vivo. Other evidences have suggested that the 
serum from many patients with chronic urticaria causes an 
immediate autologous wheal and flare response (i.e. a posi-
tive autologous serum skin test) and many of such patients 
have evidence of circulating functional IgG autoantibodies to 
the high affinity IgE receptor (FceRIa). The current main-
stream thought is that in such patients the IgG autoantibodies 
causes the visible urticarial skin lesions. It has been docu-
mented that in chronic urticaria the autoantibodies causing 
histamine release were predominantly IgGl and lgG3. Thus, 
the presence of these autoantibodies characterizes the so-
called chronic autoimmune urticaria. A cause-and-effect 
relation between levels of autoantibodies, histamine-
releasing factors, and the clinical manifestations of chronic 
urticaria has still a part of research. However, severe cases 
often suggest that autoantibodies or circulating histamine-
releasing factors do have an important role [386]. Hereditary 
angioedema is a rare autosomal dominant disorder caused by 
the absence of the inhibitor of the first component of com-
plement. 
B. Allergic Rhinitis 
Allergic rhinitis has been characterized by itching, sneez-
ing, rhinorrhea, and nasal obstruction. Perennial allergic 
rhinitis can be distinguished from non-allergic, non-
infectious forms of rhinitis [idiopathic (vasomotor) rhinitis, 
non-allergic rhinitis with eosinophilia syndrome, hormonal 
rhinitis, drug-stimulated rhinitis, and food-induced rhinitis]. 
The treatment of allergic diseases (allergic rhinitis) consists 
of allergen avoidance, anti allergic medication, and immuno-
therapy for specific allergens which is known as desensitiza-
tion or hyposensitization. Recently, the drugs commonly 
used to treat allergic rhinitis are antihistamines (histamine 
antagonists) and anticholinergic agents for the relief of 
symptoms and corticosteroids to suppress allergic inflamma-
tion. HlR-antagonists (loratadine, cetirizine, and fexofena-
dine) are less sedating and more pharmacologically selective 
than earlier antihistamines. Some HI R-antagonists (cetiriz-
ine) block allergen-sensitized infiltration of tissue by eosino-
phils, an influence that may be independent of their impacts 
onHIR[387]. 
C. Atopic Dermatitis 
Atopic dermatitis (AD) or atopic eczema is a chronic 
relapsing pruritic skin disease with a high incidence in the 
first year of life. AD can persist into childhood, symptoms 
usually remit by puberty. AD is characterized by two phases: 
P' phase with acute lesions predominated by Th2 cytokines 
(IL-4, IL-5 and IL-13), 2"'' phase that is associated with ec-
zematous chronic atopic dermatitis lesions by Thl cytokine 
(INF-y and IL-12). Atopic dermatitis can also be present in 
adults and affects more than 10% of the total population, 
with 80-90% of those affected being children under 5 years 
of age in Western population [388, 389]. Atopic dermatitis is 
often regarded as a cutaneous form of atopy; as a result, 50-
80% of children with AD will develop asthma or allergic 
rhinitis by 5 years of age later in life and the high serous 
concentration of IgE [390]. This temporal progression of 
atopic symptoms from atopic dermatitis to allergic sensitiza-
tion of the skin, food allergy, hay fever (allergic rhinitis) and 
later airway hyperresponsivness and airway inflammation or 
asthma, has been named the "allergic march" [391, 392]. 
In AD, the skin becomes extremely itchy. Scratching 
leads to redness, swelling, cracking, "weeping" clear fluid, 
and finally crusting and scaling. It is frequently perceived as 
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a minor dermatological disorder. However, the high preva-
lence of this condition carries financial and social cost not 
only for the community, regarding medical and hospital cost 
but also for the patient and the patient's family [393]. In AD, 
inflammation results from interactions of immune cells [T 
cells (Thl and Th2), dendritic cells (langerhans dendritic 
cells and inflammatory dendritic epidermal cells), mast cells 
and eosinophils] and kerotinocytes. The complex picture of 
the AD lesion is aggravated by environmental and genetic 
factors that increase the difficulty of understanding the 
mechanisms behind this complex pathology [388]. 
IX. ROLE OF HISTAMINE IN MALIGNANCIES 
Malignant melanoma is a well known life-threatening 
tumor (with a high rate of metastasis and strong malignant 
potential). Recently, the immune response against melanoma 
was compromised through multiple escape mechanisms of 
the tumor, which have been uncovered partially via thorough 
immunological and molecular analyses. These analyses were 
documented by gene-expression profiling. It has been sug-
gested that mslanoma-derived histamine should be included 
as a significant factor participated in bi-directional interac-
tions between the tumor tissue and infiltrating immune cells. 
Notably, the presence and activity of histamine has been 
demonstrated to be relevant by directly stimulating or sup-
pressing growth of the melanoma (i.e. depending on the local 
histamine receptor balance) and indirectly shifting the local 
T-cell polarization towards a predominance of Th2 cells 
[394]. 
X. RELATION OF HISTAMINE-CYTOKINE DURING 
HEMATOPOIESIS 
Many researchers have reported that exogenous hista-
mine promote the entry of colony-forming units-spleen 
(CFU-S) into cell cycle and showed that this mediator stimu-
lated granulocyte precursors, when added during in vitro 
cultures [395, 396]. Recently, it has been demonstrated that a 
similar positive effect on hematopoietic progenitors was in-
duced by endogenous histamine. Histamine is synthesized in 
response to hematopoietic growth factors (IL-3, GM-CSF 
and IL-I) generated during the immune response. It was 
probably not needed for maintaining bone marrow homeo-
stasis, but involved in inducible hematopoiesis, and satisfies 
the enhanced requirements of an efficient host defense. 
There were several reports in support of a positive effect of 
histamine on granulopoiesis, but side effects of some hista-
mine receptor ligands have also been described. Rare cases 
of agranulocytosis have been observed in response to H2-
receptor antagonist (cimetidine) and H4R antagonist (clozap-
ine). Jt should be confirmed and re-evaluated by several re-
ports, as regards the significant role of various histamine 
receptors; those expressions are most abundant in bone mar-
row [14]. 
XI. FUTURE PROSPECTS 
Histamine i-eceptors have been important drug targets for 
many years. Their physiological and pathological relevance 
and distribution in various tissues are being documented, 
while the exact role of histamine receptors in immunomodu-
lation is still unclear. The previous studies have shown im-
munomodulatory role of HI- and H2-receptors and their po-
tent role on lymphocytes (T-cells and B-cells), but all these 
reports have studied the antibody concentrations at a single 
time period taking single blood samples from experimental 
animals [105, 188, 189, 397]. Our recent findings in im-
munoregulatory processes, demonstrated that total antibody, 
total IgM and total IgG generation profile in pheniramine 
(HlR-antagonist)-treated group is completely suppressed as 
compared to ranitidine (H2R-antagonist)- treated and control 
group, while total antibody and total IgM in ranitidine (H2R 
antagonist)-treated group is suppressed initially and en-
hanced in a later phase in comparison to control group, and 
IgG profile remained suppressed in comparison to control 
group. Thus, our results demonstrate B-cell proliferation in 
response to anti-IgM is increased in H2R-antagonist treated 
rabbits and is diminished in HIR-antagonist treated rabbits, 
and that HIR-antagonist treated rabbits display diminished 
antibody production against a T cell-dependent antigen-
SRBC as compared with H2R-antagonist treated and control 
rabbits [398]. 
The scope of histamine research has been implicated in 
immune responses of both the Thl and Th2 lymphocytes. 
The newly discovered H4-receptor plays an important role in 
inflammation and has opened a new way for the functions of 
histamine in inflammation, allergy and autoimmune diseases. 
The data on the role of H3- and H4-receptors in immune 
regulation are limited. Due to lack of immunomodulatory 
researches on H3- and H4-receptors, we planned ongoing 
studies to find out immunomodulatory role via several spe-
cific antagonists and agonists. 
The antagonists for HI- and H2-receptors have been in-
troduced into market for a long time and it is assumed that 
within the next few years the H3- and H4-receptor antago-
nists will be freely available in market. As we planned our 
ongoing researches on role of histamine receptors in immu-
nomodulation, Tocris Bioscience, Tocris Cookson Ltd. 
(United Kingdom) has donated highly potent and specific 
histaminergic product as quotation code: "Donation 
24.08.07" including products HTMT dimaleate [6-[2-(4-
imidazolyl)ethylamino]-N-(4-trifluoromethylphenyl)heptane-
carboxamide dimaleate], Amthamine dihydrobromide [2-
amino-5-(2-aminoelhyl)-4-methylthiazole dihydrobromide], 
(R)-(-)-a-methylhistamine dihydrobromide [(R)-(-)-a-
methyl-IH-imidazole-4-ethanamine], Imetit dihydrobromide 
[5-[2-(imidazol-4-yl)ethyl]isothiourea dihydrobromide], 
Clobenpropit dihydrobromide [N-(4-Chlorobenzyl)-S-[3-
(4(5)-imidazolyl)propyl]isothio urea dihydrobromide], lodo-
phenpropit dihydrobromide [N-[2-(4-iodophenyl)ethyl]-S-[3-
(4(5)-imidazolyl)propyl]isothiourea dihydrobromide] (see 
chemical structures in Fig. (12)). In future, we are planning 
to conduct researches on immunomodulation by H4-receptor 
agonist (4-Methylhistamine dihydrochloride) and antagonist 
(JNJ10191584 maleate). 
Thus, the recent data on the novel functions of histamine 
receptors (HI-, H2-, H3- and H4) have opened an interesting 
new chapter in immune regulation and immunomodulation 
in the history of histamine research and should lead to deeper 
relevance, and understanding treatments of pathological 
processes those regulating several essential events in aller-
gies and autoimmune diseases. 
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